1 00:00:06,624 --> 00:00:09,627 >> GOOD MORNING, EVERYONE. 2 00:00:09,627 --> 00:00:10,194 AMY START OFF. 3 00:00:10,194 --> 00:00:15,866 >> I'LL WELCOME YOU BACK TO THE 4 00:00:15,866 --> 00:00:24,909 HEAL ENDING END ADDICTION LONG 5 00:00:24,909 --> 00:00:26,410 TERM, MDWG. 6 00:00:26,410 --> 00:00:30,814 THIS IS OPEN TO THE PUBLIC VIA 7 00:00:30,814 --> 00:00:37,021 VIDEOCAST AND THE GROUP HAS THE 8 00:00:37,021 --> 00:00:38,455 HEALTH CARE COMMUNITY AND 9 00:00:38,455 --> 00:00:39,557 ADVOCATES RELATED TO PAIN AND 10 00:00:39,557 --> 00:00:44,261 LOOKS AT ACTIVE AND PROPOSED 11 00:00:44,261 --> 00:00:45,796 PROJECTS IN THE NIH HEAL 12 00:00:45,796 --> 00:00:47,198 INITIATIVE AND SUGGESTS AREAS 13 00:00:47,198 --> 00:00:48,999 WHERE MORE RESEARCH IS NEEDED 14 00:00:48,999 --> 00:00:51,702 AND WE GREATLY APPRECIATE YOUR 15 00:00:51,702 --> 00:00:52,970 INPUT. 16 00:00:52,970 --> 00:00:56,040 I'M AMY BANY ADAMS FOR THE 17 00:00:56,040 --> 00:00:59,777 INSTITUTE OF NEUROLOGICAL ORDERS 18 00:00:59,777 --> 00:01:02,446 AND STROKE AND THE EXEC SEC FOR 19 00:01:02,446 --> 00:01:05,983 THE MEETING AND HOPE TO KEEP 20 00:01:05,983 --> 00:01:08,519 RUNNING IT SMOOTHLY. 21 00:01:08,519 --> 00:01:12,256 WE'RE GRATEFUL FOR YOUR SERVICE 22 00:01:12,256 --> 00:01:15,059 AND YOUR PERSPECTIVE HELPS 23 00:01:15,059 --> 00:01:18,395 ENSURE WE LOOK INTO OVERDOSE AND 24 00:01:18,395 --> 00:01:19,296 PAIN MANAGEMENT. 25 00:01:19,296 --> 00:01:20,998 ALMOST EVERY NIH INSTITUTE AND 26 00:01:20,998 --> 00:01:24,201 CENTER ACCELERATES RESEARCH TO 27 00:01:24,201 --> 00:01:24,768 ADDRESS THIS PUBLIC HEALTH 28 00:01:24,768 --> 00:01:26,570 EMERGENCY FROM ALL ANGLES AND 19 29 00:01:26,570 --> 00:01:28,839 INSTITUTES AND CENTERS ARE 30 00:01:28,839 --> 00:01:30,841 ENGAGED DIRECTLY IN THE HEAL 31 00:01:30,841 --> 00:01:31,275 INITIATIVE. 32 00:01:31,275 --> 00:01:32,509 TODAY YOU'LL HEAR PRESENTATIONS 33 00:01:32,509 --> 00:01:34,211 IN THE OPEN AND CLOSED SESSIONS 34 00:01:34,211 --> 00:01:36,847 FROM SOME OF THE FANTASTIC 35 00:01:36,847 --> 00:01:37,581 INDIVIDUALS MANAGING HEAL 36 00:01:37,581 --> 00:01:40,417 PROGRAMS FROM ACROSS THESE MANY 37 00:01:40,417 --> 00:01:42,086 INSTITUTES AND CENTERS. 38 00:01:42,086 --> 00:01:43,420 I WANT TO APPRECIATE THE WORK 39 00:01:43,420 --> 00:01:48,525 THEY DO TO ADVANCE SCIENCE. 40 00:01:48,525 --> 00:01:52,196 IT ALSO TAKES A VILLAGE TO PUT A 41 00:01:52,196 --> 00:01:53,564 MEETING LIKE THIS TOGETHER AND I 42 00:01:53,564 --> 00:02:00,971 WANT TO ACKNOWLEDGE THE WORK OF 43 00:02:00,971 --> 00:02:02,172 PEOPLE BEHIND THE SCENES FOR 44 00:02:02,172 --> 00:02:03,274 THEIR WORK TO PULL THIS 45 00:02:03,274 --> 00:02:04,408 PARTICULAR MEETING TOGETHER. 46 00:02:04,408 --> 00:02:06,010 I APPRECIATE YOUR EFFORTS TO 47 00:02:06,010 --> 00:02:08,012 HAVE THIS ALL RUN SMOOTHLY AND I 48 00:02:08,012 --> 00:02:12,983 WANT TO ALSO ACKNOWLEDGE WE'VE 49 00:02:12,983 --> 00:02:14,418 HAD TECHNICAL AND I.T. ISSUES 50 00:02:14,418 --> 00:02:16,987 LEADING UP TO THE MEETING AND I 51 00:02:16,987 --> 00:02:18,956 APPRECIATE EVERYBODY'S 52 00:02:18,956 --> 00:02:21,058 APPRECIATION AND WILLINGNESS TO 53 00:02:21,058 --> 00:02:28,766 WORK THROUGH THEM. 54 00:02:28,766 --> 00:02:33,504 FOR THE MDWG MEMBERS YOU CAN 55 00:02:33,504 --> 00:02:34,938 RAISE YOUR HAND OR PUT YOUR 56 00:02:34,938 --> 00:02:36,240 QUESTION IN THE CHAT OR SAY YOU 57 00:02:36,240 --> 00:02:37,608 HAVE A QUESTION OR COMMENT IN 58 00:02:37,608 --> 00:02:39,009 THE CHAT AND WE'LL BE SURE 59 00:02:39,009 --> 00:02:39,977 YOU'RE CALLED ON AT THE 60 00:02:39,977 --> 00:02:40,477 APPROPRIATE MOMENT. 61 00:02:40,477 --> 00:02:43,914 SO WITH THAT, I WANT TO 62 00:02:43,914 --> 00:02:45,749 RECOGNIZE MDWG CO-CHAIR 63 00:02:45,749 --> 00:02:52,690 DR. WALTER KOROSHETZ AND THE 64 00:02:52,690 --> 00:02:54,124 WELCOME YOU AND PROVIDE 65 00:02:54,124 --> 00:02:56,994 HEAL/PAIN UPDATES. 66 00:02:56,994 --> 00:02:58,228 WALTER. 67 00:02:58,228 --> 00:03:08,639 >> THANK YOU, DR. ADAMS. 68 00:03:15,379 --> 00:03:16,947 I WANT TO THANK EVERYBODY COMING 69 00:03:16,947 --> 00:03:18,182 ON TODAY. 70 00:03:18,182 --> 00:03:20,117 THE HEAL PROGRAM IS THE MOST 71 00:03:20,117 --> 00:03:22,252 EXCITING THING I'VE SEEN IN MY 72 00:03:22,252 --> 00:03:31,962 LIFE AND WORKING WITH NIDA TO 73 00:03:31,962 --> 00:03:33,330 ADDRESS EVERYONE WITH MORE 74 00:03:33,330 --> 00:03:33,664 URGENCY. 75 00:03:33,664 --> 00:03:39,970 THE MDWG IS A GREAT GROUP THAT'S 76 00:03:39,970 --> 00:03:41,805 BEEN ABLE TO KEEP US CENTERED ON 77 00:03:41,805 --> 00:03:47,211 THE IMPORTANT THINGS GOING 78 00:03:47,211 --> 00:03:47,444 FORWARD. 79 00:03:47,444 --> 00:03:48,879 HOPEFULLY YOU LEARN AND GET A 80 00:03:48,879 --> 00:03:51,982 SENSE OF WHAT WE'RE DOING FROM 81 00:03:51,982 --> 00:03:55,986 THE DISCUSSIONS HERE TODAY AND 82 00:03:55,986 --> 00:03:58,021 WE REALLY VALUE YOUR INPUT. 83 00:03:58,021 --> 00:03:59,556 THAT'S WHAT THE MDWG IS ALL 84 00:03:59,556 --> 00:03:59,757 ABOUT. 85 00:03:59,757 --> 00:04:10,300 WE WORK HARD WITHIN THE BELTWAY 86 00:04:13,704 --> 00:04:17,408 BUT THE EYES ON WHAT WE'RE DOING 87 00:04:17,408 --> 00:04:18,876 MAKES THIS MORE VALUABLE. 88 00:04:18,876 --> 00:04:20,644 WE NEED YOUR THOUGHTS AND TAKE 89 00:04:20,644 --> 00:04:21,011 THEM SERIOUSLY. 90 00:04:21,011 --> 00:04:28,252 I'LL START OFF BY TALKING ABOUT 91 00:04:28,252 --> 00:04:29,353 HOW HEAL IS ADDRESSING PAIN AND 92 00:04:29,353 --> 00:04:32,256 AN UPDATE ON WHAT WE'RE DOING 93 00:04:32,256 --> 00:04:33,757 THERE AND CARLOS BLANCO IS GOING 94 00:04:33,757 --> 00:04:38,462 TO GIVE US A STATE OF THE OPIOID 95 00:04:38,462 --> 00:04:40,297 CRISIS AND NORA UNFORTUNATELY 96 00:04:40,297 --> 00:04:43,534 WAS UNABLE TO BE HERE TODAY AND 97 00:04:43,534 --> 00:04:44,868 CARLOS IS TREMENDOUSLY 98 00:04:44,868 --> 00:04:53,010 KNOWLEDGEABLE IN THIS PLACE AND 99 00:04:53,010 --> 00:04:56,713 GRATEFUL TO HAVE DR. CRISWELL A 100 00:04:56,713 --> 00:04:58,048 CO-CHAIR FOR THE PAIN INITIATIVE 101 00:04:58,048 --> 00:05:01,018 HEAL SIDE TO TALK ABOUT HER 102 00:05:01,018 --> 00:05:06,123 VISION FOR PAIN RESEARCH FROM 103 00:05:06,123 --> 00:05:11,395 OUR VANTAGE POINT AS THE NIAMS 104 00:05:11,395 --> 00:05:16,567 DIRECTOR. 105 00:05:16,567 --> 00:05:19,369 AS WE'VE TOLD YOU IN THE PAST 106 00:05:19,369 --> 00:05:24,475 THE HEAL/PAIN PORTFOLIO NOW IS 107 00:05:24,475 --> 00:05:26,076 PUT TOGETHER VERY DEMOCRATICALLY 108 00:05:26,076 --> 00:05:32,349 BY 15 DIFFERENT INSTITUTES. 109 00:05:32,349 --> 00:05:33,517 THEY HAVE THEIR DIRECTORS AROUND 110 00:05:33,517 --> 00:05:37,020 THE TABLE AND THEY'RE THE FINAL 111 00:05:37,020 --> 00:05:42,726 DECIDERS ON WHAT WE FUND AND OUR 112 00:05:42,726 --> 00:05:44,228 PLANS GOING FORWARD. 113 00:05:44,228 --> 00:05:46,263 THERE'S THINGS GOING ON BEFORE 114 00:05:46,263 --> 00:05:50,567 THINGS REACH THE DIRECTORS, 115 00:05:50,567 --> 00:06:00,744 DR. CRISWELL AND LANGEVIN 116 00:06:00,744 --> 00:06:02,980 COORDINATE TO MAKE DECISIONS AND 117 00:06:02,980 --> 00:06:04,715 BEFORE THAT WE HAVE A SMALL 118 00:06:04,715 --> 00:06:06,049 STAFF GROUP LOOKING AT THE DAY 119 00:06:06,049 --> 00:06:09,119 TO DAY ACTIVITIES OF HEAL AND 120 00:06:09,119 --> 00:06:12,623 HAVE A STEERING COMMITTEE MADE 121 00:06:12,623 --> 00:06:15,058 UP OF REPRESENTATIVES FROM THE 122 00:06:15,058 --> 00:06:16,994 INSTITUTES AND EACH OF THEIR 123 00:06:16,994 --> 00:06:18,395 REPRESENTATIVES HAS ONE VOTE IN 124 00:06:18,395 --> 00:06:19,796 THE STEERING COMMITTEE AND THEY 125 00:06:19,796 --> 00:06:22,232 PRIORITIZE THE RESEARCH COMING 126 00:06:22,232 --> 00:06:28,272 FORWARD AND THE INITIATIVES 127 00:06:28,272 --> 00:06:29,172 GOING FORWARD WHICH THEN COME 128 00:06:29,172 --> 00:06:31,375 FROM A SERIES OF WORKING GROUP 129 00:06:31,375 --> 00:06:34,278 MADE UP OF PROGRAM DIRECTORS 130 00:06:34,278 --> 00:06:35,612 THROUGHOUT THE 14 INSTITUTE -- 131 00:06:35,612 --> 00:06:37,014 15 INSTITUTES AND CENTERS. 132 00:06:37,014 --> 00:06:47,524 WOE HAVE A DYNAMIC SET UP WE 133 00:06:54,898 --> 00:06:56,867 ENGAGE ACROSS NIH IN THE HEAL. 134 00:06:56,867 --> 00:06:58,135 THIS IS SOMETHING WE NEED FOR 135 00:06:58,135 --> 00:07:02,372 PAIN BECAUSE WE DON'T HAVE THE 136 00:07:02,372 --> 00:07:03,507 EQUIVALENT OF NIDA THE INSTITUTE 137 00:07:03,507 --> 00:07:05,809 FOR DRUG ABUSE BUT THE HEAL 138 00:07:05,809 --> 00:07:09,046 GROUP IS SERVING IN A SIMILAR 139 00:07:09,046 --> 00:07:19,523 CAPACITY FOR PAIN RESEARCH. 140 00:07:19,923 --> 00:07:22,292 THIS IS TO SHOW YOU WHAT OUR 141 00:07:22,292 --> 00:07:29,633 BUDGETARY SITUATION IS NOW. 142 00:07:29,633 --> 00:07:33,003 DIFFERENT COLORS REPRESENT 143 00:07:33,003 --> 00:07:37,841 DIFFERENT FUNDING COMMITMENTS. 144 00:07:37,841 --> 00:07:40,644 THE KEY THING TO KNOW IS THE 145 00:07:40,644 --> 00:07:42,746 CIRCLES AT THE END YOU SEE THE 146 00:07:42,746 --> 00:07:43,647 DOLLARS AVAILABLE FOR NEW 147 00:07:43,647 --> 00:07:45,282 RESEARCH GOING FORWARD. 148 00:07:45,282 --> 00:07:49,019 AND THE TAKE HOME POINT IS THAT 149 00:07:49,019 --> 00:07:51,755 THE PROJECTS WE PUT TOGETHER 150 00:07:51,755 --> 00:07:56,026 OVER THE LAST COUPLE YEARS AS 151 00:07:56,026 --> 00:07:57,494 OUR FUNDINGS INCREASE ARE NOW 152 00:07:57,494 --> 00:07:59,997 OUT THERE. 153 00:07:59,997 --> 00:08:02,633 THE WORK IS BEING DONE BUT 154 00:08:02,633 --> 00:08:04,701 WITHOUT INCREASES IN FUNDING 155 00:08:04,701 --> 00:08:06,269 FROM CONGRESS THERE WILL BE NEW 156 00:08:06,269 --> 00:08:08,805 MONEY TO THE PROJECT END AND THE 157 00:08:08,805 --> 00:08:10,974 MONEY RETURNS BACK. 158 00:08:10,974 --> 00:08:13,010 PRIMARILY IN 2027 AND 159 00:08:13,010 --> 00:08:21,018 THEREAFTER. 160 00:08:21,018 --> 00:08:22,986 THAT'S GOOD TIMING TALKING ABOUT 161 00:08:22,986 --> 00:08:24,454 STRATEGIC PLANNING GOING ON NOW 162 00:08:24,454 --> 00:08:31,161 AND THROUGH 2025 WE CAN PUT UP 163 00:08:31,161 --> 00:08:33,497 CONCEPTS IN 2026 AND IN 2027 THE 164 00:08:33,497 --> 00:08:41,872 FUNDING LOOSENS UP NEW PROJECTS. 165 00:08:41,872 --> 00:08:44,007 JUST WANTED TO SHOW HERE THE 166 00:08:44,007 --> 00:08:47,377 FUNDING THAT IS AVAILABLE 167 00:08:47,377 --> 00:08:48,912 THROUGH THE HEAL INITIATIVE 168 00:08:48,912 --> 00:08:53,016 APPROPRIATIONS FROM CONGRESS. 169 00:08:53,016 --> 00:08:56,053 MONEY COMES FROM NINDS USED TO 170 00:08:56,053 --> 00:08:59,990 FUND THE PROJECTS THE RC 171 00:08:59,990 --> 00:09:02,225 DIRECTORS ALL AGREE UPON AND 172 00:09:02,225 --> 00:09:04,494 CURRENTLY HAVE $285 MILLION A 173 00:09:04,494 --> 00:09:04,995 YEAR. 174 00:09:04,995 --> 00:09:08,365 A SUBSTANTIAL NUMBER. 175 00:09:08,365 --> 00:09:12,069 AND NIDA HAS CURRENTLY $355.3 176 00:09:12,069 --> 00:09:14,504 MILLION A YEAR. 177 00:09:14,504 --> 00:09:18,508 MORE ON THE OUD THAN PAIN SIDE 178 00:09:18,508 --> 00:09:19,509 BUT STILL SUBSTANTIAL ON THE 179 00:09:19,509 --> 00:09:21,978 PAIN SIDE AND THE HOUSE BUDGET 180 00:09:21,978 --> 00:09:24,147 FOR '25, OF COURSE WE DON'T KNOW 181 00:09:24,147 --> 00:09:26,016 WHAT '25 WILL BRING US. 182 00:09:26,016 --> 00:09:27,784 WE DON'T EXPECT A BUDGET UNTIL 183 00:09:27,784 --> 00:09:29,152 AFTER THE ELECTION AND MAYBE 184 00:09:29,152 --> 00:09:33,623 DEPENDING ON THE ELECTION COULD 185 00:09:33,623 --> 00:09:36,993 BE EARLY SPRING BUT THE HOUSE 186 00:09:36,993 --> 00:09:47,537 BUDGET THE SAME $285 MILLION THE 187 00:09:51,608 --> 00:09:53,810 SENATE BUDGET WAS CHANGED AND 188 00:09:53,810 --> 00:09:57,013 MORE BY THE SENATE. 189 00:09:57,013 --> 00:10:00,383 SO THOSE ARE THE NUMBERS THAT 190 00:10:00,383 --> 00:10:02,285 WE'RE PLANNING ON GOING FORWARD 191 00:10:02,285 --> 00:10:03,620 AND FOR US IN THE PAIN SPACE YOU 192 00:10:03,620 --> 00:10:06,990 HAVE TO ERROR ON THE SIDE OF 193 00:10:06,990 --> 00:10:10,761 TAKING THE $285.3 MILLION BUT 194 00:10:10,761 --> 00:10:12,395 CERTAINLY BECAUSE OF THE SMALL 195 00:10:12,395 --> 00:10:14,765 AMOUNTS AVAILABLE TO NEW FUNDING 196 00:10:14,765 --> 00:10:17,000 WE CERTAINLY CAN DO GREAT THINGS 197 00:10:17,000 --> 00:10:21,238 AS NEW FUNDS BECOME AVAILABLE IN 198 00:10:21,238 --> 00:10:24,508 '25. 199 00:10:24,508 --> 00:10:30,514 WITH THIS FUNDING WE HAVE 200 00:10:30,514 --> 00:10:33,016 PROGRAMS THAT STRETCH ACROSS 201 00:10:33,016 --> 00:10:37,521 THIS PLAN TO GO FROM THE 202 00:10:37,521 --> 00:10:38,355 DISCOVERIES MADE IN THE BIO TECH 203 00:10:38,355 --> 00:10:43,026 OR ACADEMIC SPACE, TO BRING 204 00:10:43,026 --> 00:10:44,561 THOSE DISCOVERIES TO HEALTH, 205 00:10:44,561 --> 00:10:46,296 REDUCE THE SUFFERING DUE TO PAIN 206 00:10:46,296 --> 00:10:49,266 THROUGH CLINICAL TRIALS AND 207 00:10:49,266 --> 00:10:51,268 WORKING THROUGH IMPLEMENTATION 208 00:10:51,268 --> 00:10:52,035 AND DISSEMINATION RESEARCH. 209 00:10:52,035 --> 00:10:55,739 SOME OF THIS IS DEVELOPMENT OF 210 00:10:55,739 --> 00:10:56,907 NON-ADDICTIVE THERAPEUTICS THAT 211 00:10:56,907 --> 00:10:59,075 ARE HOPEFULLY GOING TO BE MORE 212 00:10:59,075 --> 00:11:01,211 EFFECTIVE OR EQUALLY EFFECTIVE 213 00:11:01,211 --> 00:11:03,713 SO THEY CAN SUBSTITUTE FOR 214 00:11:03,713 --> 00:11:07,818 OPIOIDS BUT A GREAT DEAL IS ALSO 215 00:11:07,818 --> 00:11:10,854 FOCUSSED ON UNDERSTANDING PAIN 216 00:11:10,854 --> 00:11:15,025 MECHANISMS THAT REALLY WERE 217 00:11:15,025 --> 00:11:17,027 UNABLE TO BE ATTACKED WITHOUT 218 00:11:17,027 --> 00:11:19,863 GETTING ALL THE I.C.s TOGETHER 219 00:11:19,863 --> 00:11:23,567 TO WORK ON THEM AND BACPAC IS A 220 00:11:23,567 --> 00:11:26,536 GOOD EXAMPLE. 221 00:11:26,536 --> 00:11:28,905 THEN WE HAVE A NUMBER OF 222 00:11:28,905 --> 00:11:30,707 CLINICAL PROGRAMS TESTING 223 00:11:30,707 --> 00:11:36,713 AVAILABLE STRATEGIES TO IMPROVE 224 00:11:36,713 --> 00:11:38,882 PAIN CARE PARTICULARLY THOSE 225 00:11:38,882 --> 00:11:40,183 WHICH HELP TO BE MORE EFFECTIVE 226 00:11:40,183 --> 00:11:42,385 AND REDUCE THE RISK OF 227 00:11:42,385 --> 00:11:42,886 ADDICTION. 228 00:11:42,886 --> 00:11:46,289 SOME VERY ROBUST PROGRAMS GOING 229 00:11:46,289 --> 00:11:56,333 ACROSS THE IDEA THERE'S NO 230 00:11:56,333 --> 00:11:58,435 BOTTLENECK THAT PRESENTS A GOOD 231 00:11:58,435 --> 00:11:59,669 IDEA BEING FROM TESTED UP TO 232 00:11:59,669 --> 00:12:04,307 HELPING PATIENTS. 233 00:12:04,307 --> 00:12:05,842 THE NEXT SLIDE SHOWS THE BROAD 234 00:12:05,842 --> 00:12:10,447 RANGE OF SCIENCE THAT WE FUND. 235 00:12:10,447 --> 00:12:14,017 SO, WE HAVE CLINICAL, 236 00:12:14,017 --> 00:12:15,452 TRANSLATIONAL AND BASIC AS YOU 237 00:12:15,452 --> 00:12:21,658 CAN SEE HERE AND THE CLINICAL I 238 00:12:21,658 --> 00:12:23,393 THINK IS THE LARGEST BUCKET. 239 00:12:23,393 --> 00:12:30,901 WE ALSO SERVE IN THE 240 00:12:30,901 --> 00:12:32,335 TRANSLATIONAL SPACE BUCK THE 241 00:12:32,335 --> 00:12:33,904 BOTTLES WITH THE LACK OF 242 00:12:33,904 --> 00:12:34,571 INTEREST FROM THE PHARMACEUTICAL 243 00:12:34,571 --> 00:12:36,306 COMPANIES ON THERAPEUTICS TO 244 00:12:36,306 --> 00:12:39,809 MAKE THE DISCOVERIES THAT COME 245 00:12:39,809 --> 00:12:43,079 OUT OF THE LABS AT LEAST GET TO 246 00:12:43,079 --> 00:12:45,348 THE SMALL BIOTECH SPACE TO GET 247 00:12:45,348 --> 00:12:46,950 TO AN IND STAGE THAT I THINK 248 00:12:46,950 --> 00:12:49,819 WOULD BRING IN THE BIGGER 249 00:12:49,819 --> 00:12:52,422 INDUSTRY FOLKS TO GO IN THE MORE 250 00:12:52,422 --> 00:12:55,558 EXPENSIVE PHASE III TRIALS. 251 00:12:55,558 --> 00:12:56,993 WE'RE ALSO PUTTING A SIGNIFICANT 252 00:12:56,993 --> 00:13:05,001 AMOUNT OF EFFORT INTO TRAINING. 253 00:13:05,001 --> 00:13:06,736 WE THINK THAT WILL BE A LEGACY 254 00:13:06,736 --> 00:13:09,005 OF HEAL BUILDING A WORKFORCE OF 255 00:13:09,005 --> 00:13:16,279 PEOPLE KNOWLEDGEABLE ABOUT PAIN 256 00:13:16,279 --> 00:13:21,117 EXPLOSION IN DISCOVERY IN PAIN 257 00:13:21,117 --> 00:13:31,328 MECHANISMS. 258 00:13:35,098 --> 00:13:37,000 DID IT INCREASE THE AMOUNT OF 259 00:13:37,000 --> 00:13:39,970 PAIN RESEARCH BEING DONE BY THE 260 00:13:39,970 --> 00:13:40,570 INSTITUTES THEMSELVES. 261 00:13:40,570 --> 00:13:42,539 THE QUESTION BEING ARE THE 262 00:13:42,539 --> 00:13:44,274 INSTITUTES GIVING UP ON PAIN AND 263 00:13:44,274 --> 00:13:45,642 SAYING LET HEAL DO IT AND THE 264 00:13:45,642 --> 00:13:46,710 ANSWER IS NO. 265 00:13:46,710 --> 00:13:49,079 THE AMOUNT OF FUNDING FOR PAIN 266 00:13:49,079 --> 00:13:52,282 RESEARCH IS GOING ON AT THE 267 00:13:52,282 --> 00:13:53,016 INSTITUTES HAS ONLY INCREASED 268 00:13:53,016 --> 00:13:58,288 SINCE HEAL STARTED. 269 00:13:58,288 --> 00:14:02,392 YOU CAN SEE HEAL IS IMPORTANT 270 00:14:02,392 --> 00:14:04,260 BUT ONLY A MINORITY AROUND 15% 271 00:14:04,260 --> 00:14:07,530 TO 20% OF THE TOTAL PAIN FUNDING 272 00:14:07,530 --> 00:14:08,498 AT NIH. 273 00:14:08,498 --> 00:14:11,034 IT DOES HAVE A SPECIAL ROLE OF 274 00:14:11,034 --> 00:14:13,003 MOVING THINGS TOWARDS PATIENTS 275 00:14:13,003 --> 00:14:15,438 AND TRANSLATION, TOWARDS TESTING 276 00:14:15,438 --> 00:14:17,407 NEW STRATEGIES IN PATIENTS AND 277 00:14:17,407 --> 00:14:21,978 ALSO AS I MENTIONED 278 00:14:21,978 --> 00:14:24,881 INVESTIGATING IMPORTANT BASIC 279 00:14:24,881 --> 00:14:26,116 MECHANISMS THAT CAN'T BE DONE BY 280 00:14:26,116 --> 00:14:30,487 ANY SINGLE INSTITUTE. 281 00:14:30,487 --> 00:14:34,290 I'LL NOT TALK ABOUT THE 282 00:14:34,290 --> 00:14:36,092 INTERAGENCY COORDINATING 283 00:14:36,092 --> 00:14:38,828 COMMITTEE HELENE SHOULD TALK 284 00:14:38,828 --> 00:14:41,998 ABOUT BECAUSE SHE'S THE CHAIR. 285 00:14:41,998 --> 00:14:47,871 IF I MAKE A MISTAKE JUST GIVE ME 286 00:14:47,871 --> 00:14:53,009 A NUDGE. 287 00:14:53,009 --> 00:14:56,746 FOR HISTORY STAKE THE HHS 288 00:14:56,746 --> 00:15:01,584 SECRETARY IN 2010 THERE WAS A 289 00:15:01,584 --> 00:15:03,219 REPORT THAT CAME OUT IN 2011 AND 290 00:15:03,219 --> 00:15:08,191 MOTIVATED THE DEVELOPMENT OF THE 291 00:15:08,191 --> 00:15:10,160 INTERAGENCY PAIN COORDINATING 292 00:15:10,160 --> 00:15:12,462 COMMITTEE A COMMITTEE THAT 293 00:15:12,462 --> 00:15:14,798 REPORTS TO HHS AND THEY HAVE 294 00:15:14,798 --> 00:15:18,334 DONE SUPERB WORK OVER THE YEARS 295 00:15:18,334 --> 00:15:20,403 RIGHT FROM THE BEGINNING THEY 296 00:15:20,403 --> 00:15:23,173 WORKED HARD ON A NATIONAL PAIN 297 00:15:23,173 --> 00:15:24,808 STRATEGY AND FEDERAL PAIN 298 00:15:24,808 --> 00:15:26,042 RESEARCH STRATEGY WHICH IS IF 299 00:15:26,042 --> 00:15:30,380 YOU HAVEN'T READ IT, IT'S WORTH 300 00:15:30,380 --> 00:15:30,780 READING. 301 00:15:30,780 --> 00:15:36,519 I DON'T SAY THAT A LOT ABOUT A 302 00:15:36,519 --> 00:15:41,024 LOT OF FEDERAL DOCUMENTS BUT IT 303 00:15:41,024 --> 00:15:44,260 POINTS OUT IN PAIN RESEARCH AND 304 00:15:44,260 --> 00:15:45,428 IT HAS INFLUENCED WHAT WE'VE 305 00:15:45,428 --> 00:15:53,002 DONE IN HEAL. 306 00:15:53,002 --> 00:15:56,439 THE IPRCC IS BRINGING IN NEW 307 00:15:56,439 --> 00:15:59,742 MEMBERS AND ESTABLISHED WORKING 308 00:15:59,742 --> 00:16:04,280 GROUPS TO LOOK TO HOW WE BETTER 309 00:16:04,280 --> 00:16:06,649 TAKE DEEP DIVES TO ADVANCED PAIN 310 00:16:06,649 --> 00:16:09,986 RESEARCH AND CARE AND LOOKING AT 311 00:16:09,986 --> 00:16:15,625 A LANDSCAPE OF EDUCATIONAL 312 00:16:15,625 --> 00:16:16,426 CRITERIA AND RESOURCES FOR PAIN 313 00:16:16,426 --> 00:16:26,603 TRAINING. 314 00:16:34,477 --> 00:16:35,945 IN COLLABORATION WITH UNIVERSITY 315 00:16:35,945 --> 00:16:38,515 OF MICHIGAN THEY'RE USING 316 00:16:38,515 --> 00:16:41,017 MACHINE LEARNING TECHNIQUE TO 317 00:16:41,017 --> 00:16:45,021 LOOKING AT PAIN GRAPHS AND 318 00:16:45,021 --> 00:16:46,322 MATCHING THEM TO THE FEDERAL 319 00:16:46,322 --> 00:16:49,959 PAIN RESEARCH STRATEGY 320 00:16:49,959 --> 00:16:54,964 PRIORITIES TO HELP IN THE HEAL 321 00:16:54,964 --> 00:17:01,337 STRATEGIC PLANNING AND MANY HAVE 322 00:17:01,337 --> 00:17:03,106 BEEN DEVELOPED AND PAIN RESEARCH 323 00:17:03,106 --> 00:17:05,808 NETWORK AND WE HAVEN'T FINISHED. 324 00:17:05,808 --> 00:17:12,048 WE HAVE WORK TO DO. 325 00:17:12,048 --> 00:17:13,816 UNDERSTAND PLASTICITY MECHANISM 326 00:17:13,816 --> 00:17:16,786 AND WORKING ON PERSISTENT PAIN. 327 00:17:16,786 --> 00:17:21,024 I THINK HELENE MENTIONED MANY 328 00:17:21,024 --> 00:17:23,059 TIMES WE HAVE TO STOP THINKING 329 00:17:23,059 --> 00:17:28,064 ABOUT THE RESOLUTION SIDE AND 330 00:17:28,064 --> 00:17:28,998 SUSTAIN WITHOUT CHRONIC PAIN AND 331 00:17:28,998 --> 00:17:31,701 DEVELOP SAFER OPIOIDS. 332 00:17:31,701 --> 00:17:37,006 WE'RE WORKING HARD ON DEVELOPING 333 00:17:37,006 --> 00:17:40,276 NEW NON-OPIOID ANALGESIC AND 334 00:17:40,276 --> 00:17:43,146 UNDERSTAND COMORBIDITIES AND 335 00:17:43,146 --> 00:17:45,014 CHRONIC PAIN, A VERY DIFFICULT 336 00:17:45,014 --> 00:17:47,884 PROBLEM, APPROACHES TO PRECISION 337 00:17:47,884 --> 00:17:49,686 MEDICINE TO EFFECTIVELY TREAT 338 00:17:49,686 --> 00:17:54,757 CHRONIC PAIN AND LOOK AT 339 00:17:54,757 --> 00:17:57,160 SUSCEPTIBILITY AND RESILIENCY 340 00:17:57,160 --> 00:18:01,497 FACTORS A LOT IN THAT SPACE AND 341 00:18:01,497 --> 00:18:03,933 MECHANISTIC TRIALS OF RISK AND 342 00:18:03,933 --> 00:18:06,970 RESILIENCE TO CHRONIC PAIN, 343 00:18:06,970 --> 00:18:08,071 DEVELOPING OPTIMAL SAFE AND 344 00:18:08,071 --> 00:18:09,072 CHRONIC PAIN MANAGEMENT 345 00:18:09,072 --> 00:18:11,007 STRATEGIES, TRYING TO IMPROVE 346 00:18:11,007 --> 00:18:12,875 MODELS OF PAIN CARE IN HEALTH 347 00:18:12,875 --> 00:18:15,345 CARE SYSTEMS AND OPTIMAL 348 00:18:15,345 --> 00:18:16,679 APPROACHES FOR MANAGEMENT OF 349 00:18:16,679 --> 00:18:19,015 PAIN AND AT THE BOTTOM IT'S 350 00:18:19,015 --> 00:18:21,017 UNFORTUNATE IT'S AT THE BOTTOM 351 00:18:21,017 --> 00:18:24,287 AND WE'RE MAKING A BIG STRIDE TO 352 00:18:24,287 --> 00:18:28,758 WORK IN PAIN WITH THE KIDS PAIN 353 00:18:28,758 --> 00:18:32,962 HEAL PROGRAM. 354 00:18:32,962 --> 00:18:37,000 SOMETHING THAT WE SHOULD I'M A 355 00:18:37,000 --> 00:18:39,168 LITTLE ASHAMED IT'S AT THE 356 00:18:39,168 --> 00:18:41,771 BOTTOM BUT WE'LL BE APPROACHING 357 00:18:41,771 --> 00:18:45,008 IT NOW WITH THE KIDS PAIN 358 00:18:45,008 --> 00:18:51,714 PROGRAM OUT OF NICHP. 359 00:18:51,714 --> 00:18:53,283 JUST A COUPLE INTERESTING POINTS 360 00:18:53,283 --> 00:18:59,188 TO MAKE ABOUT WHAT'S GONE ON. 361 00:18:59,188 --> 00:19:00,990 THERE WAS THE INTERNATIONAL 362 00:19:00,990 --> 00:19:03,359 WORLD CONGRESS OF PAIN TOOK 363 00:19:03,359 --> 00:19:05,595 PLACE IN THE NETHERLANDS AND 364 00:19:05,595 --> 00:19:10,300 THERE WAS AN INTERESTING SET OF 365 00:19:10,300 --> 00:19:14,904 TAUKSZ BY JANE BALLANTINE AND 366 00:19:14,904 --> 00:19:20,677 ALLAN BASBAUM AND LEARNED ABOUT 367 00:19:20,677 --> 00:19:24,013 THE DIFFERENCE OF THE TWO SIDES 368 00:19:24,013 --> 00:19:34,524 AND ALLAN, YOU'RE BOTH RIGHT. 369 00:19:42,899 --> 00:19:45,935 HELENE GAVE A GREAT TALK ABOUT 370 00:19:45,935 --> 00:19:46,803 WHOLE PERSON PERSPECTIVES AND 371 00:19:46,803 --> 00:19:50,239 THAT WAS GREAT TO SEE AT AN 372 00:19:50,239 --> 00:19:50,973 INTERNATIONAL MEETING AND A 373 00:19:50,973 --> 00:19:51,874 STRATEGIC PLANNING UPDATE. 374 00:19:51,874 --> 00:19:57,480 WE MENTIONED WE'RE BEGINNING OUR 375 00:19:57,480 --> 00:20:03,052 WORK TO DEVELOP A HEAL PAIN 376 00:20:03,052 --> 00:20:06,789 STRATEGIC PLAN AND GRATEFUL TO 377 00:20:06,789 --> 00:20:08,991 CO-CHAIRS AND WE HAVE A NUMBER 378 00:20:08,991 --> 00:20:17,200 OF MEMBERS OF THE WORKING GROUP 379 00:20:17,200 --> 00:20:22,905 WHO ARE WORKING TOGETHER IN THE 380 00:20:22,905 --> 00:20:28,277 AREAS OF PAIN AND AND DOING DEEP 381 00:20:28,277 --> 00:20:36,386 DIVES IN PARTICULAR AREAS. 382 00:20:36,386 --> 00:20:40,189 LIVED EXPERIENCE AND HEALTH 383 00:20:40,189 --> 00:20:42,191 EQUITY AND NON-ADDICTIVE 384 00:20:42,191 --> 00:20:44,193 THERAPEUTIC DEVELOPMENT AND 385 00:20:44,193 --> 00:20:47,196 OPTIMIZATION OF INTERVENTION TO 386 00:20:47,196 --> 00:20:49,932 REDUCE PAIN AND PAIN BIOMARKERS 387 00:20:49,932 --> 00:20:52,368 AND PREDICTORS AND SUBSTANCE USE 388 00:20:52,368 --> 00:20:54,670 DISORDER, PAIN RESEARCH AND 389 00:20:54,670 --> 00:20:55,605 COURSE IN TRAINING AND 390 00:20:55,605 --> 00:20:58,574 IMPLEMENTATION OF HEALTH 391 00:20:58,574 --> 00:20:59,475 SERVICES. 392 00:20:59,475 --> 00:21:00,543 THERE'S A LOT TO COVER. 393 00:21:00,543 --> 00:21:05,648 A LOT OF THINGS THAT GO ACROSS 394 00:21:05,648 --> 00:21:08,184 THE DIFFERENT GROUPS AND WE'RE 395 00:21:08,184 --> 00:21:10,052 ALWAYS INTERESTED TO GET TO 396 00:21:10,052 --> 00:21:11,854 THINGS THAT ARE IMPORTANT THESE 397 00:21:11,854 --> 00:21:15,224 GROUPS CAN THEN ADDRESS AS THEY 398 00:21:15,224 --> 00:21:18,828 DEVELOP A STRATEGIC PLAN AND 399 00:21:18,828 --> 00:21:20,496 THANKS TO JACKIE WARD FOR DIRECT 400 00:21:20,496 --> 00:21:22,298 BEING AND LEADING THIS GROUP AND 401 00:21:22,298 --> 00:21:26,068 LOOKING FORWARD TO THEIR WORK. 402 00:21:26,068 --> 00:21:28,905 THE WORK GROUPS AND ALSO THE 403 00:21:28,905 --> 00:21:30,273 MEETINGS THAT THEY WOULD BE 404 00:21:30,273 --> 00:21:33,276 HOLDING TOGETHER INPUT FROM THE 405 00:21:33,276 --> 00:21:43,186 COMMUNITY. 406 00:21:43,186 --> 00:21:46,289 I WANTED TO SHOUT OUT TO THE 407 00:21:46,289 --> 00:21:48,458 RESEARCH PRIORITIES THAT CAME 408 00:21:48,458 --> 00:21:56,399 OUT OF THE GROUP, THIS IS NOT 409 00:21:56,399 --> 00:22:02,872 NIH FUNDED THOUGH MICHAEL 410 00:22:02,872 --> 00:22:04,273 OSHINSKY WAS IN THE GROUP AND 411 00:22:04,273 --> 00:22:06,576 IT'S A NICE MODEL TO LOOK AT. 412 00:22:06,576 --> 00:22:08,945 THEY DID A GOOD JOB AT KIND OF 413 00:22:08,945 --> 00:22:10,913 GIVING A COMPREHENSIVE LOOK AT 414 00:22:10,913 --> 00:22:13,015 WHAT THE RESEARCH PRIORITIES ARE 415 00:22:13,015 --> 00:22:17,286 AND THE HEADACHE SPACE AND WE 416 00:22:17,286 --> 00:22:20,723 CONTINUE TO KEEP PLUGGING THESE 417 00:22:20,723 --> 00:22:22,291 PEOPLE AND TELLING THEM THEY'RE 418 00:22:22,291 --> 00:22:31,133 WELCOME IN THE HEAL COMMUNITY. 419 00:22:31,133 --> 00:22:33,302 A COUPLE ADVANCES I WANTED TO 420 00:22:33,302 --> 00:22:35,638 THROW OUT. 421 00:22:35,638 --> 00:22:37,006 I PROBABLY TALKED AD NAUSEAM 422 00:22:37,006 --> 00:22:38,307 ABOUT THE TECHNOLOGY COMING OUT 423 00:22:38,307 --> 00:22:43,012 AND HOW THEY ARE AT MODULATING 424 00:22:43,012 --> 00:22:45,648 CIRCUITS BUT THIS CAME OUT FROM 425 00:22:45,648 --> 00:22:52,288 A GROUP CLEVERLY DESIGNED AN 426 00:22:52,288 --> 00:22:53,789 EXPERIMENTAL MODEL OF PLACEBO 427 00:22:53,789 --> 00:22:54,156 EFFECT. 428 00:22:54,156 --> 00:22:55,791 ONE CAN LOOK AT THE MODEL AND 429 00:22:55,791 --> 00:23:00,897 THEY'RE NOT THE SAME AS WHAT 430 00:23:00,897 --> 00:23:02,632 HUMANS EXPERIENCE AS PLACEBO 431 00:23:02,632 --> 00:23:05,301 EFFECT BUT HAS DEFINITE 432 00:23:05,301 --> 00:23:07,670 SIMILARITIES AND IT AFFECTED THE 433 00:23:07,670 --> 00:23:10,306 BEHAVIOR OF THE ANIMALS AND 434 00:23:10,306 --> 00:23:14,076 RESPONSE TO PAINFUL STIMULUS. 435 00:23:14,076 --> 00:23:17,013 THERE'S A PLACEBO ANALGESIC AND 436 00:23:17,013 --> 00:23:19,315 THEY'LL FIND THAT THIS WAS A 437 00:23:19,315 --> 00:23:29,859 CIRCUIT SET UP IN THE ANTERIOR 438 00:23:30,793 --> 00:23:32,061 CINGULATE CORTEX AND YOU CAN NOW 439 00:23:32,061 --> 00:23:34,263 FIND OUT WHERE IT'S SENDING THE 440 00:23:34,263 --> 00:23:40,303 INPUTS TO AND IT WAS SENDING IT 441 00:23:40,303 --> 00:23:44,607 TO A NUCLEUS IN THE PONS AND 442 00:23:44,607 --> 00:23:52,281 GOING TO THE SIR BELL -- -- 443 00:23:52,281 --> 00:23:55,985 CEREBELLUM AND WE HAVE A CIRCUIT 444 00:23:55,985 --> 00:23:58,287 AMENABLE TOE MANIPULATION 445 00:23:58,287 --> 00:24:02,959 HOPEFULLY TO GET ANALGESIA THAT 446 00:24:02,959 --> 00:24:04,260 DRIVES OFF THE NATURAL PLACEBO 447 00:24:04,260 --> 00:24:05,628 RESPONSE THAT I'M SURE IS THERE 448 00:24:05,628 --> 00:24:06,963 FOR A REASON. 449 00:24:06,963 --> 00:24:10,232 COOL THING IS IT PICKED UP AREAS 450 00:24:10,232 --> 00:24:13,936 IN THE BRAIN NO ONE HAS EVER 451 00:24:13,936 --> 00:24:16,272 EXPECTED HAD TO DO WITH PLACEBO 452 00:24:16,272 --> 00:24:21,010 RESPONSE AND THE CEREBELLUM AND 453 00:24:21,010 --> 00:24:24,780 THE NUCLEUS WAS NOT KNOWN TO BE 454 00:24:24,780 --> 00:24:27,350 A PAIN CIRCUIT. 455 00:24:27,350 --> 00:24:32,588 HEAVY RECEPTORS IN THE PONS AND 456 00:24:32,588 --> 00:24:34,290 NUCLEUS AND THIS AFFECT THE 457 00:24:34,290 --> 00:24:38,361 PLACEBO A LOT BY NALOXONE. 458 00:24:38,361 --> 00:24:42,865 IT'S AN OPIOID RECEPTOR ISSUE 459 00:24:42,865 --> 00:24:45,101 THAT USES THE RECEPTORS TO HELP 460 00:24:45,101 --> 00:24:52,241 TREAT PAIN. 461 00:24:52,241 --> 00:24:55,277 NEXT SLIDE IS AN INTERESTING 462 00:24:55,277 --> 00:24:58,581 LOOK AT PERIPHERAL 463 00:24:58,581 --> 00:24:58,914 SENSITIZATION. 464 00:24:58,914 --> 00:25:08,924 WHAT WAS FOUND LOOKING AT HUMAN 465 00:25:08,924 --> 00:25:10,760 FEMALES VERSUS MALES AND 466 00:25:10,760 --> 00:25:15,131 CORRELATED WITH HUMAN TRG TISSUE 467 00:25:15,131 --> 00:25:18,534 THAT WAS INVESTIGATED AND 468 00:25:18,534 --> 00:25:21,303 PROLACTIN HAS RESPONSE IN THE 469 00:25:21,303 --> 00:25:23,506 DORSAL ROOT GANGLION CAUSING 470 00:25:23,506 --> 00:25:25,007 INCREASED FIRING AND NO RESPONSE 471 00:25:25,007 --> 00:25:30,012 AT ALL IN THE MALES. 472 00:25:30,012 --> 00:25:31,814 SO VERY INTERESTING DICHOTOMY 473 00:25:31,814 --> 00:25:32,014 THERE. 474 00:25:32,014 --> 00:25:40,289 THERE WAS A SIMILAR DICHOTOMY 475 00:25:40,289 --> 00:25:42,358 WITH AREXIN IT CAUSED 476 00:25:42,358 --> 00:25:46,562 STIMULATION IN THE MALES BUT NOT 477 00:25:46,562 --> 00:25:47,029 FEMALES. 478 00:25:47,029 --> 00:25:52,301 SO GETTING AT THESE SEX AT BIRTH 479 00:25:52,301 --> 00:25:57,006 EFFECTS MEDIATED BY THESE 480 00:25:57,006 --> 00:25:59,975 HORMONES COMING OUT OF THE 481 00:25:59,975 --> 00:26:03,212 HYPOTHALAMUS IMPORTANT TO 482 00:26:03,212 --> 00:26:04,280 UNDERSTAND POTENTIALLY A GOOD 483 00:26:04,280 --> 00:26:06,615 WAY OF DEVELOPING NON-ADDICTIVE 484 00:26:06,615 --> 00:26:08,818 PAIN THERAPEUTICS. 485 00:26:08,818 --> 00:26:18,594 FINALLY, I WANTED TO LOOK AT A 486 00:26:18,594 --> 00:26:21,030 GROUP AND PEOPLE KNOW WHEN 487 00:26:21,030 --> 00:26:22,665 SENSITIZATION OCCURS AND THE 488 00:26:22,665 --> 00:26:26,302 PAIN SYSTEM PERIPHERALLY IS MORE 489 00:26:26,302 --> 00:26:28,504 RESPONSIVE TO A PAINFUL STIMULUS 490 00:26:28,504 --> 00:26:33,008 THAN NORMAL IT OCCURS BECAUSE 491 00:26:33,008 --> 00:26:36,345 STIMULATION SETS UP PROTEIN 492 00:26:36,345 --> 00:26:40,082 SYNTHESIS AND THIS IS HEAVILY 493 00:26:40,082 --> 00:26:43,886 RELIANT UPON THE PRODUCTION OF 494 00:26:43,886 --> 00:26:44,954 IL6 DURING THAT PAIN STIMULUS 495 00:26:44,954 --> 00:26:47,757 AND THIS GROUP WAS ABLE TO SHOW 496 00:26:47,757 --> 00:26:53,662 THE IL6 IS WORKING THROUGH A 497 00:26:53,662 --> 00:26:55,698 PARTICULAR PATHWAY AGAIN NAILING 498 00:26:55,698 --> 00:26:59,435 DOWN WHICH COULD BE A PATHWAY TO 499 00:26:59,435 --> 00:27:02,071 DEVELOP NON-ADDICTIVE 500 00:27:02,071 --> 00:27:02,738 THERAPEUTICS GOING FORWARD BY 501 00:27:02,738 --> 00:27:05,107 BLOCKING SPECIFICALLY THIS 502 00:27:05,107 --> 00:27:09,845 PATHWAY WHICH LEADS TO THE 503 00:27:09,845 --> 00:27:10,346 INCREASED SENSITIZATION 504 00:27:10,346 --> 00:27:17,887 PERIPHERALLY. 505 00:27:17,887 --> 00:27:22,725 I WANT TO END BY SAY ANYTHING IN 506 00:27:22,725 --> 00:27:24,994 TERMS OF THE HUMAN TISSUE, WORK 507 00:27:24,994 --> 00:27:26,328 IS REALLY GOING QUITE WELL. 508 00:27:26,328 --> 00:27:28,564 IT WAS SOMETHING I WAS QUITE 509 00:27:28,564 --> 00:27:30,065 SURPRISED WE COULD PULL OFF. 510 00:27:30,065 --> 00:27:33,402 AS I MENTIONED FROM THE PREVIOUS 511 00:27:33,402 --> 00:27:35,704 COUPLE SLIDES ABOUT HOW VALUABLE 512 00:27:35,704 --> 00:27:38,707 HAVING THIS HUMAN DRG TISSUE IS 513 00:27:38,707 --> 00:27:41,811 AND OUR NETWORK AND U-19 CENTERS 514 00:27:41,811 --> 00:27:45,381 BRING HUMAN TISSUE INTO THE HEAL 515 00:27:45,381 --> 00:27:49,018 NETWORK FOR STUDYING PAIN IS 516 00:27:49,018 --> 00:27:57,393 REALLY WORKING. 517 00:27:57,393 --> 00:27:59,762 AND THE HEAL THERAPEUTIC 518 00:27:59,762 --> 00:28:00,996 DEVELOPMENT PROGRAM ALSO A 519 00:28:00,996 --> 00:28:03,332 NUMBER OF SUCCESSES WITH TWO 520 00:28:03,332 --> 00:28:10,272 INDs FILED THIS YEAR AND ONE IS 521 00:28:10,272 --> 00:28:12,908 LICENSE FROM DANA FARBER THE 522 00:28:12,908 --> 00:28:15,811 PROGRAM TO START FROM WHAT THE 523 00:28:15,811 --> 00:28:16,879 ASSET IS TO MOVE THROUGH THE 524 00:28:16,879 --> 00:28:25,221 STAGES TO GET THE IND. 525 00:28:25,221 --> 00:28:27,189 WE HAVE ANOTHER CLINICAL TRIALS 526 00:28:27,189 --> 00:28:29,692 STARTED FOUR OR FIVE YEARS AGO 527 00:28:29,692 --> 00:28:31,727 WHICH I THINK THE RESULTS ARE 528 00:28:31,727 --> 00:28:38,300 GOING TO HAVE A BIG EFFECT ON 529 00:28:38,300 --> 00:28:41,070 THE TREATMENT OF PAIN IN THE 530 00:28:41,070 --> 00:28:44,740 COMMUNITY AND WE'RE LOOKING 531 00:28:44,740 --> 00:28:45,708 FORWARD TO RESULTS. 532 00:28:45,708 --> 00:28:50,779 SOME ARE CLOSE TO FINISHING 533 00:28:50,779 --> 00:28:55,284 ENROLLMENT IS KEEP YOUR EYES OUT 534 00:28:55,284 --> 00:28:57,019 FOR THE PAPERS COMING OUT AND 535 00:28:57,019 --> 00:29:00,623 LOOKING FORWARD TO THE STUDIES 536 00:29:00,623 --> 00:29:04,293 AND WE NEED TO START UP A WHOLE 537 00:29:04,293 --> 00:29:09,031 NEW SET OF CLINICAL TRIALS AS 538 00:29:09,031 --> 00:29:19,408 THESE COME TO AN END. 539 00:29:20,142 --> 00:29:25,214 IN TERMS OF THE NEW NOFOs WITH 540 00:29:25,214 --> 00:29:25,848 COORDINATING HEALTH CARE SYSTEMS 541 00:29:25,848 --> 00:29:28,550 AND THIS IS CENTRAL TO OUR 542 00:29:28,550 --> 00:29:30,352 SUCCESS TRYING TO DO THE 543 00:29:30,352 --> 00:29:32,454 RESEARCH THAT WILL INFLUENCE AND 544 00:29:32,454 --> 00:29:34,189 TAKE UP BETTER PAIN MANAGEMENT 545 00:29:34,189 --> 00:29:36,792 TO HEALTH CARE SYSTEMS BECAUSE 546 00:29:36,792 --> 00:29:39,061 THEY SEE IT PROVIDES BETTER 547 00:29:39,061 --> 00:29:41,330 OUTCOMES FOR THEIR PATIENTS AND 548 00:29:41,330 --> 00:29:43,532 HOPEFULLY THEY CAN SEE IT'S 549 00:29:43,532 --> 00:29:44,466 WORTH THE INVESTMENT. 550 00:29:44,466 --> 00:29:46,435 MAY SAVE THE MONEY IN SOME 551 00:29:46,435 --> 00:29:51,373 INSTANCES IF THEY HAVE A MUCH 552 00:29:51,373 --> 00:29:52,808 MORE SYSTEMATIC APPROACH TO PAIN 553 00:29:52,808 --> 00:30:00,482 IN THE HEALTH CARE SYSTEMS. 554 00:30:00,482 --> 00:30:02,985 AND NEW FUNDING OPPORTUNITIES IN 555 00:30:02,985 --> 00:30:04,820 THE TRAINING SPACE. 556 00:30:04,820 --> 00:30:06,355 I MENTION THE HEAL KIDS PROGRAM 557 00:30:06,355 --> 00:30:10,292 IS OUT THERE TO BE LAUNCHED AND 558 00:30:10,292 --> 00:30:15,130 ALSO AN INTERACTIVE BACK PAIN 559 00:30:15,130 --> 00:30:17,032 TEAM IS OUT THERE THE NEW HEAL 560 00:30:17,032 --> 00:30:21,270 FUNDING OPPORTUNITIES. 561 00:30:21,270 --> 00:30:25,307 AND WITH THAT, I WANT TO THANK 562 00:30:25,307 --> 00:30:25,641 YOU. 563 00:30:25,641 --> 00:30:27,810 THAT'S THE REPORT FROM THE PAIN 564 00:30:27,810 --> 00:30:28,010 SIDE. 565 00:30:28,010 --> 00:30:30,279 DO WE HAVE TIME FOR QUESTIONS? 566 00:30:30,279 --> 00:30:32,247 >> I THINK WE SHOULD MOVE OVER 567 00:30:32,247 --> 00:30:32,982 AND WE'LL HAVE TIME FOR 568 00:30:32,982 --> 00:30:36,285 DISCUSSION AFTER. 569 00:30:36,285 --> 00:30:38,153 >> VERY GOOD. 570 00:30:38,153 --> 00:30:41,423 CARLOS, WOULD YOU LIKE TO -- 571 00:30:41,423 --> 00:30:45,094 >> LINDSEY'S NEXT. 572 00:30:45,094 --> 00:30:47,863 >> SORRY. 573 00:30:47,863 --> 00:30:50,132 >> ACTUALLY, I'LL BE SHARING MY 574 00:30:50,132 --> 00:30:52,301 SLIDES SO IF YOU GUYS CAN STOP 575 00:30:52,301 --> 00:31:02,444 SHARING. 576 00:31:09,618 --> 00:31:11,720 CAN YOU SEE MY SLIDES OKAY? 577 00:31:11,720 --> 00:31:12,087 >> YES. 578 00:31:12,087 --> 00:31:12,855 >> GREAT. 579 00:31:12,855 --> 00:31:14,723 >> AND CAMERA OKAY? 580 00:31:14,723 --> 00:31:15,057 >> YES. 581 00:31:15,057 --> 00:31:17,126 >> ALL RIGHT, THANK YOU VERY 582 00:31:17,126 --> 00:31:17,326 MUCH. 583 00:31:17,326 --> 00:31:18,727 IT'S A PLEASURE TO BE TO BE 584 00:31:18,727 --> 00:31:22,131 MEETING WITH YOU ALL TODAY AND 585 00:31:22,131 --> 00:31:23,298 TALK ABOUT NIAMS' VISION FOR 586 00:31:23,298 --> 00:31:23,699 PAIN RESEARCH. 587 00:31:23,699 --> 00:31:28,303 THANK YOU, WALTER FOR THE GREAT 588 00:31:28,303 --> 00:31:30,239 OVERVIEW OF WHERE WE ARE IN 589 00:31:30,239 --> 00:31:30,472 HEAL. 590 00:31:30,472 --> 00:31:34,877 NIAMS IS VERY SUPPORTIVE AND 591 00:31:34,877 --> 00:31:35,310 GRATEFUL. 592 00:31:35,310 --> 00:31:38,480 I'LL COVER FOUR AREAS. 593 00:31:38,480 --> 00:31:41,417 A BRIEF REMINDER OF NIAMS' ROLE 594 00:31:41,417 --> 00:31:44,386 IN THE HEAL ECO SPHERE AND 595 00:31:44,386 --> 00:31:48,490 PROGRAMS SUPPORTED BY NIAMS, 596 00:31:48,490 --> 00:31:50,392 ADVANCEMENT IN RELEVANT PROGRAMS 597 00:31:50,392 --> 00:31:52,261 RELATED TO PAIN AND WHAT WE'RE 598 00:31:52,261 --> 00:31:53,028 ENVISIONING FOR THE FUTURE OF 599 00:31:53,028 --> 00:31:54,963 PAIN RESEARCH. 600 00:31:54,963 --> 00:31:58,934 SO WITHIN THE BROAD HEAL 601 00:31:58,934 --> 00:32:00,669 INITIATIVE NIAMS IS FOCUSSED IN 602 00:32:00,669 --> 00:32:02,504 RESEARCH IN CHRONIC PAIN. 603 00:32:02,504 --> 00:32:04,306 PAIN IS AN IMPORTANT TOPIC IN 604 00:32:04,306 --> 00:32:14,850 MANY DISEASES WITH OUR MISSION. 605 00:32:17,619 --> 00:32:19,054 NIAMS SUPPORTS THE PAIN 606 00:32:19,054 --> 00:32:20,989 CONSORTIUM FINDING THE 607 00:32:20,989 --> 00:32:23,258 INNERVATION OF TISSUES BY 608 00:32:23,258 --> 00:32:25,094 SENSORY NEURONS THAT MEDIATE THE 609 00:32:25,094 --> 00:32:27,930 SENSATION OF PAIN AND SUPPORTING 610 00:32:27,930 --> 00:32:30,332 THE BACK PAIN CONSORTIUM YOU'RE 611 00:32:30,332 --> 00:32:31,800 PROBABLY FAMILIAR WITH TO 612 00:32:31,800 --> 00:32:33,669 DISCOVER THE MECHANISMS OF 613 00:32:33,669 --> 00:32:35,070 CHRONIC LOW BACK PAIN AND 614 00:32:35,070 --> 00:32:39,475 IDENTIFY AND TEST NEW TARGETED 615 00:32:39,475 --> 00:32:39,808 INTERVENTIONS. 616 00:32:39,808 --> 00:32:41,376 THESE ARE TWO EXAMPLES HOW IT 617 00:32:41,376 --> 00:32:42,544 BROUGHT TOGETHER INSTITUTES AND 618 00:32:42,544 --> 00:32:44,847 CENTERS TO TACKLE CHRONIC PAIN. 619 00:32:44,847 --> 00:32:49,184 SO MORE SPECIFICALLY THE REJOIN 620 00:32:49,184 --> 00:32:51,320 CONSORTIUM AIMS TO UNDERSTAND 621 00:32:51,320 --> 00:32:52,754 HOW SENSORY PATTERN NETWORKS 622 00:32:52,754 --> 00:32:53,956 CHANGE WITH DISEASE AND AGING. 623 00:32:53,956 --> 00:32:57,726 FIVE PROJECTS WERE AWARDED IN 624 00:32:57,726 --> 00:33:01,763 2023 TOTALLING ABOUT $31 MILLION 625 00:33:01,763 --> 00:33:05,534 AND FOCUSSING ON INNERVATION 626 00:33:05,534 --> 00:33:07,803 MAPPING AND MAPPING WITHIN 627 00:33:07,803 --> 00:33:10,272 ANIMALS AND HUMANS. 628 00:33:10,272 --> 00:33:12,374 REJOIN IS HARMONIZING DATA 629 00:33:12,374 --> 00:33:15,477 COLLECTION ACROSS THE SITES AND 630 00:33:15,477 --> 00:33:18,347 STUDY MODELS AND BROADLY SHARING 631 00:33:18,347 --> 00:33:20,182 RESEARCH METHODS ACROSS TRE 632 00:33:20,182 --> 00:33:21,016 CONSORTIUM. 633 00:33:21,016 --> 00:33:23,085 THESE RESEARCH TEAMS HAVE 634 00:33:23,085 --> 00:33:24,820 ALREADY DEVELOPED EXCITING NOVEL 635 00:33:24,820 --> 00:33:28,157 APPROACHES TO THREE DIMENSIONAL 636 00:33:28,157 --> 00:33:34,062 MAPPING OF JOINT INTERVENTION 637 00:33:34,062 --> 00:33:36,265 SUCH AS MICROSCOPY AND THE 638 00:33:36,265 --> 00:33:37,966 TRANSCRIPTION OF PROFILES OF 639 00:33:37,966 --> 00:33:44,006 CELLS THAT PLAY A ROLE IN JOINT 640 00:33:44,006 --> 00:33:47,809 PAIN CONDITIONS AND WAS IN THE 641 00:33:47,809 --> 00:33:52,281 PREPRINT STAGE. 642 00:33:52,281 --> 00:33:55,551 BACKPACK HAS 13 AWARDS TOTALLING 643 00:33:55,551 --> 00:33:57,653 APPROXIMATELY $131 MILLION. 644 00:33:57,653 --> 00:33:59,955 AT THE BASIC RESEARCH LEVEL, 645 00:33:59,955 --> 00:34:02,958 BACKPACK HAS DEVELOPED AN 646 00:34:02,958 --> 00:34:03,959 INTEGRATIVE MODEL OF BACK PAIN 647 00:34:03,959 --> 00:34:07,596 BASED ON IMPROVED UNDERSTANDING 648 00:34:07,596 --> 00:34:08,163 OF MECHANISMS. 649 00:34:08,163 --> 00:34:10,299 THIS MODEL IS CONTINUING TO BE 650 00:34:10,299 --> 00:34:13,569 REFINED AND SHOULD NEED TO NEW 651 00:34:13,569 --> 00:34:14,369 THERAPIES. 652 00:34:14,369 --> 00:34:18,173 AT THE TRANSLATIONAL LEVEL 653 00:34:18,173 --> 00:34:20,475 BACKPACK HAS NEW THERAPIES INTO 654 00:34:20,475 --> 00:34:21,944 MULTI-MODAL INTERVENTIONS 655 00:34:21,944 --> 00:34:28,984 CREATING COHORTS WITH DEEP 656 00:34:28,984 --> 00:34:31,086 PHENOTYPING AND CREATING 657 00:34:31,086 --> 00:34:32,087 ALGORITHMS TO MATCH EACH PAYMENT 658 00:34:32,087 --> 00:34:34,389 TO THE BEST TREATMENT BASED ON 659 00:34:34,389 --> 00:34:35,457 THEIR SPECIFIC PHENOTYPE AND 660 00:34:35,457 --> 00:34:37,993 PSYCHOSOCIAL CONTEXT. 661 00:34:37,993 --> 00:34:40,295 WE ARE VERY PLEASED WITH THE 662 00:34:40,295 --> 00:34:41,563 PROGRESS OF BACKPACK INCLUDING 663 00:34:41,563 --> 00:34:43,432 THE RECENT PRODUCTION OF A LARGE 664 00:34:43,432 --> 00:34:45,000 PUBLICATION PACKAGE AT THE END 665 00:34:45,000 --> 00:34:48,937 OF LAST YEAR THAT OUTLINES 666 00:34:48,937 --> 00:34:50,906 GOALS, STRUCTURES AND AR 667 00:34:50,906 --> 00:34:53,875 MONIZATION EFFORTS WITHIN THE 668 00:34:53,875 --> 00:34:54,476 CONSORTIUM INCLUDING IN 669 00:34:54,476 --> 00:34:57,179 PREPARATION OF HEAL DATA 670 00:34:57,179 --> 00:34:59,715 ELEMENTS. 671 00:34:59,715 --> 00:35:03,418 AND ANALYZING LARGE AMOUNTS OF 672 00:35:03,418 --> 00:35:05,254 DATA AND ALL STUDIES ARE FULLY 673 00:35:05,254 --> 00:35:07,322 ENROLLED OR COMPLETING. 674 00:35:07,322 --> 00:35:08,490 INVESTIGATORS ARE LEARNING HOW 675 00:35:08,490 --> 00:35:11,026 TO LEVERAGE NEW TECHNOLOGIES 676 00:35:11,026 --> 00:35:13,929 WITH DATA COLLECTED TO UNCOVER 677 00:35:13,929 --> 00:35:17,232 RELATIONSHIPS BETWEEN BIO 678 00:35:17,232 --> 00:35:21,003 MECHANICS AND OTHER METRICS USED 679 00:35:21,003 --> 00:35:25,240 TO CHARACTERIZE LOW BACK PAIN. 680 00:35:25,240 --> 00:35:28,143 AND THERE'S BIOMARKERS FOR 681 00:35:28,143 --> 00:35:29,511 EVALUATING SPINE TREATMENTS OR 682 00:35:29,511 --> 00:35:30,379 THE BEST TRIAL. 683 00:35:30,379 --> 00:35:32,981 THIS FOUR-ARMED TRIAL IS DESIGN 684 00:35:32,981 --> 00:35:35,517 TO ESTIMATE AN ALGORITHM TO 685 00:35:35,517 --> 00:35:38,520 ASSIGN THE SEQUENCE OF TWO 686 00:35:38,520 --> 00:35:40,289 TREATMENTS FOR BACK PAIN BASED 687 00:35:40,289 --> 00:35:43,558 ON A PATIENT'S PHENOTYPIC 688 00:35:43,558 --> 00:35:43,792 MARKERS. 689 00:35:43,792 --> 00:35:45,460 THIS EXPLORED FOUR INTERVENTIONS 690 00:35:45,460 --> 00:35:48,497 THAT HAVE ALL SHOWN SOME 691 00:35:48,497 --> 00:35:49,598 EFFECTIVENESS FOR CHRONIC LOW 692 00:35:49,598 --> 00:35:51,767 BACK PAIN AND ENHANCED BACK PAIR 693 00:35:51,767 --> 00:35:56,838 AND ACCEPTANCE AND COMMITMENT 694 00:35:56,838 --> 00:35:58,206 THERAPY, EVIDENCE BASED EXERCISE 695 00:35:58,206 --> 00:36:06,014 AND THERAPY AND DULOXETINE AND 696 00:36:06,014 --> 00:36:10,285 IS LOOKING AT WHICH IS BEST FOR 697 00:36:10,285 --> 00:36:13,355 EACH PATIENT VERSUS AVERAGE 698 00:36:13,355 --> 00:36:13,922 EFFECT. 699 00:36:13,922 --> 00:36:16,825 AND FOLLOWING THE ASSIGNMENT 700 00:36:16,825 --> 00:36:18,060 RANDOMIZED TRIAL OR SMART 701 00:36:18,060 --> 00:36:19,995 DESIGN, ALL PARTICIPANTS ARE 702 00:36:19,995 --> 00:36:21,296 INITIALLY RANDOMIZED TO ONE OF 703 00:36:21,296 --> 00:36:25,200 THE FOUR TREATMENTS FOR THE 704 00:36:25,200 --> 00:36:26,902 FIRST PERIOD. 705 00:36:26,902 --> 00:36:27,736 THE TREATMENT DURING THE SECOND 706 00:36:27,736 --> 00:36:29,805 PERIOD DEPENDS ON THEIR RESPONSE 707 00:36:29,805 --> 00:36:30,639 TO THE INITIAL TREATMENT. 708 00:36:30,639 --> 00:36:32,240 FOR EXAMPLE, IF THE FIRST 709 00:36:32,240 --> 00:36:34,176 TREATMENT IS IMPROVING PAIN AND 710 00:36:34,176 --> 00:36:35,811 QUALITY OF LIFE THEN IT'S 711 00:36:35,811 --> 00:36:37,245 MAINTAINED DURING THE SECOND 712 00:36:37,245 --> 00:36:38,313 TREATMENT PERIOD. 713 00:36:38,313 --> 00:36:39,715 IF THE TREATMENT IS IMPROVING 714 00:36:39,715 --> 00:36:41,316 PAIN BUT NOT OVER ALL QUALITY OF 715 00:36:41,316 --> 00:36:42,584 LIFE IT'S AUGMENTED WITH THE 716 00:36:42,584 --> 00:36:43,251 SECOND TREATMENT. 717 00:36:43,251 --> 00:36:45,454 IF THE TREATMENT APPEARS TO HAVE 718 00:36:45,454 --> 00:36:46,922 NO EFFECT, THEN THE PARTICIPANT 719 00:36:46,922 --> 00:36:48,724 IS RANDOMIZED TO HAVE A SECOND 720 00:36:48,724 --> 00:36:51,259 TREATMENT EITHER ADDED TO OR 721 00:36:51,259 --> 00:36:52,027 REPLACING THE FIRST TREATMENT 722 00:36:52,027 --> 00:36:54,763 AND THEN IF THE TREATMENT IS 723 00:36:54,763 --> 00:36:56,965 MAKING PAIN WORSE, THAT 724 00:36:56,965 --> 00:36:57,866 TREATMENT IS DISCONTINUED AND 725 00:36:57,866 --> 00:36:59,000 REPLACED BY A NEW TREATMENT. 726 00:36:59,000 --> 00:37:01,069 SO THE TRIAL IS NOW FULLY 727 00:37:01,069 --> 00:37:02,304 ENROLLED AND NEARLY COMPLETE 728 00:37:02,304 --> 00:37:08,677 WITH ONLY A HANDFUL OF THE 24 729 00:37:08,677 --> 00:37:17,619 VISITS THE PRIMARY END POINT. 730 00:37:17,619 --> 00:37:18,687 AS YOU MAY KNOW THERE ARE 731 00:37:18,687 --> 00:37:20,989 SEVERAL UPCOMING OR RECENTLY 732 00:37:20,989 --> 00:37:22,290 ANNOUNCED NEW PROGRAMS SUCH AS 733 00:37:22,290 --> 00:37:24,326 HEAL INTERACT AND WE'RE 734 00:37:24,326 --> 00:37:24,993 DELIGHTED TO BE LEADING THIS 735 00:37:24,993 --> 00:37:30,866 NOTICE OF FUNDING OPPORTUNITY OR 736 00:37:30,866 --> 00:37:33,969 NOFO THAT AIMS TO BUILD UPON THE 737 00:37:33,969 --> 00:37:36,605 ORIGINAL PHASE AND CONTINUE THE 738 00:37:36,605 --> 00:37:37,739 DIAGNOSIS AND TREATMENT OF 739 00:37:37,739 --> 00:37:39,441 CHRONIC LOW BACK PAIN AND THE 740 00:37:39,441 --> 00:37:41,910 TEAMS WILL DEVELOP INTEGRATIVE 741 00:37:41,910 --> 00:37:44,379 MODELS FOR UNDERSTANDING 742 00:37:44,379 --> 00:37:45,046 MULTI-DIMENSIONAL, 743 00:37:45,046 --> 00:37:46,848 MULTI-MODALITY DATA AND ANALYSES 744 00:37:46,848 --> 00:37:48,917 OF THE INTERRELATIONSHIPS WEN 745 00:37:48,917 --> 00:37:50,485 THE VARIOUS DATA TYPES. 746 00:37:50,485 --> 00:37:51,887 THEY WILL ALSO INFORM THE 747 00:37:51,887 --> 00:37:56,992 STRUCTURE AND KEY ELEMENTS OF 748 00:37:56,992 --> 00:37:59,561 FUTURE FEDERATED EFFORTS FOR 749 00:37:59,561 --> 00:38:00,429 MUSCULOSKELETAL PAIN EFFORTS. 750 00:38:00,429 --> 00:38:02,864 ONE OF OUR OVER ARCHING GOALS. 751 00:38:02,864 --> 00:38:04,433 APPLICATIONS WILL BE DUE IN 752 00:38:04,433 --> 00:38:06,134 OCTOBER. 753 00:38:06,134 --> 00:38:08,003 WALTER ALSO MENTIONED TOO OUR 754 00:38:08,003 --> 00:38:09,404 VERY IMPORTANT EFFORTS IN 755 00:38:09,404 --> 00:38:10,305 PEDIATRIC PAIN. 756 00:38:10,305 --> 00:38:15,744 SO WE'RE BUILDING UPON THE HEAL 757 00:38:15,744 --> 00:38:18,980 KIDS ACUTE PAIN CLINICAL TRIALS 758 00:38:18,980 --> 00:38:19,748 WITH THE NEW HEAL KIDS CHRONIC 759 00:38:19,748 --> 00:38:21,883 PAIN PROGRAM AONCE NOED IN THE 760 00:38:21,883 --> 00:38:22,651 NOFO LAST MONTH. 761 00:38:22,651 --> 00:38:24,986 WE LOOK FORWARD TO FUNDING 762 00:38:24,986 --> 00:38:27,322 PROGRAMS THAT WILL ENHANCE AND 763 00:38:27,322 --> 00:38:28,990 EXPAND OUR CAPACITY TO PURSUE 764 00:38:28,990 --> 00:38:31,293 THERAPEUTICS DEVELOPMENT AND 765 00:38:31,293 --> 00:38:32,327 EFFECTIVE MANAGEMENT OF CHRONIC 766 00:38:32,327 --> 00:38:33,428 PEDIATRIC PAIN CONDITIONS. 767 00:38:33,428 --> 00:38:36,565 WE EXPECT THE INTERDISCIPLINARY 768 00:38:36,565 --> 00:38:38,500 TEAMS WILL COMBINE CLINICAL 769 00:38:38,500 --> 00:38:40,302 RESEARCH WITH CUTTING EDGE 770 00:38:40,302 --> 00:38:41,369 TECHNOLOGIES AND MEASUREMENT 771 00:38:41,369 --> 00:38:43,104 SCIENCE IN THE COLLABORATIVE AND 772 00:38:43,104 --> 00:38:43,638 INTEGRATIVE WAY. 773 00:38:43,638 --> 00:38:45,006 WE'RE VERY EXCITED ABOUT THIS 774 00:38:45,006 --> 00:38:46,842 PROGRAM. 775 00:38:46,842 --> 00:38:52,147 ALSO ON THE HORIZON, NIAMS IS 776 00:38:52,147 --> 00:38:52,981 PARTICIPATING IN THE PAIN CARE 777 00:38:52,981 --> 00:38:55,917 CLINICIAN TRAINING PROGRAM 778 00:38:55,917 --> 00:38:58,920 ANNOUNCED RECENTLY IN A NOFO 779 00:38:58,920 --> 00:39:07,095 THIS PAST JUNE BY SUPPORTING THE 780 00:39:07,095 --> 00:39:08,396 CAREER DEVELOPMENT OF 781 00:39:08,396 --> 00:39:09,798 INDIVIDUALS WITH CLINICAL 782 00:39:09,798 --> 00:39:10,298 DOCTORAL DEGREES. 783 00:39:10,298 --> 00:39:13,368 THIS K23 AWARD IS DESIGNED 784 00:39:13,368 --> 00:39:14,703 SPECIFICALLY FOR APPLICANTS 785 00:39:14,703 --> 00:39:18,240 PROPOSING TO SERVE AS THE LEAD 786 00:39:18,240 --> 00:39:19,774 INVESTIGATOR OF AN INDEPENDENT 787 00:39:19,774 --> 00:39:21,743 CLINICAL TRIAL, A CLINICAL TRIAL 788 00:39:21,743 --> 00:39:25,280 FEASIBILITY STUDY OR SEPARATE 789 00:39:25,280 --> 00:39:27,449 ANCILLARY CLINICAL TRIAL AS PART 790 00:39:27,449 --> 00:39:31,486 OF THEIR OWN CAREER DEVELOPMENT 791 00:39:31,486 --> 00:39:32,254 ACTIVITIES. 792 00:39:32,254 --> 00:39:34,122 SIMILARLY NIAMS SIGNED CALLING 793 00:39:34,122 --> 00:39:37,025 FOR PARTNERSHIP TO ADVANCE 794 00:39:37,025 --> 00:39:39,394 INTERDISCIPLINARY TRAINING IN 795 00:39:39,394 --> 00:39:40,295 CLINICAL PAIN RESEARCH 796 00:39:40,295 --> 00:39:43,098 SUPPORTING T90, R90 797 00:39:43,098 --> 00:39:43,665 INSTITUTIONAL POSTDOCTORAL 798 00:39:43,665 --> 00:39:45,567 TRAINING TO PROMOTE THE NEXT 799 00:39:45,567 --> 00:39:47,669 GENERATION OF INDEPENDENT 800 00:39:47,669 --> 00:39:48,603 CLINICAL RESEARCHERS. 801 00:39:48,603 --> 00:39:50,505 EACH T90, R90 PROGRAM IS 802 00:39:50,505 --> 00:39:52,474 REQUIRED TO PROPOSE A 803 00:39:52,474 --> 00:39:56,545 PARTNERSHIP BETWEEN TWO OR MORE 804 00:39:56,545 --> 00:39:57,646 DEPARTMENTS OR COLLEGES WITHIN A 805 00:39:57,646 --> 00:39:59,481 SINGLE INSTITUTION. 806 00:39:59,481 --> 00:40:01,049 THIS IS NOW CLOSED AND NIH 807 00:40:01,049 --> 00:40:03,018 EXPECTS TO FUND UP TO FOUR 808 00:40:03,018 --> 00:40:06,688 AWARDS DEPENDING ON THE OUTCOME 809 00:40:06,688 --> 00:40:07,923 OF THE REVIEW PANEL. 810 00:40:07,923 --> 00:40:09,357 I WANT TO BRIEFLY HIGHLIGHT 811 00:40:09,357 --> 00:40:12,093 THANKS TO A BUDGET INCREASE FOR 812 00:40:12,093 --> 00:40:14,729 FISCAL 2023, NIAMS WAS ABLE TO 813 00:40:14,729 --> 00:40:17,365 PUBLISH TWO NOTICES OF SPECIAL 814 00:40:17,365 --> 00:40:21,002 INTEREST OR NOSI IN RHEUMATIC 815 00:40:21,002 --> 00:40:25,006 SKIN AND MUSCULOSKELETAL 816 00:40:25,006 --> 00:40:27,475 DISEASES AND ONE WAS TO EXPAND 817 00:40:27,475 --> 00:40:29,010 OR ADD THE RESEARCH ON PAIN AS 818 00:40:29,010 --> 00:40:31,813 IT RELATE TO THE TOPIC OF THE 819 00:40:31,813 --> 00:40:32,981 ORIGINAL APPLICATION AND WE 820 00:40:32,981 --> 00:40:35,050 FUNDED 18 SUPPLEMENTS UNDER THIS 821 00:40:35,050 --> 00:40:35,517 EFFORT. 822 00:40:35,517 --> 00:40:39,020 THE SECOND ONE ULTIMATELY 823 00:40:39,020 --> 00:40:41,423 ENABLED FIVE OF THE T32 TRAINING 824 00:40:41,423 --> 00:40:42,424 PROGRAMS TO PRIORITIZE 825 00:40:42,424 --> 00:40:43,525 UNDERSTANDING THE MECHANISMS, 826 00:40:43,525 --> 00:40:44,092 MEASUREMENT OR TREATMENT OF 827 00:40:44,092 --> 00:40:47,796 PAIN. 828 00:40:47,796 --> 00:40:52,334 NOW, IN RELATION TO PAIN 829 00:40:52,334 --> 00:40:56,171 RESEARCH OSTEOARTHRITIS PRESENCE 830 00:40:56,171 --> 00:41:00,175 A CHALLENGE WITH THE KNEE JOINT 831 00:41:00,175 --> 00:41:00,976 DEGENERATION AND IMPORTANT IS 832 00:41:00,976 --> 00:41:03,578 ADDRESSING PAIN IS THE OF THEO 833 00:41:03,578 --> 00:41:06,781 ARTHRITIS INITIATIVE WHICH IS 834 00:41:06,781 --> 00:41:09,651 DEVELOPED FROM A PUBLIC-PRIVATE 835 00:41:09,651 --> 00:41:10,552 PARTNERSHIP BACK IN 2001. 836 00:41:10,552 --> 00:41:13,622 IT'S ONE OFF THE LARGEST AND 837 00:41:13,622 --> 00:41:18,660 MOST IMPORTANT DATA SETS IN THE 838 00:41:18,660 --> 00:41:22,831 HISTORY OF RESEARCH AND DATA AND 839 00:41:22,831 --> 00:41:25,467 SPECIMENS AND X-RAY AND IMAGES 840 00:41:25,467 --> 00:41:27,268 FROM APPROXIMATELY 4800 841 00:41:27,268 --> 00:41:28,370 PARTICIPANTS WHO EITHER HAD OR 842 00:41:28,370 --> 00:41:32,007 WERE AT HIGH RISK OF DEVELOPING 843 00:41:32,007 --> 00:41:32,173 OAI. 844 00:41:32,173 --> 00:41:34,042 AND ALL THE PARTICIPANT VISITS 845 00:41:34,042 --> 00:41:36,978 THROUGH EIGHT YEARS OF FOLLOW UP 846 00:41:36,978 --> 00:41:39,080 WERE COMPLETED BACK IN 2015. 847 00:41:39,080 --> 00:41:41,416 THE DATA HAS BEEN AND CONTINUED 848 00:41:41,416 --> 00:41:46,321 TO BE FREELY AVAILABLE AT 849 00:41:46,321 --> 00:41:48,990 OAI.NIH.gov AND CAN BE STUDIED 850 00:41:48,990 --> 00:41:51,359 FOR RISK FACTORS FOR EARLY ONSET 851 00:41:51,359 --> 00:41:57,799 AND PROGRESSION AND THE DATA ARE 852 00:41:57,799 --> 00:42:00,268 ALSO A DATA RESOURCE TO APPLY 853 00:42:00,268 --> 00:42:02,003 BIG DATA METHODS TO BIOMEDICAL 854 00:42:02,003 --> 00:42:02,270 RESEARCH. 855 00:42:02,270 --> 00:42:05,373 TO DATE THERE'S BEEN OVER 700 856 00:42:05,373 --> 00:42:06,107 PEER-REVIEWED PAPERS PUBLISHED 857 00:42:06,107 --> 00:42:08,243 WITH THE DATA AND WE'RE EXCITED 858 00:42:08,243 --> 00:42:09,377 TO BE CONTINUING TO SUPPORT THIS 859 00:42:09,377 --> 00:42:17,285 EFFORT THROUGH OUR NOSI. 860 00:42:17,285 --> 00:42:20,555 ON THAT NOTE, THIS NOSI INTENDED 861 00:42:20,555 --> 00:42:24,993 TO FURTHER LEVERAGE THIS 862 00:42:24,993 --> 00:42:27,128 VALUABLE RESOURCE WAS A NIAMS 863 00:42:27,128 --> 00:42:30,331 AND NIA PARTNERSHIP AND INTENDS 864 00:42:30,331 --> 00:42:34,969 TO USE THE RICH DATABASE AS WELL 865 00:42:34,969 --> 00:42:37,605 AS THE CLINICAL DATA AND IMAGES. 866 00:42:37,605 --> 00:42:39,641 WHILE THE RESOURCE HAS BEEN 867 00:42:39,641 --> 00:42:46,347 WIDELY USED AND ACCESSED BY OAI 868 00:42:46,347 --> 00:42:49,451 INVESTIGATORS LOOKING AT 869 00:42:49,451 --> 00:42:52,320 BIOBEHAVIORAL AND OTHER 870 00:42:52,320 --> 00:42:54,289 PHARMACOLOGIC INTERVENTIONS IN 871 00:42:54,289 --> 00:42:55,523 RESPONSE TO OAI 872 00:42:55,523 --> 00:42:57,759 A AND HAPPY THE RESOURCED CAN BE 873 00:42:57,759 --> 00:42:59,227 AVAILABLE TO OTHER INVESTIGATORS 874 00:42:59,227 --> 00:43:02,197 AND ALSO IT CAN SERVE AS A 875 00:43:02,197 --> 00:43:04,332 TRAINING VEHICLE FOR FUTURE 876 00:43:04,332 --> 00:43:06,034 MUSCULOSKELETAL AND PAIN 877 00:43:06,034 --> 00:43:06,334 RESEARCHERS. 878 00:43:06,334 --> 00:43:12,407 SO I WANT TO TAKE A MOMENT TO 879 00:43:12,407 --> 00:43:13,908 DESCRIBE OUR VISION FOR THE 880 00:43:13,908 --> 00:43:15,110 RESEARCH BOTH INSIDE AND OUTSIDE 881 00:43:15,110 --> 00:43:18,446 OF HEAL. 882 00:43:18,446 --> 00:43:24,986 MAINTAINING A WHOLE PERSON 883 00:43:24,986 --> 00:43:28,256 APPROACH AND DEVELOP IN THE 884 00:43:28,256 --> 00:43:30,792 IMPLEMENTATION PROCESSES, 885 00:43:30,792 --> 00:43:31,860 PROMOTING INTERDISCIPLINARY TEAM 886 00:43:31,860 --> 00:43:34,162 SCIENCE IN THE AREA OF PAIN, 887 00:43:34,162 --> 00:43:35,830 ENHANCING OUR DATA 888 00:43:35,830 --> 00:43:36,498 INFRASTRUCTURE AND HARMONIZATION 889 00:43:36,498 --> 00:43:38,600 EFFORTS AND INTEGRATING THE HEAL 890 00:43:38,600 --> 00:43:44,272 PROGRAMS INTO A COMPREHENSIVE 891 00:43:44,272 --> 00:43:44,873 MUSCULOSKELETAL PAIN RESEARCH 892 00:43:44,873 --> 00:43:45,106 NETWORK. 893 00:43:45,106 --> 00:43:49,878 SO AS I MENTIONED, WE HAVE BEEN 894 00:43:49,878 --> 00:43:51,079 PRIORITIZING PAIN RESEARCH WITH 895 00:43:51,079 --> 00:43:53,548 A VISION OF A WHOLE PERSON 896 00:43:53,548 --> 00:43:56,050 APPROACH WHICH ACKNOWLEDGES THAT 897 00:43:56,050 --> 00:43:59,854 PAIN CAN EFFECT EACH PERSON AND 898 00:43:59,854 --> 00:44:00,989 THEIR DAILY LIFE DIFFERENTLY 899 00:44:00,989 --> 00:44:02,323 DEPENDING ON DIFFERENT FACTORS. 900 00:44:02,323 --> 00:44:04,192 ONE EXAMPLE OF A WHOLE PERSON 901 00:44:04,192 --> 00:44:05,994 APPROACH CAN BE FOUND IN THE 902 00:44:05,994 --> 00:44:07,662 BACKPACK PROGRAM WHERE 903 00:44:07,662 --> 00:44:08,463 RESEARCHERS ARE INVESTIGATING 904 00:44:08,463 --> 00:44:10,265 HEALTH INEQUITIES IN THE 905 00:44:10,265 --> 00:44:11,699 MANAGEMENT OF BACK PAIN AND HOW 906 00:44:11,699 --> 00:44:14,402 SOCIAL DETERMINATES OF HEALTH 907 00:44:14,402 --> 00:44:16,371 AND COMORBIDITIES SHAPE A 908 00:44:16,371 --> 00:44:17,338 PERSON'S EXPERIENCE OF PAIN. 909 00:44:17,338 --> 00:44:19,607 PEOPLE WITH LIVED AND LIVING 910 00:44:19,607 --> 00:44:20,275 EXPERIENCES OF CHRONIC PAIN ARE 911 00:44:20,275 --> 00:44:22,844 ALSO INVOLVED THROUGHOUT THE 912 00:44:22,844 --> 00:44:24,312 ENTIRE RESEARCH PROCESS HELPING 913 00:44:24,312 --> 00:44:27,515 TO PLAN A STUDY, IMPLEMENT IT 914 00:44:27,515 --> 00:44:29,284 AND MAKE SURE IT'S CULTURALLY 915 00:44:29,284 --> 00:44:30,118 RELEVANT TO THE INDIVIDUALS 916 00:44:30,118 --> 00:44:30,718 FAMILIES AND COMMUNITIES IT'S 917 00:44:30,718 --> 00:44:34,689 DESIGN TO HELP. 918 00:44:34,689 --> 00:44:35,824 ANOTHER EXAMPLE OF OUR WHOLE 919 00:44:35,824 --> 00:44:37,358 PERSON APPROACH CAN BE SEEN IN 920 00:44:37,358 --> 00:44:38,226 THE REJOIN CONSORTIUM. 921 00:44:38,226 --> 00:44:41,029 AS I REMINDER, THE REJOIN 922 00:44:41,029 --> 00:44:42,330 CONSORTIUM IS SEEKING TO 923 00:44:42,330 --> 00:44:46,701 UNDERSTAND JOINT PAIN AT THE 924 00:44:46,701 --> 00:44:47,735 MOLECULAR LEVEL IDENTIFYING NEW 925 00:44:47,735 --> 00:44:49,737 TARGETS FOR INTERVENTION AND 926 00:44:49,737 --> 00:44:52,006 SEEKS TO UNDERSTAND HOW JOINT 927 00:44:52,006 --> 00:44:54,008 PAIN OCCURS DIFFERENTLY ACROSS 928 00:44:54,008 --> 00:44:55,610 VARIOUS DISEASES AND HOW IT'S 929 00:44:55,610 --> 00:44:57,712 EFFECTED BY AGE AND SEX, FOR 930 00:44:57,712 --> 00:44:59,581 EXAMPLE, WHICH CAN INFORM MORE 931 00:44:59,581 --> 00:45:00,215 PRECISE THERAPEUTIC 932 00:45:00,215 --> 00:45:03,184 INTERVENTIONS. 933 00:45:03,184 --> 00:45:05,620 A LARGE GAP IN PAIN RESEARCH 934 00:45:05,620 --> 00:45:06,955 NIAMS IS TRYING TO ADDRESS IN 935 00:45:06,955 --> 00:45:08,089 HEAL IS UNDERSTANDING THE 936 00:45:08,089 --> 00:45:11,025 DRIVERS OF PAIN AT THE MOLECULAR 937 00:45:11,025 --> 00:45:13,394 AND TISSUE LEVEL AT THE SAME 938 00:45:13,394 --> 00:45:13,928 TIME UNDERSTANDING PAIN 939 00:45:13,928 --> 00:45:16,331 EXPERIENCE OF THE LEVEL OF THE 940 00:45:16,331 --> 00:45:16,998 PERSON. 941 00:45:16,998 --> 00:45:19,100 SO TO ADDRESS THIS CHALLENGE, 942 00:45:19,100 --> 00:45:20,568 NIAMS IS FOCUSSED ON 943 00:45:20,568 --> 00:45:24,205 COLLABORATIVE TEAM SCIENCE 944 00:45:24,205 --> 00:45:26,241 APPROACH TO GENERATE MODELS OF 945 00:45:26,241 --> 00:45:26,708 PAIN. 946 00:45:26,708 --> 00:45:28,276 LISTED ARE EXAMPLES OF SUCH 947 00:45:28,276 --> 00:45:29,978 COLLABORATIVE ACTIVITIES THAT 948 00:45:29,978 --> 00:45:32,680 ARE UNDERWAY THROUGH OUR 949 00:45:32,680 --> 00:45:37,018 INVOLVEMENT OF HEAL, MANY OF 950 00:45:37,018 --> 00:45:38,386 WHICH I TOUCHED ON INCLUDING 951 00:45:38,386 --> 00:45:41,756 PAIN COLLECTION AND PROTOCOLS, 952 00:45:41,756 --> 00:45:42,891 ASSEMBLING WORKING GROUPS AND 953 00:45:42,891 --> 00:45:46,361 DEVELOP A THEORETICAL MODEL OF 954 00:45:46,361 --> 00:45:48,997 CHRONIC LOW BACK PAIN AND TRIALS 955 00:45:48,997 --> 00:45:53,201 LIKE THE BEST TRIAL FROM THE 956 00:45:53,201 --> 00:45:55,570 BACPAC PROGRAM AND INTEGRATING 957 00:45:55,570 --> 00:45:57,572 DATA FROM TEAMS CREATING 3-D 958 00:45:57,572 --> 00:46:02,143 MAPS OF THE SENSORY NEURONS 959 00:46:02,143 --> 00:46:05,647 FOUND IN THE KNEES AND TEMPORO 960 00:46:05,647 --> 00:46:10,852 MANDIBULAR JOINTS AND 961 00:46:10,852 --> 00:46:12,987 INTEGRATING THE COLLECTION OF 962 00:46:12,987 --> 00:46:16,991 EFFORTS AND ACCELERATE THE DATA 963 00:46:16,991 --> 00:46:18,693 AVAILABLE TO RESEARCHERS AND 964 00:46:18,693 --> 00:46:19,928 HEALTH CARE PROVIDERS, COMMUNITY 965 00:46:19,928 --> 00:46:23,531 LEADERS, POLICY MAKERS AND OTHER 966 00:46:23,531 --> 00:46:25,266 PARTNERS TO BENEFIT FROM 967 00:46:25,266 --> 00:46:27,735 LEARNING OF RESULTS OF THE 968 00:46:27,735 --> 00:46:28,036 INITIATIVE. 969 00:46:28,036 --> 00:46:29,837 IT ALLOWS USERS TO ACCESS 970 00:46:29,837 --> 00:46:31,072 FINDINGS FROM DIFFERENT STUDIES 971 00:46:31,072 --> 00:46:34,175 WHICH CAN BE ANALYZED TO COMPARE 972 00:46:34,175 --> 00:46:36,978 AND COMBINE AND THIS TOOL 973 00:46:36,978 --> 00:46:38,546 ENABLES RESEARCHERS TO FOLLOW 974 00:46:38,546 --> 00:46:42,917 THEIR PRINCIPLE MAKING THEIR 975 00:46:42,917 --> 00:46:44,986 HEAL-GENERATED DATA FINDABLE, 976 00:46:44,986 --> 00:46:46,354 INTEROPERABLE AND INTERUSABLE 977 00:46:46,354 --> 00:46:50,325 AND THE INITIATIVE HAS DEVELOPED 978 00:46:50,325 --> 00:46:52,293 THE HEAL SOMANTIC RESEARCH WHICH 979 00:46:52,293 --> 00:46:55,129 IS MEANT TO BE A TOOL TO THE 980 00:46:55,129 --> 00:46:56,130 DATA PLATFORM AND THE SEARCH 981 00:46:56,130 --> 00:46:58,366 TOOL HELPS USERS FIND COMMON 982 00:46:58,366 --> 00:47:01,002 DATA ELEMENTS, RELEVANT HEAL 983 00:47:01,002 --> 00:47:04,005 STUDIES AND VARIABLES RELATED TO 984 00:47:04,005 --> 00:47:05,340 THE SEARCH TERMS AND SEARCH 985 00:47:05,340 --> 00:47:06,174 RESULTS OF INTEREST. 986 00:47:06,174 --> 00:47:09,811 I'M HIGHLIGHTING THE EFFORTS 987 00:47:09,811 --> 00:47:10,678 BECAUSE WE APPRECIATE THE VALUE 988 00:47:10,678 --> 00:47:17,352 THIS IS BRINGING TO THE ENTIRE 989 00:47:17,352 --> 00:47:20,989 NETWORK OF HEAL INVESTIGATORS 990 00:47:20,989 --> 00:47:23,825 AND PROJECTS. 991 00:47:23,825 --> 00:47:25,827 ALONG THOSE LINES THIS 992 00:47:25,827 --> 00:47:27,161 ILLUSTRATES EXAMPLES OF DATA 993 00:47:27,161 --> 00:47:31,099 TYPES AND THE ECO SYSTEM AND 994 00:47:31,099 --> 00:47:32,500 NOFO ARE EFFORTS TO LEAD TOWARDS 995 00:47:32,500 --> 00:47:34,335 THE VISION TO BRING PROGRAMS IN 996 00:47:34,335 --> 00:47:36,971 CLOSER ALIGNMENT FOR A LARGER 997 00:47:36,971 --> 00:47:40,975 MORE INTEGRATED APPROACH TO 998 00:47:40,975 --> 00:47:42,377 MUSCULOSKELETAL PAIN. 999 00:47:42,377 --> 00:47:45,546 OUR INTENT IS TO FACILITATE 1000 00:47:45,546 --> 00:47:47,915 INTEGRATION OF METHODOLOGIES AND 1001 00:47:47,915 --> 00:47:51,019 INTERVENTIONS AND COLLABORATIVE 1002 00:47:51,019 --> 00:47:52,954 PROJECTS TO ACCELERATE KNOWLEDGE 1003 00:47:52,954 --> 00:47:53,221 TRANSFER. 1004 00:47:53,221 --> 00:47:56,257 ON THAT NOTE I WANT TO THANK ALL 1005 00:47:56,257 --> 00:47:58,459 THE RESEARCHERS THAT HAVE 1006 00:47:58,459 --> 00:48:00,995 PARTICIPATED IN THE PROGRAMS 1007 00:48:00,995 --> 00:48:03,097 INCLUDING THE BACPAC ADVISORY 1008 00:48:03,097 --> 00:48:04,932 BOARD MEMBERS AND PROGRAM STAFF 1009 00:48:04,932 --> 00:48:06,300 PARTICULARLY THOSE AT HEAL WHO 1010 00:48:06,300 --> 00:48:09,504 HAVE BEEN SO HELPFUL IN TERMS OF 1011 00:48:09,504 --> 00:48:10,872 MANAGING SOME OF THE AWARDS. 1012 00:48:10,872 --> 00:48:12,974 I WANT TO ACKNOWLEDGE ALL THE 1013 00:48:12,974 --> 00:48:16,344 PATIENTS PARTICIPATING IN THE 1014 00:48:16,344 --> 00:48:19,714 EFFORTS AND ALL OF YOU, OUR 1015 00:48:19,714 --> 00:48:20,948 ADVISERS ON THE WORKING GROUP. 1016 00:48:20,948 --> 00:48:24,385 THANK YOU SO MUCH FOR THE TIME 1017 00:48:24,385 --> 00:48:26,054 TO PRESENT OUR INTEREST IN PAIN 1018 00:48:26,054 --> 00:48:36,364 RESEARCH AT NIAMS. 1019 00:48:41,335 --> 00:48:46,207 >> WE'LL GO TO DR. CARLOS BLANCO 1020 00:48:46,207 --> 00:48:50,545 AND HE'LL BE STANDING IN TO GIVE 1021 00:48:50,545 --> 00:48:52,647 AN UPDATE ON THE STATE OF THE 1022 00:48:52,647 --> 00:49:00,988 OPIOID CRISIS. 1023 00:49:00,988 --> 00:49:10,364 >> I HOPE TO ECHO WHAT LINDSAY 1024 00:49:10,364 --> 00:49:12,667 WAS SAYING AND THANK YOU FOR 1025 00:49:12,667 --> 00:49:14,035 BEING GIVING ADVICE ON HOW TO DO 1026 00:49:14,035 --> 00:49:20,174 THIS AND GENERATE NEW IDEAS. 1027 00:49:20,174 --> 00:49:22,310 LET ME START WITH SOME GOOD 1028 00:49:22,310 --> 00:49:23,344 NEWS. 1029 00:49:23,344 --> 00:49:26,447 FOR THE FIRST TIME WE CAN REPORT 1030 00:49:26,447 --> 00:49:27,281 A DECREASE IN DEATHS. 1031 00:49:27,281 --> 00:49:31,719 YOU CAN SEE THE PROVISIONAL 1032 00:49:31,719 --> 00:49:33,654 INFORMATION HAS SEEN A DECREASE 1033 00:49:33,654 --> 00:49:36,924 ACROSS ALL SUBSTANCES. 1034 00:49:36,924 --> 00:49:39,026 TO THE THIS IS GOOD NEWS IT 1035 00:49:39,026 --> 00:49:42,930 WOULD BE NAIVE TO THINK WE'RE AT 1036 00:49:42,930 --> 00:49:43,631 AND THE OF THE EPIDEMIC. 1037 00:49:43,631 --> 00:49:44,565 STILL PRELIMINARY AND EARLY BUT 1038 00:49:44,565 --> 00:49:48,269 WE HAVE SOME GOOD NEWS. 1039 00:49:48,269 --> 00:49:50,338 AND THERE'S AN INDICATION THOUGH 1040 00:49:50,338 --> 00:49:52,006 THE WORK PUT INTO THIS ARE 1041 00:49:52,006 --> 00:49:53,674 EFFORTS AND I EXPECT THIS TO BE 1042 00:49:53,674 --> 00:49:55,977 UPS AND DOWNS BUT HOPEFULLY THE 1043 00:49:55,977 --> 00:49:59,747 LINE IS TRENDING DOWN. 1044 00:49:59,747 --> 00:50:00,982 I WANTED TO START WITH THIS GOOD 1045 00:50:00,982 --> 00:50:02,617 NEWS AND THANK YOU FOR THE 1046 00:50:02,617 --> 00:50:04,952 EFFORTS YOU'VE MADE AND PUT INTO 1047 00:50:04,952 --> 00:50:09,323 HELPING US BUILD AND CONTINUE 1048 00:50:09,323 --> 00:50:14,929 WITH HEAL. 1049 00:50:14,929 --> 00:50:16,097 THE DRIVERS OF THE EPIDEMIC ARE 1050 00:50:16,097 --> 00:50:16,998 TOO EARLY TO KNOW. 1051 00:50:16,998 --> 00:50:18,766 IT'S BEEN ACROSS THE BOARD BUT 1052 00:50:18,766 --> 00:50:20,067 STILL TOO EARLY TO KNOW WHAT'S 1053 00:50:20,067 --> 00:50:21,869 GOING TO CHANGE. 1054 00:50:21,869 --> 00:50:24,972 IT LOOKS LIKE IT'S TRENDING DOWN 1055 00:50:24,972 --> 00:50:27,275 WHICH WOULD BE GREAT NEWS. 1056 00:50:27,275 --> 00:50:29,310 WE HAVE TO SEE THE OTHER TRENDS 1057 00:50:29,310 --> 00:50:33,181 IN THE SAME DIRECTION BUT AGAIN 1058 00:50:33,181 --> 00:50:40,354 GOOD NEWS. 1059 00:50:40,354 --> 00:50:45,960 AND SOME ARE STILL TRENDING UP 1060 00:50:45,960 --> 00:50:48,829 BUT THE BIG RISK GROUPS REMAIN 1061 00:50:48,829 --> 00:50:52,900 THE SAME BY AGE AND RACE AND 1062 00:50:52,900 --> 00:50:53,167 ETHNICITY. 1063 00:50:53,167 --> 00:50:56,971 AMERICAN INDIANS AND ALASKAN 1064 00:50:56,971 --> 00:50:58,372 NATIVES AND BLACKS ARE THE 1065 00:50:58,372 --> 00:51:02,310 GROUPS THAT CONTINUE TO BE 1066 00:51:02,310 --> 00:51:09,884 MOSTLY HURT BY THE OVERDOSE 1067 00:51:09,884 --> 00:51:10,251 EPIDEMIC. 1068 00:51:10,251 --> 00:51:14,021 ONE OF THE MAIN ISSUES WE HAVE 1069 00:51:14,021 --> 00:51:18,492 IN THE OPIATE CRISIS AND ACROSS 1070 00:51:18,492 --> 00:51:20,027 MEDICINE IS DEVELOPING EFFECTIVE 1071 00:51:20,027 --> 00:51:22,363 INTERVENTIONS AND THEY'RE VASTLY 1072 00:51:22,363 --> 00:51:24,999 UNDER UTILIZED AND DON'T REACH 1073 00:51:24,999 --> 00:51:27,401 EVERYBODY THEY COULD BENEFIT. 1074 00:51:27,401 --> 00:51:29,237 SO ONE OF THE EFFORTS WE ARE 1075 00:51:29,237 --> 00:51:31,439 PUTTING AT NIDA IS NOT ONLY 1076 00:51:31,439 --> 00:51:35,409 DEVELOPING NEW INTERVENTIONS BUT 1077 00:51:35,409 --> 00:51:38,613 MAKING SURE THE INTERVENTIONS 1078 00:51:38,613 --> 00:51:41,616 REACH EVERYBODY ESPECIALLY THOSE 1079 00:51:41,616 --> 00:51:44,685 MORE UNDER SERVED AND DON'T GET 1080 00:51:44,685 --> 00:51:45,219 OFTEN THE BENEFIT OF THE 1081 00:51:45,219 --> 00:51:51,993 INTERVENTIONS. 1082 00:51:51,993 --> 00:51:55,696 I WANTED TO ABOUT THE NEEDS FOR 1083 00:51:55,696 --> 00:51:58,566 THE OPIATE EPIDEMIC AND CRISIS 1084 00:51:58,566 --> 00:52:03,604 IS THREE BUCKETS. 1085 00:52:03,604 --> 00:52:09,343 WE NEED BETTER DATA. 1086 00:52:09,343 --> 00:52:11,679 ONE OF THE EFFORTS WE'RE MAKING 1087 00:52:11,679 --> 00:52:12,713 AND I ALWAYS THINK ABOUT IT 1088 00:52:12,713 --> 00:52:14,815 LATER IS GENERATE BEING BETTER 1089 00:52:14,815 --> 00:52:16,517 METHODS AND BETTER WAYS OF 1090 00:52:16,517 --> 00:52:17,985 GETTING DATA. 1091 00:52:17,985 --> 00:52:23,424 THE SECOND ASPECT IS PREVENTING 1092 00:52:23,424 --> 00:52:25,926 OVERDOSES AND DEVELOPING A 1093 00:52:25,926 --> 00:52:26,894 SUBSTANCE USE DISORDER ACROSS 1094 00:52:26,894 --> 00:52:27,695 THE LIFE SPAN. 1095 00:52:27,695 --> 00:52:30,831 THOUGH MOST THE EFFORTS WE HAVE 1096 00:52:30,831 --> 00:52:34,368 PUT IN TOWARDS TREATMENT, IT IS 1097 00:52:34,368 --> 00:52:35,436 CLEAR BECAUSE MOST PEOPLE DON'T 1098 00:52:35,436 --> 00:52:36,437 SEEK TREATMENT BECAUSE TREATMENT 1099 00:52:36,437 --> 00:52:37,672 IS NOT GOING TO BE ENOUGH. 1100 00:52:37,672 --> 00:52:40,241 SO ONE OF THE THINGS WE HAVE 1101 00:52:40,241 --> 00:52:44,612 EMPHASIZED IS THE DEVELOPMENT 1102 00:52:44,612 --> 00:52:46,714 AND IMPLEMENTATION OF PREVENTING 1103 00:52:46,714 --> 00:52:48,049 INTERVENTIONS AND THE THIRD 1104 00:52:48,049 --> 00:52:50,751 BUCKET TAKING MOST THE EFFORT OF 1105 00:52:50,751 --> 00:52:52,987 HIM IS DEVELOPING OF 1106 00:52:52,987 --> 00:52:54,255 INTERVENTIONS AND ONE OF THE 1107 00:52:54,255 --> 00:53:01,195 THINGS WE HAVE VTRIED TO DO IS 1108 00:53:01,195 --> 00:53:03,197 TRYING TO TAILOR THE 1109 00:53:03,197 --> 00:53:07,768 INTERVENTIONS WE HAVE TO THE 1110 00:53:07,768 --> 00:53:08,569 NEEDS AND PREFERENCES OF 1111 00:53:08,569 --> 00:53:11,172 DIFFERENT GROUPS OF PATIENTS OR 1112 00:53:11,172 --> 00:53:11,472 INDIVIDUALS. 1113 00:53:11,472 --> 00:53:13,841 SO GOING BACK TO THE ISSUE OF 1114 00:53:13,841 --> 00:53:19,947 THE DATA, THOUGH WE TALK ABOUT 1115 00:53:19,947 --> 00:53:20,981 THE OPIATE EPIDEMIC OR OVERDOSE 1116 00:53:20,981 --> 00:53:23,584 CRISIS YOU HAVE TO RECOGNIZE 1117 00:53:23,584 --> 00:53:26,854 THIS IS NOT ONLY ONE CRISIS, IT 1118 00:53:26,854 --> 00:53:28,989 IS REALLY A COMBINATION OF 1119 00:53:28,989 --> 00:53:32,393 CRISIS HETEROGENEITY IN THE 1120 00:53:32,393 --> 00:53:41,469 GROUPS AFFECTED, HETEROGENEITY 1121 00:53:41,469 --> 00:53:45,339 IN THE ACCESS TO TREATMENT OR 1122 00:53:45,339 --> 00:53:46,273 RECOVERING FROM TREATMENT OR 1123 00:53:46,273 --> 00:53:48,743 HARM REDUCTION INTERVENTIONS. 1124 00:53:48,743 --> 00:53:52,380 I'LL BE TALKING ABOUT THAT 1125 00:53:52,380 --> 00:54:02,857 BRIEFLY IN MY PRESENTATION. 1126 00:54:04,692 --> 00:54:07,328 THIS IS AN EXAMPLE OF THIS AND 1127 00:54:07,328 --> 00:54:10,364 SOME PROGRAMS WE HAVE DEVELOPED 1128 00:54:10,364 --> 00:54:15,302 ARE PREVENTING INTERVENTIONS. 1129 00:54:15,302 --> 00:54:18,639 THE HARM REDUCTION INTERVENTIONS 1130 00:54:18,639 --> 00:54:21,008 AND IMPROVING DELIVERY FOR POLY 1131 00:54:21,008 --> 00:54:22,376 SUBSTANCE USE. 1132 00:54:22,376 --> 00:54:28,015 AS WE KNOW THOUGH WE TALK ABOUT 1133 00:54:28,015 --> 00:54:32,987 OPIOIDS OR METHAMPHETAMINE, S 1134 00:54:32,987 --> 00:54:37,024 STIMULANTS AND MANY HAVE A 1135 00:54:37,024 --> 00:54:38,926 COMBINATION IT'S RARE THERE'S 1136 00:54:38,926 --> 00:54:42,863 ONLY ONE DISORDER AND WE NEED TO 1137 00:54:42,863 --> 00:54:43,831 ADDRESS THE COMBINATION OF 1138 00:54:43,831 --> 00:54:44,965 DISORDERS AND NEED TO UNDERSTAND 1139 00:54:44,965 --> 00:54:47,334 THE NATURE OF POLY SUBSTANCE USE 1140 00:54:47,334 --> 00:54:48,402 AND INTERVENTIONS THAT COULD BE 1141 00:54:48,402 --> 00:54:53,674 USED FOR A VARIETY OF PATIENTS. 1142 00:54:53,674 --> 00:54:58,012 AND WE RECENTLY STARTED THE 1143 00:54:58,012 --> 00:55:00,981 NATIVE COLLECTIVE EFFORT TO 1144 00:55:00,981 --> 00:55:04,418 ENHANCE WELLNESS TO COVER 1145 00:55:04,418 --> 00:55:12,092 SUBSTANCE USE AND PAIN. 1146 00:55:12,092 --> 00:55:16,397 LET ME START WITH PREVENTION AS 1147 00:55:16,397 --> 00:55:22,369 I WAS MENTIONING BEFORE. 1148 00:55:22,369 --> 00:55:24,371 30% OF INDIVIDUALS WITH 1149 00:55:24,371 --> 00:55:28,375 SUBSTANCE USE DISORDERS SEEK 1150 00:55:28,375 --> 00:55:28,976 TREATMENT. 1151 00:55:28,976 --> 00:55:32,980 IT'S POSSIBLE TO SOLVE THE 1152 00:55:32,980 --> 00:55:34,949 OPIATE CRISIS BY TREATMENT. 1153 00:55:34,949 --> 00:55:38,652 WE NEED TO PUT MORE EMPHASIS ON 1154 00:55:38,652 --> 00:55:38,953 PREVENTION. 1155 00:55:38,953 --> 00:55:41,188 THE EMPHASIS IS TWO REASONS. 1156 00:55:41,188 --> 00:55:43,123 ONE IT'S CERTAINLY BETTER THAN 1157 00:55:43,123 --> 00:55:46,360 TRYING TO SOLVE THEM AND WE WANT 1158 00:55:46,360 --> 00:55:48,496 AS NIH NOT ONLY TO CURE PEOPLE 1159 00:55:48,496 --> 00:55:51,065 BUT REALLY PROMOTE THE HEALTH 1160 00:55:51,065 --> 00:55:53,567 AND POTENTIAL OF INDIVIDUALS. 1161 00:55:53,567 --> 00:55:56,303 WE WORK TO AVOID THE PROBLEM AND 1162 00:55:56,303 --> 00:55:59,807 HELP THEM IN ANY WAY WE CAN. 1163 00:55:59,807 --> 00:56:01,976 SO PREVENTION IS REALLY WHAT CAN 1164 00:56:01,976 --> 00:56:02,309 HELP. 1165 00:56:02,309 --> 00:56:05,012 WHEN PEOPLE COME TO TREATMENT, 1166 00:56:05,012 --> 00:56:07,915 THEY ALREADY HAVE SOME SEQUELAE 1167 00:56:07,915 --> 00:56:09,016 FROM SUBSTANCE USE DISORDER. 1168 00:56:09,016 --> 00:56:16,490 SO PREVENTION IS KEY. 1169 00:56:16,490 --> 00:56:19,193 I'M VERY GRATEFUL THAT AMY 1170 00:56:19,193 --> 00:56:21,862 GOLDSTEIN AND HER TEAM HAVE 1171 00:56:21,862 --> 00:56:23,430 DEVELOPED A PROGRAM OF 1172 00:56:23,430 --> 00:56:25,699 PREVENTION AND HAVE SORT OF 1173 00:56:25,699 --> 00:56:27,067 IDENTIFIED FOUR AREAS THAT 1174 00:56:27,067 --> 00:56:28,569 REQUIRE ATTENTION. 1175 00:56:28,569 --> 00:56:30,504 ONE IS RISK IDENTIFICATION SO WE 1176 00:56:30,504 --> 00:56:33,007 KNOW THE DRIVERS THAT PUT PEOPLE 1177 00:56:33,007 --> 00:56:34,708 AT RISK FOR SUBSTANCE USE 1178 00:56:34,708 --> 00:56:36,477 DISORDERS AND CAN STRATIFY 1179 00:56:36,477 --> 00:56:37,545 POPULATIONS AT DIFFERENT LEVELS 1180 00:56:37,545 --> 00:56:39,446 OF RISK AND INTERVENTION 1181 00:56:39,446 --> 00:56:42,683 DEVELOPMENTS THOUGH WE HAVE GOOD 1182 00:56:42,683 --> 00:56:44,318 INTERVENTIONS WE NEED BETTER 1183 00:56:44,318 --> 00:56:46,921 ONES AND HETEROGENEITY OF 1184 00:56:46,921 --> 00:56:49,023 POPULATIONS SO WE NEED 1185 00:56:49,023 --> 00:56:50,324 INTERVENTIONS TAILORED FOR THE 1186 00:56:50,324 --> 00:56:52,426 NEEDS OF EACH GROUP AND THEN WE 1187 00:56:52,426 --> 00:56:59,533 HAVE TO INTERVENE AT THE SOCIAL 1188 00:56:59,533 --> 00:57:02,236 DETERMINATES OF RISK AND WE LIVE 1189 00:57:02,236 --> 00:57:03,571 IN DIFFERENT COMMUNITIES AND 1190 00:57:03,571 --> 00:57:04,338 NEIGHBORHOODS AND WE'RE 1191 00:57:04,338 --> 00:57:06,006 INFLUENCED BY THE ENVIRONMENT IN 1192 00:57:06,006 --> 00:57:07,808 WHICH WE LIVE NOT ONLY 1193 00:57:07,808 --> 00:57:09,209 INDIVIDUAL RISK LEVEL SO THAT'S 1194 00:57:09,209 --> 00:57:13,013 WHY WE ALSO DEVELOP INTERVE 1195 00:57:13,013 --> 00:57:20,087 INTERVENTIONS AT AND THOSE 1196 00:57:20,087 --> 00:57:21,855 INTERVENTIONS HAVE NOT ALWAYS 1197 00:57:21,855 --> 00:57:27,328 TAKEN UP OR SCALED UP OR USED 1198 00:57:27,328 --> 00:57:27,595 EQUITABLY. 1199 00:57:27,595 --> 00:57:29,630 WE'RE DEVELOPING THE 1200 00:57:29,630 --> 00:57:31,832 INTERVENTION AND MAKING SURE 1201 00:57:31,832 --> 00:57:34,435 THEY REACH EVERYBODY THAT COULD 1202 00:57:34,435 --> 00:57:34,868 BENEFIT FROM THOSE 1203 00:57:34,868 --> 00:57:37,871 INTERVENTIONS. 1204 00:57:37,871 --> 00:57:42,676 THIS IS JUST A SAMPLE OF THE 1205 00:57:42,676 --> 00:57:43,444 INTERVENTIONS THAT ARE BEING 1206 00:57:43,444 --> 00:57:43,978 DEVELOPED. 1207 00:57:43,978 --> 00:57:46,413 WE'RE ABOUT TO FINISH MOST THE 1208 00:57:46,413 --> 00:57:46,914 PROJECTS. 1209 00:57:46,914 --> 00:57:48,415 HOPEFULLY IN THE NEXT YEAR OR 1210 00:57:48,415 --> 00:57:50,884 TWO WE'LL HAVE OUTCOME DATA 1211 00:57:50,884 --> 00:57:52,353 WE'LL BE ABLE TO REPORT BUT AS 1212 00:57:52,353 --> 00:57:54,021 YOU CAN SEE IT'S A GOOD 1213 00:57:54,021 --> 00:57:54,788 INTERVENTION. 1214 00:57:54,788 --> 00:58:00,728 SOME AT THE SCHOOL LEVEL, SOME 1215 00:58:00,728 --> 00:58:02,529 TARGETING COMORBIDITIES AFTER 1216 00:58:02,529 --> 00:58:08,836 DISORDERS LIKE ADHD AND WE'RE 1217 00:58:08,836 --> 00:58:13,807 TRYING TO SORT OF DIVERSIFY 1218 00:58:13,807 --> 00:58:15,376 INVESTMENTS TRYING TO LOOK INTO 1219 00:58:15,376 --> 00:58:16,443 DIFFERENT AREAS, DIFFERENT 1220 00:58:16,443 --> 00:58:21,015 SETTINGS AND POPULATIONS TO SEE 1221 00:58:21,015 --> 00:58:23,283 WAYS AND LEARN FROM OUR 1222 00:58:23,283 --> 00:58:24,818 MISTAKES. 1223 00:58:24,818 --> 00:58:26,587 SOME INVESTMENTS ARE NOT GOING 1224 00:58:26,587 --> 00:58:28,122 TO WORK OUT AND WANT TO LEARN 1225 00:58:28,122 --> 00:58:30,624 WHAT WE NEED TO CHANGE AND 1226 00:58:30,624 --> 00:58:33,293 MODIFY TO MAKE PREVENTION MORE 1227 00:58:33,293 --> 00:58:40,100 EFFECTIVE. 1228 00:58:40,100 --> 00:58:43,404 IN ADDITION TO THE WAYS OF 1229 00:58:43,404 --> 00:58:45,005 DISSEMINATING INFORMATION AND 1230 00:58:45,005 --> 00:58:48,008 PUBLISHING PAPERS IN HIGH IMPACT 1231 00:58:48,008 --> 00:58:51,178 JOURNALS WE DISSEMINATE THROUGH 1232 00:58:51,178 --> 00:58:52,413 OTHER CHANNELS. 1233 00:58:52,413 --> 00:58:57,017 WE ENCOURAGE P.I.s AND 1234 00:58:57,017 --> 00:58:57,985 AUTHORITIES TO DISSEMINATE 1235 00:58:57,985 --> 00:59:01,422 INFORMATION IN LETTERS, 1236 00:59:01,422 --> 00:59:02,790 WEBINARS, OP-EDs. 1237 00:59:02,790 --> 00:59:04,458 WE WANT TO TAKE A FULL APPROACH 1238 00:59:04,458 --> 00:59:06,627 TO NOT ONLY GENERATING THE 1239 00:59:06,627 --> 00:59:10,064 INFORMATION BUT MAKING SURE THE 1240 00:59:10,064 --> 00:59:11,331 INFORMATION REACHES ALL RELEVANT 1241 00:59:11,331 --> 00:59:12,700 AND STAKEHOLDERS AND THEY CAN 1242 00:59:12,700 --> 00:59:16,537 GIVE IMPACT ON HOW TO DO THINGS 1243 00:59:16,537 --> 00:59:19,707 BETTER THE NEXT TIME. 1244 00:59:19,707 --> 00:59:21,709 ON THE ISSUES OF SERVICES I 1245 00:59:21,709 --> 00:59:24,545 MENTIONED BEFORE IS THE 1246 00:59:24,545 --> 00:59:25,479 INTERVENTIONS DON'T ALWAYS REACH 1247 00:59:25,479 --> 00:59:27,548 THE INTENDED TARGETS. 1248 00:59:27,548 --> 00:59:33,020 ONE OF THE STUDIES WE ARE DOING 1249 00:59:33,020 --> 00:59:35,923 IS UNDERSTANDING FROM WHAT IS IN 1250 00:59:35,923 --> 00:59:41,261 CHARGE OF PREVENTION OF THE 1251 00:59:41,261 --> 00:59:44,231 NETWORKS STAND UP THE 1252 00:59:44,231 --> 00:59:45,699 INTERVENTION AND SUSTAIN THE 1253 00:59:45,699 --> 00:59:46,033 INTERVENTIONS. 1254 00:59:46,033 --> 00:59:48,102 ONE THING WE ALSO LEARNED AND 1255 00:59:48,102 --> 00:59:51,472 I'M SURE YOU'VE HAD SIMILAR 1256 00:59:51,472 --> 00:59:52,439 EXPERIENCES IS AN INTERVENTION 1257 00:59:52,439 --> 00:59:55,275 IS SUSTAINABLE WITH THE GRANT 1258 00:59:55,275 --> 00:59:57,144 FUNDING BUT ONCE IT DISAPPEARS 1259 00:59:57,144 --> 00:59:59,580 THE INTERVENTIONS HAVE NOT 1260 00:59:59,580 --> 01:00:02,216 SUSTAIN AND TRYING TO WORK WITH 1261 01:00:02,216 --> 01:00:04,418 STATE DEPARTMENTS OF HEALTH AND 1262 01:00:04,418 --> 01:00:06,453 MAKE SURE THE INTERVENTIONS WE 1263 01:00:06,453 --> 01:00:08,055 DEVELOP ARE SUSTAINABLE AND CAN 1264 01:00:08,055 --> 01:00:12,493 BE SUPPORTED BY OTHER SOURCES OF 1265 01:00:12,493 --> 01:00:13,827 FUNDING LIKE SAMHSA OR STATE 1266 01:00:13,827 --> 01:00:15,262 DEPARTMENTS OR OTHER FOUNDATION 1267 01:00:15,262 --> 01:00:20,534 MONEY TO SUSTAIN THE 1268 01:00:20,534 --> 01:00:20,968 INTERVENTIONS. 1269 01:00:20,968 --> 01:00:22,569 AND ALSO RELATED TO THE SLIDE 1270 01:00:22,569 --> 01:00:27,441 YOU MAY WANT TO KNOW AS SOME 1271 01:00:27,441 --> 01:00:31,512 ALREADY KNOW I.C.s HAVE AN ALL 1272 01:00:31,512 --> 01:00:33,080 RIGHT ON HOW TO DEVELOP 1273 01:00:33,080 --> 01:00:36,583 INFRASTRUCTURE FOR BEHAVIORAL 1274 01:00:36,583 --> 01:00:37,017 DISORDER. 1275 01:00:37,017 --> 01:00:38,986 MANY OF THE THINGS WE'RE DOING 1276 01:00:38,986 --> 01:00:40,287 BENEFIT FROM THE RECOMMENDATION 1277 01:00:40,287 --> 01:00:43,657 OF THE REPORT AND HOPEFULLY 1278 01:00:43,657 --> 01:00:47,528 THROUGH THE INFRASTRUCTURE WE 1279 01:00:47,528 --> 01:00:52,432 CREATED TO PROVIDE PREVENTIVE 1280 01:00:52,432 --> 01:00:53,033 INTERVENTIONS THROUGHOUT THE 1281 01:00:53,033 --> 01:01:03,177 NATION. 1282 01:01:09,049 --> 01:01:11,118 ONE OF THE INITIATIVES WE HAVE 1283 01:01:11,118 --> 01:01:13,687 DEVELOPED RECENTLY IS HEAL DATA 1284 01:01:13,687 --> 01:01:18,926 COLLECTION AND THE GOAL OF THE 1285 01:01:18,926 --> 01:01:22,596 INITIATIVE IS REALLY THE 1286 01:01:22,596 --> 01:01:24,698 COMBINED PROGRAM BEING AND DATA 1287 01:01:24,698 --> 01:01:29,870 THAT CAN THEN INFORM SPECIFIC 1288 01:01:29,870 --> 01:01:35,676 INTERVENT 1289 01:01:35,676 --> 01:01:37,044 INTERVENTIONS WE HAVE PROJECTS 1290 01:01:37,044 --> 01:01:42,583 AND A MODELLING CENTER AND 1291 01:01:42,583 --> 01:01:45,485 INFRASTRUCTURE CENTER AND 1292 01:01:45,485 --> 01:01:47,888 SUPPORT CENTER BECAUSE WE KNOW 1293 01:01:47,888 --> 01:01:52,392 EVEN THOUGH WE CAN DEVELOP THE 1294 01:01:52,392 --> 01:01:54,094 INTERVENTIONS IT TAKES EFFORTS 1295 01:01:54,094 --> 01:01:55,395 AND SCIENCE AND CERTAIN SKILLS 1296 01:01:55,395 --> 01:01:56,997 TO MAKE SURE THE INTERVENTIONS 1297 01:01:56,997 --> 01:02:07,207 ARE LIMITED. 1298 01:02:08,008 --> 01:02:10,444 THIS IS AN EXAMPLE OF THE 1299 01:02:10,444 --> 01:02:16,316 PROJECTS WE'RE FUNDING, SURGERY, 1300 01:02:16,316 --> 01:02:18,852 LINKAGES, HOW TO DO BETTER AND 1301 01:02:18,852 --> 01:02:20,687 INTEREST IN TELEHEALTH AND ALSO 1302 01:02:20,687 --> 01:02:25,993 DOING NOT ONLY COLLECTING DATA 1303 01:02:25,993 --> 01:02:28,262 BUT DOING MODELLING BECAUSE WE 1304 01:02:28,262 --> 01:02:31,465 NEED TO RELY ALSO ON SIMULATIONS 1305 01:02:31,465 --> 01:02:33,600 AND MODELLING TO SEE WHAT MIGHT 1306 01:02:33,600 --> 01:02:36,336 WORK IN DIFFERENT SETTINGS. 1307 01:02:36,336 --> 01:02:37,704 IN ADDITION TO INDIVIDUAL 1308 01:02:37,704 --> 01:02:40,407 PROJECT WE HAVE SUPPORT CENTERS 1309 01:02:40,407 --> 01:02:44,444 THAT CAN HELP COORDINATE AND 1310 01:02:44,444 --> 01:02:46,513 ENHANCE THE EFFECT OF THE 1311 01:02:46,513 --> 01:02:56,857 INDIVIDUAL PROJECTS. 1312 01:03:07,567 --> 01:03:09,136 AND DISSEMINATION OF THE 1313 01:03:09,136 --> 01:03:19,446 KNOWLEDGE CREATED. 1314 01:03:25,085 --> 01:03:25,986 AND HOPEFULLY THIS WILL COMBINE 1315 01:03:25,986 --> 01:03:32,592 THE BEST OF TWO WORLDS. 1316 01:03:32,592 --> 01:03:35,329 I ALSO WANTED TO MENTION JCOIN 1317 01:03:35,329 --> 01:03:38,932 ONE OF THE STAR PROGRAMS OF HEAL 1318 01:03:38,932 --> 01:03:42,235 AND IT'S A LEARNING SYSTEM OF 1319 01:03:42,235 --> 01:03:46,440 CARE THAT COMBINES SCIENTISTS, 1320 01:03:46,440 --> 01:03:50,811 RESEARCHERS FROM THE SUBSTANCE 1321 01:03:50,811 --> 01:04:01,355 USE FIELD AND SEE THE PROTOCOLS, 1322 01:04:02,456 --> 01:04:05,425 MORE THAN 22,000 INDIVIDUALS 1323 01:04:05,425 --> 01:04:10,430 YENL ROLLED, PILOT GRANTS, IT'S 1324 01:04:10,430 --> 01:04:16,436 BEEN ALSO USEFUL TO TRAIN THEM 1325 01:04:16,436 --> 01:04:24,077 AND GENERATE ACTIVITY THIS IS A 1326 01:04:24,077 --> 01:04:26,713 MODEL PROGRAM IN MY OPINION AND 1327 01:04:26,713 --> 01:04:28,415 GENERATED OPPORTUNITIES FOR 1328 01:04:28,415 --> 01:04:31,251 CAPACITY AS I SAID NOT ONLY WITH 1329 01:04:31,251 --> 01:04:32,853 THE YOUNGER GENERATION AND 1330 01:04:32,853 --> 01:04:35,322 GENERATING COURSES THAT CAN BE 1331 01:04:35,322 --> 01:04:37,024 ACCESSED FOR PEOPLE TO LEARN 1332 01:04:37,024 --> 01:04:39,092 TECHNICAL ASSISTANCE HAS BEEN 1333 01:04:39,092 --> 01:04:42,629 USEFUL IN INCORPORATING 1334 01:04:42,629 --> 01:04:43,163 KNOWLEDGE AND A FANTASTIC 1335 01:04:43,163 --> 01:04:53,306 PROGRAM. 1336 01:04:58,478 --> 01:04:59,913 AND PRACTICE AND POLICY IMPACTS 1337 01:04:59,913 --> 01:05:02,049 WHICH FOR US WAS IMPORTANT. 1338 01:05:02,049 --> 01:05:12,559 YOU CAN SEE THEM LISTED HERE. 1339 01:05:21,068 --> 01:05:25,005 WE HAVE WE ARE GOING TO PUT MORE 1340 01:05:25,005 --> 01:05:28,008 EMPHASIS ON INNOVATION AND 1341 01:05:28,008 --> 01:05:29,009 EMPHASIS ON THE ECONOMIC AND 1342 01:05:29,009 --> 01:05:32,312 RESEARCH CENTER BECAUSE ONE OF 1343 01:05:32,312 --> 01:05:34,448 THE THINGS THAT INTERFERES WITH 1344 01:05:34,448 --> 01:05:36,216 IMPLEMENTATION IS THE COST OF 1345 01:05:36,216 --> 01:05:36,917 THE INTERVENTIONS. 1346 01:05:36,917 --> 01:05:43,990 BY BEING ABLE TO MODEL AND GIVE 1347 01:05:43,990 --> 01:05:46,893 TOOLS TO INCORPORATE 1348 01:05:46,893 --> 01:05:48,295 INTERVENTIONS WE HOPE IT WILL 1349 01:05:48,295 --> 01:05:52,365 HAVE MORE IMPACT AND HELP MANY 1350 01:05:52,365 --> 01:05:58,438 SETTINGS TO MANY OF THE 1351 01:05:58,438 --> 01:06:06,680 INTERVENTIONS WE'RE DEVELOPING. 1352 01:06:06,680 --> 01:06:13,753 EVEN THOUGH WE WANT PEOPLE TO 1353 01:06:13,753 --> 01:06:16,223 ACCESS SYSTEMS NOT EVERYBODY IS 1354 01:06:16,223 --> 01:06:21,628 READY TO ACCESS THE SYSTEMS. 1355 01:06:21,628 --> 01:06:23,063 WE DEVELOPED OTHER WAYS AND ONE 1356 01:06:23,063 --> 01:06:27,834 THING WE THINK IS INNOVATIVE IS 1357 01:06:27,834 --> 01:06:28,835 RECOVERY SUPPORT SYSTEMS. 1358 01:06:28,835 --> 01:06:30,670 WE WANT TO UNDERSTAND HOW PEOPLE 1359 01:06:30,670 --> 01:06:36,843 RECOVER AND WHAT HAD ARE THE 1360 01:06:36,843 --> 01:06:41,882 SUPPORTS THEY NEED SUPPORT 1361 01:06:41,882 --> 01:06:43,183 RESEARCH INITIATIVE WHICH IS 1362 01:06:43,183 --> 01:06:49,022 STUDYING PEER-RECOVERING CENTER 1363 01:06:49,022 --> 01:06:52,425 S AND OTHER WAYS TO SUPPORT 1364 01:06:52,425 --> 01:06:56,029 INDIVIDUALS WHO DO NOT SEEK 1365 01:06:56,029 --> 01:06:56,997 TREATMENT IN TRADITIONAL 1366 01:06:56,997 --> 01:07:07,474 SETTINGS LIKE PRIMARY CARE. 1367 01:07:08,241 --> 01:07:10,810 AND THEY HAVE CREATED THEIR OWN 1368 01:07:10,810 --> 01:07:14,381 CONSORTIUM ON ADDICTION RECOVERY 1369 01:07:14,381 --> 01:07:15,749 AND ALSO THE NATIONAL CONFERENCE 1370 01:07:15,749 --> 01:07:17,450 AND ARE BEING EXTREMELY ACTIVE. 1371 01:07:17,450 --> 01:07:21,521 WE'RE VERY EXCITED ABOUT THE 1372 01:07:21,521 --> 01:07:23,423 INITIATIVE AND WE THINK IT CAN 1373 01:07:23,423 --> 01:07:25,091 IMPACT A LOT OF PEOPLE WHO 1374 01:07:25,091 --> 01:07:27,694 OTHERWISE WOULD NOT ACCESS 1375 01:07:27,694 --> 01:07:31,031 SERVICES FOR RECOVERY AND TO 1376 01:07:31,031 --> 01:07:33,266 HELP RECOVER FROM SUBSTANCE USE 1377 01:07:33,266 --> 01:07:39,172 DISORDERS. 1378 01:07:39,172 --> 01:07:43,610 I'LL BE MOVING FASTER BECAUSE I 1379 01:07:43,610 --> 01:07:45,412 KNOW I'M RUNNING OUT OF TIME AND 1380 01:07:45,412 --> 01:07:47,480 RECOVERY SUPPORT AND IN ADDITION 1381 01:07:47,480 --> 01:07:51,318 TO SUPPORT, AS YOU KNOW, SOME 1382 01:07:51,318 --> 01:07:56,189 INDIVIDUALS ARE NOT READY OR NOT 1383 01:07:56,189 --> 01:07:58,225 WILLING AT THIS POINT IN STOMP 1384 01:07:58,225 --> 01:07:59,192 USING DRUGS. 1385 01:07:59,192 --> 01:08:00,827 IT DOES NOT MEAN THEY CANNOT 1386 01:08:00,827 --> 01:08:01,962 BENEFIT FROM OTHER INTERVENTION. 1387 01:08:01,962 --> 01:08:03,496 ONE THING WE DEVELOPED IS A 1388 01:08:03,496 --> 01:08:04,998 RESEARCH PROGRAM OR HARM 1389 01:08:04,998 --> 01:08:07,500 REDUCTION WHICH WE CALL THE HARM 1390 01:08:07,500 --> 01:08:08,635 REDUCTION RESEARCH NETWORK. 1391 01:08:08,635 --> 01:08:10,203 THE GOAL OF THAT IS TO 1392 01:08:10,203 --> 01:08:12,205 UNDERSTAND SOME OF THE PRACTICES 1393 01:08:12,205 --> 01:08:16,409 THAT ARE HAPPENING RIGHT NOW. 1394 01:08:16,409 --> 01:08:21,014 PROVIDING SPACE TO COLLABORATE 1395 01:08:21,014 --> 01:08:25,685 AND DEVELOP NEW IDEAS AND 1396 01:08:25,685 --> 01:08:27,454 ULTIMATELY PREVENT OVERDOSES AND 1397 01:08:27,454 --> 01:08:29,889 SAVE LIVES. 1398 01:08:29,889 --> 01:08:32,859 WE FUNDED 10 RO1s AND YOU CAN 1399 01:08:32,859 --> 01:08:33,893 SEE IN THE SLIDE WE ARE TRYING 1400 01:08:33,893 --> 01:08:37,664 OR STUDYING A NUMBER OF THINGS 1401 01:08:37,664 --> 01:08:39,499 SOME HARM REDUCTION APPROACHES 1402 01:08:39,499 --> 01:08:42,102 AND OVERDOSE PREVENTION CENTERS 1403 01:08:42,102 --> 01:08:48,008 AND WE'RE ALSO TRYING LOOK AT 1404 01:08:48,008 --> 01:08:50,443 MANAGEMENT AND ONE OF THE ISSUES 1405 01:08:50,443 --> 01:08:52,245 IN CONTINGENCY MANAGEMENT IS 1406 01:08:52,245 --> 01:08:54,214 THERE'S LEGAL ISSUES NOT WITH 1407 01:08:54,214 --> 01:08:55,715 STUDYING RESEARCH BUT SCALING IT 1408 01:08:55,715 --> 01:08:59,753 UP IN PRACTICE BECAUSE OF 1409 01:08:59,753 --> 01:09:02,922 REGULATIONS HHS HAS. 1410 01:09:02,922 --> 01:09:08,094 AND STUDYING THE EMERGENCY 1411 01:09:08,094 --> 01:09:16,436 DEPARTMENT AND UNDERSTANDING 1412 01:09:16,436 --> 01:09:21,007 BARRIERS FOR HARM REDUCTION AND 1413 01:09:21,007 --> 01:09:21,441 FACILITATING THOSE 1414 01:09:21,441 --> 01:09:31,685 INTERVENTIONS. 1415 01:09:38,458 --> 01:09:41,027 AND ONE OF THE INITIATIVE WE 1416 01:09:41,027 --> 01:09:46,299 HAVE NOW IS PUT INTO. 1417 01:09:46,299 --> 01:09:48,335 WE'RE MOVING AWAY FROM SPECIFIC 1418 01:09:48,335 --> 01:09:51,538 RFAs THAT DON'T ALLOW FOR 1419 01:09:51,538 --> 01:09:53,973 RESUBMISSION TO FURTHER RFAs 1420 01:09:53,973 --> 01:09:57,177 THAT ALLOW FOR TOPICS LIKELY TO 1421 01:09:57,177 --> 01:09:59,913 BE IMPORTANT IN THE NEAR FUTURE 1422 01:09:59,913 --> 01:10:01,014 AND GIVE FLEXIBILITY TO THE 1423 01:10:01,014 --> 01:10:02,816 INVESTIGATORS AND APPLICANT AND 1424 01:10:02,816 --> 01:10:06,686 RESUBMIT AND BETTER TAILOR THE 1425 01:10:06,686 --> 01:10:08,088 APPLICATIONS AND GIVES 1426 01:10:08,088 --> 01:10:09,989 FLEXIBILITY TO PUBLISH NOSIS AND 1427 01:10:09,989 --> 01:10:15,428 POINT OUT AREAS THAT ARE OF 1428 01:10:15,428 --> 01:10:17,664 INTEREST OR AREAS WHERE WE THINK 1429 01:10:17,664 --> 01:10:18,865 WE HAVE ENOUGH INFORMATION THAT 1430 01:10:18,865 --> 01:10:20,367 ARE ALREADY MATURE AND IT'S 1431 01:10:20,367 --> 01:10:21,234 BETTER TO PUT THE RESOURCES IN 1432 01:10:21,234 --> 01:10:31,444 OTHER AREAS. 1433 01:10:36,483 --> 01:10:38,485 AND IT WILL ALLOW FOR SUBMISSION 1434 01:10:38,485 --> 01:10:41,287 AND THE ABILITY FOR APPLICANTS 1435 01:10:41,287 --> 01:10:44,991 TO REVISE POLICY APPLICATIONS AN 1436 01:10:44,991 --> 01:10:45,992 ULTIMATELY FUND BETTER SCIENCE 1437 01:10:45,992 --> 01:10:46,926 LEADING TO BETTER POPULATION 1438 01:10:46,926 --> 01:10:47,160 HEALTH. 1439 01:10:47,160 --> 01:10:49,596 WITH THAT I WANT TO THANK YOU 1440 01:10:49,596 --> 01:10:50,864 FOR YOUR ATTENTION AND GIVE THE 1441 01:10:50,864 --> 01:10:54,167 FLOOR I THINK TO AMY AND 1442 01:10:54,167 --> 01:10:55,268 HOPEFULLY WE CAN HAVE SOME 1443 01:10:55,268 --> 01:10:57,003 DISCUSSION AND INPUT TO IMPROVE 1444 01:10:57,003 --> 01:10:57,404 WHAT WE ARE DOING. 1445 01:10:57,404 --> 01:11:07,714 THANKS VERY MUCH. 1446 01:11:09,582 --> 01:11:10,450 I'LL OPEN THE FLOOR TO ANY 1447 01:11:10,450 --> 01:11:13,019 PRESENTATIONS WE HEARD THIS 1448 01:11:13,019 --> 01:11:23,163 MORNING. 1449 01:11:23,363 --> 01:11:26,199 >> THANK YOU FOR WONDERFUL 1450 01:11:26,199 --> 01:11:33,006 PRESENTATIONS AND DR. BLANCO 1451 01:11:33,006 --> 01:11:35,642 THANK YOU FOR THE GOOD NEWS. 1452 01:11:35,642 --> 01:11:37,944 AND DR. CRISWELL THINKING ABOUT 1453 01:11:37,944 --> 01:11:41,714 THE EPISODE OF CARE ACROSS 1454 01:11:41,714 --> 01:11:42,949 PROVIDERS THAT A PATIENT MIGHT 1455 01:11:42,949 --> 01:11:44,784 TRAVERSE. 1456 01:11:44,784 --> 01:11:49,022 I'M WONDERING HOW TO ENSURE THE 1457 01:11:49,022 --> 01:11:50,824 PROGRAM PENETRATE DOWN TO THE 1458 01:11:50,824 --> 01:11:52,225 PROVIDERS WITH THE PATIENTS WE 1459 01:11:52,225 --> 01:11:55,395 COME IN CONTACT WITH. 1460 01:11:55,395 --> 01:12:00,967 NOT JUST THE PHYSICIAN AND BUT 1461 01:12:00,967 --> 01:12:02,035 ALSO THE NURSE BECAUSE THERE'S 1462 01:12:02,035 --> 01:12:04,070 WORK THAT SHOWS THAT PATIENTS 1463 01:12:04,070 --> 01:12:05,438 GET DIFFERENT MESSAGES FROM 1464 01:12:05,438 --> 01:12:08,241 PROVIDERS AND THEREFORE THAT 1465 01:12:08,241 --> 01:12:10,410 CONTRIBUTES TO THEIR DISABILITY 1466 01:12:10,410 --> 01:12:16,416 PARTICULARLY TO THE CONTEXT OF 1467 01:12:16,416 --> 01:12:26,359 LOW BACK PAIN AND IT IT'S 1468 01:12:26,359 --> 01:12:28,428 INFORMED AND THE SECOND THING IS 1469 01:12:28,428 --> 01:12:34,434 WHEN PATIENTS ARE IN PAIN, WE 1470 01:12:34,434 --> 01:12:36,736 ALSO KNOW THEY'LL SEEK FROM 1471 01:12:36,736 --> 01:12:38,605 WHENEVER CAN PROVIDE AND THERE'S 1472 01:12:38,605 --> 01:12:41,374 GOOD DATA TO SHOW OUT OF POCKET 1473 01:12:41,374 --> 01:12:42,809 EXPENSES PATIENTS WILL GO 1474 01:12:42,809 --> 01:12:45,011 THROUGH TO SEEKING CARE BECAUSE 1475 01:12:45,011 --> 01:12:46,913 INSURANCE COMPANIES WON'T PAY 1476 01:12:46,913 --> 01:12:49,415 FOR THINGS I'M THINKING MORE 1477 01:12:49,415 --> 01:12:52,151 OUTSIDE THE TRADITIONAL MEDICAL 1478 01:12:52,151 --> 01:12:52,418 MODELS. 1479 01:12:52,418 --> 01:12:56,523 MAYBE MASSAGE THERAPISTS AND 1480 01:12:56,523 --> 01:12:58,424 SOME STATES IS CHIROPRACTIC CARE 1481 01:12:58,424 --> 01:13:00,994 AND HOW TO PENETRATE TO REACH 1482 01:13:00,994 --> 01:13:07,433 THOSE PROVIDERS AS WELL. 1483 01:13:07,433 --> 01:13:10,370 >> YOU NICELY SUMMARIZED WHY 1484 01:13:10,370 --> 01:13:12,071 IT'S AN IMPORTANT CHALLENGING 1485 01:13:12,071 --> 01:13:13,039 AND COMPLEX ISSUE. 1486 01:13:13,039 --> 01:13:16,409 I KNOW SEEING PATIENTS WITH 1487 01:13:16,409 --> 01:13:20,079 CHRONIC PAIN HOW FRAGMENTED AND 1488 01:13:20,079 --> 01:13:22,315 INEFFECTUAL PAIN MANAGEMENT HAS 1489 01:13:22,315 --> 01:13:22,882 BEEN MANY YEARS. 1490 01:13:22,882 --> 01:13:25,018 IT'S RECOGNITION OF THE 1491 01:13:25,018 --> 01:13:26,719 CHALLENGES AND IMPORTANCE OF THE 1492 01:13:26,719 --> 01:13:28,288 PROBLEM THAT WE ARE FULLY 1493 01:13:28,288 --> 01:13:28,988 SUPPORTING THE INITIATIVE. 1494 01:13:28,988 --> 01:13:31,090 I'M NOT LEADING THIS INITIATIVE. 1495 01:13:31,090 --> 01:13:32,992 I'M HOPING ONE OF MY COLLEAGUES 1496 01:13:32,992 --> 01:13:35,662 AROUND THE TABLE WHOSE BEEN MORE 1497 01:13:35,662 --> 01:13:36,996 DEEPLY INVOLVED IN THE PLANNING 1498 01:13:36,996 --> 01:13:41,334 STAGES CAN SPEAK TO THAT AND 1499 01:13:41,334 --> 01:13:45,772 WALTER, I'M NOT SURE AMY, DO WE 1500 01:13:45,772 --> 01:13:47,807 HAVE SOMEONE ON TO DIVE INTO 1501 01:13:47,807 --> 01:13:49,008 MORE DETAILS HOW WE'LL DEAL WITH 1502 01:13:49,008 --> 01:13:55,682 THE BIG CHALLENGES? 1503 01:13:55,682 --> 01:14:04,457 I CAN PROBABLY HELP. 1504 01:14:04,457 --> 01:14:08,995 THEY'RE WORKING WITH LAURA AND I 1505 01:14:08,995 --> 01:14:12,665 HOPE IF ELIZABETH WANTS TO ADD 1506 01:14:12,665 --> 01:14:13,933 ANYTHING, PLEASE DO. 1507 01:14:13,933 --> 01:14:20,506 I THINK YOU'VE IDENTIFIED A WAY 1508 01:14:20,506 --> 01:14:21,074 BIGGER PROBLEM THAN THIS 1509 01:14:21,074 --> 01:14:24,410 INITIATIVE CAN ADDRESS. 1510 01:14:24,410 --> 01:14:27,046 IT DOES HOWEVER, INCLUDE THE 1511 01:14:27,046 --> 01:14:28,414 T90, R90. 1512 01:14:28,414 --> 01:14:34,087 THE UNIQUE PART ABOUT THIS IS 1513 01:14:34,087 --> 01:14:37,490 THAT IT INCLUDES REQUIRED TO 1514 01:14:37,490 --> 01:14:39,125 INCLUDE AREAS OF PAIN NOT 1515 01:14:39,125 --> 01:14:40,126 NECESSARILY HAPPENING IN PAIN 1516 01:14:40,126 --> 01:14:43,930 RESEARCH IN WHAT WE TYPICALLY 1517 01:14:43,930 --> 01:14:44,731 THINK OF. 1518 01:14:44,731 --> 01:14:50,937 IT'S EITHER ANESTHESIOLOGY ONLY 1519 01:14:50,937 --> 01:14:52,372 OR NEUROLOGY ONLY. 1520 01:14:52,372 --> 01:14:53,006 THEY'RE REQUIRED TO HAVE TWO 1521 01:14:53,006 --> 01:14:58,444 DISCIPLINES INCLUDED. 1522 01:14:58,444 --> 01:14:58,745 . 1523 01:14:58,745 --> 01:15:00,546 WHEN WE LOOK ACROSS PROGRAMS 1524 01:15:00,546 --> 01:15:01,381 BEING FUNDED THERE'S A BREADTH 1525 01:15:01,381 --> 01:15:05,251 OF DISCIPLINES. 1526 01:15:05,251 --> 01:15:07,420 IT'S GOING ACROSS DISCIPLINES 1527 01:15:07,420 --> 01:15:10,456 BUT DOESN'T GO UP AND DOWN WHERE 1528 01:15:10,456 --> 01:15:15,695 DOES THE PATIENT GO FROM SEEING 1529 01:15:15,695 --> 01:15:16,763 THEIR PHYSICAL THERAPIST 1530 01:15:16,763 --> 01:15:19,465 INITIALLY OR ETCETERA UP AND 1531 01:15:19,465 --> 01:15:19,666 DOWN. 1532 01:15:19,666 --> 01:15:20,833 THESE ARE COHORT TRAINING 1533 01:15:20,833 --> 01:15:22,301 PROGRAMS SO SIX PEOPLE OR FIVE 1534 01:15:22,301 --> 01:15:26,739 PEOPLE COME IN AT ONCE AND STAY 1535 01:15:26,739 --> 01:15:27,006 TOGETHER. 1536 01:15:27,006 --> 01:15:27,974 SO THERE ARE SEVERAL TRAINING 1537 01:15:27,974 --> 01:15:28,875 OPPORTUNITIES FOR THEM. 1538 01:15:28,875 --> 01:15:32,111 IT'S TIED IN WITH THE NATIONAL 1539 01:15:32,111 --> 01:15:34,080 K12 INITIATIVE WITH SPECIAL 1540 01:15:34,080 --> 01:15:35,181 TRAINING PROGRAMS AND OUR 1541 01:15:35,181 --> 01:15:37,383 PURPOSE NETWORK WITH SPECIAL 1542 01:15:37,383 --> 01:15:41,888 TRAINING PROGRAMS. 1543 01:15:41,888 --> 01:15:47,527 WE CAN TALK TO PURPOSE OR K12S 1544 01:15:47,527 --> 01:15:48,661 THEY ARE WORK THROUGH THEIR 1545 01:15:48,661 --> 01:15:49,729 RESOURCES FOR TRAINING AND SEE 1546 01:15:49,729 --> 01:15:50,963 IF THIS IS SOMETHING THEY SCAN 1547 01:15:50,963 --> 01:15:52,598 START TO THINK ABOUT BUT IT'S 1548 01:15:52,598 --> 01:15:54,300 NOT YET REALLY BUILT INTO THE 1549 01:15:54,300 --> 01:15:55,068 PROGRAM. 1550 01:15:55,068 --> 01:15:58,438 SO ELIZABETH, I SEE YOUR CAMERA 1551 01:15:58,438 --> 01:16:01,607 ON. 1552 01:16:01,607 --> 01:16:10,483 WOULD YOU LIKE TO ADD 1553 01:16:10,483 --> 01:16:12,919 >> WIRE HOPING TO TARGET NURSES 1554 01:16:12,919 --> 01:16:16,456 AND INDIVIDUALS WITH 1555 01:16:16,456 --> 01:16:18,024 NON-STANDARD BACKGROUNDS AND 1556 01:16:18,024 --> 01:16:20,126 THEN ALONG WITH THE PURPOSE 1557 01:16:20,126 --> 01:16:21,794 NETWORK WE'LL MAKE THE TRAINING 1558 01:16:21,794 --> 01:16:23,329 MATERIALS PUBLIC AND NOT JUST 1559 01:16:23,329 --> 01:16:24,997 AVAILABLE FOR MEMBERS OF THE 1560 01:16:24,997 --> 01:16:27,934 COHORT BUT SPREAD THEM AND SHARE 1561 01:16:27,934 --> 01:16:29,235 THAT WHILE WE'RE NOT AIMING TO 1562 01:16:29,235 --> 01:16:33,406 ESTABLISH A STANDARD ACROSS THE 1563 01:16:33,406 --> 01:16:35,041 FIELD I THINK IT'S AN 1564 01:16:35,041 --> 01:16:35,942 OPPORTUNITY TO START HAVING 1565 01:16:35,942 --> 01:16:37,009 CONVERSATIONS AND IT'S A PLACE 1566 01:16:37,009 --> 01:16:40,446 WHERE WE CAN HAVE DISCUSSIONS. 1567 01:16:40,446 --> 01:16:41,247 THANK YOU. 1568 01:16:41,247 --> 01:16:43,783 >> I THINK IT'S WORTH BRINGING 1569 01:16:43,783 --> 01:16:50,556 TO THE TABLE TO TAKE THE POINT 1570 01:16:50,556 --> 01:16:51,858 OF VIEW AND PENETRATE THE 1571 01:16:51,858 --> 01:16:53,459 WORKFORCE MORE DEEPLY. 1572 01:16:53,459 --> 01:17:02,935 IT'S AN IDEA TO CONSIDER. 1573 01:17:02,935 --> 01:17:04,771 >> WE'RE INTERESTED IN THE 1574 01:17:04,771 --> 01:17:07,240 PATIENT PERSPECTIVE. 1575 01:17:07,240 --> 01:17:13,379 >> I THINK WHAT YOU'RE ALLUDING 1576 01:17:13,379 --> 01:17:22,455 TO IT'S IMPORTANT THE PROVIDERS 1577 01:17:22,455 --> 01:17:26,793 OF INTERVENTIONS THESE TYPES OF 1578 01:17:26,793 --> 01:17:27,193 PROVIDERS -- 1579 01:17:27,193 --> 01:17:32,832 >> CAN YOU TALK LOUDER? 1580 01:17:32,832 --> 01:17:33,166 >> I'M SORRY. 1581 01:17:33,166 --> 01:17:35,201 THESE TYPE OF PROVIDERS NEED TO 1582 01:17:35,201 --> 01:17:36,235 PARTICIPATE IN RESEARCH AND NEED 1583 01:17:36,235 --> 01:17:38,004 TO BE PART OF THE TEAM THAT 1584 01:17:38,004 --> 01:17:41,541 DESIGN THE CLINICAL PROTOCOLS. 1585 01:17:41,541 --> 01:17:45,178 SO THE TYPES OF PROVIDERS 1586 01:17:45,178 --> 01:17:46,212 SOMETIMES A LOT OF THEM ARE 1587 01:17:46,212 --> 01:17:47,580 CLINICIAN, THEY CAN HAVE SOME 1588 01:17:47,580 --> 01:17:49,015 TRAINING IN RESEARCH BUT NOT A 1589 01:17:49,015 --> 01:17:49,282 LOT. 1590 01:17:49,282 --> 01:17:52,451 IT'S A CHALLENGE FOR THEM TO DO 1591 01:17:52,451 --> 01:17:54,921 THAT AND BECOME RESEARCHERS AND 1592 01:17:54,921 --> 01:17:55,855 TO BE SUCCESSFUL. 1593 01:17:55,855 --> 01:17:57,990 SO ONE OF THE THINGS WE'RE DOING 1594 01:17:57,990 --> 01:18:04,430 AT NCCIA WE RECENTLY LAUNCHED A 1595 01:18:04,430 --> 01:18:06,666 RESOURCE CENTER A VIRTUAL 1596 01:18:06,666 --> 01:18:12,004 RESOURCE CENTER THAT 1597 01:18:12,004 --> 01:18:15,908 PARTICULARLY SUPPORTS THE 1598 01:18:15,908 --> 01:18:19,412 SCHOOLS OF FOR EXAMPLE 1599 01:18:19,412 --> 01:18:21,848 CHIROPRACTIC SCHOOL SO HELP THEM 1600 01:18:21,848 --> 01:18:25,017 AND ASSIST THEM IN READING FOR 1601 01:18:25,017 --> 01:18:26,886 EXAMPLE FUNDING OPPORTUNITIES. 1602 01:18:26,886 --> 01:18:29,655 WRITING A GRANT APPLICATION, 1603 01:18:29,655 --> 01:18:34,227 FIGURING OUT LOGISTIC AL DETAIL, 1604 01:18:34,227 --> 01:18:34,827 ADMINISTRATIVE SUPPORT. 1605 01:18:34,827 --> 01:18:45,371 THOSE TYPES OF PROVIDERS HAVE A 1606 01:18:49,075 --> 01:18:55,047 HARD TIME AND THE TYPE OF 1607 01:18:55,047 --> 01:18:56,983 RESOURCE WE GET OUT THAT WILL BE 1608 01:18:56,983 --> 01:18:59,252 MORE CLINICALLY IMPACTFUL. 1609 01:18:59,252 --> 01:19:00,686 >> AND COLLABORATE WITH 1610 01:19:00,686 --> 01:19:01,320 PROFESSIONAL ORGANIZATIONS AS 1611 01:19:01,320 --> 01:19:11,731 ANOTHER WAY TO DO THAT. 1612 01:19:37,790 --> 01:19:40,593 >> THIS IS PERSONS WITH PAIN WHO 1613 01:19:40,593 --> 01:19:46,232 MAY BE MISUSING OPIOIDS AND HOW 1614 01:19:46,232 --> 01:19:52,872 TO ADDRESS THAT SUBPOPULATION IN 1615 01:19:52,872 --> 01:19:54,640 A WAY THAT'S EQUITABLE. 1616 01:19:54,640 --> 01:19:56,108 WE KNOW HOW THORNY THAT PROBLEM 1617 01:19:56,108 --> 01:19:58,444 IS BUT IT'S A LARGE SWATH OF 1618 01:19:58,444 --> 01:20:02,214 PEOPLE MISUSING OPIOID. 1619 01:20:02,214 --> 01:20:08,087 THEY MAY NOT EVEN HAVE OUD. 1620 01:20:08,087 --> 01:20:15,127 EVEN THE TERMINOLOGY, CARLOS, I 1621 01:20:15,127 --> 01:20:19,598 TAKE CARE OF SICKLE CELL DISEASE 1622 01:20:19,598 --> 01:20:20,833 PATIENTS SO THE TERMINOLOGY IS 1623 01:20:20,833 --> 01:20:21,734 NOT ACCURATE TO DATE AND WE 1624 01:20:21,734 --> 01:20:27,373 DON'T HAVE PROGRAMS IN MY MIND 1625 01:20:27,373 --> 01:20:29,909 TO ADDRESS MISTAKEN USE OF 1626 01:20:29,909 --> 01:20:32,578 OPIOIDS IF YOU WANT TO USE THAT 1627 01:20:32,578 --> 01:20:34,347 TERM FOR CHRONIC PAIN 1628 01:20:34,347 --> 01:20:36,949 POPULATIONS WITH WHAT TO 1629 01:20:36,949 --> 01:20:38,384 SUBSTITUTE IT WITH AND HOW TO 1630 01:20:38,384 --> 01:20:42,221 IDENTIFY IT AND I WONDERED IF 1631 01:20:42,221 --> 01:20:45,624 YOU CAN IDENTIFY, WALTER AND 1632 01:20:45,624 --> 01:20:46,459 CARLOS, WHERE IN YOUR PORTFOLIO 1633 01:20:46,459 --> 01:20:56,902 YOU'RE FOCUSSING ON THAT. 1634 01:21:17,289 --> 01:21:23,396 >> WE HAVE FOLKS THAT HAVE SOME 1635 01:21:23,396 --> 01:21:27,900 RISK FACTORS FOR HARMFUL EFFECTS 1636 01:21:27,900 --> 01:21:28,334 OF OPIOIDS. 1637 01:21:28,334 --> 01:21:29,301 THAT'S ONE STUDY. 1638 01:21:29,301 --> 01:21:33,005 AND THE OTHER IS A STUDY OF 1639 01:21:33,005 --> 01:21:36,142 TREATING PAIN AND PEOPLE HAVE 1640 01:21:36,142 --> 01:21:37,476 OPIOID USE DISORDER. 1641 01:21:37,476 --> 01:21:40,446 THOSE ARE THE TWO ONGOING 1642 01:21:40,446 --> 01:21:44,984 PROJECTS IN THIS SPACE RIGHT 1643 01:21:44,984 --> 01:21:46,385 NOW. 1644 01:21:46,385 --> 01:21:51,190 THEY'RE BOTH ANYBODY HAVE ANY -- 1645 01:21:51,190 --> 01:22:01,634 HAS ANYBODY HAVE UPDATES? 1646 01:22:14,180 --> 01:22:21,220 >> IT'S ONE IS WHAT IS THE BEST 1647 01:22:21,220 --> 01:22:31,597 WAY TO TREAT PATIENTS. 1648 01:22:31,797 --> 01:22:34,033 WE HAVE A WORKING GROUP WITH CMS 1649 01:22:34,033 --> 01:22:35,801 AND ONE ISSUE THAT GETS IN THE 1650 01:22:35,801 --> 01:22:37,970 WAY OF PEOPLE GETTING TREATMENT 1651 01:22:37,970 --> 01:22:40,339 ESPECIALLY WITH MORE LIMITED 1652 01:22:40,339 --> 01:22:41,373 RESOURCES IS COVERAGE. 1653 01:22:41,373 --> 01:22:47,313 WE NEED TO DEVELOP THE SCIENCE 1654 01:22:47,313 --> 01:22:51,283 ON HOW TO TREAT PEOPLE WITHOUT 1655 01:22:51,283 --> 01:22:52,518 PUTTING THEM AT RISK OF 1656 01:22:52,518 --> 01:23:00,993 ADDICTION AND GET DATA TO GET 1657 01:23:00,993 --> 01:23:03,629 FDA APPROVAL AND EQUALLY 1658 01:23:03,629 --> 01:23:08,300 IMPORTANT FOR CMS COVERAGE. 1659 01:23:08,300 --> 01:23:09,568 MEDICARE COVERAGE DECIDES WHAT 1660 01:23:09,568 --> 01:23:10,102 WILL PAY FOR IN TERMS OF 1661 01:23:10,102 --> 01:23:19,378 TREATMENT. 1662 01:23:19,378 --> 01:23:24,750 >> THERE'S A GROUP OF PATIENTS 1663 01:23:24,750 --> 01:23:28,454 WITH A RISK FACTOR AND THEY'LL 1664 01:23:28,454 --> 01:23:30,055 GET RELIEF WHEREVER THEY CAN 1665 01:23:30,055 --> 01:23:32,424 INCLUDING THE STREETS AND PEOPLE 1666 01:23:32,424 --> 01:23:34,727 ARE AT RISK OF OPIOID MISUSE OUT 1667 01:23:34,727 --> 01:23:40,065 OF NEED TO HAVE THEIR PAIN 1668 01:23:40,065 --> 01:23:41,267 RELIEVED AND HAVING NO 1669 01:23:41,267 --> 01:23:44,170 APPROPRIATE COVERAGE OR SOURCE 1670 01:23:44,170 --> 01:23:48,274 OF RELIEF OTHER THAN MISUSE OF 1671 01:23:48,274 --> 01:23:48,507 OPIOIDS. 1672 01:23:48,507 --> 01:23:51,944 I'D LIKE TO SEE EMPHASIS ON THAT 1673 01:23:51,944 --> 01:23:55,247 AS WE GO ALONG. 1674 01:23:55,247 --> 01:23:56,982 I'D LIKE TO SEE A LARGER 1675 01:23:56,982 --> 01:24:00,386 PORTFOLIO THAN THE ONE YOU 1676 01:24:00,386 --> 01:24:00,986 DESCRIBED. 1677 01:24:00,986 --> 01:24:02,888 DEVOTED TO THAT YOU'D GET A 1678 01:24:02,888 --> 01:24:04,890 PROPORTION SURVEY AND SEE A 1679 01:24:04,890 --> 01:24:07,593 LARGE PROPORTION OF OPIOID 1680 01:24:07,593 --> 01:24:08,994 MISUSE IS AMONG PEOPLE WITH 1681 01:24:08,994 --> 01:24:19,238 CHRONIC PAIN. 1682 01:24:22,007 --> 01:24:28,581 >> I AGREE WITH YOU. 1683 01:24:28,581 --> 01:24:32,585 ONE OF THE DIFFICULTYIES 1684 01:24:32,585 --> 01:24:34,386 THERAPIES NOT COVERED OR 1685 01:24:34,386 --> 01:24:36,322 MEDICATION BASED THERAPIES ARE 1686 01:24:36,322 --> 01:24:41,026 NOT COVERED BY PUBLIC OR PRIVATE 1687 01:24:41,026 --> 01:24:42,795 INSURANCE LEADING TO OTHER 1688 01:24:42,795 --> 01:24:47,600 POTENTIAL AVENUES LIKE OPIOID 1689 01:24:47,600 --> 01:24:49,702 MISUSE IN A MALADAPTIVE WAY TO 1690 01:24:49,702 --> 01:24:52,471 RELIEVE PAIN. 1691 01:24:52,471 --> 01:24:57,009 ONE ISSUE KNOW AS WELL AS I DO 1692 01:24:57,009 --> 01:25:00,980 INAPPROPRIATE USE CAN LEAD TO 1693 01:25:00,980 --> 01:25:04,450 HYPERALG 1694 01:25:04,450 --> 01:25:04,950 HYPERALGESIA. 1695 01:25:04,950 --> 01:25:09,154 I THINK WE'RE ALL SAYING THE 1696 01:25:09,154 --> 01:25:12,992 SAME PROBLEM WE IDENTIFY BUT I'M 1697 01:25:12,992 --> 01:25:23,369 GLAD YOU BRING IT UP. 1698 01:25:25,104 --> 01:25:29,675 THEY'VE IDENTIFIED THIS CARTOON 1699 01:25:29,675 --> 01:25:31,977 ALMOST LIKE, PLEASE, GIVE US 1700 01:25:31,977 --> 01:25:34,179 SOMETHING TO PAY FOR. 1701 01:25:34,179 --> 01:25:37,783 HAS ANYONE SEEN THE CARTOON I'M 1702 01:25:37,783 --> 01:25:38,117 TALKING ABOUT? 1703 01:25:38,117 --> 01:25:48,527 >> IT'S A GREAT CARTOON. 1704 01:25:56,001 --> 01:26:02,007 >> EMPOWER DEVELOPED INTEGRATION 1705 01:26:02,007 --> 01:26:04,009 TREATMENT FOR CHRONIC PAIN AND 1706 01:26:04,009 --> 01:26:06,779 OPIOID DISORDER AND MISUSE. 1707 01:26:06,779 --> 01:26:11,050 THE TOPIC TIES INTO MIRACLE 1708 01:26:11,050 --> 01:26:15,587 DESCRIBING WHEN OPIOID HARMS 1709 01:26:15,587 --> 01:26:16,322 OUTWEIGH BENEFITS FOR CHRONIC 1710 01:26:16,322 --> 01:26:17,523 PAIN MANAGEMENT. 1711 01:26:17,523 --> 01:26:19,425 WE FUNDED TWO PROGRAMS WHO WILL 1712 01:26:19,425 --> 01:26:20,826 BE WORKING TOGETHER TO DEVELOP 1713 01:26:20,826 --> 01:26:22,528 SOLUTIONS AND INSIGHT INTO THE 1714 01:26:22,528 --> 01:26:24,463 ISSUE. 1715 01:26:24,463 --> 01:26:28,033 ONE OF THEM IS FROM THE YALE 1716 01:26:28,033 --> 01:26:31,970 KAISER SIDE AND LINDA BARNES IS 1717 01:26:31,970 --> 01:26:33,005 PART OF THE GROUP USING 1718 01:26:33,005 --> 01:26:34,840 QUALITATIVE APPROACHES TO GET AT 1719 01:26:34,840 --> 01:26:36,975 THE ISSUE. 1720 01:26:36,975 --> 01:26:39,511 THAT'S WHAT YALE IS DOING AND 1721 01:26:39,511 --> 01:26:41,647 OTHER GRANTEES. 1722 01:26:41,647 --> 01:26:44,983 THEY'LL BE LOOKING AT CLAIMS 1723 01:26:44,983 --> 01:26:47,786 ANALYSIS OF MISUSE OR OPIOID 1724 01:26:47,786 --> 01:26:51,056 RISK BEHAVIORS USING 1725 01:26:51,056 --> 01:26:52,358 ADMINISTRATIVE DATA SETS THAT 1726 01:26:52,358 --> 01:26:53,692 WILL GIVE US THE POPULATION 1727 01:26:53,692 --> 01:26:56,995 LEVEL AND SCOPING ADVANTAGE THAT 1728 01:26:56,995 --> 01:27:02,468 IS NOT OFFERED BY YALE. 1729 01:27:02,468 --> 01:27:05,771 THE QUESTION ON WHAT OPIOID RISK 1730 01:27:05,771 --> 01:27:11,243 AND HARMS WILL GO TO A PARTNER 1731 01:27:11,243 --> 01:27:15,280 CONSULTATION BOARD FROM PRIVATE 1732 01:27:15,280 --> 01:27:16,482 PAYERS AND PROFESSIONAL 1733 01:27:16,482 --> 01:27:17,149 ORGANIZATIONS, LIVED EXPERIENCE 1734 01:27:17,149 --> 01:27:19,184 COMMUNITY MEMBERS TO HELP US 1735 01:27:19,184 --> 01:27:21,019 DRIVE DATA DRIVEN EVIDENCE TO 1736 01:27:21,019 --> 01:27:22,054 THIS. 1737 01:27:22,054 --> 01:27:24,289 RIGHT NOW WE JUST HAVE OPINIONS 1738 01:27:24,289 --> 01:27:24,923 WITHOUT A LOT OF DATA TO SUPPORT 1739 01:27:24,923 --> 01:27:29,695 THAT. 1740 01:27:29,695 --> 01:27:31,530 THERE'S QUESTIONS ON OPIOID 1741 01:27:31,530 --> 01:27:32,931 RELATED HARMS AND WHO DECIDES 1742 01:27:32,931 --> 01:27:36,735 WHEN HARMS OUTWAY BENEFITS ARE 1743 01:27:36,735 --> 01:27:37,536 QUESTIONS WE'LL BE EXPLORING. 1744 01:27:37,536 --> 01:27:41,807 WE JUST ENTERED OUR SECOND YEAR 1745 01:27:41,807 --> 01:27:42,374 YEAR. 1746 01:27:42,374 --> 01:27:43,609 WE HAVE A LONG ROAD AHEAD. 1747 01:27:43,609 --> 01:27:45,677 IF YOU HAVE SPECIFIC SUGGESTIONS 1748 01:27:45,677 --> 01:27:48,981 OR INPUT WE DEFINITELY WELCOME 1749 01:27:48,981 --> 01:27:50,315 YOUR INSIGHT. 1750 01:27:50,315 --> 01:27:51,150 >> THANK YOU SO MUCH. 1751 01:27:51,150 --> 01:27:52,684 I WANT TO CHECK AND SEE IF THE 1752 01:27:52,684 --> 01:27:54,620 OTHER HANDS ARE RELATED TO THIS 1753 01:27:54,620 --> 01:28:05,130 POINT OR IF WE SHOULD MOVE ON? 1754 01:28:09,001 --> 01:28:11,136 >> THIS IS EXACTLY THE INPUT 1755 01:28:11,136 --> 01:28:13,572 WE'RE LOOKING FOR SO WE GREATLY 1756 01:28:13,572 --> 01:28:15,107 PATIENT IT THOUGH WE'RE RUNNING 1757 01:28:15,107 --> 01:28:15,574 A LITTLE BIT BEHIND. 1758 01:28:15,574 --> 01:28:18,243 >> I'M HAPPY TO HEAR ABOUT THE 1759 01:28:18,243 --> 01:28:19,845 PREVENTION INITIATIVES. 1760 01:28:19,845 --> 01:28:20,946 I'M WONDERING WHETHER PART OF 1761 01:28:20,946 --> 01:28:25,617 THIS IF THERE'S AN EFFORT TO 1762 01:28:25,617 --> 01:28:28,187 DEVELOP EARLY BIOMARKERS OF RISK 1763 01:28:28,187 --> 01:28:28,987 FOR ADDICTION. 1764 01:28:28,987 --> 01:28:31,757 WHICH INDIVIDUALS ARE 1765 01:28:31,757 --> 01:28:32,991 SUSCEPTIBLE TO THE EFFECTS OF 1766 01:28:32,991 --> 01:28:34,460 PARTICULAR DRUGS. 1767 01:28:34,460 --> 01:28:35,694 IT'S CLEAR MOST OF THE -- 1768 01:28:35,694 --> 01:28:38,197 THERE'S ONLY A SEGMENT OF THE 1769 01:28:38,197 --> 01:28:40,332 POPULATION REALLY SUSCEPTIBLE TO 1770 01:28:40,332 --> 01:28:44,503 THE ENFORCING EFFECTS OF ANY 1771 01:28:44,503 --> 01:28:46,839 GIVEN DRUG AND PROBABLY 1772 01:28:46,839 --> 01:28:47,739 CHALLENGING TO DEVELOP 1773 01:28:47,739 --> 01:28:48,807 BIOMARKERS LIKE THAT BUT 1774 01:28:48,807 --> 01:28:50,843 WONDERING IF THERE'S EFFORTS IN 1775 01:28:50,843 --> 01:28:51,543 THAT DIRECTION. 1776 01:28:51,543 --> 01:28:57,316 >> I THINK WE CAN THINK OF 1777 01:28:57,316 --> 01:29:01,220 BIOMARKERS IN TWO DIFFERENT WAYS 1778 01:29:01,220 --> 01:29:04,523 ONE IS FOR RISK STRATIFICATION 1779 01:29:04,523 --> 01:29:05,290 AND RESPONSE. 1780 01:29:05,290 --> 01:29:09,294 RIGHT NOW THE BEST PREDICTORS 1781 01:29:09,294 --> 01:29:16,268 ARE PONG BASED MORE FOR SOCIO 1782 01:29:16,268 --> 01:29:19,037 DEMOGRAPHICS, COMORBIDITIES 1783 01:29:19,037 --> 01:29:20,305 LOOKING AT BIOMARKERS. 1784 01:29:20,305 --> 01:29:21,773 IT'S DIFFICULT NOT ONLY IN 1785 01:29:21,773 --> 01:29:25,010 SUBSTANCE USE BUT ACROSS ALL 1786 01:29:25,010 --> 01:29:27,045 PSYCHIATRY BIOMARKERS. 1787 01:29:27,045 --> 01:29:34,853 ONE PAPER IF YOU HAVE NOT READ 1788 01:29:34,853 --> 01:29:44,029 IS A PAPER THAT PROVIDES A GOOD 1789 01:29:44,029 --> 01:29:46,498 METHODS TO IDENTIFY PREDICTIVE 1790 01:29:46,498 --> 01:29:49,234 BIOMARKERS TO HELP IN MEDICATION 1791 01:29:49,234 --> 01:29:49,535 DEVELOPMENT. 1792 01:29:49,535 --> 01:29:51,970 THE PAPER IS NOT SPECIFICALLY 1793 01:29:51,970 --> 01:29:55,974 FOR SUBSTANCE USE BUT CERTAINLY 1794 01:29:55,974 --> 01:30:01,880 MANY LESSONS OR THOUGHTS HE HAS 1795 01:30:01,880 --> 01:30:02,881 AND WE SHOULD THINK ABOUT 1796 01:30:02,881 --> 01:30:04,483 DEVELOP BEING BIOMARKERS FOR 1797 01:30:04,483 --> 01:30:14,893 MEDICATION DEVELOPMENT. 1798 01:30:19,398 --> 01:30:20,766 >> ONE COMMENT WAS AROUND 1799 01:30:20,766 --> 01:30:21,700 CHRONIC PAIN. 1800 01:30:21,700 --> 01:30:26,705 WE SEE THIS A LOT AND IT'S 1801 01:30:26,705 --> 01:30:36,982 DIFFICULT TO TEASE INDIVIDUALS 1802 01:30:36,982 --> 01:30:39,618 OUT AND SOMETIMES THEY DON'T GET 1803 01:30:39,618 --> 01:30:43,956 WHAT THEY WANT AND THEY GO AN 1804 01:30:43,956 --> 01:30:54,499 AND BUE -- BUPRENORPHINE IS A 1805 01:30:57,069 --> 01:31:00,973 GREAT MEDICATION FOR THIS AND 1806 01:31:00,973 --> 01:31:03,442 MANY I FOLLOW-UP UP WITH GO ON 1807 01:31:03,442 --> 01:31:06,411 TO WORK AND THE FOOD INDUSTRIES 1808 01:31:06,411 --> 01:31:08,614 AND THINGS THEY'RE WORKING AND 1809 01:31:08,614 --> 01:31:12,284 CONSTANTLY HAVING TO LIFT AND 1810 01:31:12,284 --> 01:31:12,985 CARRY THINGS. 1811 01:31:12,985 --> 01:31:16,054 WE NEED MORE INTEREST IN USING 1812 01:31:16,054 --> 01:31:18,757 BUPRENORPHINE FOR INDIVIDUALS. 1813 01:31:18,757 --> 01:31:21,960 AGAIN, I HAVE ANECDOTAL EVIDENCE 1814 01:31:21,960 --> 01:31:27,432 BUT IT WOULD BE GREAT TO HAVE 1815 01:31:27,432 --> 01:31:27,633 THAT. 1816 01:31:27,633 --> 01:31:28,500 THE OTHER THING AND THANK YOU 1817 01:31:28,500 --> 01:31:30,469 FOR THE OVERVIEW OF EVERYTHING. 1818 01:31:30,469 --> 01:31:32,771 I CAN'T STRESS ENOUGH ABOUT HOW 1819 01:31:32,771 --> 01:31:35,374 THESE TOUCH POINTS FOR PEOPLE 1820 01:31:35,374 --> 01:31:36,341 WITH OPIATE USE DISORDER NEEDS 1821 01:31:36,341 --> 01:31:36,541 TO BE. 1822 01:31:36,541 --> 01:31:38,577 THEY DON'T GO TO PRIMARY CARE. 1823 01:31:38,577 --> 01:31:44,516 SO WE NEED TO FIND THEM PLACES, 1824 01:31:44,516 --> 01:31:47,252 COMMUNITY CENTERS WE'RE STARTING 1825 01:31:47,252 --> 01:31:51,456 THINGS AT OUR COMMUNITY PLACE 1826 01:31:51,456 --> 01:31:53,325 PEOPLE CAN WALK IN AND PROVIDE 1827 01:31:53,325 --> 01:31:53,859 TREATMENT THERE. 1828 01:31:53,859 --> 01:31:56,995 EMS, I CAN'T TELL YOU ENOUGH 1829 01:31:56,995 --> 01:31:58,664 ABOUT HOW MANY PEOPLE ARE SEEN 1830 01:31:58,664 --> 01:32:00,866 BY EMS AND HAVE OVERDOSES AND 1831 01:32:00,866 --> 01:32:05,470 CAN HAVE INITIATION OF TREATMENT 1832 01:32:05,470 --> 01:32:07,406 AT THAT POINT AND ALSO BESIDES 1833 01:32:07,406 --> 01:32:08,907 LOOKING AT THE LOW BARRIER 1834 01:32:08,907 --> 01:32:14,346 ACCESS WHERE PEOPLE CAN COME IN 1835 01:32:14,346 --> 01:32:19,651 AND OUT AND THE FACT SO MANY ARE 1836 01:32:19,651 --> 01:32:21,853 HOMELESS OR UNSTABLE HOUSING IS 1837 01:32:21,853 --> 01:32:23,088 HURTING US THE MOST. 1838 01:32:23,088 --> 01:32:25,057 HOW CAN WE DO THIS? 1839 01:32:25,057 --> 01:32:26,692 I HAVE INCREDIBLE IDEAS THAT 1840 01:32:26,692 --> 01:32:28,460 WOULD TAKE MILLIONS OF DOLLARS 1841 01:32:28,460 --> 01:32:31,029 BUT WE OFTEN TRY TO TAKE ONE 1842 01:32:31,029 --> 01:32:32,197 PERSON FROM A HOMELESS COMMUNITY 1843 01:32:32,197 --> 01:32:34,166 AND TRY TO GET THEM AND READY 1844 01:32:34,166 --> 01:32:35,967 BUT NOT NOT TAKE A COMMUNITY OF 1845 01:32:35,967 --> 01:32:39,571 PEOPLE WHO ARE HOMELESS, THOSE 1846 01:32:39,571 --> 01:32:41,606 ARE THEIR COMMUNITY AND TAKE THE 1847 01:32:41,606 --> 01:32:42,641 GROUP AND SEE WHICH ONES WOULD 1848 01:32:42,641 --> 01:32:47,612 WANT TO BE HOUSED AND PUT THE 1849 01:32:47,612 --> 01:32:48,513 RESOURCES IN THAT AREA FOR 1850 01:32:48,513 --> 01:32:49,314 TREATMENT AS WELL AS OTHER 1851 01:32:49,314 --> 01:32:51,316 RESOURCES BUT YOU NEED TO TAKE A 1852 01:32:51,316 --> 01:32:53,518 GROUP OF PEOPLE AND IT WOULD 1853 01:32:53,518 --> 01:32:56,254 TAKE LOTS OF MONEY. 1854 01:32:56,254 --> 01:33:01,460 THAT IS A RATE LIMITING STEP THE 1855 01:33:01,460 --> 01:33:01,860 OUTREACH. 1856 01:33:01,860 --> 01:33:03,095 WHEN YOU PUT PEOPLE BACK TO A 1857 01:33:03,095 --> 01:33:05,363 COMMUNITY THAT ARE USING, IT'S 1858 01:33:05,363 --> 01:33:06,431 NOT GOING TO WORK. 1859 01:33:06,431 --> 01:33:07,966 NO MATTER HOW MOTIVATED IS OR 1860 01:33:07,966 --> 01:33:10,502 GET SOMEONE ON TREATMENT YOU GO 1861 01:33:10,502 --> 01:33:13,505 BACK TO THAT COMMUNITY WHERE 1862 01:33:13,505 --> 01:33:14,506 EVERYONE IS USING. 1863 01:33:14,506 --> 01:33:15,540 YOU'RE NEVER GOING TO BE ABLE TO 1864 01:33:15,540 --> 01:33:17,642 GET OUT OF IT. 1865 01:33:17,642 --> 01:33:18,577 EVEN TAKING SMALLER COMMUNITIES 1866 01:33:18,577 --> 01:33:20,746 OF WHO IS LIVING IN CERTAIN 1867 01:33:20,746 --> 01:33:23,248 AREAS AND THAT ENCAMPMENT AND 1868 01:33:23,248 --> 01:33:27,285 PLACING THEM ALL IN PLACES AND 1869 01:33:27,285 --> 01:33:28,987 WORKING WITH THAT, THAT MAY BE 1870 01:33:28,987 --> 01:33:36,962 WORTH A LOT OF RESOURCES. 1871 01:33:36,962 --> 01:33:38,530 >> I BROUGHT UP A COUPLE 1872 01:33:38,530 --> 01:33:39,798 IMPORTANT ISSUES. 1873 01:33:39,798 --> 01:33:43,535 ONE IS THE IMPORTANCE OF SOCIAL 1874 01:33:43,535 --> 01:33:44,770 DETERMINATES OF HEALTH AND HOW 1875 01:33:44,770 --> 01:33:46,471 MUCH YOU PUT INTO SOCIAL 1876 01:33:46,471 --> 01:33:47,973 SERVICES VERSUS HEALTH CARE. 1877 01:33:47,973 --> 01:33:52,778 THAT'S A VERY DIFFICULT 1878 01:33:52,778 --> 01:33:53,044 DECISION. 1879 01:33:53,044 --> 01:33:55,614 THE OTHER ONE IS TALKING ABOUT 1880 01:33:55,614 --> 01:33:58,216 QUALITY OF CARE. 1881 01:33:58,216 --> 01:34:02,554 WE'RE WORKING IN NIDA AND HOW DO 1882 01:34:02,554 --> 01:34:08,994 WE BALANCE PROVIDING QUALITY 1883 01:34:08,994 --> 01:34:15,700 CARE WITH GIVING TO EVERYBODY 1884 01:34:15,700 --> 01:34:21,406 RESPECTING AND ENSURING WE 1885 01:34:21,406 --> 01:34:30,882 QUALITY OF CARE. 1886 01:34:30,882 --> 01:34:35,954 WE'RE DEVELOPING DIFFERENT 1887 01:34:35,954 --> 01:34:38,590 OFFERS TO DIFFERENT PEOPLE TO 1888 01:34:38,590 --> 01:34:41,593 GIVE SOMETHING THAT IS USEFUL. 1889 01:34:41,593 --> 01:34:44,462 AS WE DISCUSSED MANY TIMES AND 1890 01:34:44,462 --> 01:34:46,498 SOMETHING THAT COULD BE COVERED 1891 01:34:46,498 --> 01:34:50,035 BY MEDICARE OR MEDICAID OR 1892 01:34:50,035 --> 01:34:51,036 PRIVATE INSURANCE. 1893 01:34:51,036 --> 01:34:53,605 TRYING TO THREAD THAT NEEDLE IS 1894 01:34:53,605 --> 01:34:53,872 IMPORTANT. 1895 01:34:53,872 --> 01:34:56,741 I'M THANKFUL YOU REMIND US. 1896 01:34:56,741 --> 01:34:59,811 >> I THINK WE HAVE TO BE 1897 01:34:59,811 --> 01:35:04,449 COGNIZANT. 1898 01:35:04,449 --> 01:35:07,786 IT MAY NOT BE THE PERFECT THING 1899 01:35:07,786 --> 01:35:08,820 TO SAY AND I WOULDN'T SAY TAKE 1900 01:35:08,820 --> 01:35:11,289 WHAT YOU WANT AND I'LL GIVE YOU 1901 01:35:11,289 --> 01:35:12,390 THAT. 1902 01:35:12,390 --> 01:35:14,459 I'D CONSTANTLY GO OVER THIS IS 1903 01:35:14,459 --> 01:35:16,494 WHAT IS PROVEN TO BE EFFECTIVE 1904 01:35:16,494 --> 01:35:18,797 AND I WOULD CONSTANTLY TRY TO 1905 01:35:18,797 --> 01:35:20,298 MOTIVATE PEOPLE TO USE THAT 1906 01:35:20,298 --> 01:35:21,633 TREATMENT AND OF COURSE IF THEY 1907 01:35:21,633 --> 01:35:23,602 WERE NOT READY AT THAT POINT I 1908 01:35:23,602 --> 01:35:25,270 WOULD OFFER SOMETHING ELSE BUT I 1909 01:35:25,270 --> 01:35:26,738 WOULD NEVER STOP WITH WHAT I 1910 01:35:26,738 --> 01:35:28,473 THINK IS THE BEST TREATMENT. 1911 01:35:28,473 --> 01:35:31,243 SOMETIMES I FEEL LIKE WE'RE 1912 01:35:31,243 --> 01:35:35,513 REACHING A LITTLE BIT TOO FAR IN 1913 01:35:35,513 --> 01:35:37,048 THE OPPOSITE DIRECTION WITH 1914 01:35:37,048 --> 01:35:41,419 SUBSTANCE USE DISORDERS AND 1915 01:35:41,419 --> 01:35:42,487 PARTICULARLY OPIATE USE 1916 01:35:42,487 --> 01:35:44,189 DISORDER. 1917 01:35:44,189 --> 01:35:47,392 I GIVE OUT TONS OF NARCAN BUT 1918 01:35:47,392 --> 01:35:48,059 IT'S NOT THE TREATMENT. 1919 01:35:48,059 --> 01:35:50,528 I ALWAYS GO BACK TO WHAT THE 1920 01:35:50,528 --> 01:35:52,497 TREATMENT IS AND GIVE IT ANOTHER 1921 01:35:52,497 --> 01:35:56,201 SHOT. 1922 01:35:56,201 --> 01:35:59,237 MOST THE TIME I CAN GET PEOPLE 1923 01:35:59,237 --> 01:36:00,005 TO MOVE A LITTLE BIT. 1924 01:36:00,005 --> 01:36:06,111 >> IT'S A MATTER OF LET'S JUST 1925 01:36:06,111 --> 01:36:08,580 TALK ABOUT IT A LITTLE BIT AND 1926 01:36:08,580 --> 01:36:10,682 HOW ONE DOES THAT IN THE HEALTH 1927 01:36:10,682 --> 01:36:12,284 ENVIRONMENT SYSTEM. 1928 01:36:12,284 --> 01:36:13,985 WE CAN'T LOSE TRACK OF THAT OR 1929 01:36:13,985 --> 01:36:16,154 WE'LL END UP NOT REALLY MOVING 1930 01:36:16,154 --> 01:36:18,156 THE NEEDLE WHICH IS WHAT COULD 1931 01:36:18,156 --> 01:36:20,358 HAVE HAPPENED WITH A COMMUNITY 1932 01:36:20,358 --> 01:36:22,494 LIKE PEOPLE ARE STILL DYING WITH 1933 01:36:22,494 --> 01:36:24,663 HEAL AND PEOPLE ARE STILL 1934 01:36:24,663 --> 01:36:25,630 OVERDOSING. 1935 01:36:25,630 --> 01:36:29,401 I CAN'T GIVE OUT ENOUGH NARCAN 1936 01:36:29,401 --> 01:36:30,335 TO STOP THAT. 1937 01:36:30,335 --> 01:36:33,138 I HAVE TO START WITH GETTING 1938 01:36:33,138 --> 01:36:36,574 PEOPLE INTO TREATMENT. 1939 01:36:36,574 --> 01:36:37,642 AND TOTALLY WITH PREVENTION. 1940 01:36:37,642 --> 01:36:40,478 ALL RIGHT. 1941 01:36:40,478 --> 01:36:40,812 I'LL BE QUIET. 1942 01:36:40,812 --> 01:36:44,783 THANK YOU. 1943 01:36:44,783 --> 01:36:46,418 >> YOU CAN MAKE YOUR COMMENT BUT 1944 01:36:46,418 --> 01:36:49,020 I WANT TO NOTE WE'RE ALMOST 20 1945 01:36:49,020 --> 01:36:49,988 MINUTES BEHIND. 1946 01:36:49,988 --> 01:36:53,725 >> I'LL BE QUICK AND I HAVE TWO 1947 01:36:53,725 --> 01:36:54,059 COMMENTS. 1948 01:36:54,059 --> 01:36:59,965 ONE FALLS ON WHAT GAIL AND WALLY 1949 01:36:59,965 --> 01:37:08,974 BROUGHT UP. 1950 01:37:08,974 --> 01:37:16,481 WE HAVE AND A SUBSTANTIAL OF 1951 01:37:16,481 --> 01:37:18,083 PROPORTION OF PEOPLE IN OUR 1952 01:37:18,083 --> 01:37:19,184 TRIAL ARE PEOPLE WHO HAVE 1953 01:37:19,184 --> 01:37:21,019 CHRONIC PAIN AND WE HAVE VERY 1954 01:37:21,019 --> 01:37:24,322 DIFFERENT APPROACHES IN OUR 1955 01:37:24,322 --> 01:37:26,257 CLINICAL SITES ABOUT WHETHER TO 1956 01:37:26,257 --> 01:37:27,158 USE BUPRENORPHINE OR NOT AND 1957 01:37:27,158 --> 01:37:29,995 IT'S A SHAME WE DON'T HAVE THE 1958 01:37:29,995 --> 01:37:31,629 RESOURCE TO EXPLORE THIS FURTHER 1959 01:37:31,629 --> 01:37:35,867 BECAUSE OF THE MECHANISM. 1960 01:37:35,867 --> 01:37:39,170 SO JUST TO PUT A PLUG IN THERE'S 1961 01:37:39,170 --> 01:37:41,740 WAYS FOR SOME STUDIES WHERE 1962 01:37:41,740 --> 01:37:43,641 THERE'S GAINS IN THE MARGINS 1963 01:37:43,641 --> 01:37:46,478 WE'RE NOT ALWAYS ABLE TO 1964 01:37:46,478 --> 01:37:49,314 REALIZE. 1965 01:37:49,314 --> 01:37:52,017 MY QUESTION AND COMMENT WAS FOR 1966 01:37:52,017 --> 01:37:53,251 WALTER IS YOU HAD GONE THROUGH 1967 01:37:53,251 --> 01:37:55,754 THE LIST OF RECOMMENDATIONS BY 1968 01:37:55,754 --> 01:37:56,688 THE FEDERAL PAIN RESEARCH 1969 01:37:56,688 --> 01:37:56,955 STRATEGY. 1970 01:37:56,955 --> 01:37:59,724 THE FIRST BEING TO DEVELOP A 1971 01:37:59,724 --> 01:38:01,559 PAIN RESEARCH NETWORK AND I'M 1972 01:38:01,559 --> 01:38:03,061 CURIOUS, I KNOW THERE'S THE 1973 01:38:03,061 --> 01:38:06,398 PURPOSE NET WORK, THERE'S THE 1974 01:38:06,398 --> 01:38:08,400 PAIN ERN AND WHAT DR. CRISWELL 1975 01:38:08,400 --> 01:38:11,202 IS TALKING ABOUT IN TERMS OF 1976 01:38:11,202 --> 01:38:13,304 BACKPACK GETS AT SOME OF THIS 1977 01:38:13,304 --> 01:38:15,907 AND THEY GET AT A PIECE OF WHAT 1978 01:38:15,907 --> 01:38:19,411 THE FPRS WAS SUGGESTING WITH THE 1979 01:38:19,411 --> 01:38:20,879 PAIN RESEARCH NET WORK BUT NONE 1980 01:38:20,879 --> 01:38:22,680 SEEM FULLY ALIGNED WITH THAT. 1981 01:38:22,680 --> 01:38:25,216 I DON'T KNOW IF YOU HAVE ANY 1982 01:38:25,216 --> 01:38:28,486 OTHER THOUGHTS OR COMMENTS. 1983 01:38:28,486 --> 01:38:29,921 I KNOW WE'RE EARLY IN HEAL TOO 1984 01:38:29,921 --> 01:38:31,856 BUT IT WOULD BE GREAT TO SEE 1985 01:38:31,856 --> 01:38:36,261 SOME ELEMENTS UNDER THE PAIN 1986 01:38:36,261 --> 01:38:37,996 RESEARCH NETWORK GET MORE 1987 01:38:37,996 --> 01:38:40,498 ATTENTION AND DEVELOPMENT THAN 1988 01:38:40,498 --> 01:38:48,573 WE CURRENTLY HAVE. 1989 01:38:48,573 --> 01:38:50,809 >> WE CAN WORK ON THAT. 1990 01:38:50,809 --> 01:38:58,416 WE ALSO HAVE THE PRISM NETWORK. 1991 01:38:58,416 --> 01:39:00,452 WE HAVE DIFFERENT NETWORKS FOR 1992 01:39:00,452 --> 01:39:04,122 DIFFERENT AUDIENCES, ACADEMIC, 1993 01:39:04,122 --> 01:39:07,358 HEALTH CARE SYSTEMS. 1994 01:39:07,358 --> 01:39:08,960 >> CAN YOU TALK LOUDER. 1995 01:39:08,960 --> 01:39:10,495 >> WE SHOULD TALK OFFLINE HOW TO 1996 01:39:10,495 --> 01:39:16,801 DO BETTER. 1997 01:39:16,801 --> 01:39:18,570 >> THANK YOU. 1998 01:39:18,570 --> 01:39:19,804 COLLECTIVELY THEY'RE RESPONSIVE 1999 01:39:19,804 --> 01:39:23,441 TO THIS. 2000 01:39:23,441 --> 01:39:23,675 THANKS. 2001 01:39:23,675 --> 01:39:25,910 >> DR. GARLAND, LAST COMMENT. 2002 01:39:25,910 --> 01:39:27,112 THANK YOU. 2003 01:39:27,112 --> 01:39:30,448 I WAS STRUCK BY DR. BLANCO'S 2004 01:39:30,448 --> 01:39:32,450 COMMENT ABOUT NIDA'S HEAL 2005 01:39:32,450 --> 01:39:34,486 EFFORTS TO TRY TO TAKE PROGRAMS 2006 01:39:34,486 --> 01:39:37,021 THAT HAVE BEEN SHOWN TO BE 2007 01:39:37,021 --> 01:39:41,726 EFFICACIOUS AND SUSTAIN THEM IN 2008 01:39:41,726 --> 01:39:42,927 THE REAL WORLD AFTER THE HEAL 2009 01:39:42,927 --> 01:39:43,928 FUNDING HAS ENDED. 2010 01:39:43,928 --> 01:39:48,066 I'D LIKE TO HEAR MORE ABOUT THAT 2011 01:39:48,066 --> 01:39:52,036 AND BACK TO WALLY'S POINT ABOUT 2012 01:39:52,036 --> 01:39:56,474 PEOPLE WITH CHRONIC PAIN WHO 2013 01:39:56,474 --> 01:39:58,476 ALSO MAY BE MISUSING OPIOIDS AND 2014 01:39:58,476 --> 01:40:00,979 THE NEED TO ADDRESS THIS 2015 01:40:00,979 --> 01:40:01,279 POPULATION. 2016 01:40:01,279 --> 01:40:04,015 FOR EXAMPLE, WE'VE DEVELOPED IT 2017 01:40:04,015 --> 01:40:08,987 AN EVIDENCE BASED TREATMENT FOR 2018 01:40:08,987 --> 01:40:13,458 THIS POPULATION AND THE CLINICAL 2019 01:40:13,458 --> 01:40:16,995 TRIAL WAS SUCCESSFUL AND 2020 01:40:16,995 --> 01:40:18,163 REPLICATED IN MULTIPLE CLINICAL 2021 01:40:18,163 --> 01:40:19,797 TRIALS AT THIS POINT AND 2022 01:40:19,797 --> 01:40:22,700 EXPERIENCED THIS TRANSLATIONAL 2023 01:40:22,700 --> 01:40:24,936 GAP BETWEEN CONTROLLED RESEARCH 2024 01:40:24,936 --> 01:40:27,772 TO BRING THIS INTERVENTION OUT 2025 01:40:27,772 --> 01:40:30,708 IN THE REAL WORLD AND REALLY I 2026 01:40:30,708 --> 01:40:32,310 THINK THE BARRIER WE'VE 2027 01:40:32,310 --> 01:40:32,944 EXPERIENCED IS COMMENTS THAT 2028 01:40:32,944 --> 01:40:39,284 MOST PEOPLE IN THIS PIPELINE OF 2029 01:40:39,284 --> 01:40:41,553 TREATMENT DEVELOPMENT RESEARCH 2030 01:40:41,553 --> 01:40:43,054 IT SEEMS TO FALL INTO A BLACK 2031 01:40:43,054 --> 01:40:46,858 HOLE OF FUNDING AND THIS RELATES 2032 01:40:46,858 --> 01:40:49,394 TO POLICY BOTH AT THE LOCAL AND 2033 01:40:49,394 --> 01:40:50,495 STATE LEVELS. 2034 01:40:50,495 --> 01:40:52,497 I'M WONDERING WHAT CAN BE DONE 2035 01:40:52,497 --> 01:41:01,539 TO HELP BROKER THIS PATHWAY OF 2036 01:41:01,539 --> 01:41:02,874 TRANSLATIONAL GAP TO GET 2037 01:41:02,874 --> 01:41:04,976 THERAPIES THAT HAVE SHOWN TO BE 2038 01:41:04,976 --> 01:41:10,648 EFFICACIOUS OUT IN THE REAL 2039 01:41:10,648 --> 01:41:12,984 WORLD. 2040 01:41:12,984 --> 01:41:14,986 >> 2041 01:41:14,986 --> 01:41:19,123 >> WE SPECIFICALLY REQUIRED THE 2042 01:41:19,123 --> 01:41:20,325 APPLICANT WITH THE POTENTIAL 2043 01:41:20,325 --> 01:41:22,794 PARTNER THAT WE SUSTAINED THE 2044 01:41:22,794 --> 01:41:24,996 INTERVENTION AFTER THE RESEARCH 2045 01:41:24,996 --> 01:41:26,097 IS COMPLETED. 2046 01:41:26,097 --> 01:41:27,465 AND THERE ARE DIFFERENT LEVELS 2047 01:41:27,465 --> 01:41:28,132 OF REQUIREMENT. 2048 01:41:28,132 --> 01:41:29,400 WE HAVE TO BE FLEXIBLE. 2049 01:41:29,400 --> 01:41:31,135 WE WANT TO ENCOURAGE THAT. 2050 01:41:31,135 --> 01:41:33,004 AT THE SAME TIME WE HAVE TO 2051 01:41:33,004 --> 01:41:34,672 REALIZE THE TRADITION FOR MANY 2052 01:41:34,672 --> 01:41:36,841 YEARS HAS NOT BEEN THAT BUT 2053 01:41:36,841 --> 01:41:39,277 WE'RE MAKING PROGRESS AND PEOPLE 2054 01:41:39,277 --> 01:41:40,979 ARE GETTING VERY INTERESTED AND 2055 01:41:40,979 --> 01:41:42,180 WE'RE GENERATING MUCH BETTER 2056 01:41:42,180 --> 01:41:43,014 RESEARCH BECAUSE WE'RE 2057 01:41:43,014 --> 01:41:44,148 GENERATING RESEARCH THAT 2058 01:41:44,148 --> 01:41:47,051 RESPONDS TO THE NEEDS AND 2059 01:41:47,051 --> 01:41:48,720 CAPACITIES OF THE SYSTEMS WE 2060 01:41:48,720 --> 01:41:50,255 HAVE TO SCALE UP AND IMPLEMENT 2061 01:41:50,255 --> 01:41:50,521 THOSE. 2062 01:41:50,521 --> 01:41:52,490 SO THAT'S ONE THING WE'RE DOING. 2063 01:41:52,490 --> 01:41:56,127 THE SECOND THING WE'RE DOING IS 2064 01:41:56,127 --> 01:41:58,997 WE'RE WORKING ALL THE TIME AND 2065 01:41:58,997 --> 01:42:03,001 IT TAKES TIME AND EFFORT AND WE 2066 01:42:03,001 --> 01:42:06,504 WORK WITH MOSTLY CMS AND SAMHSA 2067 01:42:06,504 --> 01:42:08,940 TO SEE WHAT SOURCES OF REVENUES 2068 01:42:08,940 --> 01:42:09,207 THERE ARE. 2069 01:42:09,207 --> 01:42:11,576 THERE ARE POCKETS OF REVENUES 2070 01:42:11,576 --> 01:42:13,411 FOR OTHER SERVICES, THE JUSTICE 2071 01:42:13,411 --> 01:42:15,213 SYSTEM BUT WE TRY TO WORK WITH 2072 01:42:15,213 --> 01:42:18,650 DIFFERENT FUNDERS TO SEE IF 2073 01:42:18,650 --> 01:42:20,018 THOSE INTERVENTIONS WILL BE 2074 01:42:20,018 --> 01:42:22,487 SUSTAINABLE FOR THEM AND TO 2075 01:42:22,487 --> 01:42:32,964 IDENTIFY SOURCES OF FUNDING. 2076 01:42:44,509 --> 01:42:46,177 AND WE LOOKED AT STANDARD OF 2077 01:42:46,177 --> 01:42:48,813 CARE DISCOVERY AND SCIENTIFIC 2078 01:42:48,813 --> 01:42:49,113 TREATMENTS. 2079 01:42:49,113 --> 01:42:50,581 WE TRY TO EDUCATE DIFFERENT 2080 01:42:50,581 --> 01:42:52,183 STAKEHOLDERS WHEN YOU THINK OF 2081 01:42:52,183 --> 01:42:53,851 DOING RESEARCH, WHO IS GOING TO 2082 01:42:53,851 --> 01:42:55,753 BE THE USER KNOWLEDGE. 2083 01:42:55,753 --> 01:42:58,523 NOT ONLY IS IT GOING TO GO TO A 2084 01:42:58,523 --> 01:43:04,329 GOOD JOURNAL BUT CARRY THE 2085 01:43:04,329 --> 01:43:06,664 KNOWLEDGE FORWARD. 2086 01:43:06,664 --> 01:43:08,232 AND WE'RE TALKING ABOUT WHAT 2087 01:43:08,232 --> 01:43:10,435 SYSTEM IS GOING TO PAY FOR THIS. 2088 01:43:10,435 --> 01:43:14,372 IS KAISER GOING TO PAY FOR IT OR 2089 01:43:14,372 --> 01:43:15,406 MEDICARE OR MEDICAID? 2090 01:43:15,406 --> 01:43:17,008 COMMERCIAL INSURANCE, THE STATE 2091 01:43:17,008 --> 01:43:18,242 HEALTH DEPARTMENT? 2092 01:43:18,242 --> 01:43:21,212 WE'RE TRYING TO MOVE IN THOSE 2093 01:43:21,212 --> 01:43:21,446 TRACKS. 2094 01:43:21,446 --> 01:43:23,781 THINGS TAKE TIME IN LIFE BUT 2095 01:43:23,781 --> 01:43:25,883 THESE IS A THREE-PRONGED 2096 01:43:25,883 --> 01:43:27,785 APPROACH THAT WILL TAKE IMPACT. 2097 01:43:27,785 --> 01:43:30,955 I'M A SCIENTIST. 2098 01:43:30,955 --> 01:43:32,990 I'M A CLINICIAN AND WILLING TO 2099 01:43:32,990 --> 01:43:33,391 LEARN. 2100 01:43:33,391 --> 01:43:38,730 IF YOU HAVE SUGGESTIONS HOW TO 2101 01:43:38,730 --> 01:43:49,273 DO THINGS BETTER IF YOU HAVE AN 2102 01:43:50,908 --> 01:43:51,909 IDEA, THIS IS NOT HIGH SCHOOL I 2103 01:43:51,909 --> 01:43:53,177 DON'T WANT TO PUT YOU ON THE 2104 01:43:53,177 --> 01:43:58,483 SPOT BUT WE WANT TO GET THE BEST 2105 01:43:58,483 --> 01:43:59,917 IDEAS WE CAN. 2106 01:43:59,917 --> 01:44:02,920 AND WANT TO KNOW WHO GENERATES 2107 01:44:02,920 --> 01:44:03,855 THE IDEAS. 2108 01:44:03,855 --> 01:44:04,689 HOPEFULLY WE'LL GET SOMETHING 2109 01:44:04,689 --> 01:44:07,525 BACK FROM OTHERS. 2110 01:44:07,525 --> 01:44:08,693 >> THAT'S A LONGER CONVERSATION 2111 01:44:08,693 --> 01:44:11,729 BUT I THINK IT'S A CRITICAL ROLE 2112 01:44:11,729 --> 01:44:15,032 FOR HEAL TO HELP BROKER THOSE 2113 01:44:15,032 --> 01:44:16,467 RELATIONSHIPS BETWEEN P.I.s WHO 2114 01:44:16,467 --> 01:44:18,870 HAVE PULLED OFF THESE SUCCESSFUL 2115 01:44:18,870 --> 01:44:20,271 PROJECTS AND GENERATED 2116 01:44:20,271 --> 01:44:22,373 COMPELLING EVIDENCE AND THEN 2117 01:44:22,373 --> 01:44:26,010 CONNECTING THEM WITH POLICY 2118 01:44:26,010 --> 01:44:27,979 MAKERS AT THE STATE AND LOCAL 2119 01:44:27,979 --> 01:44:34,252 LEVEL WHO ARE DECIDING HOW TO 2120 01:44:34,252 --> 01:44:35,420 SPEND OPIOID SETTLEMENT FUNDS 2121 01:44:35,420 --> 01:44:37,822 AND OTHER RESOURCES TO GENERATE 2122 01:44:37,822 --> 01:44:39,924 EVIDENCE-BASED PRACTICE FOR 2123 01:44:39,924 --> 01:44:40,725 THEIR COMMUNITIES. 2124 01:44:40,725 --> 01:44:42,193 THAT'S A CRITICAL ROLE. 2125 01:44:42,193 --> 01:44:44,228 IF WE WANT THE EFFORTS THAT PUT 2126 01:44:44,228 --> 01:44:46,497 INTO HEAL TO MATTER PE HAVE TO 2127 01:44:46,497 --> 01:44:49,934 GET THAT FIGURED OUT SO THANK 2128 01:44:49,934 --> 01:44:50,134 YOU. 2129 01:44:50,134 --> 01:44:51,068 >> THANK YOU SO MUCH. 2130 01:44:51,068 --> 01:44:52,670 I APPRECIATE THE LIVELY 2131 01:44:52,670 --> 01:44:52,970 DISCUSSION. 2132 01:44:52,970 --> 01:44:55,573 NOW WE'LL GO TO OUR NEXT AGENDA 2133 01:44:55,573 --> 01:44:55,907 TOPIC. 2134 01:44:55,907 --> 01:44:58,109 SO I'D LIKE TO NOW WELCOME 2135 01:44:58,109 --> 01:44:59,277 DR. REDONNA CHANDLER. 2136 01:44:59,277 --> 01:45:01,646 SHE'S A LICENSED PSYCHOLOGIST 2137 01:45:01,646 --> 01:45:03,214 AND SERVES AT THE DIRECTOR OF 2138 01:45:03,214 --> 01:45:06,884 THE NIDA RESEARCH PROGRAM AND 2139 01:45:06,884 --> 01:45:08,252 ALSO THE DIRECTORS OF THE HEAL 2140 01:45:08,252 --> 01:45:10,054 AND COMMUNITY CENTER HER AREAS 2141 01:45:10,054 --> 01:45:12,924 OF EXPERTISE ARE INDIVIDUALS 2142 01:45:12,924 --> 01:45:15,293 1R068D WITH THE CRIMINAL JUSTICE 2143 01:45:15,293 --> 01:45:16,461 SYSTEM, CRIMINALS AND ADHERENCE 2144 01:45:16,461 --> 01:45:19,797 TO DRUG ABUSE TREATMENT AND HIV 2145 01:45:19,797 --> 01:45:20,631 CARE AND EVIDENCE-BASED 2146 01:45:20,631 --> 01:45:22,300 TREATMENT IN CLINICAL PRACTICE 2147 01:45:22,300 --> 01:45:22,567 SETTINGS. 2148 01:45:22,567 --> 01:45:23,701 DR. CHANDLER. 2149 01:45:23,701 --> 01:45:26,571 >> IS IT POSSIBLE FOR ME TO 2150 01:45:26,571 --> 01:45:28,739 SHARE MY SCREEN AND PRESENT MY 2151 01:45:28,739 --> 01:45:38,950 OWN SLIDES? 2152 01:46:09,046 --> 01:46:10,314 >> THANK YOU FOR THE OPPORTUNITY 2153 01:46:10,314 --> 01:46:11,582 TO SPEAK WITH YOU ALL. 2154 01:46:11,582 --> 01:46:15,520 IT'S BEEN A REAL PRIVILEGE TO BE 2155 01:46:15,520 --> 01:46:16,287 PART OF THE STUDY. 2156 01:46:16,287 --> 01:46:18,689 THIS STUDY HAS INVOLVED AN 2157 01:46:18,689 --> 01:46:20,992 AMAZING TEAM OF HUNDREDS OF 2158 01:46:20,992 --> 01:46:22,527 COMMUNITY MEMBERS, RESEARCHERS 2159 01:46:22,527 --> 01:46:30,201 AND NIDA STAFF. 2160 01:46:30,201 --> 01:46:31,936 BRIEFLY I'M GOING TO COVER AN 2161 01:46:31,936 --> 01:46:35,006 OVERVIEW OF THE STUDY AND THEN 2162 01:46:35,006 --> 01:46:40,478 DELVE INTO SPECIFIC RESULTS 2163 01:46:40,478 --> 01:46:42,580 ABOUT NALOXONE DISTRIBUTION FOR 2164 01:46:42,580 --> 01:46:43,548 DISTRIBUTION BUT SOME OF OUR 2165 01:46:43,548 --> 01:46:44,882 DISSEMINATION ACTIVITIES AND 2166 01:46:44,882 --> 01:46:46,717 SOME OF OUR LESSONS LEARNED TO 2167 01:46:46,717 --> 01:46:46,918 DATE. 2168 01:46:46,918 --> 01:46:48,586 AS A REMINDER, THE HEALING 2169 01:46:48,586 --> 01:46:52,490 COMMUNITY STUDY WAS CONDUCTED IN 2170 01:46:52,490 --> 01:46:54,825 HIGHLY IMPACTING COMMUNITIES IN 2171 01:46:54,825 --> 01:46:57,028 FOUR STATES INCLUDING A TOTAL 2172 01:46:57,028 --> 01:47:00,398 POPULATION OF OVER 10 BILLION 2173 01:47:00,398 --> 01:47:06,971 LIVES TO REDUCE OPIOID RELATED 2174 01:47:06,971 --> 01:47:08,973 OVERDOSES AND WE ALSO HAD 2175 01:47:08,973 --> 01:47:10,474 IMPORTANT SECONDARY OUTCOMES 2176 01:47:10,474 --> 01:47:12,276 INCLUDING INCREASING NALOXONE 2177 01:47:12,276 --> 01:47:12,977 DISTRIBUTION WHICH I'LL TALK 2178 01:47:12,977 --> 01:47:18,182 ABOUT AND INCREASING ACCESS AND 2179 01:47:18,182 --> 01:47:20,618 UTILIZATION OF OUD AND 2180 01:47:20,618 --> 01:47:22,186 DECREASING HIGH-USE PRESCRIBING. 2181 01:47:22,186 --> 01:47:25,356 THE STUDY WAS A PARALLEL ARM 2182 01:47:25,356 --> 01:47:26,390 RANDOMIZED WEIGHT LIST CONTROL 2183 01:47:26,390 --> 01:47:28,526 TRIAL WITH HALF THE 67 2184 01:47:28,526 --> 01:47:30,761 COMMUNITIES RANDOMIZED TO THE 2185 01:47:30,761 --> 01:47:33,497 INTERVENTION AND HALF TO 2186 01:47:33,497 --> 01:47:33,731 CONTROL. 2187 01:47:33,731 --> 01:47:35,766 PRIMARY AND SECONDARY OUTCOMES 2188 01:47:35,766 --> 01:47:37,368 COMPARED OVER A COMPARISON 2189 01:47:37,368 --> 01:47:39,170 PERIOD BETWEEN INTERVENTION AND 2190 01:47:39,170 --> 01:47:43,708 CONTROL AND HERE YOU CAN SEE THE 2191 01:47:43,708 --> 01:47:48,512 TIME LINE WE'RE CURRENTLY IN THE 2192 01:47:48,512 --> 01:47:50,815 GRAY BOX WITH DISSEMINATION 2193 01:47:50,815 --> 01:47:52,583 ACTIVITIES AND CLOSE OUT. 2194 01:47:52,583 --> 01:47:57,021 THE INTERVENTION HAD THREE 2195 01:47:57,021 --> 01:48:00,024 COMPONENTS AND COMMUNITY 2196 01:48:00,024 --> 01:48:02,627 ENGAGEMENT AND PROVIDED DATA AND 2197 01:48:02,627 --> 01:48:05,463 DASHBOARDS FOR A STRATEGY TO 2198 01:48:05,463 --> 01:48:08,833 DECREASE OPIOID OVERDOSE FATAL. 2199 01:48:08,833 --> 01:48:10,501 THE OPIOID CONTINUUM OF CARE 2200 01:48:10,501 --> 01:48:12,436 APPROACH A MENU OF 2201 01:48:12,436 --> 01:48:14,872 EVIDENCE-BASED PRACTICES 2202 01:48:14,872 --> 01:48:20,511 INTENDED TO AID COMMUNITIES IN 2203 01:48:20,511 --> 01:48:22,513 IMPLEMENTING THREE SPECIFIC 2204 01:48:22,513 --> 01:48:28,519 AREAS OVERDOSE EDUCATION AND 2205 01:48:28,519 --> 01:48:30,655 NALOXONE PRESCRIBING AND 2206 01:48:30,655 --> 01:48:31,889 CAMPAIGNS TO INCREASE EDUCATION 2207 01:48:31,889 --> 01:48:33,624 AND REDUCE STIGMA. 2208 01:48:33,624 --> 01:48:36,894 I'LL TALK ABOUT THE NALOXONE 2209 01:48:36,894 --> 01:48:38,863 DISTRIBUTION FINDINGS WE HOPE 2210 01:48:38,863 --> 01:48:39,697 WILL BE ACCEPTED IN THE AMERICAN 2211 01:48:39,697 --> 01:48:41,532 JOURNAL OF HEALTH. 2212 01:48:41,532 --> 01:48:45,369 THE DATA IS EMBARGO. 2213 01:48:45,369 --> 01:48:51,609 A REMINDER REGARDING NALOXONE 2214 01:48:51,609 --> 01:48:59,250 IT'S AN OPIOID AGONIST THAT 2215 01:48:59,250 --> 01:49:01,018 INCREASES THE ODDS OF SURVIVAL 2216 01:49:01,018 --> 01:49:03,454 COMPARED TO NO NALOXONE 2217 01:49:03,454 --> 01:49:04,255 DISTRIBUTION AND COMMUNITIES 2218 01:49:04,255 --> 01:49:10,428 WITH ENROLLMENT IN EDUCATION 2219 01:49:10,428 --> 01:49:11,662 HAVE LOWER RATES OF OPIOID 2220 01:49:11,662 --> 01:49:12,997 OVERDOSE DEATHS. 2221 01:49:12,997 --> 01:49:20,504 IN ADDITION, WE CREATED A LOT OF 2222 01:49:20,504 --> 01:49:21,739 OPIOID EDUCATION HUNDREDS OF 2223 01:49:21,739 --> 01:49:22,373 MATERIALS AVAILABLE WITHIN OUR 2224 01:49:22,373 --> 01:49:27,878 COMMUNITIES I'LL SHARE LATER. 2225 01:49:27,878 --> 01:49:30,147 THEY WERE DONE IN DIFFERENT 2226 01:49:30,147 --> 01:49:31,415 FORMATS AND TRAINING AND 2227 01:49:31,415 --> 01:49:31,849 MULTIPLE LANGUAGES. 2228 01:49:31,849 --> 01:49:34,785 I'LL SHOW THE TIME LINE FOR A 2229 01:49:34,785 --> 01:49:37,021 SPECIFIC REASON THAT APPLIES TO 2230 01:49:37,021 --> 01:49:38,789 THE NALOXONE DISTRIBUTION 2231 01:49:38,789 --> 01:49:39,890 EFFORTS. 2232 01:49:39,890 --> 01:49:43,694 YOU CAN SEE THE START OF THE 2233 01:49:43,694 --> 01:49:45,262 INTERVENTION JANUARY 2020. 2234 01:49:45,262 --> 01:49:49,533 THE INTERVENTION IS THAT WE WERE 2235 01:49:49,533 --> 01:49:50,101 STARTING TO IMPLEMENT OUR 2236 01:49:50,101 --> 01:49:50,901 EVIDENCE-BASED PRACTICES AND 2237 01:49:50,901 --> 01:49:52,536 WERE SUPPOSED TO BEGIN IN 2238 01:49:52,536 --> 01:49:55,473 OCTOBER AND HAD THE NATIONAL 2239 01:49:55,473 --> 01:49:56,507 SHUT DOWN WITH THE COVID-19 2240 01:49:56,507 --> 01:50:02,546 PANDEMIC WHICH BEGAN IN MARCH. 2241 01:50:02,546 --> 01:50:06,317 AS MANY RECALL IN APRIL OF THAT 2242 01:50:06,317 --> 01:50:09,487 YEAR WE SAW UNPRECEDENTED 2243 01:50:09,487 --> 01:50:11,489 UPTICKS IN OVERDOSE FATALITIES. 2244 01:50:11,489 --> 01:50:14,892 AUR FOUL OF OUR STATES HAD 2245 01:50:14,892 --> 01:50:16,527 FATALITIES THAT SURPASSED THOSE 2246 01:50:16,527 --> 01:50:17,762 OF ANY PREVIOUS TIME. 2247 01:50:17,762 --> 01:50:19,764 BASED ON THAT, THIS WAS IN A 2248 01:50:19,764 --> 01:50:22,533 COMMUNITY ENGAGED STUDY. 2249 01:50:22,533 --> 01:50:26,137 OUR COMMUNITY COALITION PIVOTED 2250 01:50:26,137 --> 01:50:26,871 RAPIDLY TO COORDINATION AND CAME 2251 01:50:26,871 --> 01:50:32,843 BACK TO US AND SAID WE CAN'T 2252 01:50:32,843 --> 01:50:34,345 REALLY WAIT UNTIL OCTOBER TO GO 2253 01:50:34,345 --> 01:50:38,249 THROUGH THE NICE STEPS OF THE 2254 01:50:38,249 --> 01:50:40,518 INTERVENTION AND DEVELOP A 2255 01:50:40,518 --> 01:50:44,555 COMPREHENSIVE RESPONSE STRATEGY. 2256 01:50:44,555 --> 01:50:48,125 THERE ARE THINGS WE CAN DO TO 2257 01:50:48,125 --> 01:50:49,193 GET NALOXONE DISTRIBUTED AND 2258 01:50:49,193 --> 01:50:51,095 EDUCATION OUT THERE. 2259 01:50:51,095 --> 01:50:53,597 WE DEVELOPED A FAST TRACK 2260 01:50:53,597 --> 01:50:55,966 INTERVENTION THAT BEGAN OVERDOSE 2261 01:50:55,966 --> 01:50:59,003 EDUCATION AS EARLY AS MAY 2020 2262 01:50:59,003 --> 01:51:00,437 WITH A FOCUS ON SECTORS WHERE 2263 01:51:00,437 --> 01:51:03,174 PEOPLE HAD BEEN OUT OF THE 2264 01:51:03,174 --> 01:51:05,976 COMMUNITY AND WERE TRANSITIONS 2265 01:51:05,976 --> 01:51:06,877 BACK LIKE THOSE IN JAILS. 2266 01:51:06,877 --> 01:51:09,013 WHEN I TALK ABOUT THE RESULTS I 2267 01:51:09,013 --> 01:51:09,947 WILL MAKE SURE YOU UNDERSTAND 2268 01:51:09,947 --> 01:51:16,520 HOW WE DEFINED OUR OUTCOMES FOR 2269 01:51:16,520 --> 01:51:19,723 NALOXONE DISTRIBUTION AND LOOKED 2270 01:51:19,723 --> 01:51:20,891 AT COMMUNITY DISTRIBUTION 2271 01:51:20,891 --> 01:51:22,426 INCLUDING ALL THE UNITS 2272 01:51:22,426 --> 01:51:26,130 DISTRIBUTED TO OUR PARTNER 2273 01:51:26,130 --> 01:51:28,265 AGENCIES AND PROGRAMS AND 2274 01:51:28,265 --> 01:51:31,635 PREVENTION SPECIALISTS, PHARMACY 2275 01:51:31,635 --> 01:51:33,137 DISPENSING WITH ANY NALOXONE 2276 01:51:33,137 --> 01:51:35,406 DISPOSED BY PHARMACIES IN 2277 01:51:35,406 --> 01:51:38,075 COMMUNITIES AND ALSO LOOKING AT 2278 01:51:38,075 --> 01:51:40,511 A TOTAL COMBINATION OF COMMUNITY 2279 01:51:40,511 --> 01:51:42,713 PLUS PHARMACY DISTRIBUTION. 2280 01:51:42,713 --> 01:51:44,148 THE DATA CAME FROM DIFFERENT 2281 01:51:44,148 --> 01:51:45,015 SOURCES THAT WERE IDENTIFIED 2282 01:51:45,015 --> 01:51:48,118 THROUGH OUR PARTNERSHIPS WITH 2283 01:51:48,118 --> 01:51:50,321 OUR COMMUNITIES AND THEY VARIED 2284 01:51:50,321 --> 01:51:51,188 SLIGHTLY ACROSS THE FOUR STATES 2285 01:51:51,188 --> 01:51:54,692 BECAUSE WE DO NOT HAVE CURRENTLY 2286 01:51:54,692 --> 01:51:56,193 ANY KIND OF NATIONAL LEVEL 2287 01:51:56,193 --> 01:51:57,094 ACCOUNTING OF THE DISTRIBUTION 2288 01:51:57,094 --> 01:52:04,235 OF NALOXONE. 2289 01:52:04,235 --> 01:52:11,008 THEN FOR AN IQVIA THEY MEASURED 2290 01:52:11,008 --> 01:52:13,077 NALOXONE UNITS DISPENSED BY 2291 01:52:13,077 --> 01:52:23,387 RETAIL PHARMACIES. 2292 01:52:26,624 --> 01:52:29,593 WE LOOKED AT ACTIVE PROACTIVELY 2293 01:52:29,593 --> 01:52:31,195 DELIVERING AT-RISK INDIVIDUALS 2294 01:52:31,195 --> 01:52:32,796 TO SOCIAL NETWORKS OR DELIVERING 2295 01:52:32,796 --> 01:52:34,965 IT TO EVERYONE IN SOME TYPE OF A 2296 01:52:34,965 --> 01:52:38,402 HIGH RISK VENUE. 2297 01:52:38,402 --> 01:52:40,504 THAT WOULD BE LIKE IN A JAIL 2298 01:52:40,504 --> 01:52:48,078 THAT IS GOING TO BE RELEASED AND 2299 01:52:48,078 --> 01:52:49,480 WE TARGETED HEALTH CARE SECTORS 2300 01:52:49,480 --> 01:52:57,288 LIKE HOSPITALS, FOR EXAMPLE. 2301 01:52:57,288 --> 01:52:59,156 WE REQUIRED ONE STRATEGY AS PART 2302 01:52:59,156 --> 01:53:00,424 OF THEIR RESPONSE STRATEGY. 2303 01:53:00,424 --> 01:53:01,458 WE WANTED TO PARTNER AND WORK 2304 01:53:01,458 --> 01:53:04,762 WITH THEM SO WE MADE OUR 2305 01:53:04,762 --> 01:53:09,500 REQUIREMENTS LIGHT. 2306 01:53:09,500 --> 01:53:15,906 YOU'LL SEE IN A MINUTE THE 2307 01:53:15,906 --> 01:53:22,513 SUCCESS OF PARTNERING AND WE HAD 2308 01:53:22,513 --> 01:53:25,716 SOMEONE WHO MADE A REQUEST AND A 2309 01:53:25,716 --> 01:53:27,217 PHARMACY OR COMMUNITY EVENT AND 2310 01:53:27,217 --> 01:53:28,285 WE ALSO HAD PROGRAMS. 2311 01:53:28,285 --> 01:53:32,790 THAT WAS OPTIONAL AND THEN ALSO 2312 01:53:32,790 --> 01:53:35,459 OPTIONAL WAS WORKING WITH FIRST 2313 01:53:35,459 --> 01:53:38,128 RESPONDER ADMINISTRATORS AROUND 2314 01:53:38,128 --> 01:53:42,566 INCREASING CAPACITY FOR HAVING 2315 01:53:42,566 --> 01:53:42,833 NALOXONE. 2316 01:53:42,833 --> 01:53:44,668 IF EACH OF THE INTERVENTION 2317 01:53:44,668 --> 01:53:45,936 COMMUNITIES CHOSE THE MINIMUM 2318 01:53:45,936 --> 01:53:47,237 NUMBER OF REQUIRED STRATEGIES 2319 01:53:47,237 --> 01:53:49,006 WEEDS HAVE A TOTAL OF 33. 2320 01:53:49,006 --> 01:53:52,509 WE HAVE A TOTAL OF 254 2321 01:53:52,509 --> 01:53:54,845 STRATEGIES THAT ARE COMMUNITIES 2322 01:53:54,845 --> 01:53:56,714 IN OUR INTERVENTION GROUP 2323 01:53:56,714 --> 01:53:57,014 SELECTED. 2324 01:53:57,014 --> 01:53:58,515 YOU CAN SEE HERE HOW THEY'RE 2325 01:53:58,515 --> 01:53:59,683 DIVIDED OUT ACROSS THE DIFFERENT 2326 01:53:59,683 --> 01:54:03,187 STATES WITH KENTUCKY LEADING THE 2327 01:54:03,187 --> 01:54:03,754 WAY. 2328 01:54:03,754 --> 01:54:06,623 KENTUCKY HAD THE LEAST AMOUNT OF 2329 01:54:06,623 --> 01:54:08,359 NALOXONE DISTRIBUTION SO THEY 2330 01:54:08,359 --> 01:54:10,527 LEANED INTO THAT PARTICULAR 2331 01:54:10,527 --> 01:54:11,095 COMPONENT OF THEIR RESPONSE 2332 01:54:11,095 --> 01:54:18,335 STRATEGY. 2333 01:54:18,335 --> 01:54:22,539 YOU SEE HOW THERE WERE ACTIVE 2334 01:54:22,539 --> 01:54:24,308 AND PASSIVE AND CAPACITY FOR 2335 01:54:24,308 --> 01:54:26,276 FIRST RESPONDERS AND ACTIVE OEND 2336 01:54:26,276 --> 01:54:31,515 INITIATIVES AND HERE YOU CAN SEE 2337 01:54:31,515 --> 01:54:33,417 THE DIFFERENT VENUES WHERE 2338 01:54:33,417 --> 01:54:35,619 NALOXONE DISTRIBUTION WITH THE 2339 01:54:35,619 --> 01:54:37,888 MAJORITY OF THOSE BEING WIN THE 2340 01:54:37,888 --> 01:54:38,789 BEHAVIORAL HEALTH SETTINGS 2341 01:54:38,789 --> 01:54:39,456 INCLUDING SUBSTANCE USE AND 2342 01:54:39,456 --> 01:54:39,957 MENTAL HEALTH TREATMENT 2343 01:54:39,957 --> 01:54:45,396 PROGRAMS. 2344 01:54:45,396 --> 01:54:47,064 GETTING TOWARDS THE RESULT I'LL 2345 01:54:47,064 --> 01:54:49,333 TALK ABOUT THE STATISTICAL 2346 01:54:49,333 --> 01:54:49,566 METHODS. 2347 01:54:49,566 --> 01:54:50,367 WE COMPARED RATES BETWEEN 2348 01:54:50,367 --> 01:54:52,102 INTERVENTION AND CONTROL 2349 01:54:52,102 --> 01:54:56,173 COMMUNITIES FROM JULY 1 OF 2021 2350 01:54:56,173 --> 01:55:00,711 THROUGH JUNE 30, 2022 WITH A 2351 01:55:00,711 --> 01:55:09,787 BASELINE PERIOD OF JANUARY 1, 2352 01:55:09,787 --> 01:55:13,257 2019 AND SMALL SAMPLE SIZES WERE 2353 01:55:13,257 --> 01:55:15,426 ADJUSTED WITH EMPIRICAL STANDARD 2354 01:55:15,426 --> 01:55:22,533 ERRORS FOR TESTING AND YOU CAN 2355 01:55:22,533 --> 01:55:28,138 SEE WE HAD DIFFERENT MODELS 2356 01:55:28,138 --> 01:55:30,541 ADJUSTED FOR RULES, STATUS, 2357 01:55:30,541 --> 01:55:32,843 STATE, OPIOID DEATH RATE AND 2358 01:55:32,843 --> 01:55:34,511 COMMUNITY-LEVEL RATE PER 100,000 2359 01:55:34,511 --> 01:55:37,014 RESIDENTS OF THE OUTCOME WHICH 2360 01:55:37,014 --> 01:55:40,684 IN THIS CASE IS NALOXONE 2361 01:55:40,684 --> 01:55:50,928 DISTRIBUTION. 2362 01:55:52,863 --> 01:55:54,331 IT'S VERY SIMILAR AND HERE'S 2363 01:55:54,331 --> 01:55:54,698 OUTCOMES. 2364 01:55:54,698 --> 01:55:58,502 YOU SEE THE THREE OUTCOMES WITH 2365 01:55:58,502 --> 01:56:02,339 RELATIVE RATES PER 100,000 2366 01:56:02,339 --> 01:56:02,606 RESIDENTS. 2367 01:56:02,606 --> 01:56:03,807 THERE'S STATISTICALLY 2368 01:56:03,807 --> 01:56:05,008 SIGNIFICANT INCREASE FOR 2369 01:56:05,008 --> 01:56:06,243 NALOXONE DISTRIBUTION AND 2370 01:56:06,243 --> 01:56:07,611 COMMUNITY PROGRAM DISTRIBUTION 2371 01:56:07,611 --> 01:56:13,550 WITH A 79% INCREASE BETWEEN 2372 01:56:13,550 --> 01:56:19,022 CONTROL AND INTERVENTION 2373 01:56:19,022 --> 01:56:22,159 COMMUNITY AND 104% INCREASE FOR 2374 01:56:22,159 --> 01:56:23,527 COMMUNITY PROGRAM DISTRIBUTION. 2375 01:56:23,527 --> 01:56:27,197 THERE WAS NOT A STATISTICALLY 2376 01:56:27,197 --> 01:56:28,165 SIGNIFICANT DIFFERENCE FOR 2377 01:56:28,165 --> 01:56:30,467 PHARMACY DISPENSED NALOXONE BUT 2378 01:56:30,467 --> 01:56:33,871 THAT WAS NOT SURPRISING. 2379 01:56:33,871 --> 01:56:34,505 COMMUNITIES DIDN'T FOCUS HEAVILY 2380 01:56:34,505 --> 01:56:36,640 ON PHARMACIES. 2381 01:56:36,640 --> 01:56:37,708 THEY TOOK THE RESPONSE 2382 01:56:37,708 --> 01:56:40,978 STRATEGIES THEY SELECTED FROM 2383 01:56:40,978 --> 01:56:42,446 INFORMATION THEY GLEANED FROM 2384 01:56:42,446 --> 01:56:44,381 MEMBERS AND THEIR COALITIONS 2385 01:56:44,381 --> 01:56:45,549 INCLUDING PEOPLE WITH LIVING 2386 01:56:45,549 --> 01:56:49,019 EXPERIENCE AND THEY LEARNED A 2387 01:56:49,019 --> 01:56:51,989 LOT ABOUT HOW UNCOMFORTABLE 2388 01:56:51,989 --> 01:56:53,023 PEOPLE ARE USING DRUGS GOING 2389 01:56:53,023 --> 01:56:55,092 INTO PHARMACIES AND HOW 2390 01:56:55,092 --> 01:56:57,361 UNCOMFORTABLE COMMUNITY MEMBERS 2391 01:56:57,361 --> 01:57:00,998 WERE GOING TOO A PHARMACY TO GET 2392 01:57:00,998 --> 01:57:11,375 NALOXONE AND BARRIERS. 2393 01:57:16,580 --> 01:57:19,116 THIS IS FROM A VENDING MACHINE 2394 01:57:19,116 --> 01:57:28,725 TO AN EVENT TO A GROUP OF 2395 01:57:28,725 --> 01:57:29,793 MOTORCYCLERS GOING OUT AND 2396 01:57:29,793 --> 01:57:31,128 DISTRIBUTING THIS TO THEIR 2397 01:57:31,128 --> 01:57:32,996 COMMUNITY AND THERE'S COMMUNITY 2398 01:57:32,996 --> 01:57:37,701 COALITIONS WITH THEY COMPLETE 2399 01:57:37,701 --> 01:57:40,537 SURVEYS AND THEY HAD PERCEIVED 2400 01:57:40,537 --> 01:57:44,074 BARRIERS TO SCALING UP OND IN 2401 01:57:44,074 --> 01:57:46,510 THEIR COMMUNITY AND THEY LOOKED 2402 01:57:46,510 --> 01:57:48,645 AT BASELINE INTERVENTION AND 2403 01:57:48,645 --> 01:57:51,114 FOUND THERE WAS A STATISTICALLY 2404 01:57:51,114 --> 01:57:52,416 SIGNIFICANT DECREASE AND 2405 01:57:52,416 --> 01:57:55,018 PERCEIVED BARRIERS FOR OND FOR 2406 01:57:55,018 --> 01:57:56,453 THE INTERVENTION GROUP AND 2407 01:57:56,453 --> 01:57:57,154 HEALTH CARE AND BEHAVIORAL 2408 01:57:57,154 --> 01:57:59,223 HEALTH SETTINGS AND 2409 01:57:59,223 --> 01:58:02,526 NON-TRADITIONAL VENUES WHICH 2410 01:58:02,526 --> 01:58:03,994 INCLUDED THINGS LIKE SYRINGE 2411 01:58:03,994 --> 01:58:05,028 SERVICE PROGRAMS AND IN THE OVER 2412 01:58:05,028 --> 01:58:07,264 ALL JUSTICE SETTINGS. 2413 01:58:07,264 --> 01:58:10,234 KENTUCKY ALONE HAD A 2414 01:58:10,234 --> 01:58:10,801 STATISTICALLY SIGNIFICANT 2415 01:58:10,801 --> 01:58:12,603 DIFFERENCE IN CHANGING 2416 01:58:12,603 --> 01:58:15,005 PERCEPTIONS OF BARRIERS FOR OEND 2417 01:58:15,005 --> 01:58:17,874 AND JUSTICE SETTINGS FOR THE 2418 01:58:17,874 --> 01:58:18,575 TREATMENT GROUP. 2419 01:58:18,575 --> 01:58:22,512 SO WE HAD STUDY LIMITATIONS. 2420 01:58:22,512 --> 01:58:24,548 THE PRIMARY LIMITATION OF THE 2421 01:58:24,548 --> 01:58:26,750 STUDY OF THE RESEARCH AT THIS 2422 01:58:26,750 --> 01:58:28,518 LEVEL IS THERE'S NO UNIFORM 2423 01:58:28,518 --> 01:58:29,586 CENTRALIZED SYSTEM FOR 2424 01:58:29,586 --> 01:58:31,188 COLLECTING DATA OR FOR 2425 01:58:31,188 --> 01:58:33,123 HARMONIZING THE DATA AT THE 2426 01:58:33,123 --> 01:58:36,994 COMMUNITY LEVEL. 2427 01:58:36,994 --> 01:58:40,664 IN SOME INSTANCES BECAUSE OF THE 2428 01:58:40,664 --> 01:58:43,200 OVERDOSE SPIKES IN FATALES THEY 2429 01:58:43,200 --> 01:58:44,835 INITIATED THEIR OWN EFFORTS THAT 2430 01:58:44,835 --> 01:58:46,270 IMPACTED ALL OF THE COMMUNITIES 2431 01:58:46,270 --> 01:58:51,008 BOTH INTERVENTION AND CONTROL. 2432 01:58:51,008 --> 01:58:54,244 IN OHIO THERE WAS AN UNDER 2433 01:58:54,244 --> 01:58:57,014 COUNTING OF THE NALOXONE 2434 01:58:57,014 --> 01:58:57,581 DISTRIBUTED. 2435 01:58:57,581 --> 01:59:00,050 IN SUMMARY, HCS WAS ABLE TO 2436 01:59:00,050 --> 01:59:01,518 QUICKLY MOBILIZE COMMUNITIES 2437 01:59:01,518 --> 01:59:02,753 DURING THE COVID-19 PANDEMIC AND 2438 01:59:02,753 --> 01:59:06,990 SCALE UP OEND. 2439 01:59:06,990 --> 01:59:16,500 OVERALL 33 STRATEGY REQUIRED AND 2440 01:59:16,500 --> 01:59:25,375 254 WERE DE MROIDZ AND TH -- DE 2441 01:59:25,375 --> 01:59:28,312 AND NALOXONE AVAILABILITY 2442 01:59:28,312 --> 01:59:32,582 INCREASED 79% AND THERE WERE 2443 01:59:32,582 --> 01:59:36,019 REDUCED PERCEIVED BARRIERS TO 2444 01:59:36,019 --> 01:59:36,353 DISTRIBUTION. 2445 01:59:36,353 --> 01:59:37,721 THESE ARE SOME OF OUR ACTIVITIES 2446 01:59:37,721 --> 01:59:38,422 THUS FAR. 2447 01:59:38,422 --> 01:59:44,995 AS PART OF A STUDY LIKE THE 2448 01:59:44,995 --> 01:59:47,831 STUDY WE'RE NOT JUST DEVELOPING 2449 01:59:47,831 --> 01:59:50,067 A PROTOCOL. 2450 01:59:50,067 --> 01:59:50,667 YOU'RE DEVELOPING COMMUNITY 2451 01:59:50,667 --> 01:59:53,537 FRIENDLY MATERIALS HOW TO BE 2452 01:59:53,537 --> 01:59:55,072 ABLE TO UP TAKE CERTAIN THINGS 2453 01:59:55,072 --> 01:59:58,975 AND HOW TO DO CERTAIN THINGS 2454 01:59:58,975 --> 02:00:00,177 LIKE DISTRIBUTE NALOXONE OR 2455 02:00:00,177 --> 02:00:01,578 START A BRIDGE CLINIC AND WE 2456 02:00:01,578 --> 02:00:04,514 BUILT OFF THOSE MATERIALS TO TRY 2457 02:00:04,514 --> 02:00:05,582 TO CREATE DISSEMINATION 2458 02:00:05,582 --> 02:00:05,949 PRODUCTS. 2459 02:00:05,949 --> 02:00:10,120 WE WORKED WITH SAMHSA AND 2460 02:00:10,120 --> 02:00:15,492 DEVELOPED TWO DISSEMINATION 2461 02:00:15,492 --> 02:00:17,694 PRODUCTS THROUGH THE PROGRAMS 2462 02:00:17,694 --> 02:00:20,330 AND WORKED TO DEVELOP CONNECTS 2463 02:00:20,330 --> 02:00:25,001 YOU SEE AND YOU'LL SEE AN ASK 2464 02:00:25,001 --> 02:00:28,939 THE EXPERT VIDEO AND WE 2465 02:00:28,939 --> 02:00:31,174 DEVELOPED A TOOL KIT FOR OPIOID 2466 02:00:31,174 --> 02:00:34,411 OVERDOSES AS A PRACTICAL GUIDE 2467 02:00:34,411 --> 02:00:35,779 FOR EMPLOYERS, COMMUNITY MEMBERS 2468 02:00:35,779 --> 02:00:37,080 AND FAITH LEADERS TO GIVE PRACT 2469 02:00:37,080 --> 02:00:39,282 CAM INFORMATION ON HOW THEY CAN 2470 02:00:39,282 --> 02:00:43,220 WORK ON TURNING THE TIDE ON THE 2471 02:00:43,220 --> 02:00:44,988 OPIOID CRISIS INCLUDING 2472 02:00:44,988 --> 02:00:46,156 COMMUNICATION MATERIALS AND HOW 2473 02:00:46,156 --> 02:00:47,724 THEY COMMUNICATE THROUGH STIGMA 2474 02:00:47,724 --> 02:00:52,529 AND ENCOURAGE TREATMENT AND TO 2475 02:00:52,529 --> 02:01:01,004 REVERSE OVERDOSES. 2476 02:01:01,004 --> 02:01:03,206 THERE ARE 181 PEOPLE REGISTERED 2477 02:01:03,206 --> 02:01:04,207 AUGUST 21. 2478 02:01:04,207 --> 02:01:08,445 I WAS NOT ABLE TO ATTEND THAT 2479 02:01:08,445 --> 02:01:10,347 AND NOT SURE HOW MANY PEOPLE 2480 02:01:10,347 --> 02:01:12,716 ATTENDED BUT WE HAVE HAD LARGE 2481 02:01:12,716 --> 02:01:16,987 NUMBERS OF PEOPLE ATTENDING ALL 2482 02:01:16,987 --> 02:01:19,055 OF THESE. 2483 02:01:19,055 --> 02:01:21,024 THIS IS INSIDES FOR HOW TO 2484 02:01:21,024 --> 02:01:22,626 ASSESS NEEDS AND WHAT FEATURES 2485 02:01:22,626 --> 02:01:33,170 TO BUILD IN AND BEST PRACTICES. 2486 02:01:34,671 --> 02:01:36,907 WE FOUND TRANSPORTATION WAS A 2487 02:01:36,907 --> 02:01:40,076 REALLY IMPORTANT BARRIER TO 2488 02:01:40,076 --> 02:01:47,284 PEOPLE INITIATING AND STAYING ON 2489 02:01:47,551 --> 02:01:50,487 MOUD AND THEY CONNECTED OVER 2490 02:01:50,487 --> 02:01:52,022 4,000 PATIENT TO TRANSPORTATION 2491 02:01:52,022 --> 02:01:54,758 SERVICE HELPED NOT ONLY 2492 02:01:54,758 --> 02:01:56,993 INITIATIVE MOUD BUT HELPED STAY 2493 02:01:56,993 --> 02:02:02,466 ON IT AND WE'RE PLEASED ABOUT AN 2494 02:02:02,466 --> 02:02:04,267 UPCOMING LEARN COLLABORATIVE. 2495 02:02:04,267 --> 02:02:05,902 WE HAD 206 APPLICATIONS 2496 02:02:05,902 --> 02:02:07,771 SUBMITTED AND WE'RE GOING TO BE 2497 02:02:07,771 --> 02:02:13,009 ABLE TO ACCEPT ONLY ABOUT 30. 2498 02:02:13,009 --> 02:02:16,513 SO THERE IS THIS HUNGER WITHIN 2499 02:02:16,513 --> 02:02:18,381 COMMUNITIES FOR LEARNING HOW TO 2500 02:02:18,381 --> 02:02:20,817 USE DATA AND CREATE DASHBOARDS 2501 02:02:20,817 --> 02:02:23,587 HELPFUL IN RESPONDING TO THE 2502 02:02:23,587 --> 02:02:24,521 OPIOID CRISIS. 2503 02:02:24,521 --> 02:02:26,923 THE APPLICATIONS ARE DUE AND 2504 02:02:26,923 --> 02:02:29,759 CURRENTLY BEING REVIEWED. 2505 02:02:29,759 --> 02:02:32,963 THIS IS A BRIEF SNIPPET OF OUR 2506 02:02:32,963 --> 02:02:33,196 SCRIPTS. 2507 02:02:33,196 --> 02:02:36,833 WE HAVE 80 PUBLISHED TO DATE. 2508 02:02:36,833 --> 02:02:39,069 WE HAVE OVER 76 MULTI-SITE 2509 02:02:39,069 --> 02:02:40,537 INVOLVING DATA FROM ACROSS THE 2510 02:02:40,537 --> 02:02:45,008 FOUR SITES AND HUNDREDS OF 2511 02:02:45,008 --> 02:02:47,077 SINGLE SITES IN PROCESS. 2512 02:02:47,077 --> 02:02:49,145 A FEW OF LESSONS LEARNED I'LL 2513 02:02:49,145 --> 02:02:51,448 FOCUS ON QUICKLY. 2514 02:02:51,448 --> 02:02:52,516 HCS IS THE LARGEST 2515 02:02:52,516 --> 02:02:54,317 IMPLEMENTATION STUDY EVER FUNDED 2516 02:02:54,317 --> 02:02:54,551 BY NIDA. 2517 02:02:54,551 --> 02:02:56,686 IT'S INTENDED TO DO WHAT YOU'RE 2518 02:02:56,686 --> 02:02:58,522 DOING IN YOUR PREVIOUS 2519 02:02:58,522 --> 02:03:00,991 DISCUSSION WHICH IS TO TAKE 2520 02:03:00,991 --> 02:03:01,958 EVIDENCE-BASED PRACTICES AND SEE 2521 02:03:01,958 --> 02:03:04,361 THEM STOOD UP ACROSS 2522 02:03:04,361 --> 02:03:04,661 COMMUNITIES. 2523 02:03:04,661 --> 02:03:09,533 CRITICAL TO THE SUCCESS OF THE 2524 02:03:09,533 --> 02:03:11,835 HUMAN COMMUNITY STUDY AND 2525 02:03:11,835 --> 02:03:13,503 APPROACH INVOLVING MULTI-LEVEL 2526 02:03:13,503 --> 02:03:18,375 PARTNERSHIPS AND MEETING PEOPLE 2527 02:03:18,375 --> 02:03:22,379 WHERE THEY WERE. 2528 02:03:22,379 --> 02:03:24,347 SOME COMMUNITIES HAD A LOT OF 2529 02:03:24,347 --> 02:03:26,216 STIGMA AND RESISTANCE AT FIRST 2530 02:03:26,216 --> 02:03:27,284 TO OPIOID USE DISORDER AND HAD 2531 02:03:27,284 --> 02:03:32,689 TO TRUST AND HAVE FAITH AND 2532 02:03:32,689 --> 02:03:38,328 CONFIDENCE IN THEM THEIR 2533 02:03:38,328 --> 02:03:38,995 EARNESTNESS WOULD COME TO THE 2534 02:03:38,995 --> 02:03:45,969 TABLE WHEN WE PROVIDED THEM WITH 2535 02:03:45,969 --> 02:03:47,904 DATA AND DEMONSTRATED SOME 2536 02:03:47,904 --> 02:03:49,806 INTERVENTIONS COULD BRING TO 2537 02:03:49,806 --> 02:03:51,508 BEAR ON DECREASING OVERDOSE 2538 02:03:51,508 --> 02:03:54,811 FATALITIES AND ABSOLUTELY SAW 2539 02:03:54,811 --> 02:03:55,979 THAT AND SAW OUR COMMUNITIES 2540 02:03:55,979 --> 02:03:57,447 STEP INTO SPACES AND PLACES THEY 2541 02:03:57,447 --> 02:04:03,820 NEVER IMAGINED THEY WOULD. 2542 02:04:03,820 --> 02:04:06,456 TIMELY DATA IS ESSENTIAL IN DEAL 2543 02:04:06,456 --> 02:04:08,491 WITH A HEALTH CRISIS INCLUDING 2544 02:04:08,491 --> 02:04:10,527 THE OPIOID HEALTH CRISIS AND WE 2545 02:04:10,527 --> 02:04:12,996 UNFORTUNATELY DON'T HAVE TIMELY 2546 02:04:12,996 --> 02:04:16,533 DATA SYSTEMS AT A PUBLIC HEALTH 2547 02:04:16,533 --> 02:04:17,000 LEVEL. 2548 02:04:17,000 --> 02:04:22,872 WE EXPERIENCED DELAYS ANYWHERE 2549 02:04:22,872 --> 02:04:26,543 FROM 24 TO 6 MONTHS AND IF 2550 02:04:26,543 --> 02:04:28,712 YOU'RE TRYING TO SAVE LIVES IT'S 2551 02:04:28,712 --> 02:04:30,080 FAR TOO LONG. 2552 02:04:30,080 --> 02:04:35,251 THERE'S MANY THINGS WE FOUND AT 2553 02:04:35,251 --> 02:04:38,755 A COUNTY LEVEL TO HAVE MORE 2554 02:04:38,755 --> 02:04:40,523 TIMELY DATA. 2555 02:04:40,523 --> 02:04:43,460 AND THERE'S AN APPROACH TO 2556 02:04:43,460 --> 02:04:44,060 IMPLEMENTING EVIDENCE-BASED 2557 02:04:44,060 --> 02:04:48,832 PRACTICES AND LEARNED OEND WAS 2558 02:04:48,832 --> 02:04:52,535 EASIER FOR THEM. 2559 02:04:52,535 --> 02:04:55,438 MOUD SERVED AS A GATEWAY TO GET 2560 02:04:55,438 --> 02:04:58,341 PEOPLE INTERESTED BUT IT TAKES A 2561 02:04:58,341 --> 02:05:01,511 LOT OF TIME TO PUT INTO PLACE 2562 02:05:01,511 --> 02:05:04,214 THESE DIFFERENT PROGRAMS FOR 2563 02:05:04,214 --> 02:05:06,616 MOUD BECAUSE OF REASONS 2564 02:05:06,616 --> 02:05:07,717 INCLUDING REGULATORY ISSUES. 2565 02:05:07,717 --> 02:05:09,019 AND SEE THE PUBLIC HEALTH 2566 02:05:09,019 --> 02:05:15,125 IMPACT. 2567 02:05:15,125 --> 02:05:16,993 AND THEY INDICATE WE WERE ABLE 2568 02:05:16,993 --> 02:05:20,430 TO CHANGE BEHAVIORS BY 2569 02:05:20,430 --> 02:05:23,500 INCREASING NALOXONE BECAUSE OF 2570 02:05:23,500 --> 02:05:27,270 OUR CAMPAIGNS AND THEN WE START 2571 02:05:27,270 --> 02:05:29,005 FROM DAY ONE PLANNING FOR 2572 02:05:29,005 --> 02:05:31,141 SUSTAINABILITY AND FOUND THAT 2573 02:05:31,141 --> 02:05:32,742 WAS CRITICAL. 2574 02:05:32,742 --> 02:05:34,878 WE WANTED THE ACTIVITIES TO 2575 02:05:34,878 --> 02:05:36,513 REMAIN AFTER RESEARCH SUPPORT 2576 02:05:36,513 --> 02:05:37,213 ENDED. 2577 02:05:37,213 --> 02:05:39,282 WE DID ALL KINDS OF THINGS FROM 2578 02:05:39,282 --> 02:05:41,017 TEACHING COMMUNITIES HOW TO 2579 02:05:41,017 --> 02:05:44,821 WRITE GRANTS AND APPLY FOR 2580 02:05:44,821 --> 02:05:47,657 FUNDING AND WORKING WITH THEM TO 2581 02:05:47,657 --> 02:05:49,392 THINK THROUGH WHOA MIGHT BE ABLE 2582 02:05:49,392 --> 02:05:52,529 AND WHERE THEY MIGHT BE ABLE TO 2583 02:05:52,529 --> 02:05:57,033 GET ONGOING SUPPORT. 2584 02:05:57,033 --> 02:05:59,769 SO THE COMMUNITY HAD A HUGE 2585 02:05:59,769 --> 02:06:00,036 ENDEAVOR. 2586 02:06:00,036 --> 02:06:02,806 A HUGE THANK YOU TO HUNDREDS OF 2587 02:06:02,806 --> 02:06:03,239 PEOPLE. 2588 02:06:03,239 --> 02:06:05,308 OUR COMMUNITY ADVISORY BOARDS 2589 02:06:05,308 --> 02:06:07,377 AND KEY GOVERNMENTAL OFFICIALS 2590 02:06:07,377 --> 02:06:12,248 AND COMMUNITY PARTNERS AND 2591 02:06:12,248 --> 02:06:13,316 INVESTIGATORS AND STAFF AND THEY 2592 02:06:13,316 --> 02:06:20,023 HELPED TO MAKE THIS A SUCCESS. 2593 02:06:20,023 --> 02:06:28,298 WITH THAT I WILL STOP SHARING. 2594 02:06:28,298 --> 02:06:29,065 >> I APPRECIATE THAT. 2595 02:06:29,065 --> 02:06:39,509 DO WE HAVE ANY QUESTIONS? 2596 02:06:46,883 --> 02:06:49,018 I THINK YOU WERE EXCEPTIONALLY 2597 02:06:49,018 --> 02:06:49,285 CLEAR. 2598 02:06:49,285 --> 02:06:51,087 THANK YOU FOR AN EXCEPTIONAL 2599 02:06:51,087 --> 02:06:51,888 OVERVIEW OF THAT IMPORTANT 2600 02:06:51,888 --> 02:06:52,122 PROGRAM. 2601 02:06:52,122 --> 02:06:56,059 I'LL TAKE A MOMENT TO MAKE SURE. 2602 02:06:56,059 --> 02:06:56,259 OKAY. 2603 02:06:56,259 --> 02:06:56,693 THANK YOU, SO MUCH. 2604 02:06:56,693 --> 02:06:58,895 WITH THAT, I JUST WANT TO NOTE 2605 02:06:58,895 --> 02:07:03,466 WE ARE NOW MOVING TO A BREAK. 2606 02:07:03,466 --> 02:07:09,005 WE ARE SCHEDULED FOR THE BREAK 2607 02:07:09,005 --> 02:07:11,040 TO END AT 1:15 BUT THAT'S NOT 2608 02:07:11,040 --> 02:07:13,309 ENOUGH SO I'LL GIVE US A 2609 02:07:13,309 --> 02:07:17,680 10-MINUTE BREAK AND RECONVENE 2610 02:07:17,680 --> 02:07:17,981 AROUND 1:20. 2611 02:07:17,981 --> 02:07:20,950 2612 02:07:38,617 --> 02:07:40,519 >> I'LL START WITH THE 2613 02:07:40,519 --> 02:07:42,955 MOTIVATION AND THE MISSION AND 2614 02:07:42,955 --> 02:07:43,255 GOALS. 2615 02:07:43,255 --> 02:07:45,357 THEN I'LL GO THROUGH THE 2616 02:07:45,357 --> 02:07:46,725 SPECIFIC PROGRAMS AND FUNDING 2617 02:07:46,725 --> 02:07:47,559 OPPORTUNITIES WE HAVE AVAILABLE 2618 02:07:47,559 --> 02:07:50,128 AND PROVIDE AN OVERVIEW OF OUR 2619 02:07:50,128 --> 02:07:51,964 PROGRAM'S ACCOMPLISHMENTS AND 2620 02:07:51,964 --> 02:07:52,664 FINISH BY HIGHLIGHTING SOME 2621 02:07:52,664 --> 02:07:57,736 PROJECTS WE FUNDED. 2622 02:07:57,736 --> 02:08:00,639 SO WHAT WAS AND WHAT IS THE 2623 02:08:00,639 --> 02:08:02,608 MOTIVATION FOR THE TRANSLATIONAL 2624 02:08:02,608 --> 02:08:03,809 DEVICES PROGRAM? 2625 02:08:03,809 --> 02:08:10,115 I THINK WE ALL REALIZE TO 2626 02:08:10,115 --> 02:08:11,516 EFFECTIVELY ADDRESS PAIN WE NEED 2627 02:08:11,516 --> 02:08:13,652 TO DELIVER THE BEST POSSIBLE 2628 02:08:13,652 --> 02:08:15,153 OUTCOMES FOR PATIENTS BOTH 2629 02:08:15,153 --> 02:08:16,622 HAVING ACCURATE DIAGNOSES OF A 2630 02:08:16,622 --> 02:08:18,924 PATIENT'S CONDITION AND MAKING A 2631 02:08:18,924 --> 02:08:21,660 MULTI-FACETED APPROACH TO 2632 02:08:21,660 --> 02:08:23,195 TREATMENT WHICH COULD INCLUDE 2633 02:08:23,195 --> 02:08:27,666 PHYSICAL AND PSYCHOLOGICAL AND 2634 02:08:27,666 --> 02:08:30,168 PHARMACOLOGIC AND 2635 02:08:30,168 --> 02:08:30,802 NON-PHARMACOLOGIC. 2636 02:08:30,802 --> 02:08:32,638 SEVERAL KEY CHALLENGES OR 2637 02:08:32,638 --> 02:08:35,340 LIMITATIONS PERSIST SUCH AS THE 2638 02:08:35,340 --> 02:08:38,276 ABILITY TO ACCURATELY DIAGNOSIS 2639 02:08:38,276 --> 02:08:39,778 WITH VALIDATED BIOMARKERS AND IN 2640 02:08:39,778 --> 02:08:41,647 THE TREATMENT SPACE THE EFFICACY 2641 02:08:41,647 --> 02:08:43,649 OF INTERVENTIONS VARIES WIDELY. 2642 02:08:43,649 --> 02:08:46,051 SOME HAVE ADDICTION LIABILITY 2643 02:08:46,051 --> 02:08:50,055 AND UNWANTED OFF-TARGET EFFECTS 2644 02:08:50,055 --> 02:08:52,357 AND FOR MANY THERAPIES, COST AND 2645 02:08:52,357 --> 02:08:54,860 ACCESS TO CARE IS A CHALLENGE. 2646 02:08:54,860 --> 02:08:58,363 AND THE TIME IT TAKES TO GET TO 2647 02:08:58,363 --> 02:09:00,632 PATIENTS IN NEED TAKES LONGER 2648 02:09:00,632 --> 02:09:10,108 THAN WE PREFER. 2649 02:09:10,108 --> 02:09:13,345 MEDICAL DEVICES CAN SERVE AS A 2650 02:09:13,345 --> 02:09:14,780 COMPLEMENT OR ALTERNATIVE 2651 02:09:14,780 --> 02:09:15,180 TREATMENT OPTION. 2652 02:09:15,180 --> 02:09:16,381 THERE'S MANY TYPES AVAILABLE 2653 02:09:16,381 --> 02:09:17,783 THAT CAN HELP ADDRESS THE 2654 02:09:17,783 --> 02:09:20,652 CHALLENGES I MENTIONED BEFORE 2655 02:09:20,652 --> 02:09:22,954 SUCH AS DIAGNOSTICS, IMPLANTABLE 2656 02:09:22,954 --> 02:09:26,825 DEVICES AND NON-INVASIVES AND 2657 02:09:26,825 --> 02:09:27,926 WEARABLE TECHNOLOGY. 2658 02:09:27,926 --> 02:09:32,097 THE MULTIPLE MODALITIES ALLOW 2659 02:09:32,097 --> 02:09:36,635 THEM TO BE APPLIED AT DIFFERENT 2660 02:09:36,635 --> 02:09:37,936 ANATOMICAL INTERVENTIONS 2661 02:09:37,936 --> 02:09:39,204 INTERACTING WITH THE SPINAL CORD 2662 02:09:39,204 --> 02:09:40,372 AND BRAIN. 2663 02:09:40,372 --> 02:09:41,173 THE FLEXIBILITY AND DESIGN OF 2664 02:09:41,173 --> 02:09:42,708 NEW INTERVENTIONS AND BECAUSE OF 2665 02:09:42,708 --> 02:09:45,644 THESE OPTIONS, DEVICES CAN OFFER 2666 02:09:45,644 --> 02:09:52,350 PRECISE TARGETING OR RECORDING 2667 02:09:52,350 --> 02:09:54,986 CAPABILITIES AND POSE LITTLE TO 2668 02:09:54,986 --> 02:09:56,321 NO ADDICTION LIABILITY. 2669 02:09:56,321 --> 02:09:59,691 THERE'S ALSO MULTIPLE REGULATORY 2670 02:09:59,691 --> 02:10:02,594 PATHWAYS WHICH CAN ACCELERATE TO 2671 02:10:02,594 --> 02:10:04,262 NEW PATIENTS WHO NEED THEM. 2672 02:10:04,262 --> 02:10:06,965 FOR HEAL IN OUR MISSION TO 2673 02:10:06,965 --> 02:10:08,800 ADDRESS PAIN AND OUD MORE 2674 02:10:08,800 --> 02:10:11,336 EFFECTIVELY DEVICES COULD MORE 2675 02:10:11,336 --> 02:10:13,905 ACCURATE DIAGNOSTICS AND GREATER 2676 02:10:13,905 --> 02:10:15,407 EFFICACY THROUGH PRECISE 2677 02:10:15,407 --> 02:10:18,677 TARGETING AND DESIGN OPTIONS AND 2678 02:10:18,677 --> 02:10:20,278 FLEXIBILITIES CAN ADDRESS NEW 2679 02:10:20,278 --> 02:10:21,980 INDICATIONS PROVIDING ADDITIONAL 2680 02:10:21,980 --> 02:10:24,649 OPTION FOR PATIENTS AND 2681 02:10:24,649 --> 02:10:32,290 CLINICIANS. 2682 02:10:32,290 --> 02:10:33,658 THIS ILLUSTRATES DISCOVERY 2683 02:10:33,658 --> 02:10:39,097 SCIENCE TO DEVELOPMENT AND 2684 02:10:39,097 --> 02:10:40,999 CLINICAL TRIALS AND FULL 2685 02:10:40,999 --> 02:10:42,667 CLINICAL IMPLEMENTATION AND 2686 02:10:42,667 --> 02:10:43,001 DISSEMINATION. 2687 02:10:43,001 --> 02:10:44,069 IN THE CENTER IS OUR 2688 02:10:44,069 --> 02:10:45,704 TRANSLATIONAL DEVICES PROGRAM. 2689 02:10:45,704 --> 02:10:47,038 THROUGH OUR VARIOUS FUNDING 2690 02:10:47,038 --> 02:10:50,642 OPTIONS WE'RE TARGETING TO 2691 02:10:50,642 --> 02:10:52,043 ADVANCE THE DEVELOPMENT OF 2692 02:10:52,043 --> 02:10:56,281 PROMISING NEW TECHNOLOGIES TO 2693 02:10:56,281 --> 02:11:01,119 THE CLINICAL RESEARCH SPACE. 2694 02:11:01,119 --> 02:11:03,021 IN 2018 WE LAUNCHED THE INITIAL 2695 02:11:03,021 --> 02:11:04,656 VERSION WITH THE GOAL OF 2696 02:11:04,656 --> 02:11:07,959 SUPPORTING NEXT GENERATION 2697 02:11:07,959 --> 02:11:11,363 MEDICAL DEVICES TO DIAGNOSE AND 2698 02:11:11,363 --> 02:11:13,231 TREAT PAIN MODELLING AFTER 2699 02:11:13,231 --> 02:11:15,233 COMPANION PROGRAMS LIKE HEAL 2700 02:11:15,233 --> 02:11:16,434 INITIATIVE AND OFFER FUNDING 2701 02:11:16,434 --> 02:11:18,203 OPPORTUNITIES THAT SPAN FROM 2702 02:11:18,203 --> 02:11:20,505 DEVELOPMENT TO EARLY STAGE 2703 02:11:20,505 --> 02:11:26,478 CLINICAL TRIALS. 2704 02:11:26,478 --> 02:11:28,180 TOWARDS THE LEFT WE HAVE 2705 02:11:28,180 --> 02:11:29,347 PROGRAMS TO SUPPORT DEVICE 2706 02:11:29,347 --> 02:11:30,549 DEVELOPMENT AND OPTIMIZE RATION 2707 02:11:30,549 --> 02:11:32,651 AND ON THE RIGHT SEVERAL 2708 02:11:32,651 --> 02:11:33,985 TRANSLATIONAL RESEARCH PROGRAMS 2709 02:11:33,985 --> 02:11:36,655 TO ADVANCE NEW DEVICE THERAPIES 2710 02:11:36,655 --> 02:11:37,189 INTO EARLY STAGE CLINICAL 2711 02:11:37,189 --> 02:11:46,565 TRIALS. 2712 02:11:46,565 --> 02:11:49,668 IN 2021 AND 2022 WE TACKLED NEW 2713 02:11:49,668 --> 02:11:50,602 ASPECTS OF THE TECHNOLOGY 2714 02:11:50,602 --> 02:11:52,637 RESEARCH SPACE. 2715 02:11:52,637 --> 02:11:54,739 WE EXPANDED THE SCOPE OF OUR 2716 02:11:54,739 --> 02:11:56,274 THERAPEUTIC DEVELOPMENT PROGRAMS 2717 02:11:56,274 --> 02:12:00,512 TO NOT ONLY INCLUDE DEVICES POR 2718 02:12:00,512 --> 02:12:03,148 PAIN BUT TO EXPAND TO OPIOID USE 2719 02:12:03,148 --> 02:12:05,283 DISORDER AND ANNOUNCED 2720 02:12:05,283 --> 02:12:08,019 INVOLVEMENT IN THE PROGRAM TO 2721 02:12:08,019 --> 02:12:08,520 FURTHER ENHANCE OUR 2722 02:12:08,520 --> 02:12:13,258 TRANSLATIONAL OFFERINGS AND IN 2723 02:12:13,258 --> 02:12:16,828 RESPONSE TO FEEDBACK SUPPORTING 2724 02:12:16,828 --> 02:12:18,430 MECHANISTIC RESEARCH INTO 2725 02:12:18,430 --> 02:12:19,130 MEDICAL DEVICES. 2726 02:12:19,130 --> 02:12:19,698 I'LL TAKE YOU THROUGH THE 2727 02:12:19,698 --> 02:12:28,073 PROGRAMS IN MORE DETAIL. 2728 02:12:28,073 --> 02:12:31,543 WE HAVE A TECHNOLOGY DEVELOPMENT 2729 02:12:31,543 --> 02:12:39,284 GRANT PROGRAM LED BY NIDID AND 2730 02:12:39,284 --> 02:12:42,487 THESE ARE GRANTS NOT HYPOTHESIS 2731 02:12:42,487 --> 02:12:44,789 DRIVEN BUT FOCUS ON DESIGN AND 2732 02:12:44,789 --> 02:12:46,691 DEVELOPMENT OR A NEW APPROACH IN 2733 02:12:46,691 --> 02:12:48,426 ADDRESSING PAIN OR OUD. 2734 02:12:48,426 --> 02:12:50,729 IN THEIR PROJECTS THEY NEED TO 2735 02:12:50,729 --> 02:12:52,197 DEMONSTRATE AND VALIDATE THE 2736 02:12:52,197 --> 02:12:54,366 TECHNOLOGY IN ASSAYS OR MODELS 2737 02:12:54,366 --> 02:12:56,334 RELEVANT FOR THE INDICATION OF 2738 02:12:56,334 --> 02:13:01,006 PAIN OR OUD. 2739 02:13:01,006 --> 02:13:07,545 THE GOAL IS TO PREPARE THEM FOR 2740 02:13:07,545 --> 02:13:09,080 FUTURE TRANSLATION AND THE DUE 2741 02:13:09,080 --> 02:13:09,981 DATE IS IN OCTOBER. 2742 02:13:09,981 --> 02:13:14,286 REACH OUT TO THE LEAD FOR THE 2743 02:13:14,286 --> 02:13:20,292 PROGRAM MY COLLEGIATE NIDID IF 2744 02:13:20,292 --> 02:13:24,629 YOU'RE INTERESTED. 2745 02:13:24,629 --> 02:13:29,067 WE HAVE PROGRAMS TO SUPPORT THE 2746 02:13:29,067 --> 02:13:30,568 ADVANCEMENT OF PAIN AND OUD IN 2747 02:13:30,568 --> 02:13:32,637 THE PAIN AND RESEARCH SPACE. 2748 02:13:32,637 --> 02:13:38,310 HEAL HAS PUBLISHED A NOTICE OF 2749 02:13:38,310 --> 02:13:41,880 SPECIAL INTEREST IN THE PROGRAM. 2750 02:13:41,880 --> 02:13:45,317 OPERATED BY THE BLUEPRINT FOR 2751 02:13:45,317 --> 02:13:46,918 NEUROSCIENCE RESEARCH IT'S AN 2752 02:13:46,918 --> 02:13:52,424 NIH INCUBATOR TO CATALYZE FROM 2753 02:13:52,424 --> 02:13:56,227 EARLY STAGE DEVELOPMENT TO FIRST 2754 02:13:56,227 --> 02:13:59,164 IN HUMAN CLINICAL TRIALS. 2755 02:13:59,164 --> 02:14:02,267 HERE IS VALIDATION AND IDE 2756 02:14:02,267 --> 02:14:03,735 ENABLING STUDIES AS WELL AS 2757 02:14:03,735 --> 02:14:06,037 EARLY STAGE CLINICAL TRIALS TO 2758 02:14:06,037 --> 02:14:07,739 DEMONSTRATE SAFETY AND INITIAL 2759 02:14:07,739 --> 02:14:12,944 INDICATORS OF EF CAS -- EFFICACY 2760 02:14:12,944 --> 02:14:16,681 FOR THERAPIES AND I'LL TAKE YOU 2761 02:14:16,681 --> 02:14:26,124 THROUGH HOW IT WORKS. 2762 02:14:26,124 --> 02:14:29,694 THERE'S TWO AIMS AND THE 2763 02:14:29,694 --> 02:14:31,296 DEVELOPMENT STAGE AND 2764 02:14:31,296 --> 02:14:33,598 TRANSLATION STAGE. 2765 02:14:33,598 --> 02:14:38,269 THE DEVELOPMENT STAGE IS TO NIH 2766 02:14:38,269 --> 02:14:42,774 FUNDED INCUBATOR HUBS ONE AT 2767 02:14:42,774 --> 02:14:44,642 JOHNS HOPKINS AND ONE AT HOWARD 2768 02:14:44,642 --> 02:14:46,745 UNIVERSITY AND ONE AT MGH. 2769 02:14:46,745 --> 02:14:49,614 THEY APPLY THROUGH AN 2770 02:14:49,614 --> 02:14:52,617 ACCELERATED APPLICATION PROCESS 2771 02:14:52,617 --> 02:15:00,625 THROUGH THE WEBSITE NEURO 2772 02:15:00,625 --> 02:15:04,062 BLUEPRINT.org. 2773 02:15:04,062 --> 02:15:05,797 SEEDLINGS ARE SMALL-SCALE GRANTS 2774 02:15:05,797 --> 02:15:08,266 FOR TEAMS WITH A COMPELLING 2775 02:15:08,266 --> 02:15:11,703 CONCEPT BUT MAY NEED TO ANSWER 2776 02:15:11,703 --> 02:15:14,272 ABOUT PLAN TO ADVANCING THROUGH 2777 02:15:14,272 --> 02:15:18,176 THE DEVELOPMENT PROCESS. 2778 02:15:18,176 --> 02:15:19,477 OPTIMIZER PROJECT RECEIVE LARGER 2779 02:15:19,477 --> 02:15:21,179 AWARDS THAT HAVE VALIDATION 2780 02:15:21,179 --> 02:15:31,122 THROUGH PRECLINICAL STUDIES. 2781 02:15:31,122 --> 02:15:35,927 FOR APPLICANTS WE HAVE A 2782 02:15:35,927 --> 02:15:39,864 TRANSLATOR PROGRAM. 2783 02:15:39,864 --> 02:15:42,700 APPLICANTS TO THIS PROGRAM CAN 2784 02:15:42,700 --> 02:15:43,802 FINISH UP WORK AND COMPLETE 2785 02:15:43,802 --> 02:15:46,938 ENABLING STUDIES AND BY THE END 2786 02:15:46,938 --> 02:15:50,041 OF THE FIRST PHASE GRANT IRB 2787 02:15:50,041 --> 02:15:52,010 APPROVAL TO INITIATE A CLINICAL 2788 02:15:52,010 --> 02:15:53,044 TRIAL IN THE SECOND PHASE OF THE 2789 02:15:53,044 --> 02:15:53,311 GRANT. 2790 02:15:53,311 --> 02:15:56,181 FOR THE TRANSLATOR PROGRAM, WE 2791 02:15:56,181 --> 02:16:00,051 OFFER A UG3 FUNDING OPTION FOR 2792 02:16:00,051 --> 02:16:01,953 ALL APPLICANTS AS WELL AS AN 2793 02:16:01,953 --> 02:16:04,856 SBIR U44 FAST TRACK PROGRAM FOR 2794 02:16:04,856 --> 02:16:10,462 SMALL BUSINESSES. 2795 02:16:10,462 --> 02:16:12,630 THE PROGRAM OFFERS RESOURCES AND 2796 02:16:12,630 --> 02:16:14,999 SUPPORT SERVICES TO FUNDED TEAMS 2797 02:16:14,999 --> 02:16:16,401 AT NO COST. 2798 02:16:16,401 --> 02:16:18,069 THROUGH CONTRACT RESEARCH 2799 02:16:18,069 --> 02:16:19,504 ORGANIZATIONS WE CAN PROVIDER A 2800 02:16:19,504 --> 02:16:21,372 VARIETY OF PRE CLINICAL 2801 02:16:21,372 --> 02:16:24,209 SERVICES, REGULATORY CONSULTING 2802 02:16:24,209 --> 02:16:25,643 AND CLINICAL CONSULTING TO HELP 2803 02:16:25,643 --> 02:16:27,879 DE RISK THE PATHWAY TO THE 2804 02:16:27,879 --> 02:16:29,214 CLINIC AND COMMERCIALIZATION. 2805 02:16:29,214 --> 02:16:30,548 INVESTIGATORS DON'T NEED TO 2806 02:16:30,548 --> 02:16:31,483 BUDGET FOR THESE SERVICES IN 2807 02:16:31,483 --> 02:16:35,153 THEIR GRANT APPLICATION. 2808 02:16:35,153 --> 02:16:36,621 THEY'RE PROVIDED SEPARATE VIA 2809 02:16:36,621 --> 02:16:39,557 THE CONTRACTS. 2810 02:16:39,557 --> 02:16:41,526 WE HAVE MULTIPLE UPCOMING 2811 02:16:41,526 --> 02:16:42,393 APPLICATION DUE DATES TO REACH 2812 02:16:42,393 --> 02:16:44,295 OUT IF YOU'RE INTERESTED IN THE 2813 02:16:44,295 --> 02:16:51,336 PROGRAM AS WELL. 2814 02:16:51,336 --> 02:16:55,240 OUR MECHANISTIC RESEARCH PROGRAM 2815 02:16:55,240 --> 02:17:00,445 INVESTIGATES THE MECHANISMS BY 2816 02:17:00,445 --> 02:17:02,380 WHICH FDA DEVICES WORK TO 2817 02:17:02,380 --> 02:17:06,151 DECREASE PAIN AND FROM THE 2818 02:17:06,151 --> 02:17:07,719 OBSERVATION MANY ARE ON MARKET 2819 02:17:07,719 --> 02:17:10,121 TO TREAT PAIN BUT IN MANY CASES 2820 02:17:10,121 --> 02:17:12,056 IT'S UNCLEAR HOW THEY WORK TO 2821 02:17:12,056 --> 02:17:13,224 RELIEVE PAIN. 2822 02:17:13,224 --> 02:17:14,759 PATIENTS EXPERIENCE A WIDE RANGE 2823 02:17:14,759 --> 02:17:16,528 OF OUTCOMES AND THERE CAN BE A 2824 02:17:16,528 --> 02:17:17,962 SIGNIFICANT GROUP OF PATIENTS 2825 02:17:17,962 --> 02:17:20,698 THAT DON'T RESPOND TO THERAPY. 2826 02:17:20,698 --> 02:17:22,167 THROUGH THE PROJECTS WE AIM TO 2827 02:17:22,167 --> 02:17:25,303 UNCOVER THE MECHANISMS, IDENTIFY 2828 02:17:25,303 --> 02:17:26,504 PHYSIOLOGICAL MARKERS OF PAIN 2829 02:17:26,504 --> 02:17:30,108 AND PAIN RELIEF AND IDENTIFY NEW 2830 02:17:30,108 --> 02:17:32,277 APPROACHES TO IMPROVE PATIENT 2831 02:17:32,277 --> 02:17:37,916 CARE WITH THE DEVICES. 2832 02:17:37,916 --> 02:17:40,618 WE REQUIRE APPLICANT TO USE TEAM 2833 02:17:40,618 --> 02:17:43,354 SCIENCE APPROACH BRINGING 2834 02:17:43,354 --> 02:17:44,422 SCIENTIFIC DISCIPLINES TO TACKLE 2835 02:17:44,422 --> 02:17:45,857 THESE ISSUES IN NEW WAYS AND 2836 02:17:45,857 --> 02:17:47,425 MAKE A STEP CHANGE IN THE BODY 2837 02:17:47,425 --> 02:17:49,594 OF EVIDENCE FOR THE UNDERLYING 2838 02:17:49,594 --> 02:17:50,328 MECHANISMS. 2839 02:17:50,328 --> 02:17:54,966 PROJECTS CAN FOCUS ON PRE 2840 02:17:54,966 --> 02:17:56,100 CLINICAL STUDIES AND MECHANISTIC 2841 02:17:56,100 --> 02:18:01,439 TRIALS OR A COMBINATION OF THE 2842 02:18:01,439 --> 02:18:02,273 TWO. 2843 02:18:05,710 --> 02:18:08,279 6:SO WHAT RESEARCH HAVE WE 2844 02:18:08,279 --> 02:18:08,546 SUPPORTED? 2845 02:18:08,546 --> 02:18:16,521 HEAL HAS INVESTED $87 MILLION 2846 02:18:16,521 --> 02:18:17,922 FOR 13 DISTINCT TECHNOLOGIES AND 2847 02:18:17,922 --> 02:18:19,190 INDICATIONS OF PAIN AND OUD. 2848 02:18:19,190 --> 02:18:23,861 THESE PROJECTS HAVE GARNERED 2849 02:18:23,861 --> 02:18:24,629 FIVE INVESTIGATIONAL DEVICE 2850 02:18:24,629 --> 02:18:25,964 EXEMPTIONS AND 11 CLINICAL 2851 02:18:25,964 --> 02:18:30,435 TRIALS ARE ONGOING AND COMPLETED 2852 02:18:30,435 --> 02:18:31,102 INCLUDING FEASIBILITY TRIALS AND 2853 02:18:31,102 --> 02:18:32,704 FIVE MECHANISTIC TRIALS. 2854 02:18:32,704 --> 02:18:36,507 SO FAR THE RESEARCH HAS RESULTED 2855 02:18:36,507 --> 02:18:40,178 IN OVER 100 PUBLICATIONS AS 2856 02:18:40,178 --> 02:18:42,513 TEAMS MEET THEIR ENDS POINTS IN 2857 02:18:42,513 --> 02:18:42,880 THEIR PROJECTS. 2858 02:18:42,880 --> 02:18:45,216 THE INVESTMENT REPRESENTS ABOUT 2859 02:18:45,216 --> 02:18:48,620 2.5% OF THE HEAL BUDGET OVER 2860 02:18:48,620 --> 02:18:56,494 THIS PERIOD OF TIME. 2861 02:18:56,494 --> 02:18:58,029 THIS ILLUSTRATED THE 2862 02:18:58,029 --> 02:19:00,598 DISTRIBUTION OR THE INTENDED 2863 02:19:00,598 --> 02:19:01,966 CLINICAL INDICATION ON THE 2864 02:19:01,966 --> 02:19:02,166 RIGHT. 2865 02:19:02,166 --> 02:19:08,273 THE SMALLEST CIRCLES AND SQUARES 2866 02:19:08,273 --> 02:19:10,942 HAVE MORE PROJECTS FUNDED AND 2867 02:19:10,942 --> 02:19:13,144 THERE'S BEEN A VARIETY OF DEVICE 2868 02:19:13,144 --> 02:19:16,214 TYPE AND ANATOMICAL LOCATIONS 2869 02:19:16,214 --> 02:19:16,714 TARGETED AND PAIN AND 2870 02:19:16,714 --> 02:19:27,091 INDICATIONS EXPLORED. 2871 02:19:27,625 --> 02:19:36,634 THIS SHOWS THE PROJECTS FUNDED 2872 02:19:36,634 --> 02:19:44,142 AND YOU CAN SEE WHETHER THEY'RE 2873 02:19:44,142 --> 02:19:46,444 DIAGNOSTIC OR THERAPEUTIC AND 2874 02:19:46,444 --> 02:19:48,279 THE PROJECT FOCUS AND OUD OR 2875 02:19:48,279 --> 02:19:48,680 PAIN POPULATIONS. 2876 02:19:48,680 --> 02:19:51,516 YOU CAN SEE WE SPREAD OUR 2877 02:19:51,516 --> 02:19:53,785 INVESTMENTS OVER A COMPREHENSIVE 2878 02:19:53,785 --> 02:19:56,287 COMBINATION OF DEVICE TYPES AND 2879 02:19:56,287 --> 02:20:06,564 OUD INDICATIONS. 2880 02:20:07,231 --> 02:20:09,734 WE HAVE EARLY FEASIBILITY TRIALS 2881 02:20:09,734 --> 02:20:14,305 IN CANCER PAIN AND IBS AND 2882 02:20:14,305 --> 02:20:14,872 SPINAL CORD INJURY PAIN AND 2883 02:20:14,872 --> 02:20:16,641 THEY'RE USING A VARIETY OF 2884 02:20:16,641 --> 02:20:20,311 DEVICE TYPES TO PROVIDE 2885 02:20:20,311 --> 02:20:22,113 THERAPIES. 2886 02:20:22,113 --> 02:20:25,116 WE HAVE MECHANISTIC TRIALS 2887 02:20:25,116 --> 02:20:28,419 FOCUSSED ON SPINAL CORD 2888 02:20:28,419 --> 02:20:30,355 STIMULATION AND STIMULATION FOR 2889 02:20:30,355 --> 02:20:31,289 PAIN DURING OPIOID WITHDRAWAL 2890 02:20:31,289 --> 02:20:35,193 AND BETTER UNDERSTANDING 2891 02:20:35,193 --> 02:20:36,627 PERIPHERAL NERVE STIMULATION FOR 2892 02:20:36,627 --> 02:20:42,200 CHRONIC NEURAL PATHIC PAIN. 2893 02:20:42,200 --> 02:20:45,770 I WANTED TO DIVE DEEPER INTO THE 2894 02:20:45,770 --> 02:20:47,004 TRANSLATIONAL DEVICES PROGRAM. 2895 02:20:47,004 --> 02:20:48,673 THE FIRST IS A DEVELOPMENT 2896 02:20:48,673 --> 02:20:54,812 PROJECT FROM UNIVERSITY OF 2897 02:20:54,812 --> 02:20:56,647 WISCONSIN-MADISON AND CARNEGIE 2898 02:20:56,647 --> 02:21:02,320 MELON UNIVERSITY AND AN 2899 02:21:02,320 --> 02:21:08,326 INJECTRODE THAT OVERCOMES 2900 02:21:08,326 --> 02:21:11,763 IMPROPER INJECTION AND HAS 2901 02:21:11,763 --> 02:21:13,030 ANCHORING FEATURES TO PREVENT 2902 02:21:13,030 --> 02:21:15,333 MIGRATION AND FULLY REMOVABLE. 2903 02:21:15,333 --> 02:21:16,634 THROUGH THE PROJECT THE TEAM 2904 02:21:16,634 --> 02:21:19,537 DEVELOPED SEVERAL PROTOTYPES AND 2905 02:21:19,537 --> 02:21:21,839 DEMONSTRATED FEASIBILITY OF GRD 2906 02:21:21,839 --> 02:21:24,642 STIMULATION IN A LARGE ANIMAL 2907 02:21:24,642 --> 02:21:30,648 MODEL AND MET WITH TO THE FDA TO 2908 02:21:30,648 --> 02:21:33,818 SEEK FEEDBACK AND THE TECHNOLOGY 2909 02:21:33,818 --> 02:21:35,753 HAS NOW BEGUN CLINICAL TRIALS 2910 02:21:35,753 --> 02:21:36,621 AND ADVANCING TOWARDS 2911 02:21:36,621 --> 02:21:46,631 COMMERCIALIZATION. 2912 02:21:46,631 --> 02:21:48,599 THE NEXT PROJECT FROM VANDERBILT 2913 02:21:48,599 --> 02:21:50,334 UNIVERSITY DEVELOPED FROM AN 2914 02:21:50,334 --> 02:21:51,702 IMAGE GUIDES NEURAL MODULATION 2915 02:21:51,702 --> 02:21:56,340 SYSTEM FOR PRECISELY TARGETING 2916 02:21:56,340 --> 02:21:57,842 PAIN CIRCUITS. 2917 02:21:57,842 --> 02:22:00,311 THE TEAM DEVELOPED THE 2918 02:22:00,311 --> 02:22:05,383 ULTRASOUND SYSTEM TO BE 2919 02:22:05,383 --> 02:22:10,021 COMPATIBLE WITH MRI SYSTEMS 2920 02:22:10,021 --> 02:22:10,721 TARGETING. 2921 02:22:10,721 --> 02:22:12,523 THEY WERE ABLE TO DEMONSTRATE 2922 02:22:12,523 --> 02:22:14,258 FEASIBILITY OF THE SYSTEM FOR 2923 02:22:14,258 --> 02:22:15,493 TARGETING NOT JUST PAIN SECTORS 2924 02:22:15,493 --> 02:22:19,263 IN A LARGE ANIMAL MODEL AND 2925 02:22:19,263 --> 02:22:20,331 AFTER COMPLETION THE TEAM HAS 2926 02:22:20,331 --> 02:22:30,808 NOW GRADUATED TO OUR PROGRAM TO 2927 02:22:30,808 --> 02:22:36,647 TRANSLATE AS A TREATMENT THE 2928 02:22:36,647 --> 02:22:39,383 TEAM IS TESTING A DEEP BRAIN 2929 02:22:39,383 --> 02:22:41,786 STIMULATION APPROACH FOR 2930 02:22:41,786 --> 02:22:43,087 TREATMENT OF REFRACTORY CHRONIC 2931 02:22:43,087 --> 02:22:46,290 PAIN IN A SMALL COHORT OF 2932 02:22:46,290 --> 02:22:46,557 PATIENTS. 2933 02:22:46,557 --> 02:22:47,892 THROUGH HEAL INITIATIVE AND 2934 02:22:47,892 --> 02:22:49,460 FUNDING THE TEAM IDENTIFIED AN 2935 02:22:49,460 --> 02:22:50,328 AREA OF THE BRAIN ASSOCIATED 2936 02:22:50,328 --> 02:22:52,230 WITH CHRONIC PAIN AND HAS BEEN 2937 02:22:52,230 --> 02:22:54,332 ABLE TO FIND OBJECTIVE 2938 02:22:54,332 --> 02:22:57,768 BIOMARKERS OF CHRONIC PAIN IN 2939 02:22:57,768 --> 02:22:58,970 INDIVIDUAL PATIENTS. 2940 02:22:58,970 --> 02:23:04,408 GECK -- GOING FORWARD THEY'LL 2941 02:23:04,408 --> 02:23:05,710 LOOK TO DEVELOP A CLOSE LOOP 2942 02:23:05,710 --> 02:23:07,478 DEEP BRAIN STIMULATION APPROACH 2943 02:23:07,478 --> 02:23:10,181 TO EFFECTIVELY MANAGE PAIN. 2944 02:23:10,181 --> 02:23:12,216 THE RESULTS FROM THEIR 2945 02:23:12,216 --> 02:23:13,584 NEUROSCIENCE PAPERWORK WAS 2946 02:23:13,584 --> 02:23:14,519 FEATURED AT THE HEAL SCIENTIFIC 2947 02:23:14,519 --> 02:23:17,054 MEETING AND THE PRESENTATION 2948 02:23:17,054 --> 02:23:22,994 INCLUDED A POWERFUL TESTIMONY 2949 02:23:22,994 --> 02:23:26,330 FROM A PATIENT ON THE TRIAL 2950 02:23:26,330 --> 02:23:27,665 WHICH IS STILL AVAILABLE IF YOU 2951 02:23:27,665 --> 02:23:28,633 MISSED IT. 2952 02:23:28,633 --> 02:23:31,168 THE TIME PROJECT I'D LIKE TO 2953 02:23:31,168 --> 02:23:35,273 HIGHLIGHT IS ONE OF OUR 2954 02:23:35,273 --> 02:23:36,440 MECHANISTIC CLINICAL TRIALS 2955 02:23:36,440 --> 02:23:39,443 DETERMINING THE WAY SPINAL CORD 2956 02:23:39,443 --> 02:23:40,211 STIMULATORS EFFECT PAIN WITH 2957 02:23:40,211 --> 02:23:41,045 THOSE WITH CHRONIC PAIN. 2958 02:23:41,045 --> 02:23:45,516 THIS IS AN INTERDISCIPLINARY 2959 02:23:45,516 --> 02:23:46,984 COLLABORATION BETWEEN MANY 2960 02:23:46,984 --> 02:23:48,185 ORGANIZATIONS AND THEY'RE 2961 02:23:48,185 --> 02:23:49,787 COMBINING MULTIPLE INNOVATIVE 2962 02:23:49,787 --> 02:23:53,558 TECHNIQUES TO BE ABLE TO 2963 02:23:53,558 --> 02:23:56,327 ELUCIDATE THE MECHANISMS USING 2964 02:23:56,327 --> 02:24:05,002 NERVE CONDUCTION STUDIES, MIC 2965 02:24:05,002 --> 02:24:05,670 MICRON 2966 02:24:05,670 --> 02:24:10,007 MICRONEUROGRAPHY AND MODULATING 2967 02:24:10,007 --> 02:24:12,843 THE EXCITABILITY LEEKED TO DROWN 2968 02:24:12,843 --> 02:24:13,344 STREAM PAIN RESPONSE. 2969 02:24:13,344 --> 02:24:16,614 FOR THE TRIAL RECRUITMENT IS 2970 02:24:16,614 --> 02:24:20,318 UNDERWAY AT THE VARIOUS 2971 02:24:20,318 --> 02:24:20,918 LOCATIONS FOR THE MULTI-SITE 2972 02:24:20,918 --> 02:24:27,124 TRIAL. 2973 02:24:27,124 --> 02:24:28,025 ED A LIKE TO CLOSE BY 2974 02:24:28,025 --> 02:24:30,761 RECOGNIZING THE AMAZING TEAM 2975 02:24:30,761 --> 02:24:35,800 THAT SUPPORT DEEPS TRANSLATION. 2976 02:24:35,800 --> 02:24:38,736 THESE ARE THE PROGRAMS NIBIB AND 2977 02:24:38,736 --> 02:24:41,439 NIDA AND MAKING ALL THE WORK 2978 02:24:41,439 --> 02:24:42,473 POSSIBLE. 2979 02:24:42,473 --> 02:24:43,908 ANYONE INTERESTED IN OUR PROGRAM 2980 02:24:43,908 --> 02:24:45,743 PLEASE REACH OUT AND WE'LL BE 2981 02:24:45,743 --> 02:24:48,646 HAPPY TO CHAT FURTHER ABOUT THE 2982 02:24:48,646 --> 02:24:52,416 OPPORTUNITIES. 2983 02:24:52,416 --> 02:24:54,485 NOW WE HAVE A FEW MINUTES FOR 2984 02:24:54,485 --> 02:24:54,785 DISCUSSION. 2985 02:24:54,785 --> 02:24:55,853 THERE ARE SOME PROMPTS TO 2986 02:24:55,853 --> 02:24:57,755 CONSIDER ON THE SCREEN AND THANK 2987 02:24:57,755 --> 02:25:00,992 YOU SO MUCH FOR YOUR ATTENTION 2988 02:25:00,992 --> 02:25:10,201 TODAY. 2989 02:25:10,201 --> 02:25:12,036 >> THANK YOU SO MUCH. 2990 02:25:12,036 --> 02:25:13,170 DOES ANYONE HAVE QUESTIONS FOR 2991 02:25:13,170 --> 02:25:23,280 ERIC? 2992 02:25:24,015 --> 02:25:24,649 ALLAN, PLEASE. 2993 02:25:24,649 --> 02:25:28,352 >> THIS IS PRETTY EXCITING, ALL 2994 02:25:28,352 --> 02:25:29,920 OF IT. 2995 02:25:29,920 --> 02:25:31,856 WHAT I FIND INTERESTING IS THE 2996 02:25:31,856 --> 02:25:36,661 USING OF SPINAL CORD STIMULATION 2997 02:25:36,661 --> 02:25:40,398 FOR SAY BACK PAIN. 2998 02:25:40,398 --> 02:25:42,400 THAT GETS BACK TO THE ISSUE WHEN 2999 02:25:42,400 --> 02:25:43,968 WALTER GAVE THE TALK IF THE 3000 02:25:43,968 --> 02:25:46,404 ASSUMPTION IS IT'S AN EFFECT ON 3001 02:25:46,404 --> 02:25:48,673 THE SPINAL CORD THE ASSUMPTION 3002 02:25:48,673 --> 02:25:51,642 IS THERE'S AN ABNORMAL INPUT 3003 02:25:51,642 --> 02:25:52,476 WHICH SUGGESTS THERE'S A DRIVER 3004 02:25:52,476 --> 02:25:54,345 IN THE PERIPHERY WHICH IS 3005 02:25:54,345 --> 02:25:56,347 EXACTLY THE OPPOSITE OF WHAT 3006 02:25:56,347 --> 02:26:06,757 ANOTHER PERSPECTIVE IS. 3007 02:26:10,628 --> 02:26:12,096 THERE'S EXISTING NOTION IT'S A 3008 02:26:12,096 --> 02:26:15,132 PRIMARY PAIN NOT A SECONDARY 3009 02:26:15,132 --> 02:26:19,236 PAIN NAMELY IT'S A PRODUCT OF 3010 02:26:19,236 --> 02:26:24,642 THE BRAIN NOT THE SPINAL CORD OR 3011 02:26:24,642 --> 02:26:30,014 PERIPHERY. 3012 02:26:30,014 --> 02:26:32,149 >> IT'S AN ONGOING CONSIDERATION 3013 02:26:32,149 --> 02:26:33,851 AND DISCUSSED AT LENGTH IN THE 3014 02:26:33,851 --> 02:26:35,419 TWO PROJECTS WE HAVE FUNDED 3015 02:26:35,419 --> 02:26:37,254 THROUGH THE MECHANISTIC RESEARCH 3016 02:26:37,254 --> 02:26:39,523 PROGRAM FOR SPINAL CORD 3017 02:26:39,523 --> 02:26:39,824 STIMULATION. 3018 02:26:39,824 --> 02:26:43,127 WE DO HAVE IN ADDITION TO THE 3019 02:26:43,127 --> 02:26:44,295 CLINICAL TRIAL PROJECT I 3020 02:26:44,295 --> 02:26:45,563 MENTIONED HERE WE HAVE A PROJECT 3021 02:26:45,563 --> 02:26:48,666 THAT'S FOCUSSING SOLELY ON PRE 3022 02:26:48,666 --> 02:26:50,367 CLINICAL STUDIES AND VARIOUS 3023 02:26:50,367 --> 02:26:52,670 ANIMAL MODELS TO SORT OF MORE 3024 02:26:52,670 --> 02:26:55,639 THE GRANULAR BASIC LEVEL TEASE 3025 02:26:55,639 --> 02:27:00,644 OUT WHAT THE MECHANISMS ARE IN 3026 02:27:00,644 --> 02:27:03,280 PAIN MODELS AND WHETHER THEY CAN 3027 02:27:03,280 --> 02:27:04,648 PROVIDE EVIDENCE FOR WHAT THE 3028 02:27:04,648 --> 02:27:07,218 ACTUAL MECHANISM IS AS YOU 3029 02:27:07,218 --> 02:27:08,352 SUGGESTED. 3030 02:27:08,352 --> 02:27:10,187 I SEE MICHAEL HAS HIS HAND 3031 02:27:10,187 --> 02:27:10,588 RAISED. 3032 02:27:10,588 --> 02:27:13,491 >> THANK YOU FOR THE QUESTION. 3033 02:27:13,491 --> 02:27:14,792 IF YOU LOOK AT THE PROJECT WHICH 3034 02:27:14,792 --> 02:27:17,695 ERIC ALLUDED TO EARLIER THAT'S A 3035 02:27:17,695 --> 02:27:20,598 DEEP BRAIN STIMULATOR -- FIRST 3036 02:27:20,598 --> 02:27:24,101 OF ALL IT'S RECORDING, AND THEN 3037 02:27:24,101 --> 02:27:26,370 LOOKING FOR ELECTROPHYSIOLOGICAL 3038 02:27:26,370 --> 02:27:28,939 SIGNATURE IN THE BRAIN AND 3039 02:27:28,939 --> 02:27:30,474 HAVING A CLOSED LOOP RESPONSE. 3040 02:27:30,474 --> 02:27:31,776 IT'S ALL RECORDING IN THE BRAIN 3041 02:27:31,776 --> 02:27:32,943 AND THEN STIMULATION IN THE 3042 02:27:32,943 --> 02:27:35,045 BRAIN AND FOR SOME PATIENTS, 3043 02:27:35,045 --> 02:27:38,883 IT'S BEEN ABSOLUTELY 3044 02:27:38,883 --> 02:27:39,550 TRANSFORMATIVE THEIR EXPERIENCE 3045 02:27:39,550 --> 02:27:41,418 AND QUALITY OF LIFE AND THEN 3046 02:27:41,418 --> 02:27:43,154 GETTING BACK TO WORK. 3047 02:27:43,154 --> 02:27:44,255 LIKE ERIC MENTIONED EARLIER ONE 3048 02:27:44,255 --> 02:27:47,591 OF THE PATIENTS THAT CAME TO THE 3049 02:27:47,591 --> 02:27:49,493 HEAL INVESTIGATOR MEETING AND 3050 02:27:49,493 --> 02:27:50,327 PRESENTED OVER THERE. 3051 02:27:50,327 --> 02:27:53,364 I THINK THROUGH THE COMBINATIONS 3052 02:27:53,364 --> 02:27:56,367 OF THE PROJECTS, AS WALTER 3053 02:27:56,367 --> 02:27:57,768 MENTIONED, THERE'S A ROLE FOR 3054 02:27:57,768 --> 02:27:57,968 BOTH. 3055 02:27:57,968 --> 02:28:00,671 THE CHANGES IN THE PHYSIOLOGY IN 3056 02:28:00,671 --> 02:28:04,642 THE PERIPHERY AND CHANGES IN THE 3057 02:28:04,642 --> 02:28:12,316 CIRCUIT CENTRALLY. 3058 02:28:12,316 --> 02:28:14,351 >> HAD I'D LIKE TO SHARE A 3059 02:28:14,351 --> 02:28:16,353 QUESTION REGARDING THE Q&A AND 3060 02:28:16,353 --> 02:28:18,889 METHODS FOR MEASURING PAIN AT 3061 02:28:18,889 --> 02:28:20,357 THE PEDIATRIC POPULATION FOR 3062 02:28:20,357 --> 02:28:29,967 INFANTS AND NEWBORN. 3063 02:28:29,967 --> 02:28:34,872 WHEREIN OUR PROGRAM WE DON'T 3064 02:28:34,872 --> 02:28:37,141 HAVE TARGETS WHETHER ON THE 3065 02:28:37,141 --> 02:28:38,275 MARKET OR AVAILABLE IN THE 3066 02:28:38,275 --> 02:28:39,977 CLINICAL RESEARCH SPACE THAT MAY 3067 02:28:39,977 --> 02:28:42,112 BE POINTING TO THAT. 3068 02:28:42,112 --> 02:28:44,648 >> WE DON'T CURRENTLY HAVE A 3069 02:28:44,648 --> 02:28:46,050 PROJECT FOR MEASURING OR 3070 02:28:46,050 --> 02:28:47,885 DIAGNOSING PAIN IN THE 3071 02:28:47,885 --> 02:28:50,354 POPULATION THAT MAY HAVE 3072 02:28:50,354 --> 02:28:51,922 DIFFICULTY ARTICULATING THEIR 3073 02:28:51,922 --> 02:28:55,626 PAIN OR VERBALLY DESCRIBING IT 3074 02:28:55,626 --> 02:29:00,664 BUT HAVE HAD HBAR PROJECT 3075 02:29:00,664 --> 02:29:05,936 TARGETED AT THE PEDIATRIC MARKET 3076 02:29:05,936 --> 02:29:12,176 SPERT ED -- SUPPORTED BY SBIR 3077 02:29:12,176 --> 02:29:14,378 AND HELPING OTHER INDIVIDUALS 3078 02:29:14,378 --> 02:29:18,249 WITH INJECTION PHOBIAS OR 3079 02:29:18,249 --> 02:29:19,717 SUSCEPTIBLE TO INJECTION PAIN. 3080 02:29:19,717 --> 02:29:21,385 >> AT THE MEASURE LEVEL THE 3081 02:29:21,385 --> 02:29:24,655 PERSON DOING MORE THAN THIS IS 3082 02:29:24,655 --> 02:29:27,858 REBECCA SLATER AT OXFORD WHO 3083 02:29:27,858 --> 02:29:29,426 DOES fMRI IN INFANTS. 3084 02:29:29,426 --> 02:29:30,828 TEA REMARKABLE AND THEY'RE 3085 02:29:30,828 --> 02:29:32,663 LOOKING AT MANAGEMENT. 3086 02:29:32,663 --> 02:29:35,032 I DON'T KNOW THEY'RE TRYING ANY 3087 02:29:35,032 --> 02:29:40,671 PARTICULAR TECHNOLOGIES TO TREAT 3088 02:29:40,671 --> 02:29:48,646 BUT THAT'S USED MUCH IN THE 3089 02:29:48,646 --> 02:29:48,879 STATES. 3090 02:29:48,879 --> 02:29:56,053 >> WE'LL LOOK INTO THAT. 3091 02:29:56,053 --> 02:29:58,856 >> HOPEFULLY WE'LL HAVE MORE 3092 02:29:58,856 --> 02:30:00,824 APPLICATIONS IN THE AREA TO 3093 02:30:00,824 --> 02:30:09,433 SUPPORT THE RESEARCH. 3094 02:30:09,433 --> 02:30:14,371 WE HAVE A PRECLINICAL PROJECT 3095 02:30:14,371 --> 02:30:24,915 WITH A PULSE OXIMETRY TECHNIQUE 3096 02:30:26,317 --> 02:30:28,085 FOR WITHDRAWAL SYNDROME TO 3097 02:30:28,085 --> 02:30:29,320 HOPEFULLY DEVELOP AN OBJECTIVE 3098 02:30:29,320 --> 02:30:34,825 MEASURE OF CONDITIONS FOR 3099 02:30:34,825 --> 02:30:42,733 INFANTS THAT LOOK AT SUBJECTIVE 3100 02:30:42,733 --> 02:30:43,233 MEASURES FROM STAFF AT 3101 02:30:43,233 --> 02:30:53,410 HOSPITALS. 3102 02:31:03,887 --> 02:31:05,289 >> IT'S TERRIBLE. 3103 02:31:05,289 --> 02:31:08,959 PARTICULARLY IN THE NEUROLOGICAL 3104 02:31:08,959 --> 02:31:10,361 DISORDERS WITH SEVERE 3105 02:31:10,361 --> 02:31:11,228 INTELLECTUAL DISABILITY IT WOULD 3106 02:31:11,228 --> 02:31:12,763 BE GREAT IF WE HAD A BETTER WAY 3107 02:31:12,763 --> 02:31:21,071 OF DOING THAT. 3108 02:31:21,071 --> 02:31:23,741 >> ONE OF THE OUTCOMES IS IT'S 3109 02:31:23,741 --> 02:31:28,712 UNIQUE TO THE INDIVIDUAL. 3110 02:31:28,712 --> 02:31:31,648 WITHOUT THAT INPUT VERBAL OR 3111 02:31:31,648 --> 02:31:33,851 OTHER SIGNS THE INDIVIDUAL IS IN 3112 02:31:33,851 --> 02:31:38,789 PAIN AND LOOKING AT THE SYMPHONY 3113 02:31:38,789 --> 02:31:41,525 GOING ON IN THE PAIN IT'S HARD 3114 02:31:41,525 --> 02:31:46,697 TO LOOK AT THE PAIN SIGNATURE 3115 02:31:46,697 --> 02:31:47,131 ACROSS INDIVIDUALS. 3116 02:31:47,131 --> 02:31:51,802 >> THE SAME GROUP HAS DONE 3117 02:31:51,802 --> 02:31:56,373 COMPARABLE THINGS IN EPILEPSY 3118 02:31:56,373 --> 02:32:02,946 RECORDING SEIZURES OVER TIME AND 3119 02:32:02,946 --> 02:32:05,449 THE SAME APPROACH WITH EDDIE 3120 02:32:05,449 --> 02:32:05,649 CHANG. 3121 02:32:05,649 --> 02:32:15,993 IT'S VERY EXCITING. 3122 02:32:17,227 --> 02:32:18,962 >> WE'LL NOW HAVE OUR NEXT 3123 02:32:18,962 --> 02:32:20,831 PRESENTATION FOCUSSED ON 3124 02:32:20,831 --> 02:32:24,668 REPORTING OUT FROM A RECENT 3125 02:32:24,668 --> 02:32:26,370 HEALTH EQUITY AND PAIN EQUITY 3126 02:32:26,370 --> 02:32:26,970 RESEARCH. 3127 02:32:26,970 --> 02:32:36,647 IT'S MY PLEASURE TO INTRODUCE 3128 02:32:36,647 --> 02:32:44,388 DR. CHERYSE SANKAR AND THE NEXT 3129 02:32:44,388 --> 02:32:48,792 IS DR. JANELLE LETZEN IN THE 3130 02:32:48,792 --> 02:32:50,461 OFFICE OF POLICY AND PLANNING. 3131 02:32:50,461 --> 02:32:52,963 >> I'M PRESENTING THIS 3132 02:32:52,963 --> 02:32:54,832 INFORMATION ON BEHALF OF 3133 02:32:54,832 --> 02:33:01,305 DR. SANKAR AND MYSELF AND TO 3134 02:33:01,305 --> 02:33:05,843 TOOT CHERYSE' HORN FOR A SECOND. 3135 02:33:05,843 --> 02:33:07,544 THE CREATED THE FIRST PORTFOLIO 3136 02:33:07,544 --> 02:33:10,347 OF PROGRAM TARGETING HEALTH 3137 02:33:10,347 --> 02:33:12,683 EQUITY AT NIH AND HIS WORKSHOP 3138 02:33:12,683 --> 02:33:17,955 WAS INSPIRED BY HER LEADERSHIP 3139 02:33:17,955 --> 02:33:18,589 IN THIS SPACE. 3140 02:33:18,589 --> 02:33:22,593 THE REASON WE NEEDED THE 3141 02:33:22,593 --> 02:33:25,696 WORKSHOP IS AND WE WANTED TO 3142 02:33:25,696 --> 02:33:27,865 GATHER EXPERTS FROM VARIOUS 3143 02:33:27,865 --> 02:33:29,833 BACKBOUNDS TO BEST UNDERSTAND 3144 02:33:29,833 --> 02:33:31,735 WHAT IS NEEDED TO START MOVING 3145 02:33:31,735 --> 02:33:32,736 THE NEEDLE FORWARD ON HEALTH 3146 02:33:32,736 --> 02:33:37,808 EQUITY. 3147 02:33:37,808 --> 02:33:40,644 PAIN DISPARITIES IS DEFINED BY 3148 02:33:40,644 --> 02:33:46,850 NIH AS PAIN DIFFERENCES THAT 3149 02:33:46,850 --> 02:33:48,385 HARM SOCIALLY DISADVANTAGED 3150 02:33:48,385 --> 02:33:50,387 POPULATIONS COMPARED TO 3151 02:33:50,387 --> 02:33:52,656 ADVANTAGED POPULATIONS AND THE 3152 02:33:52,656 --> 02:33:55,759 SOCIAL DISADVANTAGE STEMS FROM 3153 02:33:55,759 --> 02:33:57,594 SYSTEMIC FORMS OF DISCRIMINATION 3154 02:33:57,594 --> 02:34:01,031 AND RACISM, CLASSISM, ABLISM AND 3155 02:34:01,031 --> 02:34:04,668 OTHER FORMS OF SOCIAL 3156 02:34:04,668 --> 02:34:07,337 DISCRIMINATION. 3157 02:34:07,337 --> 02:34:09,173 THE NIH HAS SEVERAL DESIGNATED 3158 02:34:09,173 --> 02:34:10,207 POPULATION OR COMMUNITIES THAT 3159 02:34:10,207 --> 02:34:12,643 EXPERIENCE HEALTH DISPARITIES 3160 02:34:12,643 --> 02:34:14,311 AND THIS INCLUDES MINORITIZED 3161 02:34:14,311 --> 02:34:16,513 RACIAL AND ETHNIC GROUPS, PEOPLE 3162 02:34:16,513 --> 02:34:21,685 WITH LOWER SOCIO ECONOMIC 3163 02:34:21,685 --> 02:34:26,390 STATUS, UNDERSERVED RURAL 3164 02:34:26,390 --> 02:34:27,024 COMMUNITIES, MINORITIES AND 3165 02:34:27,024 --> 02:34:29,092 PEOPLE WITH DISABILITIES. 3166 02:34:29,092 --> 02:34:32,396 NOW MOVING TOWARDS HEALTH 3167 02:34:32,396 --> 02:34:39,603 EQUITY. 3168 02:34:39,603 --> 02:34:41,705 IT'S DEFINED AS A CONTINUAL 3169 02:34:41,705 --> 02:34:46,977 PROCESS MAKING SURE POPULATIONS 3170 02:34:46,977 --> 02:34:49,880 HAVE THE OPTIMAL OPPORTUNITY FOR 3171 02:34:49,880 --> 02:34:53,817 THE BEST HEALTH POSSIBLE AND 3172 02:34:53,817 --> 02:34:54,084 FAIRNESS. 3173 02:34:54,084 --> 02:34:56,587 THE MAJOR CONTRIBUTORS TO PAIN 3174 02:34:56,587 --> 02:34:58,222 DISPARITIES ARE THE SOCIAL 3175 02:34:58,222 --> 02:34:59,089 DETERMINATES OF HEALTH. 3176 02:34:59,089 --> 02:35:02,893 THIS INCLUDES THE NON-MEDICAL 3177 02:35:02,893 --> 02:35:05,028 FACTORS THAT EFFECT HEALTH LIKE 3178 02:35:05,028 --> 02:35:06,897 THE CONDITIONS WHERE PEOPLE ARE 3179 02:35:06,897 --> 02:35:09,399 BORN, GROW, LIVE, WORK AND AGE 3180 02:35:09,399 --> 02:35:10,834 AND ACCESS TO QUALITY EDUCATION 3181 02:35:10,834 --> 02:35:13,537 AND HEALTH CARE, A PERSON'S 3182 02:35:13,537 --> 02:35:14,404 NEIGHBORHOOD OR BUILT 3183 02:35:14,404 --> 02:35:16,673 ENVIRONMENT, THEIR SOCIAL AND 3184 02:35:16,673 --> 02:35:20,410 COMMUNITY CONTEXT AND ECONOMIC 3185 02:35:20,410 --> 02:35:26,049 STABILITY. 3186 02:35:26,049 --> 02:35:29,419 THE SOCIAL DETERMINATES OF 3187 02:35:29,419 --> 02:35:30,487 HEALTH AT DIFFERENT LEVELS AND 3188 02:35:30,487 --> 02:35:32,389 THERE'S INTERACTIONS WITH PEOPLE 3189 02:35:32,389 --> 02:35:34,491 AROUND THEM AND COME INTO 3190 02:35:34,491 --> 02:35:35,892 CONTACT WITH ORGANIZATIONS OR 3191 02:35:35,892 --> 02:35:37,294 INSTITUTIONS, LIVE IN THE 3192 02:35:37,294 --> 02:35:39,363 COMMUNITY AND OF COURSE ARE 3193 02:35:39,363 --> 02:35:39,997 MEMBERS OF THE GENERAL SOCIETY 3194 02:35:39,997 --> 02:35:48,639 ALL OF US LIVE IN. 3195 02:35:48,639 --> 02:35:50,974 WHERE WITH HAVE PAIN PREVENTION 3196 02:35:50,974 --> 02:35:52,643 AND RESEARCH HAPPENING IS AT THE 3197 02:35:52,643 --> 02:35:54,678 INDIVIDUAL LEVEL TARGETING THE 3198 02:35:54,678 --> 02:35:57,414 PERSON LIVING WITH PAIN. 3199 02:35:57,414 --> 02:35:59,383 SO THERE'S A GAP BETWEEN WHERE 3200 02:35:59,383 --> 02:36:00,083 INTERVENTIONS ARE NEEDED TO 3201 02:36:00,083 --> 02:36:00,917 ADDRESS PAIN DISPARITIES AND 3202 02:36:00,917 --> 02:36:06,256 WHERE THEY'RE HAPPENING. 3203 02:36:06,256 --> 02:36:07,824 BEFORE WE STARTED TO PLAN THE 3204 02:36:07,824 --> 02:36:10,394 WORKSHOP, WE WANTED TO FIRST GET 3205 02:36:10,394 --> 02:36:15,832 A SENSE OF WHAT THE PROGRAMS 3206 02:36:15,832 --> 02:36:17,467 THAT WERE ALREADY PROPOSED AT 3207 02:36:17,467 --> 02:36:19,569 LEAST WITHIN THE HEALTH EQUITY 3208 02:36:19,569 --> 02:36:21,905 AND PAIN MANAGEMENT RESEARCH 3209 02:36:21,905 --> 02:36:24,441 PORTFOLIO THE WAY THEY WERE 3210 02:36:24,441 --> 02:36:25,342 APPROACHING THE QUESTIONS. 3211 02:36:25,342 --> 02:36:27,511 WE REVIEWED THE 11-FUNDED 3212 02:36:27,511 --> 02:36:28,879 STUDIES WITHIN THE PROGRAMS TO 3213 02:36:28,879 --> 02:36:31,648 SEE WHAT THEY HAD PROPOSED IN 3214 02:36:31,648 --> 02:36:33,517 TERMS OF THREE DIFFERENT AREAS 3215 02:36:33,517 --> 02:36:35,619 THAT IN THE FIELD OF HEALTH 3216 02:36:35,619 --> 02:36:36,620 EQUITY RESEARCH ARE IMPORTANT 3217 02:36:36,620 --> 02:36:37,921 FOR SCIENCE. 3218 02:36:37,921 --> 02:36:39,890 SCO THE FIRST IS COMMUNITY 3219 02:36:39,890 --> 02:36:41,758 ENGAGEMENT AND WE WANTED TO 3220 02:36:41,758 --> 02:36:43,527 UNDERSTAND HOW THE RESEARCH 3221 02:36:43,527 --> 02:36:45,629 PROPOSALS WERE LOOKING AT ONE 3222 02:36:45,629 --> 02:36:47,631 AND HOW POPULATIONS EXPERIENCING 3223 02:36:47,631 --> 02:36:50,534 PAIN DISPARITIES WERE ENGAGED IN 3224 02:36:50,534 --> 02:36:53,203 THE RESEARCH PROJECT OR WOULD BE 3225 02:36:53,203 --> 02:36:54,338 ENGAGED IN THE RESEARCH PROJECT 3226 02:36:54,338 --> 02:36:55,906 FOR MULTI-LEVEL INTERVENTIONS. 3227 02:36:55,906 --> 02:36:57,741 WE WANTED TO SEE HOW THE 3228 02:36:57,741 --> 02:37:00,477 PROJECTS WERE PROPOSAL TO TARGET 3229 02:37:00,477 --> 02:37:01,611 SOCIAL DETERMINATES AT HEALTH 3230 02:37:01,611 --> 02:37:03,714 AND AT WHICH LEVELS OF SOCIETY 3231 02:37:03,714 --> 02:37:05,082 AND FINALLY WE WANTED TO 3232 02:37:05,082 --> 02:37:07,250 UNDERSTAND WHO WAS ON THE STUDY 3233 02:37:07,250 --> 02:37:10,153 TEAM AND WHETHER THERE WAS 3234 02:37:10,153 --> 02:37:12,589 ADEQUATE REPRESENTATION OF 3235 02:37:12,589 --> 02:37:21,398 COMMUNITY ENGAGEMENT EXPERTISE. 3236 02:37:21,398 --> 02:37:25,869 TO SUMMARIZE THE 11 PROPOSALS. 3237 02:37:25,869 --> 02:37:27,838 THE COMMUNITY ENGAGEMENT WAS 3238 02:37:27,838 --> 02:37:29,473 STRONGLY PROPOSED IN STUDYING 3239 02:37:29,473 --> 02:37:31,842 THE METHODS AND RECRUITMENT OF 3240 02:37:31,842 --> 02:37:34,010 PARTICIPANTS FOR STUDY WHERE 3241 02:37:34,010 --> 02:37:35,445 FEWER PROJECTS PROPOSED 3242 02:37:35,445 --> 02:37:37,013 COMMUNITY ENGAGEMENT AT THE 3243 02:37:37,013 --> 02:37:46,490 STAGES OF DEVELOPING THE IDEA 3244 02:37:46,490 --> 02:37:48,525 INVOLVING THE PEOPLE AND 3245 02:37:48,525 --> 02:37:50,227 DISSEMINATING BACK TO 3246 02:37:50,227 --> 02:37:50,527 COMMUNITIES. 3247 02:37:50,527 --> 02:37:51,595 WE WANTED TO UNDERSTAND WHAT 3248 02:37:51,595 --> 02:37:53,130 KINDS OF INTERVENTIONS WERE 3249 02:37:53,130 --> 02:37:55,532 PROPOSED AND TARGET THE 3250 02:37:55,532 --> 02:38:00,036 INDIVIDUAL WITH SOME TARGETING 3251 02:38:00,036 --> 02:38:00,637 SOCIAL DETERMINATES OF 3252 02:38:00,637 --> 02:38:01,538 ORGANIZATIONAL LEVEL. 3253 02:38:01,538 --> 02:38:04,641 IN TERMS OF THE HEALTH EQUITY 3254 02:38:04,641 --> 02:38:06,009 EXPERTISE REPRESENTED IN THE 3255 02:38:06,009 --> 02:38:08,345 GRANTS WE HAD A VARIETY OF 3256 02:38:08,345 --> 02:38:11,181 DIFFERENT SORTS OF PERSONNEL 3257 02:38:11,181 --> 02:38:12,649 WITH THE EXPERTISE AND SOME 3258 02:38:12,649 --> 02:38:19,156 PROJECTS HAD P.I.s ONE THE 3259 02:38:19,156 --> 02:38:20,390 EXPERTISE SOME HAD P.I.s AND 3260 02:38:20,390 --> 02:38:21,057 SOME A MIX. 3261 02:38:21,057 --> 02:38:23,026 USING THE INFORMATION WE TOOK IT 3262 02:38:23,026 --> 02:38:24,795 BACK TO HONE THE CHARGE OF THE 3263 02:38:24,795 --> 02:38:26,396 WORKSHOP AND BROADLY WE WANTED 3264 02:38:26,396 --> 02:38:28,665 TO KNOW HOW TO IMPROVE COMMUNITY 3265 02:38:28,665 --> 02:38:30,434 ENGAGEMENT ESPECIALLY ONE THE 3266 02:38:30,434 --> 02:38:32,002 POPULATIONS EXPERIENCING HEALTH 3267 02:38:32,002 --> 02:38:39,042 DISPARITIES IN PAIN RESEARCH? 3268 02:38:39,042 --> 02:38:40,644 AND LOOK AT INTERVENTIONS IN A 3269 02:38:40,644 --> 02:38:47,617 WAY THAT IS FEASIBLE AND HOW TO 3270 02:38:47,617 --> 02:38:50,420 PREVENT LEATH XT TOURISM WHEN 3271 02:38:50,420 --> 02:38:52,656 RESEARCHERS OUTSIDE THE HEALTH 3272 02:38:52,656 --> 02:38:57,027 EQUITY FIELD WHO PIVOT WHEN A 3273 02:38:57,027 --> 02:39:00,130 FUNDING ANNOUNCEMENT COMES OUT 3274 02:39:00,130 --> 02:39:05,302 BUT PIVOT OUT ONCE THE PROJECT 3275 02:39:05,302 --> 02:39:13,443 IS DONE. 3276 02:39:13,443 --> 02:39:15,612 WE HAD TWO PEOPLE WHO I'LL 3277 02:39:15,612 --> 02:39:18,181 HIGHLIGHT IN ADDITION TO CHERYSE 3278 02:39:18,181 --> 02:39:25,989 AND MYSELF IS JENNY AND KATIE 3279 02:39:25,989 --> 02:39:27,424 AND WE REALLY WANTED TO MAKE 3280 02:39:27,424 --> 02:39:32,629 SURE IT WOULD BE A POSITIVE 3281 02:39:32,629 --> 02:39:35,665 EXPERIENCE. 3282 02:39:35,665 --> 02:39:46,209 AND AS FAR AS THE STRUCTURE AND 3283 02:39:48,545 --> 02:39:49,980 THE VISUAL REPRESENTATION OF THE 3284 02:39:49,980 --> 02:39:54,885 PRESENTATION GIVEN BY CAMERON 3285 02:39:54,885 --> 02:39:57,854 YOUNG WHO IS AN 18-YEAR-OLD 3286 02:39:57,854 --> 02:40:01,358 TRANSGENDER MAN WITH A SYNDROME 3287 02:40:01,358 --> 02:40:04,060 HE'S HAD THROUGH CHILDHOOD AND 3288 02:40:04,060 --> 02:40:06,630 HIS SPEECH LITERALLY MOVED SOME 3289 02:40:06,630 --> 02:40:07,597 AUDIENCE MEMBERS TO TEARS AND 3290 02:40:07,597 --> 02:40:16,640 WERE SO HAPPY TO HAVE HIM THERE. 3291 02:40:16,640 --> 02:40:21,311 AS FAR AS THOSE DISCUSSION 3292 02:40:21,311 --> 02:40:27,751 PANELS, SOMETHING THAT WAS 3293 02:40:27,751 --> 02:40:32,422 IMPORTANT AND WE TRIED TO 3294 02:40:32,422 --> 02:40:33,623 PROMOTE EQUAL REPRESENTATION OF 3295 02:40:33,623 --> 02:40:34,858 HEALTH EQUITY LEVEL RESEARCHERS 3296 02:40:34,858 --> 02:40:36,326 OUTSIDE THE FIELD OF PAIN TO TRY 3297 02:40:36,326 --> 02:40:39,429 TO BRING IN NEW PERSPECTIVES. 3298 02:40:39,429 --> 02:40:40,764 ALSO OF PEOPLE WITH LIVED 3299 02:40:40,764 --> 02:40:43,500 EXPERIENCE OF PAIN WHO WE REFER 3300 02:40:43,500 --> 02:40:46,169 TO AS LIVED EXPERIENCE EXPERTS 3301 02:40:46,169 --> 02:40:47,804 AND THEN PAIN RESEARCHERS WHO 3302 02:40:47,804 --> 02:40:48,738 HAVE EXPERTISE IN PAIN 3303 02:40:48,738 --> 02:40:52,475 DISPARITIES. 3304 02:40:52,475 --> 02:40:54,878 THE NEXT THREE SLIDES I'LL SHARE 3305 02:40:54,878 --> 02:40:56,212 SUMMARIZE THE HIGH-LEVEL 3306 02:40:56,212 --> 02:40:57,581 TAKEAWAYS FROM THE PANEL 3307 02:40:57,581 --> 02:40:58,214 DISCUSSION AND REPRESENT THE 3308 02:40:58,214 --> 02:41:05,989 PANELIST VIEWS. 3309 02:41:05,989 --> 02:41:08,224 AND WE WERE CHARGED WITH TRYING 3310 02:41:08,224 --> 02:41:11,061 TO UNDERSTAND HOW TO STRENGTHEN 3311 02:41:11,061 --> 02:41:13,229 CONNECTEDNESS WITH COMMUNITIES 3312 02:41:13,229 --> 02:41:15,298 EXPERIENCING PAIN DISPARITIES. 3313 02:41:15,298 --> 02:41:16,499 THE WAY WE APPROACHED THE 3314 02:41:16,499 --> 02:41:17,968 DISCUSSION TOPIC IS THE ANALOGY 3315 02:41:17,968 --> 02:41:20,437 OF A HOUSE AND BUILDING A HOUSE 3316 02:41:20,437 --> 02:41:22,138 AS BUILDING RELATIONSHIPS WITH 3317 02:41:22,138 --> 02:41:22,906 COMMUNITIES. 3318 02:41:22,906 --> 02:41:24,674 WHAT THE PANELISTS DISCUSSED WAS 3319 02:41:24,674 --> 02:41:26,810 THAT IN A LOT OF CASES WE NEED 3320 02:41:26,810 --> 02:41:31,748 TO REALLY REPAIR THE FOUNDATION 3321 02:41:31,748 --> 02:41:33,516 AND HEAL BROKEN RELATIONSHIPS 3322 02:41:33,516 --> 02:41:34,217 WITH COMMUNITIES IT'S IMPORTANT 3323 02:41:34,217 --> 02:41:39,289 TO UNDERSTAND THE HISTORY OF THE 3324 02:41:39,289 --> 02:41:43,426 COMMUNITIES BOTH IN TERMS OF 3325 02:41:43,426 --> 02:41:45,328 DISCRIMINATION AND EXPERIENCES 3326 02:41:45,328 --> 02:41:47,063 HARMED WITHIN INSTITUTIONS AND 3327 02:41:47,063 --> 02:41:48,665 THE TYPE OF VALIDATION THAT 3328 02:41:48,665 --> 02:41:50,600 OFTEN OCCURS BECAUSE PAIN IS 3329 02:41:50,600 --> 02:41:52,636 INVISIBLE. 3330 02:41:52,636 --> 02:41:55,138 AND THEN ANOTHER IMPORTANT POINT 3331 02:41:55,138 --> 02:41:57,474 THEY RAISED TO REPAIR THESE 3332 02:41:57,474 --> 02:41:59,376 FOUNDATIONS WAS TO EMBED THE 3333 02:41:59,376 --> 02:42:01,144 RESEARCH TEAM INTO THE COMMUNITY 3334 02:42:01,144 --> 02:42:03,480 AND SO A COUPLE OF THE 3335 02:42:03,480 --> 02:42:05,582 RESEARCHERS HAD TALKED ABOUT HOW 3336 02:42:05,582 --> 02:42:07,050 ONCE A MONTH THEY PROVIDE TIME 3337 02:42:07,050 --> 02:42:08,685 FOR THEIR STAFF TO GO VOLUNTEER 3338 02:42:08,685 --> 02:42:10,487 INTO THE COMMUNITY AND REALLY 3339 02:42:10,487 --> 02:42:12,789 FOCUS ON BUILDING THOSE 3340 02:42:12,789 --> 02:42:14,324 RELATIONSHIPS. 3341 02:42:14,324 --> 02:42:16,426 AN DITION TO REPAIRING THE 3342 02:42:16,426 --> 02:42:18,828 FOUNDATION THEY TALKED ABOUT 3343 02:42:18,828 --> 02:42:20,630 KNOCKING DOWN WALLS IN HOPES OF 3344 02:42:20,630 --> 02:42:24,601 RECONCILING RELATIONSHIPS. 3345 02:42:24,601 --> 02:42:27,637 SO THEY DESCRIBED THIS BY 3346 02:42:27,637 --> 02:42:30,106 SHARING POWER AND VALUING 3347 02:42:30,106 --> 02:42:32,442 KNOWLEDGE AND COMMUNITY STRENGTH 3348 02:42:32,442 --> 02:42:32,642 S. 3349 02:42:32,642 --> 02:42:34,577 OFTEN TIMES WITH THE PAIN 3350 02:42:34,577 --> 02:42:37,380 INVISIBLE THE POWER IS IN THE 3351 02:42:37,380 --> 02:42:38,415 PROVIDER'S HANDS TO DECIDE WHAT 3352 02:42:38,415 --> 02:42:39,649 KINDS OF MEDICATIONS THEY'RE 3353 02:42:39,649 --> 02:42:43,086 GOING TO OFFER AND SAME WITH 3354 02:42:43,086 --> 02:42:47,791 RESEARCH, THE POWER IS IN THE 3355 02:42:47,791 --> 02:42:48,658 RESEARCHER'S HANDS WHAT THE 3356 02:42:48,658 --> 02:42:49,492 PARTICIPANT WILL GO THROUGH IN 3357 02:42:49,492 --> 02:42:53,697 THE STUDY AND WORKING ON SHARING 3358 02:42:53,697 --> 02:42:58,268 THAT POWER AND VALUING DIFFERENT 3359 02:42:58,268 --> 02:42:59,502 KNOWLEDGE, INDIGENOUS KNOWLEDGE 3360 02:42:59,502 --> 02:43:01,504 AND EXPERIENCE ARE IMPORTANT TO 3361 02:43:01,504 --> 02:43:02,572 BUILD RELATIONSHIPS WITH 3362 02:43:02,572 --> 02:43:04,374 COMMUNES. 3363 02:43:04,374 --> 02:43:05,709 EXPANDING THE SPACE WAS A WAY 3364 02:43:05,709 --> 02:43:08,244 THEY USED TO DESCRIBE BEING MORE 3365 02:43:08,244 --> 02:43:10,013 TRANSPARENT WITH COMMUNITIES AND 3366 02:43:10,013 --> 02:43:13,049 THIS IS REALLY ABOUT RESEARCHERS 3367 02:43:13,049 --> 02:43:18,722 BEING VULNERABLE ABOUT BOTH 3368 02:43:18,722 --> 02:43:23,827 THEIR LIMITATIONS OF RESEARCH IN 3369 02:43:23,827 --> 02:43:28,198 GENERAL AND THERE'S CERTAIN 3370 02:43:28,198 --> 02:43:30,133 THINGS RESEARCH CAN AND CAN'T 3371 02:43:30,133 --> 02:43:31,267 ANSWER AND THESE DISCUSSION 3372 02:43:31,267 --> 02:43:31,534 VALUABLE. 3373 02:43:31,534 --> 02:43:32,669 SOMETIMES WITH THE FOUNDATION 3374 02:43:32,669 --> 02:43:35,305 INSTEAD OF REPAIRING YOU MAY 3375 02:43:35,305 --> 02:43:36,639 NEED TO BUILD A NEW FOUNDATION. 3376 02:43:36,639 --> 02:43:39,442 THIS IS A WAY THE GROUP WAS 3377 02:43:39,442 --> 02:43:40,110 TALKING ABOUT CHANGING SYSTEMS 3378 02:43:40,110 --> 02:43:43,012 TO SUPPORT ENGAGEMENT AND SO FOR 3379 02:43:43,012 --> 02:43:45,915 EXAMPLE IN DOING COMMUNITY 3380 02:43:45,915 --> 02:43:47,350 ENGAGED RESEARCH IT REQUIRES A 3381 02:43:47,350 --> 02:43:48,651 LOT OF TIME AND RESOURCES 3382 02:43:48,651 --> 02:43:53,323 TOWARDS BUILDING THOSE 3383 02:43:53,323 --> 02:43:55,458 PARTNERSHIPS VERSUS PEOPLE OR 3384 02:43:55,458 --> 02:43:56,426 RESEARCHERS NOT DOING COMMUNITY 3385 02:43:56,426 --> 02:43:59,262 ENGAGEMENT MAY HAVE MORE TIME TO 3386 02:43:59,262 --> 02:44:01,531 DEDICATE TOWARDS PUBLISHING 3387 02:44:01,531 --> 02:44:04,033 PAPERS OR APPLYING FOR GRANTS. 3388 02:44:04,033 --> 02:44:06,236 ONE OF THE THINGS THE PANELIST 3389 02:44:06,236 --> 02:44:08,438 WAS TALKING ABOUT IS THE WAY 3390 02:44:08,438 --> 02:44:09,706 THAT PRODUCTIVITY IS MEASURED 3391 02:44:09,706 --> 02:44:11,174 COULD BE CHANGED. 3392 02:44:11,174 --> 02:44:15,311 AND FINALLY ADDING NEW FEATURES 3393 02:44:15,311 --> 02:44:18,414 WERE RESOURCES THEY DISCUSSED 3394 02:44:18,414 --> 02:44:23,086 WOULD BE HELPFUL FOR IMPROVING 3395 02:44:23,086 --> 02:44:24,654 COMMUNITY ENGAGEMENT WITH THOSE 3396 02:44:24,654 --> 02:44:29,559 COMMUNITIES. 3397 02:44:29,559 --> 02:44:31,294 FOR THE MULTI LEVEL INTERVENTION 3398 02:44:31,294 --> 02:44:34,664 PANEL WHAT THE GROUP FOCUSES ON 3399 02:44:34,664 --> 02:44:35,832 DISCUSSING WERE THE SOCIAL 3400 02:44:35,832 --> 02:44:36,599 DETERMINATES OF PAIN AT 3401 02:44:36,599 --> 02:44:39,035 DIFFERENT LEVELS OF SOCIETY AND 3402 02:44:39,035 --> 02:44:41,805 WHAT KINDS OF RESEARCH PROGRAMS 3403 02:44:41,805 --> 02:44:45,975 COULD BE BUILT TO TEST 3404 02:44:45,975 --> 02:44:47,343 INTERVENTIONS FOR THE SOCIAL 3405 02:44:47,343 --> 02:44:47,677 DETERMINATES. 3406 02:44:47,677 --> 02:44:52,115 I'M HIGHLIGHT A FEW THE GROUP 3407 02:44:52,115 --> 02:44:52,649 UP. 3408 02:44:52,649 --> 02:44:55,685 AT THE COMMUNITY OR NEIGHBORHOOD 3409 02:44:55,685 --> 02:44:56,519 LEVEL THE SOCIAL DETERMINATES OF 3410 02:44:56,519 --> 02:44:59,289 HEALTH THAT WAS PULLED OUT WAS 3411 02:44:59,289 --> 02:45:03,860 THE LACK OF NEARBY SERVICE OR 3412 02:45:03,860 --> 02:45:05,128 SERVICES OFFERED DURING WORK 3413 02:45:05,128 --> 02:45:06,930 HOURS WHERE PEOPLE MAY NOT BE 3414 02:45:06,930 --> 02:45:08,298 ABLE TO TAKE TIME OFF THEIR WORK 3415 02:45:08,298 --> 02:45:10,633 SCHEDULE TO SEEK THOSE SERVICE. 3416 02:45:10,633 --> 02:45:12,302 SO SOME RESEARCH PROGRAM AREAS 3417 02:45:12,302 --> 02:45:13,970 THAT WERE DISCUSSED WERE THINGS 3418 02:45:13,970 --> 02:45:16,239 LIKE BUILDING UNIQUE COMMUNITY 3419 02:45:16,239 --> 02:45:19,242 PARTNERSHIPS FOR PAIN MANAGEMENT 3420 02:45:19,242 --> 02:45:20,643 SERVICES, FOR EXAMPLE, WITH HIGH 3421 02:45:20,643 --> 02:45:23,446 SCHOOLS THAT MIGHT HAVE POOLS OR 3422 02:45:23,446 --> 02:45:25,381 WITH COMMUNITIES THAT MIGHT HAVE 3423 02:45:25,381 --> 02:45:27,350 POOLS THAT AREN'T USED DURING 3424 02:45:27,350 --> 02:45:29,385 THEIR PEAK HOURS TO PROVIDER 3425 02:45:29,385 --> 02:45:33,523 THOSE POOLS DURING OFF HOURS TO 3426 02:45:33,523 --> 02:45:35,091 PROVIDER GROUP AQUA THERAPY FOR 3427 02:45:35,091 --> 02:45:35,758 PEOPLE WITH PAIN. 3428 02:45:35,758 --> 02:45:44,434 ANOTHER THING WOULD BE TO 3429 02:45:44,434 --> 02:45:47,437 INCENTIVIZE PHARMACIES TO KEEP 3430 02:45:47,437 --> 02:45:50,073 THEIR STORED OPEN AND IN OTHER 3431 02:45:50,073 --> 02:45:54,644 AREAS AND IN CARDIOVASCULAR 3432 02:45:54,644 --> 02:46:05,154 HEALTH AND OBESITY THERE HAVE 3433 02:46:09,058 --> 02:46:14,364 BEEN BODEGAS TO HELP WITH HEALTH 3434 02:46:14,364 --> 02:46:16,299 AND ANOTHER IS NAVIGATING THE 3435 02:46:16,299 --> 02:46:17,367 HEALTH CARE SYSTEM AND THAT 3436 02:46:17,367 --> 02:46:18,968 SHOWS UP AT THE ORGANIZATIONAL 3437 02:46:18,968 --> 02:46:20,670 OR INSTITUTIONAL LEVEL AND CAN 3438 02:46:20,670 --> 02:46:23,973 BE AT THE INTERPERSONAL LEVEL AS 3439 02:46:23,973 --> 02:46:24,240 WELL. 3440 02:46:24,240 --> 02:46:26,409 SO SOME PROGRAMS OF RESEARCH 3441 02:46:26,409 --> 02:46:30,079 THAT WERE TALKED ABOUT IN THE 3442 02:46:30,079 --> 02:46:32,448 AREA WOULD BE THINGS LIKE HAVING 3443 02:46:32,448 --> 02:46:35,218 PEER NAVIGATORS FOR PAIN CARE AS 3444 02:46:35,218 --> 02:46:36,653 WELL AS COMMUNITY HEALTH WORKERS 3445 02:46:36,653 --> 02:46:45,495 PAIRED TOGETHER. 3446 02:46:45,495 --> 02:46:48,665 FINALLY THE WORKFORCE AND 3447 02:46:48,665 --> 02:46:49,866 COLLABORATION PANEL AT 3448 02:46:49,866 --> 02:46:51,267 UNDERSTANDING WHAT CORE 3449 02:46:51,267 --> 02:46:52,735 COMPETENCIES WOULD BE NEEDED TO 3450 02:46:52,735 --> 02:46:55,805 BUILD THE PAIN MANAGEMENT 3451 02:46:55,805 --> 02:46:56,072 WORKFORCE. 3452 02:46:56,072 --> 02:46:58,408 THERE ARE THREE BUCKETS THE CORE 3453 02:46:58,408 --> 02:47:00,643 COMPETENCIES FALL INTO THE 3454 02:47:00,643 --> 02:47:02,111 PERSONAL ATTRIBUTES OF THE 3455 02:47:02,111 --> 02:47:05,715 RESEARCHER, THE KNOWLEDGE AREAS 3456 02:47:05,715 --> 02:47:06,215 AND SKILLS. 3457 02:47:06,215 --> 02:47:08,651 AS FAR AS PERSONAL ATTRIBUTES 3458 02:47:08,651 --> 02:47:09,819 THEY HIGHLIGHTED CULTURAL 3459 02:47:09,819 --> 02:47:11,521 HUMANITY AND EMPATHY AS TWO 3460 02:47:11,521 --> 02:47:14,424 IMPORTANT ATTRIBUTES. 3461 02:47:14,424 --> 02:47:16,259 FOR KNOWLEDGE, DIFFERENT TOPIC 3462 02:47:16,259 --> 02:47:20,029 AREAS THAT WOULD BE IMPORTANT 3463 02:47:20,029 --> 02:47:23,366 ARE THE BIO PSYCHOSOCIAL MODEL 3464 02:47:23,366 --> 02:47:24,634 OF PAIN AND BETTER UNDERSTANDING 3465 02:47:24,634 --> 02:47:28,237 OF SOCIAL SYSTEMS INFLUENCE OF 3466 02:47:28,237 --> 02:47:29,806 PAIN AS WELL AS CULTURE'S 3467 02:47:29,806 --> 02:47:34,010 INFLUENCE ON PAIN AND TOOLS AND 3468 02:47:34,010 --> 02:47:36,112 INTERVENTIONS TO ANSWER RESEARCH 3469 02:47:36,112 --> 02:47:36,713 QUESTIONS. 3470 02:47:36,713 --> 02:47:39,816 NOT NECESSARILY HAVING FACILITY 3471 02:47:39,816 --> 02:47:41,684 WITH TOOLS AND INTERVENTION AND 3472 02:47:41,684 --> 02:47:44,454 KNOWLEDGE AND WHO THE KEY 3473 02:47:44,454 --> 02:47:45,822 COLLABORATORS COULD BE TO USE 3474 02:47:45,822 --> 02:47:47,423 THE TOOLS AND INTERVENTIONS. 3475 02:47:47,423 --> 02:47:50,193 AND FOR SKILLS THEY HAD 3476 02:47:50,193 --> 02:47:56,299 HIGHLIGHTED THAT ADVOCACY FOR 3477 02:47:56,299 --> 02:48:00,003 COMMUNITIES FACILITATE 3478 02:48:00,003 --> 02:48:01,337 COMMUNITY-LED RESEARCH AND 3479 02:48:01,337 --> 02:48:02,872 COLLABORATING ON 3480 02:48:02,872 --> 02:48:04,207 INTERDISCIPLINARY TEAMS AND 3481 02:48:04,207 --> 02:48:04,874 MENTORING IMPORTANT SKILLS TO 3482 02:48:04,874 --> 02:48:07,944 CULTIVATE IN THIS AREA. 3483 02:48:07,944 --> 02:48:13,916 FOR WHO SHOULD BE A PART OF THE 3484 02:48:13,916 --> 02:48:20,423 WORKFORCE, IN ADDITION TO THE 3485 02:48:20,423 --> 02:48:24,027 TRAINING WITH RESEARCH AND THOSE 3486 02:48:24,027 --> 02:48:26,863 BIG LIVED EXPERIENCE BECAUSE IT 3487 02:48:26,863 --> 02:48:27,797 NECESSITATES COMMUNITY 3488 02:48:27,797 --> 02:48:28,898 ENGAGEMENT SO HAVING THOSE WITH 3489 02:48:28,898 --> 02:48:31,167 LIVED EXPERIENCE PREPARED TO BE 3490 02:48:31,167 --> 02:48:31,768 PARTNERS IN RESEARCH PROJECTS 3491 02:48:31,768 --> 02:48:34,070 WOULD BE IMPORTANT. 3492 02:48:34,070 --> 02:48:37,807 THEY ALSO TALKED ABOUT HOW 3493 02:48:37,807 --> 02:48:40,343 DEVELOPING THESE CORE 3494 02:48:40,343 --> 02:48:42,078 COMPETENCIES NEEDED TO BE 3495 02:48:42,078 --> 02:48:43,846 MULTI-FACETED IN TERMS OF 3496 02:48:43,846 --> 02:48:44,447 LEARNING APPROACHES. 3497 02:48:44,447 --> 02:48:46,416 THE ONE THEY THOUGHT WAS 3498 02:48:46,416 --> 02:48:47,817 EXPERIENCE WAS EXPERIENTIAL 3499 02:48:47,817 --> 02:48:48,084 LEARNING. 3500 02:48:48,084 --> 02:48:50,586 BEING IN THE COMMUNITY WITH 3501 02:48:50,586 --> 02:48:51,320 COMMUNITIES, LEARNING FROM 3502 02:48:51,320 --> 02:48:53,489 COMMUNITIES BUT THEN ALSO OF 3503 02:48:53,489 --> 02:48:57,360 COURSE SOME TRAINING COURSES 3504 02:48:57,360 --> 02:48:59,162 THAT COULD COMPLEMENT THOSE 3505 02:48:59,162 --> 02:49:02,432 EXPERIENTIAL LEARNING MORE DA 3506 02:49:02,432 --> 02:49:04,901 DALT -- MODALITIES AND NOT 3507 02:49:04,901 --> 02:49:06,736 RELYING ON JUST ONE MENTOR BUT 3508 02:49:06,736 --> 02:49:08,438 HAVING DIFFERENT MENTORS FOR 3509 02:49:08,438 --> 02:49:15,144 DIFFERENT NEEDS. 3510 02:49:15,144 --> 02:49:16,646 WE WANT TO MAKE SURE THE 3511 02:49:16,646 --> 02:49:18,648 WORKSHOP DISCUSSIONS THEMSELVES 3512 02:49:18,648 --> 02:49:20,349 ARE NOT THE PLACE WHERE THE 3513 02:49:20,349 --> 02:49:21,117 WORKSHOP ENDS. 3514 02:49:21,117 --> 02:49:23,886 WE HAVE FOLLOW-UP ACTIVITIES 3515 02:49:23,886 --> 02:49:24,987 WE'RE CURRENTLY WORKING ON. 3516 02:49:24,987 --> 02:49:27,890 THE FIRST IS A WEBINAR WITH THE 3517 02:49:27,890 --> 02:49:30,193 WORKSHOP ATTENDEES HAPPENING IN 3518 02:49:30,193 --> 02:49:30,426 OCTOBER. 3519 02:49:30,426 --> 02:49:32,261 AND AT THE WEBINAR WE'RE GOING 3520 02:49:32,261 --> 02:49:34,964 TO DISCUSS A COUPLE OF PRODUCTS 3521 02:49:34,964 --> 02:49:36,299 COMING OUT OF THE WORKSHOP. 3522 02:49:36,299 --> 02:49:38,434 ONE IS AN EXECUTIVE SUMMARY. 3523 02:49:38,434 --> 02:49:42,905 ANOTHER IS A PROCEEDINGS PAPER 3524 02:49:42,905 --> 02:49:44,474 AND FINALLY ON THE PURPOSE 3525 02:49:44,474 --> 02:49:46,008 NETWORK PROMOTING COLLABORATION. 3526 02:49:46,008 --> 02:49:47,343 WE HAVE A COLLABORATION PAGE FOR 3527 02:49:47,343 --> 02:49:50,213 THE WORKSHOP ATTENDEES ON THE 3528 02:49:50,213 --> 02:49:51,848 PURPOSE NETWORK SO THEY CAN 3529 02:49:51,848 --> 02:49:53,716 CONTINUE TO WORK TOGETHER EVEN 3530 02:49:53,716 --> 02:49:55,084 OUTSIDE THESE ACTIVITIES THAT 3531 02:49:55,084 --> 02:49:59,155 WE'RE WORKING ON AS A GROUP TO 3532 02:49:59,155 --> 02:50:06,095 CONTINUE THEIR PROJECTS FORWARD. 3533 02:50:06,095 --> 02:50:07,463 SO WE HAVE A FEW DISCUSSION 3534 02:50:07,463 --> 02:50:09,265 QUESTIONS FOR ALL OF YOU TO 3535 02:50:09,265 --> 02:50:09,632 CONSIDER. 3536 02:50:09,632 --> 02:50:16,405 WE'D LOVE TO HEAR YOUR FEEDBACK 3537 02:50:16,405 --> 02:50:17,373 THE FIRST ONE ARE WHAT THIS ME 3538 02:50:17,373 --> 02:50:18,941 MOST IMPORTANT TOPICS TO ON IN 3539 02:50:18,941 --> 02:50:20,443 CONTINUING TO BUILD A PROGRAM. 3540 02:50:20,443 --> 02:50:22,645 WE'RE ALSO WONDERING WHAT 3541 02:50:22,645 --> 02:50:23,613 CONTENT RELATED TO HEALTH EQUITY 3542 02:50:23,613 --> 02:50:25,481 AND PAIN MANAGEMENT WAS NOT 3543 02:50:25,481 --> 02:50:26,482 COVERED IN THE WORKSHOP BUT 3544 02:50:26,482 --> 02:50:29,051 SHOULD BE FOCUSSED ON IN FUTURE 3545 02:50:29,051 --> 02:50:30,653 PROGRAMMING AND ASIDE FROM 3546 02:50:30,653 --> 02:50:32,455 BUILDING CORE COMPETENCIES HOW 3547 02:50:32,455 --> 02:50:35,658 ELSE CAN WE CREATE A SUSTAINABLE 3548 02:50:35,658 --> 02:50:36,659 RESEARCH WORKFORCE IN HEALTH 3549 02:50:36,659 --> 02:50:39,162 EQUITY AND PAIN MANAGEMENT? 3550 02:50:39,162 --> 02:50:43,166 AND WITH THAT, I'LL WRAP UP THE 3551 02:50:43,166 --> 02:50:44,467 PRESENTATION AND INVITE 3552 02:50:44,467 --> 02:50:46,536 DR. CHERYSE SANKAR TO JOIN FOR 3553 02:50:46,536 --> 02:50:47,036 THE QUESTION AND ANSWER 3554 02:50:47,036 --> 02:50:48,638 QUESTION. 3555 02:50:48,638 --> 02:50:58,514 THANK YOU. 3556 02:50:58,514 --> 02:51:05,154 >> I JUST GOT OFF A PLANE AND 3557 02:51:05,154 --> 02:51:07,857 DIDN'T THINK I'D MAKE IT IN TIME 3558 02:51:07,857 --> 02:51:09,725 SO THANK YOU, JANELLE AND WAIT 3559 02:51:09,725 --> 02:51:20,203 TO TAKE QUESTIONS IF NEEDED. 3560 02:51:32,715 --> 02:51:35,251 >> CHECKING IN IF ANYONE HAS 3561 02:51:35,251 --> 02:51:38,588 QUESTION OR FEEDBACK FOR JANELLE 3562 02:51:38,588 --> 02:51:44,460 OR CHERYSE? 3563 02:51:44,460 --> 02:51:44,961 OKAY. 3564 02:51:44,961 --> 02:51:47,997 WELL, THANK YOU SO MUCH TO EACH 3565 02:51:47,997 --> 02:51:58,441 OF YOU FOR AN EXCELLENT 3566 02:52:02,511 --> 02:52:03,112 PRESENTATION. 3567 02:52:03,112 --> 02:52:06,816 THIS IS OUR LAST PRESENTATION IN 3568 02:52:06,816 --> 02:52:09,685 OPEN SESSION AND FOCUSSED ON THE 3569 02:52:09,685 --> 02:52:11,988 THERAPEUTIC PROGRAM OUT OF NIDA. 3570 02:52:11,988 --> 02:52:16,225 I WANT TO WELCOME DR. JANE ACRI 3571 02:52:16,225 --> 02:52:21,464 THE DEPUTY DIRECTOR OF NIDA'S 3572 02:52:21,464 --> 02:52:23,466 DIVISION OF THERAPEUTICS AND 3573 02:52:23,466 --> 02:52:25,801 CONSEQUENCES AND WAS CHIEF OF 3574 02:52:25,801 --> 02:52:27,937 THE TOXICOLOGY BRANCH AND 3575 02:52:27,937 --> 02:52:31,107 DIRECTOR OF THE PRECLINICAL 3576 02:52:31,107 --> 02:52:31,907 ADDICTION TREATMENT DISCOVERY 3577 02:52:31,907 --> 02:52:32,642 PROGRAM. 3578 02:52:32,642 --> 02:52:35,011 UP ADDITION TO HER DUTIES AS 3579 02:52:35,011 --> 02:52:36,545 DEPUTY DIRECTOR SHE SERVES ON 3580 02:52:36,545 --> 02:52:38,714 THE EXECUTIVE COMMITTEE FOR THE 3581 02:52:38,714 --> 02:52:39,949 HEAL PRE CLINICAL SCREENING 3582 02:52:39,949 --> 02:52:43,586 PROGRAM AND HAS PARTICIPATED AS 3583 02:52:43,586 --> 02:52:44,854 AN AD HOC MEETING IN THREE FDA 3584 02:52:44,854 --> 02:52:48,658 ADVISORY PANEL FOR THE REVIEW OF 3585 02:52:48,658 --> 02:52:53,829 NEW DRUG APPLICATIONS. 3586 02:52:53,829 --> 02:52:55,698 >> THANK YOU FOR THE 3587 02:52:55,698 --> 02:52:56,032 INTRODUCTION. 3588 02:52:56,032 --> 02:52:56,832 I WASN'T EXPECTING THAT. 3589 02:52:56,832 --> 02:52:57,600 THANK YOU FOR THE OPPORTUNITY TO 3590 02:52:57,600 --> 02:53:00,636 PRESENT AN UPDATE ON OUR 3591 02:53:00,636 --> 02:53:02,338 THERAPEUTICS DEVELOPMENT PROGRAM 3592 02:53:02,338 --> 02:53:02,538 TODAY. 3593 02:53:02,538 --> 02:53:08,477 I'M GOING TO FOCUS ON THE CHANGE 3594 02:53:08,477 --> 02:53:12,648 S AND UPDATES FROM OCTOBER OF 3595 02:53:12,648 --> 02:53:17,186 2023. 3596 02:53:17,186 --> 02:53:19,822 THE DIVISION OF THERAPEUTICS AND 3597 02:53:19,822 --> 02:53:21,691 MEDICAL CONSEQUENCES WAS 3598 02:53:21,691 --> 02:53:23,426 ACTUALLY ESTABLISHED BY AN ACT 3599 02:53:23,426 --> 02:53:25,461 OF CAUCUS IN 1990 WITH A MISSION 3600 02:53:25,461 --> 02:53:29,932 TO ADDRESS THE CRACK COPAIN 3601 02:53:29,932 --> 02:53:32,468 PROBLEM THAT WAS PREVALENT AT 3602 02:53:32,468 --> 02:53:34,403 THAT TIME BY DEVELOPING 3603 02:53:34,403 --> 02:53:35,571 TREATMENT MEDICATIONS FOR 3604 02:53:35,571 --> 02:53:39,208 SUBSTANCE USE DISORDERS MAINLY 3605 02:53:39,208 --> 02:53:39,608 COCAINE. 3606 02:53:39,608 --> 02:53:41,777 INS SINCE THAT TIME OUR MISSION 3607 02:53:41,777 --> 02:53:42,812 HAS EXPANDED TO FOR THE 3608 02:53:42,812 --> 02:53:50,119 DEVELOPMENT OF MEDICATIONS, 3609 02:53:50,119 --> 02:53:51,687 BIOLOGICS, BEHAVIORAL THERAPIES 3610 02:53:51,687 --> 02:53:54,290 AND MECHANISMS FOR THE TREATMENT 3611 02:53:54,290 --> 02:53:58,227 OF SUBSTANCE USE DISORDERS WITH 3612 02:53:58,227 --> 02:53:58,994 STIMULANTS, CANNABIS AND 3613 02:53:58,994 --> 02:53:59,695 NICOTINE. 3614 02:53:59,695 --> 02:54:03,466 OUR GOAL IS TO THE DEVELOPMENT 3615 02:54:03,466 --> 02:54:08,537 OF SAFE AND EFFECTIVE 3616 02:54:08,537 --> 02:54:09,505 THERAPEUTICS. 3617 02:54:09,505 --> 02:54:12,641 WE HAVE FIVE FLAGSHIP FUNDING 3618 02:54:12,641 --> 02:54:15,244 OPPORTUNITY ANNOUNCEMENTS. 3619 02:54:15,244 --> 02:54:17,313 THEY HAVE SPECIAL REVIEW PANEL 3620 02:54:17,313 --> 02:54:18,214 TO ENSURE THE APPROPRIATE 3621 02:54:18,214 --> 02:54:20,716 EXPERTISE IS AVAILABLE IN 3622 02:54:20,716 --> 02:54:20,950 REVIEW. 3623 02:54:20,950 --> 02:54:23,219 MANY ARE U MECHANISMS OR 3624 02:54:23,219 --> 02:54:23,986 COOPERATIVE AGREEMENTS THAT 3625 02:54:23,986 --> 02:54:26,989 INCLUDE A SIGNIFICANT 3626 02:54:26,989 --> 02:54:28,824 INVOLVEMENT OF PROGRAM FOR 3627 02:54:28,824 --> 02:54:29,091 GUIDANCE. 3628 02:54:29,091 --> 02:54:35,131 ALL ARE MILESTONE DRIVEN WITH 3629 02:54:35,131 --> 02:54:39,068 SPECIFIC AND UNIQUE MARKERS OF 3630 02:54:39,068 --> 02:54:41,871 PROGRESS SPECIFIC TO THE PROJECT 3631 02:54:41,871 --> 02:54:47,109 AND SOME ARE PHASED AWARDS 3632 02:54:47,109 --> 02:54:49,478 ALLOWING AN ASSESSMENT OF 3633 02:54:49,478 --> 02:54:54,216 PROJECT PROCESS AND FEASIBILITY. 3634 02:54:54,216 --> 02:54:58,988 THE UHGs AND TREATING STIMULANT 3635 02:54:58,988 --> 02:55:00,556 USE DISORDER AND OPIOID DISORDER 3636 02:55:00,556 --> 02:55:03,292 AND THE AGREEMENT IS A FIVE-YEAR 3637 02:55:03,292 --> 02:55:03,759 PROGRAM. 3638 02:55:03,759 --> 02:55:05,628 THE GRANT OPPORTUNITY AND 3639 02:55:05,628 --> 02:55:06,595 MEDICATION DEVELOPMENT FOR 3640 02:55:06,595 --> 02:55:08,431 SUBSTANCE USE DISORDERS IS AN UL 3641 02:55:08,431 --> 02:55:12,034 1 A THREE-YEAR PROJECT WITH A 3642 02:55:12,034 --> 02:55:14,503 LARGER PROJECT THAN THE UG3s AND 3643 02:55:14,503 --> 02:55:16,505 THE DEVICE-BASED TREATMENT FOR 3644 02:55:16,505 --> 02:55:23,012 SUBSTANCE USE DISORDERS IS UH3, 3645 02:55:23,012 --> 02:55:29,652 UG3 WITH MILESTONES AND 3646 02:55:29,652 --> 02:55:31,420 DEVELOPING DIGITAL BASED 3647 02:55:31,420 --> 02:55:36,625 TREATMENTS IS A UGB AND UH3 AND 3648 02:55:36,625 --> 02:55:41,397 FINAL THE BEHAVIORAL IS R21s. 3649 02:55:41,397 --> 02:55:44,166 FOR THE TWO FLAGSHIP NOFOs THE 3650 02:55:44,166 --> 02:55:46,302 DEVELOPMENT OF MEDICATIONS TO 3651 02:55:46,302 --> 02:55:48,304 TREAT OPIOID AND STIMULANT USE 3652 02:55:48,304 --> 02:55:50,005 DISORDERS IN OVERDOSE AND THE 3653 02:55:50,005 --> 02:55:51,874 GRANT OPPORTUNITY FOR MEDICATION 3654 02:55:51,874 --> 02:55:53,075 DEVELOPMENT FOR SUBSTANCE USE 3655 02:55:53,075 --> 02:55:55,511 DISORDERS, WE HAVE AN OVER ALL 3656 02:55:55,511 --> 02:56:05,955 SUCCESS RATE OF ABOUT 20%. 3657 02:56:06,255 --> 02:56:08,958 WE HAVE SOME THAT CAME INTO HEAL 3658 02:56:08,958 --> 02:56:10,559 LATER AND THE SUCCESS RATES FOR 3659 02:56:10,559 --> 02:56:11,961 THE LAST ROUNDS HAVE BEEN ONLY 3660 02:56:11,961 --> 02:56:15,297 ABOUT 10% BUT WE'RE HOPING THAT 3661 02:56:15,297 --> 02:56:17,266 WILL INCREASE IN FUTURE ROUNDS. 3662 02:56:17,266 --> 02:56:21,437 I THINK THAT'S DRIVEN BY THE 3663 02:56:21,437 --> 02:56:24,640 FACT WE'RE GETTING MORE 3664 02:56:24,640 --> 02:56:28,043 APPLICATIONS PER ROUND. 3665 02:56:28,043 --> 02:56:29,812 THIS IS A SNAPSHOT OF WHAT WE 3666 02:56:29,812 --> 02:56:33,048 CALL OUR PIPELINE WHICH IS SET 3667 02:56:33,048 --> 02:56:36,185 UP AS A MEDICATION DEVELOPMENT 3668 02:56:36,185 --> 02:56:38,521 FOR PROGRESSION STARTING WITH 3669 02:56:38,521 --> 02:56:43,125 EARLY PRECLINICAL WHICH COULD 3670 02:56:43,125 --> 02:56:47,496 INCLUDE DISCOVERY WORK AND 3671 02:56:47,496 --> 02:56:50,499 PREDICTIVE TOXICOLOGY AND 3672 02:56:50,499 --> 02:56:51,534 SYNTHESIS PROCESS DEVELOPMENT 3673 02:56:51,534 --> 02:56:58,841 AND PRE CLINICAL IS USUALLY IND 3674 02:56:58,841 --> 02:57:03,112 ENABLING STUDIES AND PHASE 1 IS 3675 02:57:03,112 --> 02:57:06,582 FIRST IN MAN OR DRUG-DRUG 3676 02:57:06,582 --> 02:57:07,850 INTERACTION STUDIES WITH OTHER 3677 02:57:07,850 --> 02:57:10,452 TREATMENT DRUGS REQUIRED WITH 3678 02:57:10,452 --> 02:57:14,523 THE FDA AND PHASE 2 IS FURTHER 3679 02:57:14,523 --> 02:57:16,158 INTERACTIONS STUDIES AND PHASE 3680 02:57:16,158 --> 02:57:18,627 III WOULD BE REGISTRATION 3681 02:57:18,627 --> 02:57:19,962 TRIALS. 3682 02:57:19,962 --> 02:57:24,500 NEW REGISTRATIONS ARE GIVEN 3683 02:57:24,500 --> 02:57:26,502 THEIR OWN COLUMN. 3684 02:57:26,502 --> 02:57:28,637 THE PATHWAY DOESN'T ALLOW 3685 02:57:28,637 --> 02:57:32,541 BIOLOGICAL COMPARISONS WITH 3686 02:57:32,541 --> 02:57:35,177 MARKETS PATHWAYS AND 3687 02:57:35,177 --> 02:57:36,679 FORMULATIONS OF EXISTING DRUGS. 3688 02:57:36,679 --> 02:57:44,520 WE HAVE A TOTAL SHOWN OF 82 AND 3689 02:57:44,520 --> 02:57:53,228 IT'S BETWEEN 81 AND 83. 3690 02:57:53,228 --> 02:57:54,697 THIS SHOWS THE PROJECTS THAT 3691 02:57:54,697 --> 02:57:56,532 HAVE FALLEN OFF THE RADAR SINCE 3692 02:57:56,532 --> 02:58:06,775 THE BEGINNING. 3693 02:58:36,105 --> 02:58:38,507 THEY RELINQUISHED THE COUNT SO 3694 02:58:38,507 --> 02:58:40,909 IN SOME CASES THE INACTIVE 3695 02:58:40,909 --> 02:58:42,144 PROJECTS REPRESENT A FAILURE BUT 3696 02:58:42,144 --> 02:58:42,678 IN SOME THEY REPRESENT A 3697 02:58:42,678 --> 02:58:52,821 SUCCESS. 3698 02:58:56,959 --> 02:58:58,627 THIS IS GOING TO SHOW YOU THE 3699 02:58:58,627 --> 02:58:59,595 PROJECTS APPROVED FOR FUNDING 3700 02:58:59,595 --> 02:59:00,796 SINCE THE LAST UPDATE IN OCTOBER 3701 02:59:00,796 --> 02:59:08,537 OF 2023. 3702 02:59:08,537 --> 02:59:10,139 THERE'S SIX IN YELLOW ACROSS 3703 02:59:10,139 --> 02:59:11,240 THE SPAN OF DEVELOPMENT WHICH IS 3704 02:59:11,240 --> 02:59:12,708 A FUNCTION OF WHERE THEY COME TO 3705 02:59:12,708 --> 02:59:22,985 US AND COME IN. 3706 02:59:30,426 --> 02:59:34,797 THE FIRST PROJECT IS A 3707 02:59:34,797 --> 02:59:36,031 LONG-ACTING NEW OPIOID 3708 02:59:36,031 --> 02:59:37,700 ANTAGONIST SHOWN TO HAVE A LONG 3709 02:59:37,700 --> 02:59:39,935 DURATION IN THE BLOCKADE OF NEW 3710 02:59:39,935 --> 02:59:44,973 OPIOID INDUCED RESPIRATORY 3711 02:59:44,973 --> 02:59:47,676 DEPRESSION AND OPIOID INDUCED 3712 02:59:47,676 --> 02:59:49,411 ADMINISTRATION AND SOME HAVE 3713 02:59:49,411 --> 02:59:51,780 FOCUSSED ON FENTANYL AND 3714 02:59:51,780 --> 03:00:02,191 BLOCKING THOSE EFFECTS. 3715 03:00:06,962 --> 03:00:08,464 STHIGS -- 3716 03:00:11,400 --> 03:00:14,269 >> THIS IS A FOLLOW-UP GRANT AND 3717 03:00:14,269 --> 03:00:15,637 WORKED OUT THE PROCESS 3718 03:00:15,637 --> 03:00:19,441 DEVELOPMENT AND IN THE UL 1 THEY 3719 03:00:19,441 --> 03:00:20,542 WILL COMPLETE THE SYNTHESIS 3720 03:00:20,542 --> 03:00:22,544 FOLLOWING THE IND AND MOVE INTO 3721 03:00:22,544 --> 03:00:32,354 PHASE I FIRST IN HUMAN STUDIES. 3722 03:00:32,354 --> 03:00:36,725 WE HOPE TO HAVE AN IND BY THE 3723 03:00:36,725 --> 03:00:41,463 END OF THE YEAR. 3724 03:00:41,463 --> 03:00:51,974 GM3009 IS A NEW SET OF THESE 3725 03:01:01,550 --> 03:01:05,988 THERAPEUTIC WHILE ADDRESSING THE 3726 03:01:05,988 --> 03:01:16,498 RISK TO PATIENT SAFETY IT HAS 3727 03:01:22,504 --> 03:01:32,881 ENHANCED EFFICACY THERE'S 3728 03:01:34,850 --> 03:01:38,187 INTOXIN PK AND THE UH3 ASSUMING 3729 03:01:38,187 --> 03:01:39,621 IT'S SUCCESSFUL WILL CONDUCT 3730 03:01:39,621 --> 03:01:43,058 FIRST IN HUMAN TRIALS IN HEALTHY 3731 03:01:43,058 --> 03:01:45,027 VOLUNTEERS FOLLOWED BY EFFICACY 3732 03:01:45,027 --> 03:01:45,427 STUDIES. 3733 03:01:45,427 --> 03:01:48,597 THE COMPOUND IS EXPECTED TO 3734 03:01:48,597 --> 03:01:50,132 PROVIDE RAPID AND LONG-TERM 3735 03:01:50,132 --> 03:01:53,902 MITIGATION OF ACUTE AND 3736 03:01:53,902 --> 03:01:56,605 PROTRACTED WITHDRAWALS IN 3737 03:01:56,605 --> 03:02:06,915 SYMPTOMS WITH OUD. 3738 03:02:08,283 --> 03:02:11,854 LOFEXADINE IS BEING DEVELOPED 3739 03:02:11,854 --> 03:02:15,123 AND IT DEVELOPED AN ALPHA 2 3740 03:02:15,123 --> 03:02:16,491 AGONIST FOR THE TREATMENT OF 3741 03:02:16,491 --> 03:02:19,228 OPIOID WITHDRAWALS IN ADULTS. 3742 03:02:19,228 --> 03:02:24,633 APPROVED BY THE FDA IN 2018 OR 3743 03:02:24,633 --> 03:02:30,606 '19. 3744 03:02:30,606 --> 03:02:32,641 THEY WORKED WITH THE FDA TO 3745 03:02:32,641 --> 03:02:37,913 DETERMINE WHAT THE DEVELOPMENT 3746 03:02:37,913 --> 03:02:41,650 PATH WOULD BE AND CONDUCTING 3747 03:02:41,650 --> 03:02:44,253 NON-CLINICAL SAFETY STUDIES FOR 3748 03:02:44,253 --> 03:02:46,188 AGE-SPECIFIC FORMULATION TO 3749 03:02:46,188 --> 03:02:52,227 VEELT THE PK IN 12 TO 3750 03:02:52,227 --> 03:02:52,861 17-YEAR-OLDS AND EVALUATE THE 3751 03:02:52,861 --> 03:03:00,636 RISK AND BENEFITS. 3752 03:03:02,604 --> 03:03:02,604 6: 3753 03:03:03,906 --> 03:03:07,109 THIS WOULD BE A FIRST MEDICATION 3754 03:03:07,109 --> 03:03:13,715 SPECIFICALLY FOR ADOLESCENTS. 3755 03:03:13,715 --> 03:03:19,721 NRS033 IS A LONG ACTING OPIOID 3756 03:03:19,721 --> 03:03:21,957 ANTAGONIST TO MARKET AS AN 3757 03:03:21,957 --> 03:03:28,630 INJECTABLE AND STABLE AND READY 3758 03:03:28,630 --> 03:03:32,601 IN PRE-FILLEDED SYRINGES AND THE 3759 03:03:32,601 --> 03:03:36,638 COMPLETION OF PHASE I STUDIES 3760 03:03:36,638 --> 03:03:40,642 OCCURRED IN THE PREVIOUS GRANT 3761 03:03:40,642 --> 03:03:51,053 SO AND IT'S LONGER THAN 3762 03:03:59,928 --> 03:04:02,331 NALTREXONE AND WILL CONDUCT 3763 03:04:02,331 --> 03:04:04,633 PHASE III REGISTRATION TRIALS 3764 03:04:04,633 --> 03:04:14,943 FOR FDA APPROVAL. 3765 03:04:24,686 --> 03:04:33,762 AND THIS IS A FAST-TRACKED FDA 3766 03:04:33,762 --> 03:04:35,864 PRODUCT THIS IS COMPLICATED 3767 03:04:35,864 --> 03:04:38,500 BECAUSE THE OXYCODONE FORMULATED 3768 03:04:38,500 --> 03:04:47,776 SO IT REQUIRE THE ENZYME TRIPSAN 3769 03:04:47,776 --> 03:04:52,647 TO RELEASE IT AND THE INHIBITOR 3770 03:04:52,647 --> 03:04:55,951 IS RELEASED AND THAT BLOCKS IT 3771 03:04:55,951 --> 03:04:57,552 IN THE QUAIS MULTIPLE DOSE UNITS 3772 03:04:57,552 --> 03:05:01,857 ARE CONSUMED. 3773 03:05:01,857 --> 03:05:05,594 THE ACTIVATION IS CALLED TRIP 3774 03:05:05,594 --> 03:05:07,129 AND BOTH TECHNOLOGIES ARE ALSO 3775 03:05:07,129 --> 03:05:13,769 BEING USED TO DEVELOP DRUGS FOR 3776 03:05:13,769 --> 03:05:14,536 OUD. 3777 03:05:14,536 --> 03:05:20,175 THIS RESOURCE D FAST TRACK 3778 03:05:20,175 --> 03:05:25,180 APPROVAL AND APPROVED FOR 3779 03:05:25,180 --> 03:05:25,680 FUNDING SINCE THE LAST 3780 03:05:25,680 --> 03:05:31,987 PRESENTATION IN OCTOBER. 3781 03:05:31,987 --> 03:05:34,056 SO WE HAVE SEVERAL PROJECTS THAT 3782 03:05:34,056 --> 03:05:35,690 TRANSITION MEANING IN THE UG3 3783 03:05:35,690 --> 03:05:38,560 PHASE AND TRANSITIONED TO THE 3784 03:05:38,560 --> 03:05:39,961 UH3 PHASE WHICH WE CONSIDER TO 3785 03:05:39,961 --> 03:05:42,130 BE A BIG DEAL BECAUSE WE DO 3786 03:05:42,130 --> 03:05:44,566 QUITE AN EXTENSIVE REVIEW OF THE 3787 03:05:44,566 --> 03:05:47,035 PROGRESS AT THE END OF THE UG3 3788 03:05:47,035 --> 03:05:51,139 TO MAKE SURE THE PROJECT IS 3789 03:05:51,139 --> 03:05:52,507 FEASIBLE AND PRACTICAL FOR 3790 03:05:52,507 --> 03:05:54,242 TRANSITION TO UH3. 3791 03:05:54,242 --> 03:05:59,648 WE HAVE PROJECTS THAT HAVE 3792 03:05:59,648 --> 03:06:05,821 TRANSITIONED AND THE FIRST ONE 3793 03:06:05,821 --> 03:06:13,895 IS AZD4041 FIRST IN CLASS. 3794 03:06:13,895 --> 03:06:16,565 IT'S BEN PENETRANT AND ENGAGES 3795 03:06:16,565 --> 03:06:18,300 RECEPTORS IN RATS AND IN HUMANS. 3796 03:06:18,300 --> 03:06:21,803 THE COMPANY WHICH IS 3797 03:06:21,803 --> 03:06:23,171 ASTRAZENECA, THE GRANTEE 3798 03:06:23,171 --> 03:06:25,574 INSTITUTION COMPLETED A 3799 03:06:25,574 --> 03:06:29,111 SUCCESSFUL FIRST IN STUDY TRIAL 3800 03:06:29,111 --> 03:06:32,247 IN THE UG 3 AND WILL POISE A 3801 03:06:32,247 --> 03:06:36,618 TRIAL IN COMBINATION WITH 3802 03:06:36,618 --> 03:06:40,622 BUPRENORPHINE TO IMPROVE 3803 03:06:40,622 --> 03:06:46,294 ABSTINENCE FROM A 12 WEEK STUDY. 3804 03:06:46,294 --> 03:06:48,630 ANOTHER PROJECT THAT'S 3805 03:06:48,630 --> 03:06:54,136 SUCCESSFUL TRANSITIONED WILL BE 3806 03:06:54,136 --> 03:07:04,546 LOOKING AT SEMAGLUTIDE. 3807 03:07:10,552 --> 03:07:15,857 AND THEY'VE BEEN SHOWN TO REDUCE 3808 03:07:15,857 --> 03:07:17,125 HEROIN STREAKING AND STRESS 3809 03:07:17,125 --> 03:07:19,361 REDUCED REINSTATEMENT IN RATS. 3810 03:07:19,361 --> 03:07:25,967 SO THIS IS A TRANSITION OF A UB 3811 03:07:25,967 --> 03:07:30,672 3 TO A UH3. 3812 03:07:30,672 --> 03:07:34,409 THE P.I. IS FROM PENN STATE AND 3813 03:07:34,409 --> 03:07:36,378 THEY CONDUCTED A SMALL TRIAL IN 3814 03:07:36,378 --> 03:07:36,945 A TREATMENT CENTER. 3815 03:07:36,945 --> 03:07:38,780 IT'S NOT PUBLISHED BUT HAS BEEN 3816 03:07:38,780 --> 03:07:44,586 PRESENTED PUBLICALLY SO WE CAN 3817 03:07:44,586 --> 03:07:54,829 TALK ABOUT IT. 3818 03:07:55,030 --> 03:07:58,133 THEY HAD A SHORTER AGONIST 3819 03:07:58,133 --> 03:08:02,571 COMPARED TO PLACEBO IN PATIENTS 3820 03:08:02,571 --> 03:08:12,647 MANE -- MAINTAINED ON 3821 03:08:12,647 --> 03:08:19,054 BUPRENORPHINE. 3822 03:08:19,054 --> 03:08:21,122 AND WE'LL HAVE A FOLLOW-UP TO 3823 03:08:21,122 --> 03:08:31,533 LOOK AT THE EFFICACY OF 3824 03:08:34,736 --> 03:08:36,972 SEMAGLUTIDE FOR THOSE ON THIS 3825 03:08:36,972 --> 03:08:40,709 DISORDER. 3826 03:08:40,709 --> 03:08:43,411 SO BIOPIN 6 AN UG 3 THAT 3827 03:08:43,411 --> 03:08:45,814 TRANSITIONED TO THE UH3 IN THE 3828 03:08:45,814 --> 03:08:48,383 NEW FORMULATION COLUMN. 3829 03:08:48,383 --> 03:08:54,889 THIS IS AN ABSORBABLE NALTREXONE 3830 03:08:54,889 --> 03:08:56,157 IMPLANT THAT PROVIDES OPIOID 3831 03:08:56,157 --> 03:08:58,026 BLOCKADE FOR AT LEAST THREE 3832 03:08:58,026 --> 03:08:58,260 MONTHS. 3833 03:08:58,260 --> 03:09:02,564 IT'S EXPLORED DIFFERENT 3834 03:09:02,564 --> 03:09:13,008 FORMULATIONS, A LIPOSOMAL 3835 03:09:14,509 --> 03:09:19,614 TRANSITION OF THE IMPLANT AND TO 3836 03:09:19,614 --> 03:09:21,216 EF THE THERAPEUTIC SERUM LEVELS 3837 03:09:21,216 --> 03:09:23,385 WHICH WOULD BE REQUIRED FOR THE 3838 03:09:23,385 --> 03:09:25,487 LONG-TERM IMPLANT, THEY FOCUSSED 3839 03:09:25,487 --> 03:09:27,489 ON REFINEMENT MUCH THE SURGICAL 3840 03:09:27,489 --> 03:09:30,792 PROCEDURES FOR IMPLANTATION AND 3841 03:09:30,792 --> 03:09:33,261 THE INSTRUMENTATION USED. 3842 03:09:33,261 --> 03:09:35,530 THEY'LL CONDUCT A SIX TO 3843 03:09:35,530 --> 03:09:36,665 12-MONTH STUDY TO EXAMINE THE 3844 03:09:36,665 --> 03:09:37,499 SAFETY AND EFFICACY OF THE 3845 03:09:37,499 --> 03:09:47,642 IMPLANT. 3846 03:09:50,945 --> 03:09:56,584 THE NEXT SLIDE GOES TO OUR 3847 03:09:56,584 --> 03:10:02,957 STIMULANT USE DISORDER AND I'LL 3848 03:10:02,957 --> 03:10:08,430 TALK ABOUT A COUPLE OF THE 3849 03:10:08,430 --> 03:10:08,697 PROJECTS. 3850 03:10:08,697 --> 03:10:18,640 SO THE FIRST OR THE ONLY ONE 3851 03:10:18,640 --> 03:10:25,013 I'LL TALK ABOUT IS BEING 3852 03:10:25,013 --> 03:10:30,985 DEVELOPED BY BIOCOREX A 3853 03:10:30,985 --> 03:10:37,726 SUBCUTANEOUS NALTREXONE IMPLANT 3854 03:10:37,726 --> 03:10:38,560 FOR METHAMPHETAMINE USE DISORDER 3855 03:10:38,560 --> 03:10:40,628 WHERE WE HAVE FEW PROJECTS IN 3856 03:10:40,628 --> 03:10:50,872 THE PIPELINE. 3857 03:10:54,008 --> 03:10:56,611 THE PHASE I WHAT'S BEEN 3858 03:10:56,611 --> 03:11:02,283 COMPLETED AND SHOWN IT BE SAFE 3859 03:11:02,283 --> 03:11:06,621 AND EACH DRUG ALONE IN A 3860 03:11:06,621 --> 03:11:07,055 MULTI-ARM STUDY. 3861 03:11:07,055 --> 03:11:08,623 SO WE'RE LOOKING FORWARD TO 3862 03:11:08,623 --> 03:11:16,164 SEEING THOSE RESULTS. 3863 03:11:16,164 --> 03:11:20,468 AND NOW I'M GOING TO TALK ABOUT 3864 03:11:20,468 --> 03:11:21,936 SOME OF OUR THERAPEUTIC DEVICES 3865 03:11:21,936 --> 03:11:23,705 IN OUR PIPELINE. 3866 03:11:23,705 --> 03:11:26,241 THESE ARE SHOWN HERE IN YELLOW 3867 03:11:26,241 --> 03:11:31,446 ARE THE ONES FUNDED BY HEAL. 3868 03:11:31,446 --> 03:11:33,715 SO THIS IS A PROJECT YOU MIGHT 3869 03:11:33,715 --> 03:11:37,352 HAVE SEEN ON 60 MINUTES. 3870 03:11:37,352 --> 03:11:44,592 THIS IS A UH3 AWARDED TO WEST 3871 03:11:44,592 --> 03:11:45,794 VIRGINIA UNIVERSITY. 3872 03:11:45,794 --> 03:11:48,897 STARTED USING DEEP BRAIN 3873 03:11:48,897 --> 03:11:52,634 STIMULATION OF THE NUCLEUS 3874 03:11:52,634 --> 03:11:56,304 ACCUMBENS IN THOSE TERMED 3875 03:11:56,304 --> 03:11:57,872 TREATMENT RESISTANT AND BEEN IN 3876 03:11:57,872 --> 03:11:59,908 SEVERAL TREATMENTS AN FAILED AND 3877 03:11:59,908 --> 03:12:02,610 FOUND THIS TO BE SAFE AND 3878 03:12:02,610 --> 03:12:08,483 EFFECTIVE AND HE INTERVIEWS SOME 3879 03:12:08,483 --> 03:12:11,920 OF THE PATIENTS WHOSE SITUATION 3880 03:12:11,920 --> 03:12:13,621 WAS GREATLY IMPROVED AND BECAUSE 3881 03:12:13,621 --> 03:12:16,624 THE PROCEDURE IS SO INVASIVE HE 3882 03:12:16,624 --> 03:12:23,264 HAS SHIFTED TO LOOKING AT LOW 3883 03:12:23,264 --> 03:12:24,332 INTENSITY ULTRASOUND AND SHOWN 3884 03:12:24,332 --> 03:12:27,669 IT TO BE SAFE AND WELL TOLERATE 3885 03:12:27,669 --> 03:12:29,471 AND REPORTED IT DECREASED 3886 03:12:29,471 --> 03:12:32,173 CRAVING ACUTELY AND AT 90-DAY 3887 03:12:32,173 --> 03:12:32,607 FOLLOW-UP. 3888 03:12:32,607 --> 03:12:36,277 IT'S PREFERABLE BECAUSE IT'S NOT 3889 03:12:36,277 --> 03:12:39,881 INVASIVE AND COMPARED TO SHAM 3890 03:12:39,881 --> 03:12:44,285 SONICATIONS WITH THE PUSH 3891 03:12:44,285 --> 03:12:49,691 PROCEDURE IT HAS SHOWN TO 3892 03:12:49,691 --> 03:12:53,094 DISCONNECT BETWEEN CUE INDUCED 3893 03:12:53,094 --> 03:12:56,598 CRAVING IN PEOPLE WITH OPIOID 3894 03:12:56,598 --> 03:13:02,537 USE DISORDER. 3895 03:13:02,537 --> 03:13:03,671 THIS USES DIRECT CRANIAL 3896 03:13:03,671 --> 03:13:07,742 STIMULATION WITH ENGAGEMENT OF 3897 03:13:07,742 --> 03:13:09,611 THE COGNITIVE CONTROL NETWORK 3898 03:13:09,611 --> 03:13:14,182 WITH THOSE ON BUPRENORPHINE OR 3899 03:13:14,182 --> 03:13:16,885 IN METHADONE. 3900 03:13:16,885 --> 03:13:19,521 THE CURRENT STIMULATION INCLUDES 3901 03:13:19,521 --> 03:13:23,291 THIS OVER THE RIGHT PREFRONTAL 3902 03:13:23,291 --> 03:13:24,626 CORTEX AND ACTIVATION OF THE 3903 03:13:24,626 --> 03:13:25,927 COGNITIVE CONTROL NETWORK MEANS 3904 03:13:25,927 --> 03:13:29,564 THE SUBJECT IS ENGAGED IN 3905 03:13:29,564 --> 03:13:30,598 COGNITIVE TASKS WHILE THE 3906 03:13:30,598 --> 03:13:32,500 STIMULATION IS GOING ON. 3907 03:13:32,500 --> 03:13:34,502 SO APPARENTLY BOTH HAVE TO BE 3908 03:13:34,502 --> 03:13:36,504 DONE TOGETHER. 3909 03:13:36,504 --> 03:13:38,606 THE PRELIMINARY STUDIES SUGGEST 3910 03:13:38,606 --> 03:13:40,642 INCREASED ACTIVITY RELEVANT TO 3911 03:13:40,642 --> 03:13:43,811 SHAM PROCEDURE AND DECREASED IN 3912 03:13:43,811 --> 03:13:45,880 OPIOID CRAVINGS THAT WERE 3913 03:13:45,880 --> 03:13:46,814 REPORTED POST TREATMENT. 3914 03:13:46,814 --> 03:13:50,618 THIS WORK IS BEING CONDUCTED AT 3915 03:13:50,618 --> 03:13:52,620 BUTLER HOSPITAL IN PROVIDENCE, 3916 03:13:52,620 --> 03:13:57,058 RHODE ISLAND. 3917 03:13:57,058 --> 03:13:59,427 THE FINAL PROJECT AND THE FINAL 3918 03:13:59,427 --> 03:14:05,433 PROJECT IS NON-INVASIVE VAGAL 3919 03:14:05,433 --> 03:14:09,370 NERVE STIMULATION WITH 3920 03:14:09,370 --> 03:14:11,072 STIMULATION OF THE VAGUS NERVE 3921 03:14:11,072 --> 03:14:13,141 USED DURING OPIOID WITHDRAWAL TO 3922 03:14:13,141 --> 03:14:16,644 MITIGATE SOME SYMPTOMS. 3923 03:14:16,644 --> 03:14:24,619 IT'S EXPECTED TO BLOCK SIM PA 3924 03:14:24,619 --> 03:14:31,326 PATH -- SYMPATHETIC RESPONSES 3925 03:14:31,326 --> 03:14:33,728 AND HAS BEEN SHOWN TO HAVE 3926 03:14:33,728 --> 03:14:35,997 CHANGES IN PATIENTS WITH ANXIETY 3927 03:14:35,997 --> 03:14:39,233 AND PTSD AND USED WITH A SHAM 3928 03:14:39,233 --> 03:14:40,101 CONTROL TO EVALUATE IT FOR 3929 03:14:40,101 --> 03:14:41,369 TREATMENT DURING THE FIRST TWO 3930 03:14:41,369 --> 03:14:43,371 WEEKS OF WITHDRAWAL. 3931 03:14:43,371 --> 03:14:46,774 THE MEASURES THAT WILL BE TAKEN 3932 03:14:46,774 --> 03:14:49,110 WILL INCLUDE SOME BRAIN IMAGING 3933 03:14:49,110 --> 03:14:52,146 AND ASSESS CRAVING AND LOOK AT 3934 03:14:52,146 --> 03:14:52,814 CARDIOVASCULAR AND INFLAMMATORY 3935 03:14:52,814 --> 03:14:53,481 MEASURES AS WELL. 3936 03:14:53,481 --> 03:14:55,216 THIS IS BEING CONDUCTED BY EMORY 3937 03:14:55,216 --> 03:15:03,358 UNIVERSITY. 3938 03:15:03,358 --> 03:15:08,529 LET ME MENTION ALL THESE 3939 03:15:08,529 --> 03:15:12,634 PIPELINES ARE SHOWN ON THE NIDA 3940 03:15:12,634 --> 03:15:23,244 WEB PAGE WITH HOT LINKS IN 3941 03:15:23,444 --> 03:15:25,813 REPORTER AND GO ON OUR WEB PAGE 3942 03:15:25,813 --> 03:15:28,683 AND CLICK ON THE LINK AND IT 3943 03:15:28,683 --> 03:15:32,587 WILL TAKE YOU THERE. 3944 03:15:32,587 --> 03:15:37,425 THIS IS A SUMMARY OF OUR 3945 03:15:37,425 --> 03:15:38,393 REGULATORY PROGRESS FOR OPIOID 3946 03:15:38,393 --> 03:15:38,893 USE DISORDER. 3947 03:15:38,893 --> 03:15:40,862 WE'RE VERY PROUD OF THE FACT 3948 03:15:40,862 --> 03:15:42,697 THAT SINCE THE BEGINNING OF THE 3949 03:15:42,697 --> 03:15:46,734 HEAL WORK WE HAVE BEEN ABLE TO 3950 03:15:46,734 --> 03:15:47,669 FILE 39 INDs. 3951 03:15:47,669 --> 03:15:50,004 I SAY WE FILED THEM PUT WE 3952 03:15:50,004 --> 03:15:51,673 WORKED WITH GRANTEES TO FILE 3953 03:15:51,673 --> 03:15:52,640 THEM. 3954 03:15:52,640 --> 03:15:54,509 THE TOTAL ACTIVE ARE 29. 3955 03:15:54,509 --> 03:15:57,945 AND SINCE OCTOBER WE HAVE FILED 3956 03:15:57,945 --> 03:15:59,013 TWO AND SEVEN INDs BECAME 3957 03:15:59,013 --> 03:16:03,184 ACTIVE. 3958 03:16:03,184 --> 03:16:04,619 FOR INVESTIGATIONAL DEVICE 3959 03:16:04,619 --> 03:16:05,653 EXEMPTIONS WHICH IS THE 3960 03:16:05,653 --> 03:16:07,989 REGULATORY PATHWAY FOR THE 3961 03:16:07,989 --> 03:16:10,591 ADVANCEMENT OF DEVICES, WE'VE 3962 03:16:10,591 --> 03:16:12,794 FILED A TOTAL OF TWO IDEs AND 3963 03:16:12,794 --> 03:16:16,631 HAVE A TOTAL OF ONE ACTIVE IED 3964 03:16:16,631 --> 03:16:19,400 AND SINCE OCTOBER OF '23, ONE 3965 03:16:19,400 --> 03:16:20,601 IDE WAS FILED AND ONE BECAME 3966 03:16:20,601 --> 03:16:22,437 ACTIVE. 3967 03:16:22,437 --> 03:16:27,241 WE HAVE TWO PROJECTS THAT HAVE 3968 03:16:27,241 --> 03:16:32,146 GOTTEN FAST-TRACK DESIGNATION 3969 03:16:32,146 --> 03:16:33,481 FROM THE FDA. 3970 03:16:33,481 --> 03:16:40,621 ONE AND WE HAVE A SOLUBLE 3971 03:16:40,621 --> 03:16:45,393 INHIBITOR THAT IS BEING 3972 03:16:45,393 --> 03:16:48,629 DEVELOPED FOR CHRONIC PAIN 3973 03:16:48,629 --> 03:16:54,435 DIABETIC NEUROPATHY AND A LEGAL 3974 03:16:54,435 --> 03:16:56,571 METHADONE FORMULATION THAT'S 3975 03:16:56,571 --> 03:17:01,075 BEING DEVELOPED AND THE ONE 3976 03:17:01,075 --> 03:17:02,076 BREAKTHROUGH THERAPY DESIGNATION 3977 03:17:02,076 --> 03:17:05,780 WHICH IS THE NEW FORMULATION FOR 3978 03:17:05,780 --> 03:17:08,616 OVERDOSE PROTECTION FOR THE 3979 03:17:08,616 --> 03:17:13,287 EFFECTIVE DELIVERY OF OXYCODONE 3980 03:17:13,287 --> 03:17:15,490 FOR PAIN USING THE MCAR 3981 03:17:15,490 --> 03:17:16,124 TECHNOLOGIES AND THERE'S ALSO 3982 03:17:16,124 --> 03:17:18,693 USING THESE TECHNOLOGIES FOR THE 3983 03:17:18,693 --> 03:17:20,628 DEVELOPMENT OF TREATMENT 3984 03:17:20,628 --> 03:17:22,363 MEDICATIONS FOR OUD. 3985 03:17:22,363 --> 03:17:24,632 AND THEN FINALLY IN THE PRE-NEW 3986 03:17:24,632 --> 03:17:29,470 DRUG APPLICATION STAGE WE HAVE A 3987 03:17:29,470 --> 03:17:38,646 FORM OF NALOXONE THAT IS ON 3988 03:17:38,646 --> 03:17:44,652 COTTON SWABS FOR THE REVERSAL 3989 03:17:44,652 --> 03:17:45,987 FOR OPIOID OVERDOSE AND IS OVER 3990 03:17:45,987 --> 03:17:48,656 THE COUNTER AND LOW COST. 3991 03:17:48,656 --> 03:17:50,658 THEY EXPECT THE PROJECT WILL 3992 03:17:50,658 --> 03:17:53,961 SELL FOR $10 A DOSE AND 3993 03:17:53,961 --> 03:17:55,496 AVAILABLE OVER THE COUNTER. 3994 03:17:55,496 --> 03:18:03,204 I THINK THAT IS MY LAST SLIDE. 3995 03:18:03,204 --> 03:18:05,873 I'M HAPPY TO TAKE ANY QUESTIONS 3996 03:18:05,873 --> 03:18:07,008 OR ANY FURTHER DISCUSSION. 3997 03:18:07,008 --> 03:18:08,976 I PROBABLY BLASTED THROUGH THAT 3998 03:18:08,976 --> 03:18:14,048 AND MADE UP SOME OF OUR TIME. 3999 03:18:14,048 --> 03:18:22,623 ANY QUESTIONS? 4000 03:18:22,623 --> 03:18:23,691 ALLAN YOU'RE ON MUTE. 4001 03:18:23,691 --> 03:18:26,661 >> THE QUESTION I HAVE IS A 4002 03:18:26,661 --> 03:18:29,630 GENERAL ONE AND SHAM CONTROL 4003 03:18:29,630 --> 03:18:32,767 WHEN YOU REFER TO VAGAL 4004 03:18:32,767 --> 03:18:36,170 STIMULATION. 4005 03:18:36,170 --> 03:18:39,740 AND YOU NEED A SLAM CONTROL IN 4006 03:18:39,740 --> 03:18:41,576 THESE PROCEDURES AND ALMOST 4007 03:18:41,576 --> 03:18:43,211 EVERY ONE OF THEM WILL PRODUCE 4008 03:18:43,211 --> 03:18:44,345 SOME RESPONSE TO THE INDIVIDUAL 4009 03:18:44,345 --> 03:18:46,881 WILL KNOW THEY'RE GETTING NOT TO 4010 03:18:46,881 --> 03:18:48,382 MENTION THE WHOLE DRAMA OF 4011 03:18:48,382 --> 03:18:50,017 HAVING THE PROCEDURE. 4012 03:18:50,017 --> 03:18:52,854 I'M CURIOUS HOW THAT'S DEALT 4013 03:18:52,854 --> 03:18:53,221 WITH. 4014 03:18:53,221 --> 03:18:55,489 IS THERE GENERAL SHAM CONTROL 4015 03:18:55,489 --> 03:18:56,224 THAT'S ACCEPTABLE? 4016 03:18:56,224 --> 03:18:58,226 >> THE SHAM CONTROL IS OBVIOUSLY 4017 03:18:58,226 --> 03:19:00,661 GOING TO VARY DEPENDING ON WHAT 4018 03:19:00,661 --> 03:19:03,497 THE TECHNOLOGY IS. 4019 03:19:03,497 --> 03:19:07,969 FOR THE SHAM CONTROL SAY FOR THE 4020 03:19:07,969 --> 03:19:09,604 DIRECT CURRENT STIMULATION I 4021 03:19:09,604 --> 03:19:11,439 THINK ALL THEY CAN DO IS HOOK 4022 03:19:11,439 --> 03:19:14,642 THE PERSON UP TO THE DEVICE AND 4023 03:19:14,642 --> 03:19:16,644 PRETEND THEY'RE DELIVERING IT TO 4024 03:19:16,644 --> 03:19:19,780 THE EXTENT THEY CAN BECAUSE I 4025 03:19:19,780 --> 03:19:23,184 DON'T KNOW THERE'S ANY ACTUAL 4026 03:19:23,184 --> 03:19:24,352 MARKER THAT IT'S BEING 4027 03:19:24,352 --> 03:19:26,587 ADMINISTERED THE PATIENT WOULD 4028 03:19:26,587 --> 03:19:26,988 BE AWARE OF. 4029 03:19:26,988 --> 03:19:32,660 IT'S OBVIOUSLY GOING TO VARY FOR 4030 03:19:32,660 --> 03:19:35,630 EACH TYPE OF TECHNOLOGY AND 4031 03:19:35,630 --> 03:19:36,197 DEVICE AND IT'S A CHALLENGE. 4032 03:19:36,197 --> 03:19:36,831 IT'S DEFINITELY A CHALLENGE. 4033 03:19:36,831 --> 03:19:39,200 >> THANK YOU. 4034 03:19:39,200 --> 03:19:40,735 >> THANK YOU. 4035 03:19:40,735 --> 03:19:43,838 WE'LL GO TO DR. NUNEZ AND THEN 4036 03:19:43,838 --> 03:19:45,306 TO THE COMMENTS. 4037 03:19:45,306 --> 03:19:48,509 >> JUST A COUPLE COMMENTS. 4038 03:19:48,509 --> 03:19:51,612 EXCITING TO SEE SO MANY INDUSTRY 4039 03:19:51,612 --> 03:19:52,647 PARTICIPATION IN THIS FIELD 4040 03:19:52,647 --> 03:19:56,651 WHICH WASN'T THE CASE EVEN A 4041 03:19:56,651 --> 03:19:58,519 DECADE AGO OR MORE AND EXCITING 4042 03:19:58,519 --> 03:20:00,655 TO SEE ALL THE DIFFERENT 4043 03:20:00,655 --> 03:20:03,824 INNOVATIVE APPROACHES 4044 03:20:03,824 --> 03:20:04,125 DEVELOPING. 4045 03:20:04,125 --> 03:20:05,693 ONE COMMENT WHICH I MAY HAVE 4046 03:20:05,693 --> 03:20:08,496 MADE BEFORE WITH THE LONG ACTING 4047 03:20:08,496 --> 03:20:11,132 IMPLANTS WHICH ARE REALLY 4048 03:20:11,132 --> 03:20:14,135 PROMISING APPROACHES, IT IS 4049 03:20:14,135 --> 03:20:20,374 IMPORTANT TO LOOK FOR THE 4050 03:20:20,374 --> 03:20:20,908 INTERINDIVIDUAL VARIATION. 4051 03:20:20,908 --> 03:20:25,646 FOR EXAMPLE, WITH JUST THE 4052 03:20:25,646 --> 03:20:26,447 VIVITROL INJECTION THERE'S MORE 4053 03:20:26,447 --> 03:20:29,583 INDIVIDUAL VARIATION THAN YOU 4054 03:20:29,583 --> 03:20:32,186 MIGHT THINK AND THERE ARE 4055 03:20:32,186 --> 03:20:35,122 PATIENTS WHO DON'T ABSORB THE 4056 03:20:35,122 --> 03:20:37,425 MEDICATION WELL AND HAVE 4057 03:20:37,425 --> 03:20:38,426 SUBTHERAPEUTIC LEVELS BY 21 DAYS 4058 03:20:38,426 --> 03:20:44,899 AFTER THE INJECTION. 4059 03:20:45,199 --> 03:20:46,400 IT'S IMPORTANT TO REALLY LOOK AT 4060 03:20:46,400 --> 03:20:48,402 THAT AS PART OF THESE PROJECTS. 4061 03:20:48,402 --> 03:20:50,638 >> THAT'S A REALLY IMPORTANT 4062 03:20:50,638 --> 03:20:51,138 CAVEAT. 4063 03:20:51,138 --> 03:20:52,773 GOING BACK TO THE INDUSTRY 4064 03:20:52,773 --> 03:20:55,910 INVOLVEMENT, WE HAVE BEEN VERY 4065 03:20:55,910 --> 03:20:57,445 WITH THE AMOUNT OF INDUSTRY 4066 03:20:57,445 --> 03:21:02,383 INVOLVEMENT WE'VE RECEIVED. 4067 03:21:02,383 --> 03:21:04,151 WE DO A LOT OF OUTREACH AND MEET 4068 03:21:04,151 --> 03:21:05,419 WITH COMPANIES THAT COME TO US 4069 03:21:05,419 --> 03:21:08,222 AND I THINK WHAT HAS REALLY MADE 4070 03:21:08,222 --> 03:21:11,425 THE DIFFERENCE IS THE FACT THAT 4071 03:21:11,425 --> 03:21:13,427 OUR TWO FLAGSHIP FUNDING 4072 03:21:13,427 --> 03:21:14,862 OPPORTUNITIES ACTUALLY OFFER 4073 03:21:14,862 --> 03:21:16,163 PEOPLE ENOUGH MONEY TO BE ABLE 4074 03:21:16,163 --> 03:21:19,100 TO DO DRUG DEVELOPMENT. 4075 03:21:19,100 --> 03:21:21,769 THE STANDARD RO1, $500,000 A 4076 03:21:21,769 --> 03:21:23,738 YEAR AND I KNOW WE SHOULDN'T 4077 03:21:23,738 --> 03:21:25,306 TALK ABOUT BUDGETS OR ANYTHING 4078 03:21:25,306 --> 03:21:27,008 ELSE IS NOT SUFFICIENT TO DO 4079 03:21:27,008 --> 03:21:29,410 DRUG DEVELOPMENT BUT THE AWARDS 4080 03:21:29,410 --> 03:21:31,512 ALLOW PEOPLE TO PROPOSE A 4081 03:21:31,512 --> 03:21:33,514 REASONABLE BUDGET TO GIVE THEM 4082 03:21:33,514 --> 03:21:36,450 ENOUGH TO COMPLETE IND ENABLING 4083 03:21:36,450 --> 03:21:40,454 STUDIES AND COMPLETE AT LEAST 4084 03:21:40,454 --> 03:21:41,822 PHASE I CLINICAL TRIALS AND 4085 03:21:41,822 --> 03:21:42,857 THAT'S MADE ALL THE DIFFERENCE. 4086 03:21:42,857 --> 03:21:44,692 >> IT'S AMAZING. 4087 03:21:44,692 --> 03:21:48,662 I AGREE IT'S AMAZING WHAT A 4088 03:21:48,662 --> 03:21:53,200 ROBUST INVESTMENT WILL DO. 4089 03:21:53,200 --> 03:21:54,268 >> THANK YOU SO MUCH. 4090 03:21:54,268 --> 03:21:55,536 LET ME QUICKLY GO TO THE 4091 03:21:55,536 --> 03:21:56,670 QUESTION THAT'S BEEN IN THE CHAT 4092 03:21:56,670 --> 03:22:00,107 A WHILE AND THEN GO BACK TO 4093 03:22:00,107 --> 03:22:00,641 HANDS. 4094 03:22:00,641 --> 03:22:05,446 THERE WAS A QUESTION ON 4095 03:22:05,446 --> 03:22:08,049 NON-INVASIVE VAGAL NERVE 4096 03:22:08,049 --> 03:22:09,417 STIMULATION AND HOW ARE 4097 03:22:09,417 --> 03:22:10,551 RESPONSES ASSESSED? 4098 03:22:10,551 --> 03:22:12,653 >> I'M NOT SURE HOW THAT'S GOING 4099 03:22:12,653 --> 03:22:13,220 TO BE DONE. 4100 03:22:13,220 --> 03:22:14,755 I'D HAVE TO GO BACK TO THE GRANT 4101 03:22:14,755 --> 03:22:16,657 AND HAVE A CLOSER LOOK. 4102 03:22:16,657 --> 03:22:17,224 >> NO PROBLEM. 4103 03:22:17,224 --> 03:22:18,192 THANK YOU. 4104 03:22:18,192 --> 03:22:21,529 I APPRECIATE THAT. 4105 03:22:21,529 --> 03:22:23,130 GALE, YOUR QUESTION. 4106 03:22:23,130 --> 03:22:27,635 >> I WANT TO FOLLOW-UP ON 4107 03:22:27,635 --> 03:22:29,203 SOMETHING YOU JUST TOUCHED. 4108 03:22:29,203 --> 03:22:32,073 ARE YOU GETTING THE GLP AGONIST 4109 03:22:32,073 --> 03:22:32,740 1 COMPANIES TO OFFER MEDICATION 4110 03:22:32,740 --> 03:22:42,116 FOR STUDIES? 4111 03:22:42,116 --> 03:22:44,085 >> ONE COMPANY DID OFFER ONE IN 4112 03:22:44,085 --> 03:22:46,287 THE ORIGINAL STUDY BUT FOR 4113 03:22:46,287 --> 03:22:48,622 REASONS I CAN'T REALLY EXPLAIN 4114 03:22:48,622 --> 03:22:50,224 OR UNDERSTAND, THEY DON'T SEEM 4115 03:22:50,224 --> 03:22:53,561 TO BE PROVIDING THEM TO ANYONE 4116 03:22:53,561 --> 03:22:55,763 FOR ANY SUBSTANCE ABUSE WORK AS 4117 03:22:55,763 --> 03:22:57,398 FAR AS I KNOW. 4118 03:22:57,398 --> 03:23:05,706 THEY ARE NOT PROVIDING THE SEMA 4119 03:23:05,706 --> 03:23:09,510 GLUTIDE FOR THIS STUDY. 4120 03:23:09,510 --> 03:23:11,378 >> THEY MAKE IT DIFFICULT. 4121 03:23:11,378 --> 03:23:14,181 IT'S SO EXPENSIVE. 4122 03:23:14,181 --> 03:23:16,984 IT'S A GREAT IDEA TRYING TO WORK 4123 03:23:16,984 --> 03:23:26,527 WITH MANY SUBSTANCES. 4124 03:23:26,527 --> 03:23:28,028 IF YOU HAVE MORE MONEY IN THAT 4125 03:23:28,028 --> 03:23:29,663 DIRECTION IT'S GOOD. 4126 03:23:29,663 --> 03:23:32,533 >> THEY HAVE MORE MONEY TO BUY 4127 03:23:32,533 --> 03:23:33,234 THE DRUG. 4128 03:23:33,234 --> 03:23:35,970 IT'S WHAT THEY HAVE TO DO. 4129 03:23:35,970 --> 03:23:37,505 >> THANK YOU. 4130 03:23:37,505 --> 03:23:39,573 >> WHAT THE COMPANY SAYS ARE 4131 03:23:39,573 --> 03:23:42,042 KEEPING IT IN COMMERCIAL DEMAND 4132 03:23:42,042 --> 03:23:43,577 IS WHAT THEY SAID. 4133 03:23:43,577 --> 03:23:44,712 >> THEY'RE ALSO INTERESTED IN 4134 03:23:44,712 --> 03:23:54,989 NEW INDICATIONS. 4135 03:24:03,330 --> 03:24:08,369 >> THERE'S A LOT GOING ON IN 4136 03:24:08,369 --> 03:24:11,138 THIS FIELD AND A LOT OF 4137 03:24:11,138 --> 03:24:11,939 POTENTIAL. 4138 03:24:11,939 --> 03:24:13,641 IT'S A FIELD JUST OFF THE 4139 03:24:13,641 --> 03:24:13,974 GROUND. 4140 03:24:13,974 --> 03:24:14,475 >> OKAY, ANY ADDITIONAL 4141 03:24:14,475 --> 03:24:18,879 QUESTIONS? 4142 03:24:18,879 --> 03:24:20,347 NO, WELL THANK YOU, SO MUCH THIS 4143 03:24:20,347 --> 03:24:21,515 WAS A GREAT TALK AND I 4144 03:24:21,515 --> 03:24:24,785 APPRECIATE ALL THE DISCUSSION. 4145 03:24:24,785 --> 03:24:25,586 >> THANK YOU. 4146 03:24:25,586 --> 03:24:27,821 >> SO, WITH THAT WE HAVE COME TO 4147 03:24:27,821 --> 03:24:29,990 THE END OF OUR OPEN SESSION. 4148 03:24:29,990 --> 03:24:31,992 I DON'T KNOW, WALTER, IF YOU 4149 03:24:31,992 --> 03:24:35,596 WANT ANY LAST WORDS FOR THE OPEN 4150 03:24:35,596 --> 03:24:38,666 SESSION BUT JUST A LITTLE BIT OF 4151 03:24:38,666 --> 03:24:39,333 HOUSEKEEPING. 4152 03:24:39,333 --> 03:24:46,173 WE'LL HAVE A BREAK UNTIL 3:00 4153 03:24:46,173 --> 03:24:47,942 P.M. AND INVITE THE MEMBERS AND 4154 03:24:47,942 --> 03:24:51,979 STAFF TO STAY ON THE ZOOM. 4155 03:24:51,979 --> 03:24:53,013 THIS IS STILL THE SAME ZOOM 4156 03:24:53,013 --> 03:24:54,815 YOU'LL BE USING FOR THE CLOSED 4157 03:24:54,815 --> 03:24:55,049 SESSION. 4158 03:24:55,049 --> 03:24:56,684 WE'LL JUST BE ENDING THE 4159 03:24:56,684 --> 03:25:02,189 VIDEOCAST PORTION. 4160 03:25:02,189 --> 03:25:03,524 >> I JUST WANT TO THANK 4161 03:25:03,524 --> 03:25:08,629 EVERYBODY FOR DOING THE WORK 4162 03:25:08,629 --> 03:25:11,532 BEHIND THE PRESENTATIONS. 4163 03:25:11,532 --> 03:25:13,300 DEMONSTRATE WHAT HEAL'S BEEN 4164 03:25:13,300 --> 03:25:15,502 ABLE TO DO WITH THE HELP FROM 4165 03:25:15,502 --> 03:25:19,006 EVERYBODY HERE ON THE CALL. 4166 03:25:19,006 --> 03:25:22,109 I WOULD SAY IF PEOPLE COULD -- 4167 03:25:22,109 --> 03:25:23,777 WE'RE ALWAYS INTERESTED HOW TO 4168 03:25:23,777 --> 03:25:28,549 MAKE THESE MORE PRODUCTIVE, 4169 03:25:28,549 --> 03:25:30,618 VALUE-ADDED, SO IF YOU HAVE 4170 03:25:30,618 --> 03:25:32,653 SUGGESTIONS FOR FUTURE MDWG 4171 03:25:32,653 --> 03:25:34,888 MEETINGS THAT WOULD BE HELPFUL 4172 03:25:34,888 --> 03:25:42,496 AND FEEL FREE TO E-MAIL NORAH 4173 03:25:42,496 --> 03:25:43,130 AND MYSELF. 4174 03:25:43,130 --> 03:25:43,931 THANK YOU VERY MUCH AND WE'LL GO 4175 03:25:43,931 --> 03:25:44,665 TO CLOSED SESSION NOW. 4176 03:25:44,665 --> 03:25:44,732